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Abstract 
High plasma levels of inflammatory mediator, high mobility group box protein 1 (HMGB1), and 
its main receptor, receptor for advanced glycation end products (RAGE), is associated with poor 
prognosis for a variety of cancers, but little is known about this signalling axis in chronic 
lymphocytic leukaemia (CLL). We have previously determined significantly increased HMGB1 
levels in the plasma of CLL patients compared to healthy controls, associated with poor clinical 
outcome. It is unknown whether the HMGB1-RAGE signalling axis contributes to disease 
progression and can directly promote CLL B-cell survival by converging with toll-like receptor 9 
(TLR9) signalling. Moreover, the role of soluble RAGE (sRAGE), a free extracellular receptor 
fragment that functions as a decoy receptor in blood plasma, is poorly documented for CLL. The 
overall aim of my PhD is to (1) determine expression of HMGB1 receptors, RAGE and TLR9, in 
CLL B-cells and their prognostic significance in patients with CLL; (2) assess global cell-signalling 
network activation following exogenous HMGB1 treatment and blockade with neutralising anti-
RAGE antibody; (3) study the impact of sRAGE in CLL.  
Lymph node RAGE expression positively correlated with TLR9, Ki67 and ZAP70 – markers of 
proliferating and aggressive disease. Patients with high lymph node RAGE expression confer 
inferior overall survival in comparison to patients with low RAGE expression. Further risk 
stratification of RAGE with Ki67 and ZAP70 lymph node expression increased the prognostic 
power of RAGE, highlighting a significant interaction between these variables. HMGB1 induced 
activation and colocalization of RAGE and TLR9 in CLL B-cells. Phosphoproteomic analysis 
highlights activation of MAPK signalling in primary CLL cells following HMGB1 treatment in vitro 
for patients with ZAP70 expression. We confirmed increased plasma levels of HMGB1 and 
surprisingly of sRAGE in CLL patients compared to healthy controls, but not of other RAGE ligand, 
S100B. Plasma sRAGE levels did not reach a high enough concentration to inflict full HMGB1 
inhibition, but RAGE shedding could be induced in vitro by stimulating metalloprotease  termed 
a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) with ionomycin in 
RAGE-transfected HEK293 cell line and primary CLL cells, and blocked when ADAM10 was 
specifically inhibited with GI254023X. 
In summary, this study demonstrates that overexpression of HMGB1 receptor, RAGE, in CLL 
lymph nodes is associated with a worse clinical outcome in patients with CLL. HMGB1 activates 
both RAGE and TLR9 in primary CLL B-cells. sRAGE has a protective effect in CLL by prolonging 
time to first treatment and sRAGE originates from ectodomain shedding, dependent on 
ADAM10. We therefore propose that HMGB1 and surface RAGE may play an important role in 
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promoting CLL cell proliferation and cell survival, and plasma sRAGE combined with HMGB1 
could be markers of disease monitoring. 
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TRAF6 Tumour-necrosis-factor-receptor associated factor 6  
T-regulatory cells TREGS 
U-CLL Unmutated CLL 
VEGF Vascular endothelial growth factor  
α-RAGE Anti-RAGE 
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1.1 Inflammation 
1.1.1 The inflammatory response 
In its simplest form, inflammation is a molecular and cellular immune response to host damage 
and homeostatic imbalance. Triggers of inflammation can range from a variety of exogenous 
and/or endogenous inducers, leading to different physiological responses to restore 
homeostasis. Injury and infection were early known activators of the inflammatory response,1,2 
where controlled, acute inflammation to such inducers is beneficial to regain tissue homeostasis 
and limit host damage. The initiating causes of systemic chronic dysregulated inflammation are 
not clear, and frequently results in harm to the host.1 Although acute inflammation in response 
to infection and injury is more aggressive than chronic in the short term, systemic chronic 
inflammation is associated with the pathogenesis of a wide variety of life-threatening diseases 
(such as sepsis, cardiovascular disease, diabetes, cancer and autoimmune disease).3 
Inflammation is a complex interplay of regulatory networks. The adaptive response can broadly 
separate into 4 categories – inducers, sensors of innate immunity, mediators and effectors 
(Table 1).3,4 Each stage contributes to a different type of inflammatory response to maximise 
effective regain of homeostasis. Different types of inducers are surveyed by a variety of sensors, 
the sensors relay the correct message via secreted cytokines, chemokines and inflammatory 
signalling pathways, to recruit the suitable effector leukocytes.  
For example, the presence of lipopolysaccharide (LPS) sensed by pattern recognition receptor 
(PRR) toll-like receptor 4 (TLR4) on tissue resident macrophages is indicative of bacterial 
infection.5 This leads to the secretion of TNF-α and IL-6 to recruit neutrophil to the site of 
infection, that release the contents of their toxic granules to eliminate the pathogen.6,7 The pro-
inflammatory microenvironment progresses to anti-inflammatory, to facilitate recruitment of 
tissue-repair monocytes and phagocytic macrophages.8 In response to trauma and injury, 
endogenous stress signals or damage-associated molecular patterns (DAMPs) alert the tissue 
remodelling and repair arms of the immune system via TGF-α/β, IL-4, IL-10 and IL-13 mediators, 
to eliminate damaged cells and regenerate tissues.9 In both settings, chronic inflammation is 
established when infection persists or host damage continues to occur, and results in the 
addition of other effector cell subsets; the polarization of the chronic inflammatory state is 
largely dependent on the type of effector T-cell and macrophage subset (Table 1).3 Although 
acute inflammation follows a clear set of mechanisms, systemic chronic inflammation initiation 
and maintenance in pathological conditions are poorly understood.   
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Table 1 The components involved in an inflammatory response 
Stage Effect Components involved 
Inducer Inducers are a group of 
specific conserved 
molecules that are found 
on micro-organisms or 
host-molecules that are 
not usually localised in 
the extracellular 
environment. They alert 
the immune system to 
danger. 
Can be from exogenous or endogenous origin 
- Exogenous: pathogen-associated molecular 
patterns (PAMPs), virulence factors, 
allergens, irritable chemicals. 
- Endogenous: Sequestered or 
compartmentalised under normal conditions 
but are released during stress or trauma. 
Include ATP, HMGB1, S100, RNA/DNA and 
potassium ions. 
Sensor Sensors recognise 
inducers of inflammation 
and are mostly 
membrane bound 
receptors. Activation of 
these receptors initiates 
cell activation and the 
beginning of an immune 
response. 
Involves PRRs: 
- Toll-like receptors (TLRs), nod-like receptors, 
C-type lectin receptors, scavenge receptors, 
RIG-like helicases, receptor for advanced 
glycation end-products (RAGE) expressed in 
immunocompetent cells, epithelium, 
endothelium and stromal cells (i.e. localised 
at barriers or tissue surveillance) 
- Other foreign bodies, not encompassed 
under the host PAMP recognition, are sensed 
by ‘missing self’ (lack of MHC-I expression) by 
natural killer cells. 
Mediator Act as messengers 
between sensing danger 
and the immune 
response. Mediators act 
on a variety of target cells 
and tissues, allowing the 
host to adapt to potential 
damaging conditions. 
Mediators originate from various sources 
including cell secretion, inactive plasma 
precursors or preformed granules. This results in 
variable inflammatory outcomes such as 
vasodilation, vasoconstriction, leukocyte 
recruitment, chemotaxis, cell differentiation. 
- Cytokines (TNF-α, IL-1, IL-6 IFN-γ,TGF-β) , 
chemokines, complement proteins, lipid 
mediators (prostaglandins), vasoactive 
amines (histamine). 
Effector Regain and maintain 
tissue homeostasis. Clear 
infection, cell-death 
debris and repair tissue 
damage. 
Different cell types mediate different responses. 
Cell-mediated killing: 
- T-helper 1 cells (TH1) elicit cell-mediated 
killing to clear infection via activation of CD8+ 
cytotoxic T cells and natural killer cells. 
- M1 macrophages support TH1 cells by 
phagocytosis and antigen presentation. 
Antibody-mediated immunity: 
- TH2 cells activate the humoral antibody-
mediated immunity to allergens. 
- M2 macrophages promote TH2 responses by 
tissue remodelling/repair and 
immunoregulation.  
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1.1.2 Inflammation and cancer 
The ability of a host cell to transform into a successful malignant cell requires various acquired 
capabilities. With increasing research, 10 hallmarks of cancer are reported as the key functional 
characteristics of cancer development that differentiates malignant cells from normal-
functioning healthy cells (Figure 1-1).10  
 
Figure 1-1 The 10 Hallmarks of Cancer 
Over the last 15 years, research has expanded our understanding and knowledge of cancer pathogenesis 
from the original 6 hallmarks, to 10 capabilities acquired for cells to transform. These new hallmarks 
include deregulating cellular energetics, avoiding immune destruction, genome instability and mutations, 
and tumour promoting inflammation.10  
 
 
As an established hallmark of cancer, a chronic inflammatory microenvironment plays an 
important role in the progression of the neoplastic process, contributing to the survival and 
migration of cancers, including chronic lymphocytic leukaemia.10-14 A normal inflammatory 
response is regulated  by release of anti-inflammatory cytokines, the action of T-regulatory cells 
and myeloid suppressor cells.15 Whereas dysregulated chronic inflammation contributes to  
immune evasion, tumour promotion, invasion, metastasis, and proliferative signalling – 4 
hallmarks of cancer. The presence of immune cells in neoplastic tissues was noted by Virchow 
in the 19th century, but it’s only in the last few decades that our understanding of tumour-
associated inflammation has supported Virchow’s hypothesis.16 Tumour infiltrating immune 
cells are able to engage with malignant cells and mediate dynamic molecular crosstalk with 
malignant cells and surrounding stroma to engineer a niche pro-tumour environment. Immune 
cells communicate with malignant cells by direct contact and through production of reactive 
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nitrogen and oxygen species, cytokines, chemokines, prostaglandins and growth factors which 
signal in a paracrine and autocrine manner to facilitate a positive pro-inflammatory pro-survival 
feedback loop.17 In fact, inflammation is involved in every step of tumourigenesis.   
Peyton Rous demonstrated cancers arise from ‘initiated cells’.18 Environmental and chemical 
carcinogens, autoimmune damage, chronic inflammatory exposure, genotoxic stress or a failure 
in DNA repair mechanisms induce DNA alterations giving rise to initiating genetic events that are 
reversible. To establish a malignant status, these initiated cells require promoter events. 
Promoter events support cell growth, recruit inflammatory cells and increase production of 
reactive nitrogen and oxygen species resulting in further DNA damage and establishment of a 
“wounds that do not heal”. This simplified cycle continues due to persistent initiator events and 
irresolvable tissue damage. Although smouldering inflammation is present in tumours with a 
relationship to chronic inflammatory initiating events, this type of inflammation is also observed 
in tumours irrespective of the trigger for tumour development, or that do not display an 
inflammatory-link (i.e. breast cancer).12 Therefore, a chronic inflammatory microenvironment is 
a vital component of tumour development and one of the hallmarks of cancer. 
1.1.3 The origin of inflammation in cancer 
The origin of chronic smouldering inflammation supporting promotion of cancer cells arises from 
intrinsic and extrinsic pathways. Intrinsic inflammatory activation occurs due to genetic events 
that lead to the upregulation of oncogenes (such as RAS, RET and MYC), or tumour suppressor 
gene inactivation (such as PTEN and TGF-β).12 The RET/PTC chromosome rearrangement in 
human papillary thyroid cancer is sufficient to induce development of this cancer by activating 
protein tyrosine kinase, RET, and downstream inflammatory response.19 Oncogene activation 
results in the activation of the inflammatory transcriptome and production of pro-inflammatory 
cytokines, chemokines and prostaglandins which in turn, promote establishment of pro-tumour 
paracrine and autocrine signalling.20 The intrinsic pathway is responsible for the inflammatory 
involvement in tumours that have no underlying inflammatory conditions.  
In the extrinsic pathway, underlying localised inflammation from inflammatory or infectious 
conditions increase the risk of cancer development. It is estimated around 20% of cancers are 
caused by chronic infection and autoimmunity.21 For example, individuals with Crohn’s disease 
have an increased risk of colon cancer, and Hepatitis C infection is associated with increased risk 
of liver cancer, highlighting the input of underlying chronic inflammation in tumour 
development.22,23 Moreover, environmental carcinogens such as tobacco smoke and UV light 
are highly mutagenic and irritable, promoting the development of lung cancer and skin cancer, 
respectively.24 The culmination of pro-inflammatory cytokines, chemokines, prostaglandins and 
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DAMPs established by underlying inflammation/infection activates pro-inflammatory 
transcription factors in tumour cells, i.e. NF-B, STAT3 and HIF1α.12 The intrinsic and extrinsic 
pathways converge at this stage and maintain tumour-associated inflammation by positive 
feedback signalling. 
Regarding inflammatory maintenance, tumours are often referred to as “wounds that do not 
heal”.25 NF-B, STAT3 and HIF1α activated tumour cells release pro-inflammatory cytokines and 
growth factors (IFN-γ, IL-1, IL-4, IL-6, IL-10, TGF-β, TNF, VEGF, CSF), as well as chemokines 
(CXCL13, CXCL1, CXCL8, CXCL10, CCL22). Cytokines are directly linked to malignant progression, 
and chemokines facilitate leukocyte recruitment, particularly cells of the polarised myeloid 
lineage and T-helper cells.26 Alike to wound healing, tumours secrete vascular endothelial 
growth factor (VEGF) which acts on the tumour stroma to persistently generate extracellular 
matrix. However, where wound healing is self-limiting, the components of the extracellular 
matrix (fibroblasts, platelets and adipocytes) are a rich source of cytokines and growth factors 
(particularly TGF-β and VEGF) contributing to angiogenesis, metastasis and tumour 
progression.27 As tumour development progresses, the centre of tumour masses are commonly 
hypoxic, and undergo necrosis, causing release of DAMPs and pro-inflammatory cytokines such 
as HMGB1, TNF, IL-1 and IL-6 – this smouldering inflammatory cycle persists.28 Moreover, radio- 
and chemotherapy induce tissue damage and cell death, causing further release of DAMPs and 
pro-inflammatory cytokines; the wound-healing response following cancer therapy can exhibit 
pro- and anti-tumour effects.21  
1.1.4 Pro- and anti-tumour inflammation 
Within the same tumour, pro- and anti-tumour inflammation coexist. Innate and adaptive 
immune cells, surrounding stroma and malignant cells communicate via direct cell-cell contact 
or through production of cytokines and chemokines. The combinatorial cytokine, chemokine, 
DAMP profile of the microenvironment will decide the activation state of these different cell 
types and dictate the balance between pro-tumour and anti-tumour inflammation (Table 2).29  
The polarised inflammatory microenvironment is sustained by autocrine and paracrine 
signalling. Although malignant cells are constantly assessed by immune surveillance 
mechanisms, once immune evasion is achieved and if tumours are left untreated, they rarely 
regress; highlighting pro-tumour inflammation usually exceeds anti-tumour immunity.30 
The driving anti-tumour mechanisms involve immune cell-subsets that mediate cell-killing. 
Infiltration of CD4+ TH1 cells secretes IFN-γ and activate CD8+ cytotoxic T lymphocytes (CTL) and 
natural killer cells (NKs).31,32 Tumour-antigen presentation by M1 polarized macrophages and 
dendritic cells prime the cytotoxic mechanisms towards tumour cells to perform cell killing.8 On 
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the other hand, wound healing immune mechanisms comprise the major components of pro-
tumour responses. M2 polarized tumour-associated macrophages (TAMs) are important players 
of pro-tumour inflammation, promoting tissue remodelling and angiogenesis compared to cell-
killing.26 This requires the action of CD4+ TH2 and TH17 cells compared to TH1 and CTL responses. 
The smouldering wound healing response supports further DNA damage and genomic instability 
in tumour cells and tumour promoting properties. The action of T-regulatory cells (TREGS) 
encompasses both anti- and pro-tumour responses by suppressing inflammation through IL-10 
production.33 
Table 2 Pro-tumour inflammation and anti-tumour immunity cellular responses 
 Anti-tumour immunity Pro-tumour inflammation 
Macrophage IL-12, IFN-γ - M1 phagocytosis and 
antigen-presenting macrophages, 
inhibit TREGS and activate TH1 
response 
IL-4/6/10/13 - M2 tumour-associated 
macrophages for wound healing, 
provides growth factors and cytokines 
for tumour growth 
Dendritic 
Cell (DC) 
Antigen presenting cells – activate 
TH1 and cell mediated-killing 
response 
Antigen presentation for TH2 cells and 
B-cells – humoral response instead of 
cytotoxic response 
CD4+ T cell TH1 response – produce IFN-γ, 
help cytotoxic T-lymphocyte 
response 
TH2 and TH17 response – wound healing 
(IL-4, IL-5, IL-10). Induce differentiation 
of macrophages, myeloid derived 
suppressor cells and activates the B-cell 
humoral response instead of cell-
mediated killing 
CD8+ T cell Cell-mediated tumour cell killing 
(granzymes, perforin; IFN-γ 
secretion) 
- 
T-regulatory 
cell 
Immune suppression  Immune suppression – IL-10, TGF-β 
inhibit CD8+ cytotoxic T-lymphocytes 
Natural 
killer (NK) 
cell 
Cell-mediated tumour cell killing - 
B-cell Produce tumour-specific 
antibodies 
Humoral response – production of 
cytokines and antibodies, does not 
mediate tumour cell death. Activate 
mast cells 
Myeloid 
derived 
suppressor 
cell (MDSC) 
- Inhibit DCs, NKs and CD4+ TH1 cells. 
Produce cytokines, chemokines, 
proteases.  
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1.1.5 Targeting cancer-associated inflammation 
The clinical manifestations of tumour-associated inflammation are associated with worse clinical 
outcomes for patients with cancer and are included in disease diagnosis/staging, particularly in 
haematological malignancies.34 B symptoms, such as high fever (over 38°C), night sweats and 
weight loss are indicative of high circulating levels of inflammatory cytokines such as TNF-α, IL-
1 and IL-6 and confer a poor prognosis in CLL.35 As our understanding of cancer-associated 
inflammation improves, particularly the mechanisms linked to pro- and anti-tumour immunity, 
therapies harnessing and manipulating aspects of the inflammatory response are of increasing 
interest.  
Methods to target tumour-associated inflammation include non-selective strategies that affect 
systemic inflammation, or selective mechanisms to manipulate specific arms of the 
inflammatory/immune response. Non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin 
are widely known preventive agents.11 NSAIDs inhibit cyclooxygenase 1 and 2, that are expressed 
in inflammatory conditions, preventing production of prostaglandins and angiogenesis;36 risk of 
colon cancer was reduced in people who had taken NSAIDs.37 However, long term use of NSAIDs 
as a cancer preventing strategy is not advised due to non-selectivity and other side effects, 
unless individuals are at high-risk of cancer development.38  
Targeted strategies manipulate specific pathways of the inflammatory response to dampen pro-
tumour signalling and amplify anti-tumour immunity. Non-tumour components of the tumour 
microenvironment pose as a stable target compared to malignant cells directly, where acquired 
chemotherapy resistance results in the failure of anti-cancer agents.34 Selective targets include 
cytokines, chemokines, integrins, inflammatory transcription factors, tumour antigens for 
immune-cell directed therapies and manipulation of T-cell functions. For example, anti-IL-6 
antibody, siltuximab, has been evaluated in prostate cancer and platinum-resistant ovarian 
cancer.39 Targeting CCL2 chemokine produced by breast cancer cells with neutralising 
antibodies, abrogates recruitment of CCR2-positive monocytes, reducing metastasis.40 The roles 
of pro-inflammatory transcription factors, STAT3, NF-B and HIF1α as central regulators of pro-
tumour signalling and angiogenesis place them as ideal microenvironment targets. Transcription 
factors are inferior drug targets, due to their nuclear localisation and lack of suitable small 
molecule binding sites,41 but targeting downstream targets such as JAK1 and JAK2 have shown 
promise for STAT3-mediated pathways in cancer.42 Finally, therapies that redirect cell-mediated 
immunity towards malignant cells are proving successful in clinic. Anti-CD20 monoclonal 
antibody, Rituximab, targets CD20 expressed on the surface of malignant cells in B-cell 
malignancies (including CLL) and promotes antibody-dependent cell cytotoxicity.43 Moreover, 
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interfering with immune checkpoints can restore T-cell function. Pembrolizumab, is FDA 
approved for the treatment of a variety of cancers including melanoma, Hodgkin’s lymphoma, 
lung cancer and is of current intense interest in CLL.44,45 
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1.2 Chronic Lymphocytic Leukaemia 
CLL is currently an incurable disease of malignant, antigen-stimulated, mature B-lymphocytes 
(expressing CD5, CD19 and CD23) present in peripheral blood and lymphoid organs. The disease 
heavily relies on the microenvironment milieu for external survival signals,13,14,46-48 as well as B-
cell receptor signalling via surface IgM, and a variety of genetic aberrations contributing to CLL 
pathogenesis.49 CLL is a highly diverse and heterogeneous disease, reflected in variations in 
clinical manifestations, prognostic biomarkers and need and type of therapeutic management. 
Clinical translation of the molecular mechanisms driving CLL progression is aiding in identifying 
high-risk patients and development of targeted therapeutic approaches.  
1.2.1 CLL development 
Two landmark studies identified the cellular origin and 2 main subsets of CLL disease, where 
patients display different disease progression and outcome rates.50,51 Gene expression profiling 
and genetic studies identified 2 origins of CLL-cell development based on the point of exit from 
B-cell maturation (Figure 1-2).52 Cells from unmutated-CLL (U-CLL) origin are pre-germinal 
centre, surface immunoglobulin-M (IgM) expressing, mature naïve B-cells that have 
encountered antigen, but have not yet undergone somatic hypermutation (SHM) of the 
immunoglobulin heavy-chain variable (IGHV) gene region. Mutated-CLL (M-CLL) derive from 
post-germinal centre B-cells that have undergone SHM of the IGHV gene region; this gives rise 
to higher affinity surface B-cell receptors (IgM and IgD) for specific antigens. M-CLL cells tend to 
display an anergic B-cell phenotype and do not retain B-cell receptor (BCR) signalling 
responsiveness compared to U-CLL cells.53 Patients with CLL cells that express unmutated IGHV 
genes generally have a more aggressive disease compared to patients with M-CLL.49 
The expression levels of surface BCRs are lower, and the Ig repertoire is limited, in CLL patients 
compared to B-cells from a healthy individual; this emphasises biased IGHV gene usage, and 
limited somatic hypermutation and combinatorial diversity.54,55 Sections of the variable region 
in Ig molecules are matched across a third of CLL patients, referred to as Ig ‘stereotypes’.56 This 
combination highlights the importance of BCR signalling in selecting and driving CLL cell survival, 
based on receptor binding activity, and the limited antigen repertoire which must select for 
these stereotyped B-cells.57 Therefore, as BCR signalling plays an important role in CLL 
development, this signalling pathway is an attractive therapeutic target. 
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Figure 1-2 CLL B-cell development  
2 main subsets of CLL exist. The first subset, U-CLL, develop from pre-germinal centre, mature B-cells 
encountering antigen in secondary lymphoid organs. The second subset are post-germinal centre B-cells 
that have undergone clonal expansion and somatic hypermutation (SHM) of their IGHV genes that give 
rise to higher affinity surface IgM/IgD (B-cells receptors). M-CLL arise before BCRs undergo isotype 
switching to different classes of Ig molecules. Figure adapted from 53.  
 
1.2.2 The molecular pathogenesis of CLL 
The difference in CLL disease severity and outcome between U-CLL and M-CLL subsets are not 
solely due to differences in IGHV mutational status. Disease molecular pathogenesis is also 
attributed to chromosomal alterations, somatic mutations, epigenetic modifications, activated 
signalling pathways and molecular crosstalk with the inflammatory microenvironment within 
the CLL lymph nodes and bone marrow.58 
1.2.2.1 Genetics 
A variety of genetic lesions contribute to disease initiation and clinical progression. Although 
chromosome translocations are highly common in haematological malignancies, they are rare 
in CLL. Instead, 80% of CLL patients harbour a chromosomal alteration – deletion in 13q14.3 
(del(13q)), deletion in 11q22-23 (del(11q)), deletion in 17p13 (del(17p)), and trisomy 12.59 
Del(13q) is observed in 50-60% of patients and occurs more frequently in patients with M-CLL. 
This chromosomal alteration is associated with a favourable prognosis, due to deletion of the 
DLEU2-mir-15-16 cluster that regulates expression of anti-apoptotic proteins.60 Both del(11q) 
and del(17p) are associated with an unfavourable outcome; del(11q) is observed in ~20% of CLL 
patients and encompasses the loss of tumour suppressor gene ATM (involved in DNA damage 
repair), whereas del(17p) is found in <10% of CLL patients and harbours loss of tumour 
suppressor gene TP53.61 Finally, an extra copy of chromosome 12 is observed in <15% of patients 
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and is associated with intermediate CLL disease risk – although, there is high co-occurrence of 
this chromosome abnormality and NOTCH1 mutations.62 
Somatic mutations have clear pathogenic impact on the course of CLL disease and contribute to 
genetic heterogeneity. Whole genome and exome sequencing studies revealed a small number 
of recurrent somatic mutations that are putative drivers of CLL development and can be 
assigned to common biological pathways.61,63,64 For example, TP53, ATM and POT1 mutations 
affect DNA damage and protection of telomeres,65 SF3B1 and XPO1 mutations result in aberrant 
RNA splicing,65 and CHD2 and ZMYM3 mutations disrupt genome/chromatin structure.65 In 
terms of cell signalling, BRAF, BIRC3, MyD88 and PAX5 mutations affect BCR-TLR-NF-κB signalling 
pathways and activation,65 while mutations in NOTCH1 result in the constitutive activation of 
Notch signalling.65 The relative frequencies of these mutations are variable between the U-CLL 
and M-CLL cohorts, but overall, mutations with notable frequency in CLL patients include SF3B1 
(21% of patients), ATM (15%), TP53 (7%), NOTCH1 (6%), BIRC3 (4%), and MyD88 (3%).64,66 
Alterations in the expression of specific miRNAs contributes to CLL disease pathogenesis. 
Del(13q) encompasses deletion of mir-15a and mir-16-1 in 50-60% of CLL patients. Loss of these 
tumour suppressor miRNAs results in the upregulation of anti-apoptotic genes BCL2 and MCL1.67 
Moreover, intense interest in understanding the CLL epigenome revealed high intra-tumour 
methylation heterogeneity and suggests a role for transcription-mediated epigenetic 
programming in CLL.68 
1.2.2.2 BCR signalling 
Functional BCR signalling is vital for the maturation and survival of B-cells, including mature 
malignant B-cells such as CLL. Alike to normal B-cells, CLL cells require continuous 
microenvironment support for survival, regardless of initiating cytogenetic and genomic 
events.69 The outcome of BCR signalling is heterogeneous in CLL; antigen engagement results in 
B-cell activation/proliferation, or anergy – an unresponsive state of cell lethargy where a 
secondary co-signal (i.e. T-cell help) was not received.70 The signalling pathway resulting in 
anergy is not well-defined, but is more common in patients with M-CLL largely giving rise to 
indolent disease.53 
BCR signalling is driven by autoantigens in CLL, supported by the restricted Ig repertoire and 
surface Ig stereotypes (Figure 1-3).47,70,71 The BCR is comprised of surface IgM or IgD complexed 
with the signalling CD79A and CD79B heterodimer. Antigen engagement induces formation of 
the signalosome, where crosslinking of surface Ig molecules triggers phosphorylation of 
immunoreceptor tyrosine-based activation motifs in CD79A and CD79B by Lyn.53 This induces 
the recruitment of Syk through tandem SH2 domains and Src-family kinase-dependent 
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phosphorylation or autophosphorylation. Lyn-mediated phosphorylation of CD19 and activation 
of Syk leads to the recruitment of B-cell linker protein (BLNK), Bruton tyrosine kinase (BTK), 
phospholipase Cγ2 (PLC-γ2), phosphoinositide 3-kinase (PI3K) and Akt.69 After formation of the 
signalosome, downstream signalling is initiated. PLC-γ2 generates inositol-1,4,5-triphosphate 
(Ins(1,4,5)P3) and diacylglycerol (DAG) triggering release of Ca2+ from the endoplasmic reticulum 
and activation of RAS and protein kinase C (PKC). Syk and RAS/RAF1 signalling pathways activate 
mitogen-activated protein kinase signalling pathway (MAPK), including extracellular signal-
regulated kinase 1/2 (ERK1/2), leading to the activation of NF-κB and the pro-inflammatory 
transcriptome.53 PI3K produces phosphatidylinositol 3,4,5-triphosphate required for full 
activation of BTK and AKT, and downstream activation of mechanistic target of rapamycin 
complex 1 (mTORC1). The activation of kinase cascades and downstream transcription factors 
including NFAT, MYC, JUN, ATF2 and NF-κB links BCR signalling to biological responses such as 
cell survival, proliferation, migration or apoptosis.70 
 
Figure 1-3 B-cell receptor signalling in CLL 
Following antigen crosslinking and BCR activation, the signalosome is formed, comprised of LYN, SYK, 
BLNK, BTK, PLC-γ2, PI3K and AKT. The production of BCR mediators DAG, Ins(1,4,5)P3 and Ca2+ release 
from the endoplasmic reticulum triggers activation of downstream signalling pathways. RAS/RAF, 
MAPK/ERK and mTORC1 are activated, leading to the activation of transcription factors NFAT, ATF2, JUN, 
NF-κB and Myc. Ultimately, BCR signalling results in B-cell activation/proliferation predominately in U-CLL, 
and anergy in M-CLL - indicative of constitutive ERK and NF-κB stimulation. Adapted from 58.  
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1.2.2.3 CLL inflammatory microenvironment 
CLL is a model system for inflammatory-driven progression of cancer. Although CLL cells circulate 
in peripheral blood, the lymph node harbours the proliferative CLL fraction in specialised 
structures called proliferation centres.46 A powerful gene expression analysis of matched CLL 
cells from peripheral blood, bone marrow and lymph nodes identified enhanced activation of 
BCR-associated signalling pathways and NF-B activation in CLL lymph nodes; this was 
significantly higher in U-CLL.47 Further assessment of CLL-cell proliferation by expression of c-
MYC, E2F, and immunohistochemical and flow-based staining of Ki67, demonstrated CLL cells 
follow chemokine gradients into lymph nodes, and proliferate in ‘proliferation centres’.47  
The CLL lymph node is a niche site rich in tumour-associated non-neoplastic cells and 
inflammatory cytokines, chemokines, integrins, autoantigen and growth factors. Within such 
proliferation centres, various key microenvironment-CLL interactions occur (Figure 1-4).72 Only 
a fraction of CLL cells actively proliferate at a given time, while other cells remain in a quiescent 
unstimulated or anergic state. First, surrounded by antigen presenting nurse-like cells (NLC; 
CD68+/CD163+ macrophage) or free autoantigens with available T-cell help, BCR stimulation can 
occur.53,73 Other pro-survival signalling pathways mediated by NLCs include secretion and 
release of TNF, BAFF and APRIL leading to the activation of NF-B in CLL cells, and production of 
CXCL12 which moderates CLL-cell CXCR4 surface expression and LN homing.74,75 Moreover, our 
group identified increased levels of extracellular HMGB1 in the plasma of CLL patients, which 
triggers activation of STAT3 and NF-κB in NLCs – HMGB1-mediated NLC differentiation and 
activation in turn, maintains CLL cell survival.76 T-cells mediate direct and indirect pro-survival 
contact with CLL-cells through the CD40L-CD40 axis, and production of pro-survival cytokines, 
such as IL-4 which upregulates surface IgM.77 The immune checkpoint interaction, PDL1 on CLL 
cells and PD1 strongly expressed by CLL CD4+ T-cells, favours immune evasion; targeting this 
interaction is of current therapeutic interest for the treatment of CLL.78 In addition, other 
microenvironmental interactions that support CLL-cell proliferation include the Wnt5a-ROR1 
signalling axis,79 contact with mesenchymal stromal cells via VCAM1-α4β1 integrin interaction,80 
(the action of several chemokines in CLL-cell migration to lymphoid tissues (CXCL12, CCL19, 
CCL21) and recruitment of further tumour-associated inflammatory cells (CCL3, CCL4, CCL12, 
CCL22) to the proliferation centre microenvironment.81 
The central coordinators of the inflammatory response, and end-point activation for many 
cytokines and chemokines upregulated in CLL, is NF-B and STAT3 transcription factor 
activation.20 These transcription factors provide a survival advantage for CLL cells by, in turn, 
inducing production and release of inflammatory cytokines and chemokines in a positive 
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feedback loop; a smouldering pro-tumour inflammatory microenvironment is established, 
sustaining CLL-cell survival.82 
 
Figure 1-4 The CLL lymph node microenvironment 
The LN is a rich source of cellular and molecular interactions. Pro-tumour interactions occur between CLL 
with CD4+ T-cells, natural killer cells, nurse-like macrophages (NLC; an M2-like macrophage) and bone 
marrow stromal cells (BMSC). Figure adapted from 72.  
 
1.2.3 Clinical disease staging 
The median onset of age for CLL is 71 years of age, and >75% of patients are 65 years or over at 
the time of diagnosis (www.cancer.org).83 Patients are usually asymptomatic at the time of 
diagnosis but can present with a wide range of clinical features including B-symptoms (fatigue, 
weight loss and excessive night sweats), enlarged lymph nodes, splenomegaly, increased risk of 
infection with hypogammaglobulinemia and autoimmune cytopenia.58 Diagnosis of CLL is usually 
made with a full blood cell count and flow cytometry; patients are diagnosed with CLL when they 
present with >5000 clonal B-cells per µl of blood that are positive for CD5, CD19 and CD23 by 
flow cytometry, express low levels of CD20 and lack CD10.35 Blood tests and blood smears are 
usually adequate to make a CLL diagnosis, but in some cases a bone marrow or lymph node 
biopsies are performed to assess lymphocytic infiltration in the bone marrow and rule out 
suspected lymphoma.58 
The Rai and Binet staging criteria are classical systems to categorise CLL disease (low to high risk 
is 0-III and A-C, respectively) based on clinical features such as thrombocytopenia, 
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lymphadenopathy and lymphocytosis.84,85 The Binet system is more popular in UK clinical 
practice and separates patients into 3 groups. Patients with low risk CLL are assigned Binet stage 
A if palpable enlarged lymph nodes are found at less than 3 sites and the patient does not have 
cytopenia. Patients have Binet stage B disease if palpable enlarged lymph nodes are observed 
at 3 or more sites (lymphoid organ sites – cervical, axillary and inguinal nodes, the spleen and 
liver), without cytopenia. High risk CLL is assigned Binet stage C if patients have cytopenia, 
characterised by a haemoglobin level lower than 10g/dl; these patients have a predicted median 
survival of 2 years.85 
1.2.4 Cytogenetic and molecular prognostic markers for CLL 
Following a diagnosis, a patient’s clinical course is highly variable – some patients do not require 
treatment for years, if at all, whereas other patients rapidly develop high risk disease and require 
treatment immediately. A wealth of prognostic factors aids CLL disease management – the use 
of multivariable models helps to identify patients that require therapy, or certain types of 
therapy, based on clinical, genetic and molecular prognostic features.86,87 
Clinical features associated with a poor disease outcome include Binet stage C disease, >65 years 
of age and male gender.86 Poor prognostic cytogenetic alterations assessed clinically at disease 
presentation include del(17p) and del(11q), where inactivating TP53 mutations are associated 
with del(17p).88 Other prognostic factors include patients with a complex karyotype, high levels 
of serum β2-microglobulin (>3.5mg per L) and a very high absolute lymphocyte count of 
(>50,000 cells per µl).89,90 
The association between IGHV mutational status and clinical outcome for CLL was a huge 
breakthrough in understanding the molecular basis of CLL disease pathogenesis.50,51 
Approximately 35% of patients carry U-CLL, associated with worse prognosis and aggressive 
disease (predicted median survival of 8 years). Conversely, 65% of patients carry somatic 
mutations in the IGHV gene region and possess more indolent disease, with a predicted survival 
of 24 years. Both U- and M-CLL share a similar gene expression profile but are differentiated by 
the upregulation of ZAP70 and CD38 in U-CLL.91,92 CLL B-cell ZAP70 expression is a common 
surrogate prognostic factor for IGHV mutation status, due to the cost and complexity in 
performing IGHV gene sequencing. The prognostic expression cut off point for ZAP70 is >20% of 
CLL peripheral B-cells by flow cytometry, and >30% for CD38.93 
The molecular basis underlying the association with ZAP70 CLL B-cell expression and poor 
prognosis was an area of speculation; as a T-cell specific tyrosine kinase, expression in B-cells is 
not common.94 However, ZAP70 expression in U-CLL increases BCR signalling capacity, reduces 
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surface IgM internalisation (allowing strong BCR activation) and crosslinks TLR9 signalling with 
the BCR pathway - this is independent of ZAP70 kinase activity.95,96 Therefore ZAP70 has a  
hypothesised  function as an adaptor/scaffold protein.93 
1.2.5 CLL therapy 
CLL risk stratification and signs of disease progression direct the decision to initiate therapy. The 
therapeutic landscape of CLL is changing, with new targeted agents increasing survival times for 
patients with high risk disease. As such, the presence or absence of prognostic markers 
described above help define therapy eligibility. Patients with Binet stage A/B disease and who 
are asymptomatic, do not require therapy and are assessed under ‘watch and wait’ for signs of 
disease progression.35 Indications to initiate treatment include symptomatic disease, Binet stage 
C disease, palpable lymphadenopathy, cytopenia and a lymphocyte doubling count in <1 year.35 
Then, the choice of therapy is largely dependent on the presence of del(17p) and TP53 
mutations, the IGHV mutational status (if available), and the patient’s clinical fitness and age.  
1.2.5.1 Chemotherapy/ chemoimmunotherapy 
Chemotherapeutic agents have conventionally been used for the treatment of CLL; classical 
agents include purine analogues such as fludarabine, and alkylating agents such as 
cyclophosphamide, chlorambucil and bendamustine. Three phase III clinical trials (including CLL8 
and CLL11 trials) demonstrated the clinical efficacy and prolonged progression-free survival 
from combining chlorambucil with anti-CD20 monoclonal antibodies rituximab, obinutuzumab 
or ofatumumab,97,98 and the combination of fludarabine and cyclophosphamide with rituximab 
(FCR).43 Consequently, patients with symptomatic disease, without del(17p) or TP53 mutations, 
are eligible for bendamustine with rituximab (BR) and patients with these treatment indication 
criteria and M-CLL disease, are eligible for FCR.99,100 However, chemoimmunotherapy does not 
yield a sustainable response in patients with del(17p) or TP53 mutations, so these patients are 
better suited for upfront targeted therapy.101 
1.2.5.2 Targeted agents 
Novel agents targeting specific pro-tumour factors are revolutionising CLL therapy;102 Ibrutinib 
and Idelalisib target BTK and PI3K respectively, involved in the BCR signalling pathway.88 Other 
novel targeted therapies under clinical development include higher specificity BCR inhibitors 
targeting SYK, BTK and PI3K; checkpoint inhibitors targeting PDL1-PD1 T-cell interactions; BCL2 
antagonists targeting anti-apoptotic responses; and chimeric antigen receptor (CAR) T-cells 
directing cell-mediated leukaemic killing towards CD19 antigen.103 
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Ibrutinib is a suitable therapy for patients without del(17p)/TP53 mutations that do not meet 
the fitness criteria to withstand chemoimmunotherapy. Moreover, Ibrutinib is approved in the 
US and Europe for front-line therapy for symptomatic patients with del(17p)/TP53 mutations 
(RESONATE-2 trial), as well as in patients with relapsed disease (RESONATE-1 trial), owing to 
higher response rates compared to ofatumumab alone.104,105 Other targeted agents not yet 
approved for front-line therapy, but approved for relapsed/refractory CLL include Idelalisib 
(targeting PI3K) and Venetoclax (targeting BCL2).106,107 Trials investigating combinatorial 
targeted therapies are providing higher response rates due to synergistic activity, but treatment 
related complications and toxicity is still a huge issue and accounts for a high proportion of 
treatment dropout.108,109 Although many targeted agents are still under investigation and not 
yet approved, many CLL patients can access these agents through clinical trials, upon meeting 
clinical trial criteria. 
Therapies modulating the immune system and cell transplantation are under clinical 
development. Targeting immune checkpoints restores T-cell recognition and cancer cell 
destruction, avoiding immune evasion. Inhibitors of proteins that act as co-stimulatory or co-
inhibitory signals to molecules expressed on T-cells is currently under clinical investigation in 
CLL.110 CLL cells express high levels of PD-L1 that bind to PD-1 receptor on T-cells, dampening 
cytotoxic T-cell responses and partly contributing to the CLL exhausted T-cell phenotype. 
Although PD-L1 blockade yielded positive responses with in vivo models, this has yet to be 
recapitulated in phase I/II clinical trials for patients with relapsed CLL.78 Allogeneic stem cell 
transplant is not a suitable or a desirable therapeutic option for many CLL patients, even though 
it has high curative potential. Patient age and fitness, adverse effects of immune suppression, 
donor availability, graft versus host disease and risk of infection renders this therapy 
inappropriate and ill-tolerated in many patients with CLL.111 An emerging cellular 
immunotherapy with therapeutic potential in CLL is T-cell therapy with CARs. T-cells from 
patients are modified ex vivo to express CARs directed to CD19 antigen expressed on malignant 
B-cells. CAR-T-cells reintroduced into the patient restore the cytotoxic T-cell response and 
specifically target malignant CLL cells. Although early trials demonstrated the clinical ability to 
reach complete remission for patients with relapsed/refractory CLL, the efficacy of this therapy 
has yielded lower responses compared to acute lymphoblastic leukaemia (ALL).112 Future studies 
looking at overcoming the exhausted T-cell phenotype to yield better CAR-T-cell responses could 
improve the clinical activity of this therapy.113 
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1.2.6 Current status of CLL 
CLL is still an incurable disease and relapse is common for high-risk patients. Inflammatory 
dysregulation, acquired immune deficiency (through the action of immunosuppressive IL-10 and 
PDL1 expression) and treatment-related complications leave patients susceptible to infection 
and clinical complications.114 Patients with immune deficiency and infection-related or 
treatment-related complications/inflammation, account for a high proportion of CLL death.58 As 
such, chronic-inflammatory symptoms worsen with disease progression, but there are no 
inflammatory markers for prognosis.82 Current targeted therapies lead to high overall response 
rates but complete responses are not common.115 There is a real need for combinatorial 
therapies targeting many different aspects of CLL biology, particularly immuno-restorative 
agents, to improve complete response rates; these strategies also need to avoid acquired 
immune deficiency and treatment toxicity. Improved understanding of molecular mechanisms 
contributing to disease pathogenesis will lead to identification of therapeutic targets and better 
risk stratification for patients with CLL. 
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1.3 High Mobility Group Box 1 Protein (HMGB1) 
HMGB1 has an established role in many types of solid cancer as an inflammatory mediator, 
associated with poor prognosis and increased mortality.116 Despite its established important 
role, HMGB1 is not a well-known inflammatory mediator and is overlooked in many areas of 
cancer pathogenesis, including in CLL disease pathogenesis.  
HMGB1 is a member of the HMG-super family and is an evolutionary ancient and highly 
conserved protein found in metazoans and mainly localised in the nuclei of all eukaryotic cells.117 
The protein was first discovered in 1978 as a non-histone DNA binding protein.118 Preferentially 
bound to bent or kinked DNA, HMGB1 promotes formation of nucleosomes and loading of 
regulatory complexes to DNA, facilitating recombination, DNA replication, transcription 
regulation and maintenance of genome stability. For this reason, HMGB1 deleted mice pups die 
within 24 hours of hypoglycaemia, due to impaired transcriptional control.119 It was not until 20 
years later, a secondary role for HMGB1 was discovered as an intercellular inflammatory 
mediator released by macrophages and other cell types.120 Once present in the extracellular 
milieu, HMGB1 acts on variety of cell types through cell-surface receptor engagement and has 
roles in various cellular processes – wound healing, autophagy, cell death, cell proliferation, 
inflammatory activation and disease pathogenesis.121-123  
1.3.1 HMGB1 protein structure 
The HMGB1 gene sequence is located on chromosome 13q12 and translates into a 25kDa 
protein. The proximal A-box and B-box folded helical domains bind DNA in a non-sequence 
dependent manner (Figure 1-5). Considered as a chromatin structural protein, HMGB1 binds 
with high affinity to the minor groove of kinked/bent DNA, particularly bent linker DNA between 
nucleosomes.124,125 HMGB1 contains 2 nuclear localisation signals (NLS), 1 is located in the A-box 
(NLS1; amino acids 28-44) and 1 in the B-box (NLS2; amino acids 179-185).126 These motifs are 
rich in lysine residues, 4 in NLS1 and 5 in NLS2, which undergo acetylation modification 
regulating the nuclear localisation of HMGB1, particularly in macrophages.127 Interactions with 
nuclear proteins is mediated by the acidic C-terminal tail, comprised of a string of glutamic and 
aspartic acid residues.128 Conserved cysteine residues located at positions 23, 45 and 106 are 
susceptible to redox modification; this regulates extracellular HMGB1 activity. Regulation of 
HMGB1 functional activity is strictly mediated by a combination of post-translational 
modifications including acetylation, oxidisation, phosphorylation, glycation, methylation and 
ADP ribosylation.  
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Figure 1-5 HMGB1 protein structure 
HMGB1 consists of 2 DNA binding boxes (A and B), nuclear localisation signals and a negatively charged 
C-terminal tail that facilitates histone/nucleosome binding. Figure adapted from.126 
 
 
1.3.2 Extracellular HMGB1 
HMGB1 has an established extracellular role as a DAMP.9,129 The extracellular role of HMGB1 
was first identified as a delayed inflammatory mediator secreted by macrophages, following 
TNF-α and IL-1 release.120 This was confirmed by observation of increased serum HMGB1 levels 
in mice, 12 hours after lipopolysaccharide (LPS) stimulation.130 Passively released by 
damaged/dying cells and actively by immunocompetent cells, HMGB1 acts as a powerful danger 
signal and adjuvant (Figure 1-6).126,131-133  
During necrotic cell death, HMGB1 is released as a free molecule, in a fully reduced state with 
immunogenic potential.134 Apoptosis is classically regarded as non-immunogenic  cell death to 
maintain healthy homeostasis. Early studies failed to observe free-molecule HMGB1 release 
during apoptosis compared to necrosis.134 However, a recent study demonstrated the release of 
HMGB1 bound to nucleosome DNA fragments during apoptosis, by a mitochondrial ROS-
dependent mechanism (Figure 1-6).135 In addition, the high levels of reactive oxygen species 
(ROS) produced during apoptosis results in the release of fully oxidised HMGB1, compared to 
the all-thiol state during necrosis. Active release of HMGB1 is mediated by immunocompetent 
cells such as monocytes, macrophages, dendritic cells and natural killer cells following cell 
activation.136 HMGB1 frequently shuttles between the cytoplasm and nucleus;127,137 
hyperacetylation of the 4 lysine residues in NLS1 and 5 lysine residues in NLS2 block re-entry 
into the nucleus and initiates extracellular release via a non-classical vesicle mediated secretory 
pathway that is specific to haematopoietic cells.127,138  
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Figure 1-6 HMGB1 release 
All cell types possess the ability to release HMGB1 passively: 1) Bound to nucleosome complexes during 
apoptosis; 2) Released as a free molecule during necrosis. Active release by immunocompetent cells is 
achieved via the non-classical secretory pathway. Monocytes (Mo), macrophages (Mφ), dendritic cells 
(DC), natural killer cells (NKs).  
 
 
Complex post-translational modifications regulate the extracellular function of HMGB1, 
dependent on the mode of cell death, metabolism and HMGB1 biology. As well as acetylation 
modifications regulating the release of HMGB1, the redox status of the 3 cysteine residues is 
specifically linked to HMGB1 cytokine or chemokine activity.139 The B-box domain of HMGB1 is 
vital for cytokine activity; substitution of cysteine 106 abrogates the HMGB1-TLR4 interaction, 
and the B-box domain alone can induce TNF secretion in macrophages.140 Disulphide bond 
formation between C23 and C45 residues are necessary for HMGB1 cytokine activity.141 
Therefore, reduction of C106 and a disulphide bond between C23 and C45 is critical for cytokine 
activity. To exert a chemotactic function, fully reduced HMGB1 at all 3 cysteines is required to 
mediate interactions with CXCL12. This chemotactic heterocomplex signals via CXCR4 on 
leukocytes, regulating inflammatory cell recruitment.139 Finally, fully oxidised HMGB1 lacks both 
cytokine and chemokine activity, and this inactivity enhances cell death responses to anticancer 
agents compared to reduced HMGB1.121  
Extracellular HMGB1 released by necrosis, apoptosis and active secretion harbour different 
acetylation and redox post-translational modifications that shape the course of the 
inflammatory response and microenvironment. Further, HMGB1 redox state is reversible, and a 
shift in the redox status of the inflammatory microenvironment acts as a point of feedback 
control for extracellular HMGB1 activity. For example, damage incurred by infection leading to 
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necrosis, induces release of fully reduced HMGB1.142 With chemotactic activity, fully reduced 
HMGB1 promotes leukocyte recruitment to the localised site of damage. Activation of cells of 
the innate immune system by pro-inflammatory and pathogenic factors results in the acetylation 
of HMGB1 NLS and active secretion. Dynamic changes in the microenvironment redox state in 
response to infection and cytotoxic inflammatory responses leads to the accumulation of 
acetylated or disulphide-bond HMGB1 with cytokine activity.141 Finally, fully oxidised 
extracellular HMGB1 accumulates due to ROS-dependent cytotoxic responses to eliminate 
pathogens, and/or induction of apoptosis;141 oxidised and inactive HMGB1 regulates and limits 
further cytokine/chemokine HMGB1 activity.142 
1.3.3 HMGB1 receptors 
Identified receptors for HMGB1 include several pattern-recognition receptors, such as RAGE and 
TLR2, 4 and 9, TIM3 and CXCR4.123,143 HMGB1 biology is complex; receptor usage is cell and 
tissue-type specific, and largely dependent on the HMGB1 redox status. Moreover, ligand 
synergism adds another level of complexity.144,145  
HMGB1 primarily signals via TLRs in myeloid cells. The HMGB1-TLR signalling axis is involved in 
the differentiation and maturation of dendritic cells, monocytes and macrophages.146 TLRs are 
a structurally conserved set of proteins that recognise PAMPs and endogenous stress signals, 
including HMGB1. TLR2 and 4 are located on the surface of innate immune cells, while TLR9 is 
located in endosomal and lysosomal compartments to sense internalised CpG DNA. Following 
receptor activation with disulphide-cytokine HMGB1, TRIF and/or MyD88 are recruited to the 
Toll/IL-IR (TIR) intracellular domain, initiating a signalling cascade. Activation of IRAK1,2,4, 
TRAF6, IKKα or IKKβ leads to NF-κB, IRF3 and IRF7 transcription factor activation and 
upregulation of the interferon (IFN) response and pro-inflammatory cytokines. This drives DC 
maturation and the activation of macrophages. RAGE predominates HMGB1-mediated somatic 
cell activation and is expressed by cells of myeloid and lymphoid lineage, endothelial cells and 
strongly expressed by lung epithelial cells.146 As an endogenous stress signal receptor, RAGE 
recognises a variety of DAMP ligands, but the exact RAGE signalling pathway is not fully 
deciphered. HMGB1-RAGE mediated cell activation is dependent on cell type and ligand 
synergism, but frequently results in the activation of MAPK, RAS pathways and NF-κB.147 As such, 
NF-κB binding-motifs are located in the promoter region of RAGE gene sequence, establishing a 
positive inflammatory feedback loop.  
HMGB1 can function synergistically with other cytokines, enhancing the immunogenicity of 
many ligands.148 The combination of functionally distinct HMGB1 isoforms and ligand synergism 
means HMGB1 targets various arms of immunological responses, and can be considered as a 
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central cytokine for myeloid and lymphoid cells.131 For example, fully reduced-chemotactic 
HMGB1 binds to CXCL12 dimers, facilitating inflammatory cell recruitment by acting through 
CXCR4.122 Bound to LPS, HMGB1 enhances TLR4 activation, encouraging anti-microbial 
responses.131 Moreover, as a DNA binding protein, HMGB1 bound to extracellular CpG DNA and 
circulating immune complexes are responsible for the activation of TLR9 and BCR in B-cells, 
respectively.149 Therefore, HMGB1 can amplify inflammation and the pathophysiology of ligands 
in inflammatory/immunogenic disease. 
Finally, to successfully fulfil its role as a DAMP, HMGB1 must not initiate signalling cascades 
under homeostatic conditions. Ubiquitous HMGB1 shuttles between the nuclei and cytoplasm 
of every cell, regulated by methylation of lysine at position 42.127 Acetylation of HMGB1 
(mediated by the JAK/STAT1 pathway) is required to block nuclear re-entry, and stimulate active 
release in DCs, monocytes and macrophages.147 To prevent stimulation of stress responses by 
inside out signalling, HMGB1 is actively released in secretory lysosomes via the non-classical 
pathway.138 Moreover, receptors (TLR2/4/9, RAGE, CXCR4, TIM3) are either located on the cell 
surface, or compartmentalised in endosomes.147 This ensures extracellular HMGB1, released 
through cell death and stress-induced secretion has access to HMGB1 receptors. 
1.3.4 Dual roles of HMGB1 in cancer 
As outlined earlier, many inflammatory inducers and mediators demonstrate both pro- and anti-
tumour functions, including HMGB1 (Figure 1-7). In this respect, HMGB1 is considered a double-
edged sword that contributes to smouldering chronic tumour-associated inflammation, and 
immunogenic malignant-cell death. As an alert signal for inflammatory sensors, HMGB1 initiates 
immune responses by acting primarily on several cells including antigen-presenting cells, 
lymphoid cells, endothelial and epithelial cells.  
On the one hand, HMGB1 has anti-tumour activity by recruiting and activating dendritic cells -
professional antigen presenting cells that augment malignant cell death via TH1 and CD8+ CTL 
responses. Moreover, HMGB1 functions as a tumour suppressor in breast cancer by interacting 
with retinoblastoma (RB), repressing transcription and inducing apoptosis. 150. HMGB1 plays a 
demonstrated role in immunogenic cell death following anticancer therapy.151 Therapy-
mediated destruction of tumour cells releases HMGB1 and tumour-antigens, which stimulate 
anti-tumour immune activity through the uptake and action of antigen presenting cells. As such, 
increased serum levels of HMGB1 have been reported in vitro following 4 and 24 hours 
chemotherapeutic treatment of glioma, melanoma and lung cancer cells, particularly with 
alkylating agents.152-154  
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In pro-tumour inflammation, HMGB1 can activate the surrounding stroma and endothelial cells 
through cell-surface receptor engagement, facilitating to the extravasation and increased 
infiltration of inflammatory cells.155  As a potent activator of monocytes, disulphide-cytokine 
HMGB1 stimulates the differentiation of M2-macrophages and tumour-associated macrophage 
subsets (TAMs), including NLCs in CLL.76 The action of M2 macrophage subsets further promote 
a TH2 and TH17 non-cytotoxic response, contributing to smouldering wound-healing 
inflammation. HMGB1 can also inhibit anti-tumour immunity by inducing the differentiation of 
myeloid derived suppressor cells – these cells block CD8+ CTL responses and promote the 
accumulation of TREGS.156  
Finally, HMGB1 can signal in a paracrine and autocrine fashion, establishing a positive feedback 
loop.116 Passively released by stressed/damaged or dying tumour cells, the consequent 
activation of immune-cell subsets initiates active HMGB1 secretion. Within the same tumour, 
the 3 functional isoforms of HMGB1 may coexist, fully reduced (chemokine), disulphide or 
acetylated HMGB1 (cytokine), and fully oxidised (inactive), resulting in the infiltration of further 
inflammatory cells and broad-scale inflammatory activation. Thus, HMGB1 likely contributes to 
both pro- and anti-tumour responses within the same malignant spatial vicinity. However, the 
overall molecular and cellular components of the tumour microenvironment will largely decide 
the polarisation of the HMGB1 response; where HMGB1 will have an additive effect on chronic 
smouldering or anti-tumour inflammation.  
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Figure 1-7 Anti- and pro-tumour roles of HMGB1 
HMGB1 can increase immunogenic cell death by activating dendritic cells and Th1-mediated killing. 
HMGB1 also increases cellular extravasation into the tumour microenvironment and support tumour 
promotion by activating a TH2 and M2 macrophage response. Finally, HMGB1 can signal in an autocrine 
fashion leading to an inflammatory positive feedback loop.  
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1.3.5 HMGB1 and disease 
Extracellular HMGB1 is implicated in a growing body of malignant and non-malignant diseases 
(Table 3). In most cases, higher plasma HMGB1 levels are associated with poor disease 
outcome.128 An increased understanding of the role of HMGB1 in disease pathogenesis is 
demonstrating the current clinical relevance of this signalling axis.  
Table 3 Increased plasma HMGB1 levels in various diseases 76,120,157-162 
Diseases HMGB1 concentration 
(median) 
Reference 
Normal 0-10 ng/ml 
 
Sepsis Non-survival 84 ng/ml 
Survival 25 ng/ml 
Wang 1999 
Mechanical trauma 526 ng/ml 2-6 hours post 
injury 
Peltz 2009 
Systemic Lupus 
Erythematosus 
27 ng/ml 
0 ng/ml 
Ma 2012/ Li 2010 
Ovarian cancer Patient 78 ng/ml 
Healthy Control 26 ng/ml 
Li 2014 
Lung cancer Patient 76 ng/ml 
Healthy Control 7.7 ng/ml 
Large tumour>small tumour 
Shang 2009 
Hepatocellar carcinoma Patient 84 ng/ml 
Healthy Control 7.0 ng/ml 
Cheng 2008 
CLL Untreated 59 ng/ml 
Relapsed 168 ng/ml 
Remission 38 ng/ml 
Healthy Control 10 ng/ml 
Jia 2014 
 
i. Non-malignant disease: 
Owing to the immunomodulatory functions of HMGB1, it is involved in autoimmune and acute 
inflammatory disease pathogenesis. Elevated HMGB1 serum levels are reported in patients with 
systemic lupus erythematosus (SLE) and rheumatoid arthritis, associated with increased 
immunogenicity of nucleosome complexes in SLE and release of TNF-α in rheumatoid 
arthritis.145,163 Acting as a DAMP, higher levels of serum HMGB1 are implicated and associated 
with worse prognosis in severe sepsis,120 and increased expression has been demonstrated 
following burn trauma and haemorrhagic shock.164 
ii. Cancer: 
Each of the 10 hallmarks of cancer are associated with alterations in HMGB1 function, 
expression and localisation.116,151 For example, extracellular HMGB1 is involved in proliferative 
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signalling, tumour-associated inflammation and immune evasion, explained earlier. HMGB1 is a 
key regulator of autophagy, and prevents induction of apoptosis – therefore resisting malignant 
cell death. Moreover, nuclear HMGB1 is involved in the maintenance of chromatin stability, 
contributing to replicative immortality.119,165 A nuclear interaction between HMGB1 and Rb is 
required to exert the tumour-suppressing transcriptional repressor activity of Rb in breast 
cancer.150 Finally, the HMGB1-RAGE signalling axis in endothelial cells results in the upregulation 
of integrins and VEGF, contributing to angiogenesis.166,167 As such, overexpression and increased 
serum levels of HMGB1 is associated with worse survival for a variety of cancers – colon, ovarian, 
prostate, breast, cervical, gastric, lung and liver.116 Although the clinical relevance of HMGB1 
serum levels have been determined, the functional mechanism associated with poor prognosis 
has not been fully studied.  
iii. CLL 
Our group have recently reported for the first time that HMGB1 is present at a higher 
concentration in the plasma of CLL patients and is associated with poor clinical outcome (Table 
3).76 We previously found that extracellular HMGB1, from passive HMGB1 release (indicative of 
high levels of extracellular DNA), induces differentiation of NLCs via RAGE and TLR9 receptors, 
which in turn promote proliferation and survival of CLL B-cells.76 Whether extracellular HMGB1 
could directly stimulate CLL B-cells and which receptor(s) binds and elicits the activation of 
signalling pathways are currently unknown. 
1.3.6 Anti-HMGB1 therapeutic agents 
Anti-HMGB1 agents have been promising at ameliorating the inflammatory-modulating effects 
of HMGB1 in experimental models of sepsis, arthritis, and murine models of cancer (glioma and 
lung). 130,163,168 Current antagonistic therapeutic agents include anti-HMGB1 antibodies, HMGB1 
recombinant A-box, soluble RAGE decoy receptor and ethyl pyruvate (EP).126 Anti-HMGB1 
antibodies neutralise extracellular HMGB1 to ameliorate its cytokine and chemokine ability 
without affecting the nuclear function of the protein. Treatment with anti-HMGB1 antibodies 
improved survival in mouse models of haemorrhagic shock and can suppress inflammation in 
vitro from studies on autoimmune conditions.130,169,170 Recombinant HMGB1 A-box (1 DNA-
binding domain) competes with HMGB1 for binding sites on HMGB1 receptors, and preclinical 
studies have demonstrated anti-inflammatory potential.130,170 EP is a potent inhibitor of HMGB1 
active release, by preventing HMGB1 phosphorylation through calcium chelation171 and 
preventing HMGB1 acetylation.172 It exerts successful anti-tumour effects in experimental 
mouse models of lung and gastric cancer.173,174 Moreover, EP was studied in a phase II clinical 
trial for the anti-inflammatory effect of EP for high-risk patients undergoing cardiac surgery. 
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Although not effective in this disease setting, the drug was safe and non-toxic in humans.175 
Overall, it’s important to consider that completely blocking HMGB1 activity using these anti-
HMGB1 agents may also target beneficial responses, particularly following anti-cancer therapy.  
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1.4 Receptor for Advanced Glycation End Products (RAGE or AGER) 
Among all HMGB1 receptors, RAGE is the only receptor demonstrating a link with HMGB1 in 
cancer.176 
RAGE is a multi-ligand transmembrane protein of the immunoglobulin superfamily expressed on 
the cell surface of all leukocytes, endothelial and epithelial cells.177,178  It was the first HMGB1 
receptor identified in neurites, and later confirmed in other cell types.179-181 To fulfil the role as 
a PRR, a wide range of endogenous stress signals, including HMGB1, S100 proteins and AGEs, 
are detected by RAGE. Due to expression on all leukocytes, RAGE links innate and adaptive 
immune responses. Perpetuation of RAGE signalling establishes inflammatory loops and is 
implicated in several chronic inflammatory disorders.182-185 
1.4.1 RAGE protein structure 
RAGE gene sequence is located on chromosome 6 within the MHC class III region, composed of 
11 exons. At the protein level, RAGE is a 404 amino acid type I transmembrane protein and is 
composed of an extracellular domain, a single transmembrane helix and a short intracellular 
cytoplasmic tail (Figure 1-8).186 The extracellular domain is composed of 3 Ig-like molecules, 1 V-
type and 2 C-type as structural subunits. The V- and C1- domains both carry a positive surface 
charge and primarily mediate ligand interactions, while the C2 domain carries a negative 
charge;187 HMGB1 interacts with the V-type subunit. RAGE ligands are structurally diverse, but 
share a common negative surface charge. A strong electrostatic ligand-RAGE interaction initiates 
receptor activation and sustained ligand-RAGE signalling.187 The 42 amino acid RAGE cytoplasmic 
tail is unstructured and lacks enzymatic activity or known signalling motifs. Despite this, the 
cytoplasmic tail is still essential for cell signalling capability.188  
1.4.1.1 Ligand binding 
Ligand binding is regulated by post-translational modifications and receptor complex pre-
assembly. RAGE undergoes N-glycosylation at Asn25 and Asn81, regulating ligand binding and 
subsequent signalling.189 Unlike many type I transmembrane proteins, RAGE pre-assembles in 
the plasma membrane of at least 4 RAGE molecules prior to ligand engagement.190 This process 
is favoured by a higher surface concentration of RAGE, and ligand engagement induces 
cytoplasmic domain conformational changes, initiating various signalling cascades.  
1.4.1.2 Splice variants 
RAGE undergoes extensive alternative splicing, producing 20 different RAGE isoforms. 12 are 
fully translated to protein level characterized by N- or C-terminus truncations (hRAGEsec, 
sRAGE1, sRAGE2, sRAGE3, N-truncated and secretory, Δ8-RAGE, RAGEΔ, NtRAGEΔ, sRAGEΔ, 
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RAGE_v4 and RAGE_v13), while the other splice variants are targeted to the nonsense-mediated 
mRNA degradation pathway.191,192 Signalling competent full-length membrane bound RAGE (FL-
RAGE) is the main isoform expressed.186 Other splice variants of RAGE are not signalling-
competent, but one isoform in particular abrogates membrane-RAGE signalling. Endogenous 
secreted RAGE (esRAGE; sRAGE1) is the predominant splice variant with notable expression in 
humans, and lacks transmembrane and cytoplasmic domains.193 All other splice variants are 
expressed at very low protein levels.191  
1.4.2 RAGE signalling pathway 
Defining RAGE signalling is complex. The receptor engages numerous ligands, with 3 
extracellular subunits capable of ligand binding, and is expressed in many cell types with 
different intracellular pathways. Moreover, HMGB1-ligand synergism offers RAGE-independent 
signalling pathways for cell activation.  
In response to HMGB1 engagement via the RAGE V-domain, conformational changes in the pre-
assembled RAGE multimer complex induce conformational changes in the cytoplasmic domain, 
or induces receptor-ligand internalisation.145,194 RAGE lacks established intracellular signalling 
motifs or enzyme activity, but is hypothesised to act as an adaptor protein.195 Conformational 
changes in the cytoplasmic domain facilitates activation of downstream signalling (i.e. MAPK 
and PI3K pathways), but the precise intracellular binding partners or signalling mediators linking 
RAGE to well-known signalling pathways are unknown. The main role of receptor internalisation 
is to dampen HMGB1-mediated signalling activation by reducing ligand-activated RAGE on the 
cell surface, but receptor endocytosis presents another pathway linking extracellular ligands to 
intracellular receptors – i.e. HMGB1 with endosomal TLR9.128  
Evidence for the activation of signalling cascades in a variety of cell types include the MAPK 
pathway (via ERK1/2, p38 activation), PI3K and AKT, the JAK-STAT pathway, and activation of 
MyD88 via TLR9 (HMGB1 binds to TLR2 and TLR4 directly).145,196,197 Activation of RAGE in 
endothelial cells leads to the activation of PI3K and MAPK signalling.186 Downstream activation 
of NF-κB induces upregulation of the inflammatory transcriptome, including expression of 
leukocyte adhesion molecular VCAM-1 and ICAM-1.198 RAGE signalling recruits mDia1 to the 
cytoplasmic domain and the activation of Src, Rac and the PI3K pathway in smooth muscle cells, 
while the full signalling pathway in monocytes, dendritic cells and lymphocytes is only partially 
resolved.186 RAGE activation is reported to activate MAPK signalling via ERK1/2 in immune cells, 
resulting in the activation of NF-κB. Pro-inflammatory RAGE signalling induces production and 
release of TNF-α, IL-1β, CCL3, CCL5 and CXCL12 from macrophages,199 and TNF-α, IL-6 and CXCR4 
from dendritic cells;200 although the exact cytokine/chemokine profile is dependent on the 
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overall inflammatory microenvironment polarisation. In B-cells, RAGE augments the 
proliferation of AM14 B-cells response by delivery of CpG-ODN ligand to intracellular TLR9 
(ligand-synergism).145,149 Well established transcription factor activation downstream of RAGE 
signalling include NF-κB and SP-1, highlighting an important role in inflammation.178 These 
pathways are key mediators of the stress response, cell activation, migration and proliferation.  
1.4.2.1 Regulation of RAGE signalling 
Regulation of RAGE signalling is a vital step in preventing chronic inflammatory dysregulation, 
owing to the role of RAGE as a linker between innate and adaptive inflammatory responses. The 
first level of regulation is implicated at the transcription level. The promoter region of RAGE 
contains 2 binding sites for NF-κB inflammatory transcription factor, propagating pro-
inflammatory signalling.201,202 Although the regulation and functionality of RAGE alternative 
splicing is less well understood, FL-RAGE and es-RAGE are the only RAGE isoforms with notable 
protein expression. Extracellular sRAGE functions as a decoy receptor, dampening RAGE 
signalling, but also originates from membrane receptor proteolytic cleavage.  
Post-translational levels of receptor regulation include i. glycosylation (at Asn25 and Asn81);189 
ii. surface RAGE pre-assembly; iii. ligand-induced receptor internalisation and exocytosis 
(receptor shuttling); iv. RAGE shedding. RAGE pre-assembles into multimers, independent of 
ligand availability/ligand levels.190 This regulates the amount of signalling-competent RAGE at 
the cell surface, regardless of FL-RAGE surface concentration. However, multimer formation is 
disrupted by the inclusion of spliced RAGE isoforms, producing non-functional receptor hetero-
multimers that are signalling incompetent.186 Upon receptor activation, the strength of RAGE 
signalling is controlled by RAGE endocytosis and exocytosis. RAGE receptor can be internalised 
via lipid rafts into vesicular structures, cutting off downstream signalling - a negative feedback 
mechanism utilised by various cell-surface receptors.203 This is observed in vitro following S100B 
stimulation.204 Conversely, receptor exocytosis following ligand-induced activation increases 
RAGE cell-surface receptor availability. Fusion of RAGE-containing vesicles with the plasma 
membrane, observed a few minutes after pro-inflammatory stimulation, perpetuates rapid 
inflammatory responses.205 Finally, ligand-induced receptor shedding also switches off RAGE-
signalling, and sequesters circulating extracellular RAGE ligands. ADAM10-mediated RAGE 
ectodomain proteolysis is regulated by Ca2+ signalling, protein kinase C (PKC), G-protein coupled 
receptors following receptor activation.206,207 
1.4.3 Soluble RAGE 
sRAGE functions as an antagonistic decoy receptor of plasma HMGB1, limiting chronic 
inflammation. The pool of plasma sRAGE originates from 2 main sources - alternative splicing to 
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produce esRAGE, or surface FL-RAGE ectodomain proteolytic cleavage. Both extracellular sRAGE 
isoforms are structurally similar, formed of the 3 extracellular domains (V, C1 and C2) with full 
RAGE ligand-binding capacity (Figure 1-8).208 In a healthy setting, HMGB1 and sRAGE plasma 
levels are inversely associated; healthy individuals with high plasma sRAGE levels exhibit low 
extracellular HMGB1 levels in a given population.209 Although this inverse relationship ensures 
inflammatory responses are regulated in healthy individuals, the concentration of plasma sRAGE 
does not exceed extracellular HMGB1 concentrations (mean± standard deviation for 640 healthy 
individuals: plasma HMGB1 1.65± 0.04ng/ml; sRAGE 0.45± 0.01ng/ml).209 In chronic disease, the 
HMGB1-sRAGE inverse relationship is frequently reversed,128 and the underlying mechanisms 
responsible for this observation is currently an active area of inflammatory research.  
1.4.3.1 Alternatively spliced endogenous secreted RAGE 
Alternatively spliced esRAGE (or sRAGE variant 1) is characterised by inclusion of the 5’ end of 
intron 9 and exclusion of exons 10 and 11 (the transmembrane domain encoding sequence). 
This results in a sequence frame shift and a premature UGA stop codon in intron 9.210 Expression 
of the esRAGE splice variant produces a 347-amino acid protein, with a distinct 16-amino acid 
C-terminal tail (encoded by part of intron 9) and lacks the transmembrane domain.211 esRAGE 
packaged into endosomes fuses with the plasma membrane where the receptor is secreted into 
the extracellular environment.191 
Regulation of RAGE splicing is still not fully understood. In vitro studies and in vivo mouse models 
revealed tissue-specific RAGE splice variant expression patterns, although the gene expression 
levels are not reflected at the protein level.212 Therefore, RAGE alternative splicing must be 
regulated by upstream unknown extracellular triggers and signalling pathways that are tissue-
specific.  
1.4.3.2 RAGE ectodomain shedding 
Alternatively spliced esRAGE constitutes ~20% of extracellular sRAGE.213 Proteolytic cleavage of 
membrane-bound FL-RAGE, releasing the extracellular domain, makes up the remainder of the 
pool of sRAGE. The stability of FL-RAGE at the cell surface is controlled by metalloproteinase, 
ADAM10.214,215 Cleavage of the extracellular domain (V, C1 and C2 subunits) catalysed by 
ADAM10, occurs following ligand-induced cell activation. This firstly disconnects surface-RAGE 
with the cytoplasmic RAGE domain and downstream signalling pathways; secondly, the free 
sRAGE fragment sequesters extracellular RAGE ligands, dampening inflammatory positive 
feedback loops.214,215  
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ADAM10 
ADAM10 (a disintegrin and metalloproteinase) is a member of the zinc metalloprotease family 
located at the plasma membrane and was originally identified as an α-secretase for myelin basic 
protein.216 Formed of multiple domains, ADAM10 undergoes various steps of post-translational 
processing and cleavage to produce a fully functional α-secretase.217 The catalytic domain of 
ADAM10 contains a zinc-binding and various glycosylation motifs, and is responsible for cleaving 
an estimated 40 proteins.218 The majority of ADAM10 substrates are type I transmembrane 
proteins (such as RAGE), some are type II transmembrane proteins (i.e. Fas ligand) and few 
ligands are glycosylphosphatidylinositol anchored proteins. ADAM10 cleaves RAGE ~12 amino 
acids upstream of the transmembrane domain. RAGE cleavage is inducible in a dose-dependent 
manner following 1-hour treatment in vitro with RAGE ligand, S100B, in comparison to positive 
controls (ADAM10 activators) ionomycin and PMA.219 Mechanisms to regulate ADAM10 activity 
and substrate cleavage include ADAM10 maturation by proteolytic processing, GPCR-mediated 
signalling, signalling via Ca2+, PKC, and PI3K in response to ligand binding.206,207,220 Moreover, 
increased levels of receptor shedding and sRAGE may also be attributed to increased expression 
or activity of ADAM10. I.e. ADAM10 is one of the α-secretases responsible for NOTCH1 cleavage 
in CLL B-cells.221 Therefore patients with NOTCH1 mutations may produce higher levels sRAGE 
as a by-product, but this has not yet been studied. 
 
Figure 1-8 RAGE alternative splicing and receptor shedding 
Full-length membrane bound RAGE is the predominant isoform. Soluble RAGE can act as a decoy receptor, 
sequestering ligands in the extracellular space and dampening membrane-RAGE activation. Origins of 
soluble RAGE include alternative splicing (endogenous secreted RAGE – esRAGE) and cell-surface 
proteolytic cleavage (cleaved – cRAGE).  
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1.4.4 RAGE and disease 
Both FL-RAGE and sRAGE are implicated in the pathogenesis of a variety of chronic inflammatory 
conditions including acute inflammation, infectious and malignant diseases.  
i. Autoimmunity: 
Acting as a receptor for HMGB1, FL-RAGE is involved in non-malignant inflammatory conditions 
such as systemic lupus erythematosus (SLE), diabetes, Alzheimer’s, multiple sclerosis and 
hepatic disorders.182,185,222 HMGB1-RAGE signalling in endothelial cells mediates SLE vasculitis, 
while RAGE and mDia1 intracellular interactions are involved in the pathogenesis of 
macrovascular complications in diabetic hyperglycaemia.223 
On the other hand, extracellular sRAGE has clinical significance as an antagonist and regulator 
of RAGE signalling. Decreased sRAGE plasma levels were observed in SLE, rheumatoid arthritis 
and Kawasaki disease, failing to act as a decoy receptor and regulate inflammatory activation.128 
Whereas elevated extracellular sRAGE levels were reported following severe trauma, acute renal 
failure and systemic inflammatory response syndrome, due to release of RAGE DAMP ligands 
during stress.128 
ii. Cancer:  
Activation and elevated expression of FL-RAGE has been demonstrated in a variety of 
cancers.123,224 In vitro and in vivo studies support a direct role for RAGE in the migration and 
invasion of tumour cells, owing to RAGE-mediated activation of tumour-associated cells and 
demonstrated roles in chemotaxis.225 RAGE expression in macrophages is necessary for 
angiogenesis in glioma,226 while RAGE blockade in vivo decreased tumour growth and metastasis 
in mice implanted with Lewis lung carcinoma cells.168 Moreover, the HMGB1-RAGE axis plays a 
key role in regulating mitochondrial bioenergetics in pancreatic cancer cells.227  
Serum levels of sRAGE are easily attainable and powerful circulating disease biomarkers.228,229 A 
meta-analysis assessing circulating extracellular sRAGE levels with cancer risks (breast, lung, 
pancreas, liver, colorectal), demonstrated the protective role of increased serum sRAGE levels 
in cancer development.230,231 However, in other studies decreased serum sRAGE levels were 
detected in breast and pancreas cancer compared to healthy controls - but this response is 
parallel to disease progression.232,233. Overexpression of spliced esRAGE in C6 glioma cells 
suppressed JNK signalling, inhibiting tumorigenesis; tumour burden was significantly decreased 
in immunodeficient severe combined immunodeficient (SCID) mice transfected with the 
esRAGE-overexpressed C6 glioma cells compared to mock transfected mice.234 Whether this 
response was specifically due to extracellular esRAGE decoy receptor ability, or disruption of 
surface RAGE pre-assembly was not fully investigated.  
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iii. CLL: 
Despite our current understanding of RAGE/sRAGE in solid cancer, plasma levels of sRAGE and 
RAGE expression in CLL B-cells, function, and association with CLL disease progression is not 
known. So far, previous work in our laboratory demonstrated a functional role for RAGE in the 
differentiation of NLCs, important for the maintenance and proliferation of CLL cells.76  
1.4.4.1 Anti-RAGE therapeutic agents 
RAGE signalling can be blocked by various antagonists to inhibit RAGE-mediated disease 
pathogenesis. Using a ligand-based drug design approach, small molecule inhibitors of RAGE 
directly bind to the RAGE V-domain, blocking RAGE-Aβ interactions and Alzheimer’s disease 
progression.235-237 Azeliragon (TTP488) is currently under investigation in a multicentre phase III 
clinical trial to evaluate the safety and efficacy of Azeliragon in patients with mild Alzheimer’s 
disease (STEADFAST study; NCT02080364). Other therapeutic options include blocking 
membrane-RAGE with a monoclonal antibody. This ameliorated sepsis and tumour progression 
in animal models.168,238 Finally, induction of FL-RAGE proteolytic cleavage could provide an 
intrinsic alternative mechanism to ameliorate RAGE-inflammatory responses.239,240 RAGE 
shedding can be induced In vitro with the use of calcium ionophores, ionomycin and phorbol 12-
myristate 13-acetate (PMA), to raise intracellular Ca2+ levels and activate PKC-dependent RAGE 
cleavage. However, these agents are not suitable for in vivo use. Physiological strategies include 
reducing cholesterol content using statins to increase RAGE shedding.241 It is important to note 
though, that statins interfere with rituximab efficacy for the treatment of CLL by inducing 
conformational changes in CD20.242 
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1.5 Toll-like Receptor 9 (TLR9) 
TLR9 is an intracellular receptor for HMGB1 located in endosomal membranes.243 Classified as a 
PRR, TLR9 has important roles in host defence, innate and adaptive immunity.244 The classical 
bacterial ligand for TLR9, unmethylated CpG (cytosine followed by guanine nucleotide), was 
identified in TLR9 deficient mice.245 Compared to bacterial genomes, CpG occurrence is rare and 
highly methylated in mammalian genomes. 
1.5.1 TLR9 protein structure 
All identified 11 TLRs are type 1 membrane glycoproteins, with up to 25 leucine rich repeat 
motifs in the extracellular domain. These motifs form a β-strand and an α-helix giving an overall 
horseshoe structure.246 Even though the leucine-rich repeat extracellular domain is highly 
conserved, each TLR recognises different PAMPs.5 The gene sequence for TLR9 is located on 
chromosome 3 (3p21.2). The transcribed TLR9 protein is located in endosomal compartments, 
suited for recognition of nucleic acids following scavenging phagocytosis.247 Unmethylated 
single strand CpG-DNA binds to TLR9 with high affinity compared to methylated or double-
strand CpG-DNA.248 Although the molecular basis of CpG-DNA-TLR9 agonistic binding has not 
been elucidated, recent structural studies demonstrate a symmetric CpG-DNA-TLR9 dimer 
complex is formed.249 Three types of CpG ligand have been identified based on the different 
elicited responses in plasmacytoid dendritic cells – CpG-A, CpG-B (mainly responsible for B-cell 
activation) and CpG-C.250 The intracellular domain of TLR9 shares homology with interleukin 
receptor (Toll/IL-1 receptor domains (TIR)). Composed of three conserved boxes, boxes 1 and 2 
are structurally positioned to reveal their side chains to mediate interactions with adaptor 
molecules.251 Important intracellular mediators of TLR9 activation include myeloid 
differentiation primary response protein (MyD88), IL-1R associated kinases (IRAKs) and tumour-
necrosis-factor-receptor associated factor 6 (TRAF6).252 
1.5.2 TLR9 signalling pathway 
TLR signalling pathways are well defined and facilitate rapid host immune responses to harmful 
pathogens. Following CpG ligand engagement, TLR9 undergoes dimerisation inducing 
conformational changes in the cytoplasmic TIR domains (Figure 1-9).246 This poises the receptor 
for adaptor interactions,  particularly with MyD88.246 Originally identified following IL-6 
induction in macrophages, MyD88 also contains TIR and death domains that are essential for 
coupling receptor-downstream signalling mediators.253 The C-terminus of MyD88 homodimers 
are recruited to the cytoplasmic TIR domain of TLR9, and associate with serine/threonine kinase, 
IRAK4, via death domain-death domain interactions. Once this triad is formed a kinase cascade 
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is initiated.253 Activation of IRAK4 phosphorylates IRAK1; IRAK1 auto-phosphorylates, recruiting 
TRAF6 to the receptor complex; TRAF6 mediates activation of the inhibitor of NF-κB (IκB) kinase 
complex (IKK). Inactive NF-κB subunits (p65, Rel-B, Rel-C, p50 and p52) are sequestered in the 
cytoplasm by IκB, blocking transcription factor activation.244 Activation of IKK complex 
phosphorylates IκB, targeting the inhibitors for polyubiquitination and proteasomal-
degradation. Free NF-κB subunits translocate to the nucleus, inducing expression of pro-
inflammatory cytokines such as type-I IFNs.254 
1.5.2.1 Regulation of TLR9 signalling 
Regulation of TLR signalling is essential to avoid over production of excess inflammatory 
cytokines. TLR9 and CpG-ODN responses are negatively regulated by IRAK-M, SOCS1 and 
Triad3A. IRAK-M expression is induced in macrophages and monocytes following TLR activation. 
IRAK-M lacks enzyme activity and prevents formation of IRAK-1-TRAF6 complex and 
downstream signalling.255 The precise mechanism by which SOCS1 downregulates TLR signalling 
is not clear, but CpG-ODN stimulation in macrophages induced expression of SOCS1.256 Finally, 
polyubiquitination of TLR9 by E3 ubiquitin ligase, Triad3A, targets TLR9 for proteolytic 
degradation.257 The combination of pro-inflammatory phosphorylation cascades and negative 
regulators limit excess innate inflammatory responses and harm to the host.  
 
 
Figure 1-9 TLR9 signalling 
CpG-TLR9 engagement in the endosome initiates interactions with MyD88, IRAK4, and IRAK1. Activation 
of a kinase cascade results in the activation of TRAF6, IKK and degradation of IκB. NF-κB subunits 
translocate to the nucleus following IκB release and upregulate expression of pro-inflammatory cytokines.  
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1.5.3 TLR9 and disease 
TLR9 contributes to the pathogenesis of inflammatory and immune diseases due to the intrinsic 
ability to recognise host-derived ligands that become available during disease progression (i.e 
host CpG-DNA and immune complexes). 
i. Autoimmunity: 
Firstly, TLR9 plays a big role in autoimmunity, particularly in SLE and rheumatoid arthritis. SLE 
pathogenesis is mediated by autoantibodies to self-DNA. SLE B-cells are activated by chromatin 
immune-complexes by dual engagement of the BCR, internalisation of this receptor complex 
and interaction with intracellular TLR9.144,258-260 Host CpG motifs are contained in the auto-
reactive IgG complexes. Moreover, dual engagement BCR and intracellular TLR9 is observed in 
rheumatoid arthritis.261 IG2a-chromatin complexes stimulate TLR9 and production of 
rheumatoid factor. 
ii. Cancer: 
TLR9 has opposing functions in cancer. Receptor expression is linked to tumour invasion and 
angiogenesis in squamous carcinoma, lung cancer and bladder cancer, but TLR9 agonists are 
clinically promising as anti-tumour adjuvants for melanoma, renal cell carcinoma and 
glioblastoma.262-267  
iii. CLL: 
TLR9 activation is more complex in CLL. Originally, CpG-oligonucleotides (ODNs) were viewed as 
potential therapeutic agents for the treatment of CLL.268 Consequent studies reported opposing 
responses to CpG-ODN-TLR9 engagement in CLL B-cells, based on unmutated or mutated IGHV 
gene status.269-271 U-CLL TLR9 stimulation drives cell proliferation, whereas induction of 
apoptosis occurred in M-CLL. The link between TLR9 signalling dichotic responses in CLL cells 
was identified to be dependent on the expression and activity of ZAP70.96 TLR9 is sufficient to 
fully engage BCR-signalling in ZAP70 positive CLL cells, protecting malignant cells from 
apoptosis.96 Here, ZAP70 acts as an adaptor between BCR signalling and TLR9. Following TLR9 
activation, Src is phosphorylated in both U- and M-CLL cells. Activated Src phosphorylates Syk, 
dependent on ZAP70 expression, at tyrosine-352 and tyrosine-525/526 (required for full Syk 
kinase activation). BCR signalling is propagated, resulting in the production and release of auto-
reactive IgM, and engagement of surface BCR in an autocrine manner.96,272,273 
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1.5.3.1 TLR9 immunomodulatory agents 
TLR9 agonists represent promising anti-cancer therapeutics, due to TLR9-mediated activation of 
T-cell immunity, antigen presentation, DC maturation, NK cell activation and type-I IFN 
response.264 CpG-ODNs have shown promising clinical activity for melanoma, and as an adjuvant 
therapy for some B-cell lymphomas.263,274,275 On the other hand, TLR9 antagonists have not been 
investigated in cancer, but a phase II clinical trial on the efficacy of IMO-8400 demonstrated a 
reduction in psoriasis severity.276 As there is a clear distinction in TLR9-mediated CLL B-cell 
proliferation or induction of apoptosis (dependent on IGHV mutational status and ZAP70 
expression), the use of TLR9 agonists or TLR9 antagonists could have potential as 
immunotherapeutic strategies for the treatment of CLL. 
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1.6 Crosstalk between HMGB1, RAGE and TLR9 
Studies on RAGE and TLR9 expression in solid cancers highlight their separate pro-tumorigenic 
roles.277-279 Few studies have assessed the co-linked functions of these receptors.280 In non-
malignant disease, interactions between HMGB1, TLRs and RAGE form an inflammatory triad, 
activating NF-κB following hyperglycaemia in diabetes.281 Moreover, HMGB1 is an established 
CpG-ODN binding partner.149 In autoreactive SLE B-cells, HMGB1 is an essential component of 
DNA-containing immune complexes that stimulate RAGE internalisation and TLR9 
activation.145,260 This represents a separate pathway for DNA ligands to undergo internalisation, 
aside from BCR endocytosis.  
Consistent with this, our group previously reported HMGB1-mediated activation of RAGE/TLR9 
in NLCs in CLL. HMGB1 binds to RAGE on the cell surface of NLCs, inducing receptor 
internalisation and colocalization with intracellular TLR9 (Figure 1-10).76 This results in the 
activation of STAT3 and NF-κB. HMGB1 signalling induces differentiation of NLCs, which was 
blocked with anti-HMGB1 neutralising antibodies.76 It is currently unknown whether 
HMGB1/RAGE/TLR9 signalling axis can directly promote CLL B-cell survival and contribute to 
disease progression.  
 
Figure 1-10 RAGE and TLR9 signalling in resposne to HMGB1 engagement in CLL NLCs 
Active or passive release of HMGB1 results in the accumulation of HMGB1 in blood plasma. Following 
HMGB1 engagement at the cell surface, RAGE is internalised and colocalises with TLR9 at the endosome. 
CpG-HMGB1 delivery to TLR9 results in the activation of with MyD88, IRAK4, and IRAK1. The kinase 
cascade results in the activation of TRAF6, IKK and degradation of IκB. NF-κB subunits translocate to the 
nucleus following IκB release and upregulate expression of pro-inflammatory cytokines.  
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1.7 Aims 
While the role of HMGB1 is well established in solid cancer, the involvement of HMGB1 in CLL 
disease pathogenesis has not been fully elucidated. We hypothesise that increased levels of 
extracellular HMGB1 in CLL patients, may promote CLL cell survival by activating CLL cells directly 
via RAGE and/or TLR9, as reported in autoreactive B-cells and CLL NLCs. Therefore, the main 
aims of this study are: 
1.7.1 Assess the prognostic impact of HMGB1 receptors RAGE and TLR9 and their 
effects on CLL overall survival 
We aim to determine the expression of HMGB1 receptors, RAGE and TLR9, in CLL lymph nodes, 
and if HMGB1 receptor expression could be used as a clinical prognostic marker for CLL. Using 
IHC and TMA technology we will determine CLL lymph node expression levels of these proteins 
and compare to clinical data to determine their prognostic significance in CLL.  
1.7.2 Determine the clinical relevance of the HMGB1-RAGE signalling axis 
Previous work in our laboratory identified increased levels of HMGB1 in CLL patient plasma, but 
the main receptor for HMGB1, RAGE, is expressed on various cell types and is multiligand. To 
infer a direct effect on CLL B-cells, the work in this chapter will assess RAGE and TLR9 expression 
on CLL B-cells and the survival outcome of HMGB1 signalling in primary CLL cells. Moreover, we 
will compare levels of extracellular HMGB1, S100B and soluble RAGE decoy receptor to assess 
the clinical likelihood of HMGB1 as the main RAGE ligand in CLL.  
1.7.3 Determine HMGB1-mediated cell signalling activation 
The full HMGB1 and RAGE cell signalling network in B-cells is unknown. To determine if RAGE 
and TLR9 function cooperatively in response to HMGB1 engagement, we will use 2 imaging 
systems to assess HMGB1-mediated colocalization of RAGE and TLR9. Further, we will use an 
unbiased phosphoproteomic approach to assess whole cell signalling network activation 
following treatment with RAGE agonist, HMGB1, and TLR9 agonist, CpG-ODN (B-class). 
1.7.4 Determine the origin of soluble RAGE in CLL 
Soluble RAGE has potential anti-HMGB1 antagonistic activity and is a promising clinical plasma 
marker for inflammatory disorders. To assess the role of sRAGE in CLL, the work in this chapter 
will determine the origin of sRAGE in CLL and further assess the activity of ADAM10 as the main 
RAGE sheddase. 
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2.1 Cell Lines and Cell Culture 
Cell lines were used to optimise cell-based treatments and experiments due to their ease of 
growth, uniform genotype, phenotype and immortality.282 The human B-CLL cell line, Mec1, was 
used for in vitro studies as a stable prolymphocytoid transformed CLL (CLL-Pro) cell model 
system with unlimited growth potential.283 HEK293 cell line was used as a vehicle for the 
expression of FL-RAGE and es-RAGE pcDNA3 plasmids due to the ease of transfection.284 Cells 
were cultured in RPMI-1640 growth complete media with 10% heat inactivated foetal bovine 
serum (FBS), 2.0mM L-glutamine, 100U/ml Penicillin and 100µg/ml Streptomycin at 37°C in 
a humidified 5% CO₂ incubator (Appendix I, 1.1). Cell line density was maintained between 0.5-
2x10⁶ cells/ml using a Luna-II™ Automated Cell Counter (Logos Biosystems; Appendix I, 1.2) and 
passaged every 2-3 days. Cell stimulations were either performed in complete growth media, 
serum-starved media (complete growth media with 0.5% FBS), or serum-free media (complete 
growth media without FBS). Serum-starved and serum-free media were used in cell-signalling 
experiments to better assess the physiological response to exogenous stimulating agents and 
limit prior cell-signalling activation from growth factors in FBS.285 
2.2 Patient Samples 
2.2.1 Ethical consideration 
Ethical approval for the use of peripheral blood mononuclear cells (PBMC), lymph node (LN) 
biopsies and plasma from CLL patients and healthy donors was obtained from the East London 
and the City Health Authority Local Research Ethics Committee. Biological material was obtained 
and stored with written informed consent from patients and volunteers in accordance with the 
Human Tissue Act (2004). All human tissue and cells were identified by patient vial ID and 
hospital number. Clinical information was provided courtesy of the clinical database manager 
Mrs. Janet Matthews. 
2.2.2 Patient sample selection 
Primary patient cells and LN biopsies were used in vitro as a more biologically and clinically 
relevant tool than cell line models. 64 CLL patients with a lymphocyte count of greater than 
20×10⁹/L were enrolled in this study to ensure samples included enough CLL cells for our in vitro 
studies. Selection criteria for CLL patients include cases that were either untreated or had not 
received treatment or steroids for over 6 months, to limit the interference of treatment with 
our in vitro assays. Fresh blood samples for this work were obtained from patients with consent 
via the Barts Cancer Institute Tissue Acquisition Officers in lithium-heparin vacutainer blood 
collection tubes, to avoid calcium chelation by EDTA. Cryopreserved CLL PBMCs were acquired 
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from the Barts Cancer Institute Tissue Bank upon request. All patient PBMC samples were 
collected from 2011-2017. LN biopsies were incorporated in tissue microarrays (TMAs) from 42 
reactive (RA) LN and 91 CLL patients where quality formalin-fixed paraffin-embedded (FFPE) 
tissue and clinical follow up data were available.76 CLL LN sections were sourced from pre-
treated, post-treated and relapsed biopsies that were excised at St Bartholomew’s Hospital 
between the years 1990-2011. RA LNs were taken from patients undergoing further testing for 
LN malignancy, but diagnosed with follicular hyperplasia that was non-malignant. These RA 
controls represent an activated B-cell non-malignant comparison. 15 healthy volunteers were 
enrolled for control plasma donation with informed consent. Healthy plasma samples 
were collected in March 2016 and were not age or sex-matched due to availability of donors.  
2.2.3 Isolation of plasma and PBMCs from fresh CLL blood  
Fresh plasma and PBMCs were removed from whole blood, received directly from clinic in 
lithium-heparin vacutainers, to isolate CLL cells for in vitro cell culture. First, plasma was 
separated by centrifugation of whole blood at 1500rpm for 5 minutes, followed by removal of 
the top plasma layer. Plasma aliquots were stored immediately at -80°C in cryovials. Fresh 
PBMCs were separated from whole blood by density gradient centrifugation over Lymphoprep 
(Axis-Shield; Appendix I, 2.0). Whole blood was diluted 1:1 in RPMI 1640 complete medium and 
10ml gently layered on top of 3ml Lymphoprep solution. Blood was centrifuged at 2000rpm for 
20 minutes with slow acceleration and deceleration settings. The PBMC monolayer was isolated 
using a Pasteur pipette and resuspended in RPMI complete medium followed by measurement 
of cell count and viability using a Luna-II™ automated cell counter (Logos Biosystems). Cells were 
washed with RPMI complete medium to remove remaining Lymphoprep and re-suspended 
at 5x10⁶ cells/ml. Cells were cultured at 37°C in a humidified 5% CO₂ incubator overnight for no 
longer than 15 hours before initiating in vitro experiments. CLL cells left longer in culture rapidly 
undergo apoptosis due to removal from supportive microenvironment interactions and soluble 
growth factors.47 
2.2.4 CD19+ positive selection and CLL negative selection 
The percentage of CLL B-cell purity is highly heterogeneous among CLL patient PBMC samples 
due to the presence of other myeloid and lymphoid cells in peripheral blood. For downstream 
studies on CLL B-cells alone, CLL B-cells were enriched from patient PBMCs using MACS CD19 
positive selection or B-CLL negative selection kits (Appendix I, 2.0; Miltenyi Biotech).  
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CD19+ B-cells were isolated by incubating 40x10⁶ CLL PBMCs with magnetic microbeads 
conjugated to human monoclonal anti-CD19 human antibody. After a 15-minute incubation, to 
ensure all CD19+ B-cells were bound to microbeads, the CD19+ microbead cell suspension was 
loaded onto a MACS LS column held in a magnetic MACS separator. The MACS LS column is 
composed of a matrix of ferromagnetic spheres that amplify the magnetic field, and capture 
flowing microbeads. CD19+ microbead labelled cells were retained in the column by binding to 
the magnetic matrix, while unlabelled non B-cells were eluted by washing the column with 4ml 
ice-cold 0.5% bovine serum albumin (BSA) phosphate-buffered saline (PBS) (Appendix I, 2.1). 
The wash buffer flows through the LS column by gravity, to prevent disruption of the CD19+ cell-
microbead to column interaction. After 3 washes, CD19+ cells were eluted by removing the 
MACS LS column from the magnetic field and collecting CD19+ cells in 5ml ice-cold wash buffer 
(0.5% BSA in PBS) by applying force on the MACS LS column with a plunger. CD19+ cells remain 
bound to microbeads for downstream experiments.  
CD19 cross-linking induced by anti-CD19 microbead binding may influence CLL B-cell viability 
and activation status. Negative B-CLL isolation depletes PBMCs of numerous cell types leaving 
B-cells unbound; this method was used as a non-manipulated B-cell comparison. 40x10⁶ CLL 
PBMCs were incubated with biotin-conjugated monoclonal antibodies against CD2, CD3, CD4, 
CD14, CD15, CD16, CD34, CD61, CD235a and FcеRIa before incubation with anti-biotin 
microbeads. The microbead-cell suspension was applied to a MACS LS column held in a magnetic 
field. The cell suspension passed through the MACS LS column by gravity-flow, allowing labelled 
cells to bind to the magnetic matrix while unlabelled CLL B-cells remain unbound. Unlabelled 
CLL B-cells were eluted in the first wash with 5ml ice-cold 0.5% BSA PBS wash buffer by gravity-
flow. Labelled cells were not eluted from the column. Both CD19+ selection and B-CLL cell 
negative selection recovered at least 20x10⁶ cells, half of the input cell count. After elution using 
either kit, cell count was measured and cells were washed once in RPMI 1640 complete medium 
prior to downstream experiments.  
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2.3 Immunohistochemistry 
Immunohistochemistry (IHC) is a well-established method to detect protein expression in tissue 
sections, utilised widely in disease diagnosis.286,287 The method is based on specific antigen-
antibody binding in tissue sections. However, due to the nature of tissue preservation and 
fixation, the tissue section needs to undergo various processing steps prior to antibody-antigen 
binding visualisation.288 Antigen retrieval, by enzyme or heat based methods, is necessary to 
remove protein cross links and structural modifications formed during formalin tissue fixation 
to unmask epitopes for antibody binding. Following antibody-antigen reactions, a labelled 
detection system is used to visualise the immune reaction. Most detection systems utilise 
secondary antibodies conjugated to enzymes (peroxidase, alkaline phosphatase) that catalyse 
formation of a coloured precipitate when a chromogen is applied (Figure 2-1). 
In the last decade, this method has greatly improved due to advances in tissue fixation, antigen 
retrieval and sensitive antibody detection systems. TMA technology allows simultaneous high 
throughput examination of hundreds of samples on a single microscope slide, saving reagents, 
reducing technical time and variability in results.289 
2.3.1 Tissue Microarray construction 
For this study, formalin-fixed paraffin embedded (FFPE) TMAs were prepared from LN biopsies 
from 91 CLL patients and 42 RA samples by our in-house histopathologist, Andrew Clear. 
Representative malignant areas were identified by Professor Maria Calaminici following 
haematoxylin and eosin staining and triplicate 1-mm² LN cores were taken from each LN using 
an automated arraying system (TMA Booster-Alphelys). Cores were arrayed onto a recipient 
empty paraffin block, cut to 3μm thick sections using a Leica RM2232 microtome and transferred 
onto Superfrost™ glass slides by Andrew Clear.76,290,291  
2.3.2 IHC Staining 
Slides were prepared for immunostaining by complete removal of paraffin wax using xylene and 
re-hydration in 100% alcohol (IMS) and running tap water (Appendix I, 3.0). Endogenous 
peroxidase activity was blocked by incubating slides in 2% H₂O₂ IMS for 2 rounds of 5 minutes 
to quench enzyme activity and ensure only applied exogenous horseradish peroxidase (HRP) 
produced coloured precipitate during the antibody reaction detection step (Appendix I, 3.1). 
Formalin fixation preserves tissue integrity but modifies the tertiary structure of proteins; heat 
induced epitope retrieval (HIER) reverses formalin-protein cross links and restores the original 
epitope conformation and electrostatic charges for antibody recognition.292 HIER was performed 
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for 10 minutes in antibody specific batches using a pressure cooker (400°C) with antigen 
unmasking solution (Appendix I, 3.2; Vector Laboratories). Slides were immediately immersed 
in wash buffer to prevent tissue sections drying out, and slides were prepared for 
immunostaining by creating a hydrophobic barrier around tissue sections with a hydrophobic 
pen (Appendix I, 3.3). Optimal primary antibody dilutions (monoclonal anti-RAGE or monoclonal 
anti-TLR9 antibody in Zytomed antibody diluent) were determined by titration, using a fixed 
incubation time of 40 minutes (Appendix I, 3.4; Table A). Tissue sections were stained using the 
Dako autostainer (Appendix I, 3.5; Table B). Antibody reactions were visualised using a 
peroxidase-labelled polymer amplification 3,3'-diaminobenzidine (DAB) system (Appendix I, 3.6; 
Super Sensitive Polymer-Horseradish Peroxidase (HRP) IHC Detection System; BioGenex) 
compared to traditional avidin-biotin method which produces high levels of background from 
endogenous biotin. A secondary antibody conjugated to HRP-polymer detects bound primary 
antibody. Multiple HRP enzymes conjugated to the bound polymer amplifies the signal from one 
distinct epitope location. In the presence of H₂O₂ and electron donor, DAB, HRP catalyses 
oxidation of DAB and formation of a coloured precipitate that is insoluble in alcohol: 
H₂O₂ + DAB  DAB precipitate and H₂O 
Tissue sections were washed in acid alcohol and counterstained in Mayer Haematoxylin 
(Appendix I, 3.1; 3.7) to identify nuclear areas. Stained slides were dehydrated in IMS and xylene 
before mounting with DPX xylene based mountant to ensure brown DAB precipitate remained 
insoluble (Appendix I, 3.8).  
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Figure 2-1. Principles of Immunohistochemistry. Adapted from Ramos JA.293 
2.3.3 Image Analysis 
Slides were scanned using the Olympus BX61 microscope and image analysis performed using 
the Ariol imaging system to quantify levels of anti-TLR9 or anti-RAGE antibody staining. 
Representative CD5 positive areas in CLL-LNs, and germinal centres of RA-LNs were selected for 
image analysis training. From these training areas, an automated algorithm to quantify RAGE 
and TLR9 staining was developed. Shape and colour image classifiers were used to measure the 
intensity of brown staining per cell. Cell shape was determined using blue haematoxylin-stained 
nuclei to identify cell number in LN cores. Colour classifier was trained based on saturation, hue 
and intensity of brown pixels. Minimum thresholds were set that excluded brown background 
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staining to ensure only positive brown pixel/protein expression was measured. Once the training 
algorithm was optimised per antibody stain, it was applied to all TMAs. Protein levels are 
expressed as the percentage of cells positive for brown staining in the LN core. Mean percent-
positive staining was calculated for each stain per patient. Incomplete or damaged LN cores 
were excluded from analysis. Data for the levels of Ki67 and ZAP70 LN expression were from the 
tissue bank databases and performed by Mr Andrew Clear from Barts Cancer Institute and Dr 
Meg Ashton-Key from the University of Southampton, respectively. 
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2.4 Flow Cytometry 
Flow cytometry is a widely used assay that utilises multi-parameter analysis of single cells in 
suspension to determine cell-population purities and cell-surface/intracellular protein/molecule 
expression.294,295 A flow cytometer measures forward and side scatter from cells that pass 
through a laser beam to differentiate cell populations, and fluorescence intensity from 
fluorescent-labelled antibodies or dyes that bind to protein or ligand targets.296  
Cell suspensions are hydrodynamically focused into a stream of single cells in sheath fluid. Single 
cells passing through the laser beam scatter light, detected by a forward-scatter detector and 
various side scatter detectors. Forward scatter measures cell size and helps exclude doublet-
cells from analysis; side scatter correlates with the granularity of cells and is useful in 
distinguishing different cell populations based on these parameters. Cells fluorescently stained 
with labelled antibodies or dyes result in photon excitation and emission at specific wavelengths 
of light. Photomultiplying tubes detect emitted wavelengths of light from multiple fluorescent 
antibodies in the same cell. However, when designing multi-colour flow cytometry assays, 
fluorochromes from distal spectral emission wavelengths should be selected to limit spectral 
overlap and production of false positive results (Figure 2-2).297 Spectral compensation by using 
single stained cells was adopted in this work to limit spectral overlap. For all flow cytometry 
experiments included in this work, data acquisition was performed using an LSR Fortessa Cell 
Analyzer (BD Biosciences) for 10,000 events and data files analysed with FlowJo Version 10 
software.  
 
Figure 2-2. Excitation and emission spectra for AF-488, AF-546 and AF-647. Arrows indicate spectral 
overlap (Interactive graph from Life Technologies).  
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Fluorochromes and lasers used throughout experiments: 
Laser Bandpass Filter Fluorochrome use 
Violet (405nm) 
450/50 DAPI 
525/50  
610/20  
660/20  
710/50  
780/60  
Blue (488nm) 
530/30 AF-488; Annexin V-FITC 
695/40 Propidium iodide 
Yellow/Green (561nm) 
582/15  
610/20  
670/30 PE/Cy5 
710/50  
780/60 PE/Cy7 
Red (641nm) 
670/14 AF-647; APC 
730/45  
780/60 APC/Cy7 
 
2.4.1 Evaluation of RAGE and TLR9 expression in CLL PBMCs 
Surface/intracellular RAGE and intracellular TLR9 expression in different PB cell types was 
assessed by flow cytometry to determine the main cell types in CLL that express RAGE and TLR9. 
By using flow cytometry, PBMCs are easily co-stained with cell markers, instead of performing 
cell-separation to isolate homogeneous cell types. Cryopreserved mononuclear CLL cells from 6 
CLL patients were incubated at 37°C in RPMI complete growth medium to recover for 2 hours 
prior to staining. Non-specific binding was blocked by incubating with 50µl 2% human anti-
globulin antibody (HAG) blocking buffer (Appendix I, 4.1; Sigma) for 20 minutes. After washing 
with 2% FBS wash buffer (Appendix I, 4.2), 1x10⁶ cells per flow tube were co-stained with anti-
CD14-PE/Cy5, anti-CD19-PE/Cy7, anti-CD3-FITC antibodies (Appendix I, 4.3; Table C) for 30 
minutes at room temperature. For intracellular staining, cells were washed with 2% FBS wash 
buffer and permeabilised and fixed with 50µl CytoFix/CytoPerm (Appendix I, 4.1; BD Biosciences) 
for 20 minutes at room temperature; while for RAGE surface staining, cells remained non-
permeabilised. Intracellular non-specific binding was blocked with 50µl 2% HAG for 20 minutes 
and cells were stained with primary antibodies for RAGE or TLR9 for 1 hour (Appendix I, 4.3; 
Table C). Cells were washed with 2% FBS wash buffer and primary RAGE and TLR9 antibody 
binding was detected using Alexa Fluor (AF) 488 or 647 conjugated IgG secondary antibodies for 
30 minutes at room temperature in 50µl 2% HAG blocking buffer (Appendix I, 4.3; Table C). Cells 
were washed with 2% FBS containing PBS wash buffer and the nuclei of all non-permeabilised 
cells were stained with 50ng/ml DAPI in 300µl 2% FBS containing wash buffer (Appendix I, 4.4-
4.5) to distinguish live/dead cells during data acquisition. Data acquisition was performed using 
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a LSR Fortessa Cell Analyser. FITC and AF-488 signals were measured using the blue laser 
(488nm) at bandpass B530/30; AF-647 signal was measured under the red laser (641nm) at 
bandpass R670/14; DAPI signal was measured using the violet laser (405nm) at bandpass 
V450/50; PE/Cy5 and PE/Cy7 signals were measured using the yellow-green laser (560nm) at 
bandpass YG670/30 and YG780/60, respectively. Lymphocytes, single cells and live cells (for non-
permeabilised cells) were gated for analysis. Values for mean fluorescence intensity (MFI) and 
percentage of cells positive for RAGE/TLR9 compared to unstained controls were exported from 
FlowJo Version 10 software for statistical analysis.  
2.4.2 Determination of ZAP70 expression in CLL cells 
ZAP70 positivity is determined in CLL by flow cytometry. However, there is currently no 
standardised flow cytometric procedure to measure ZAP70 expression.298 All published methods 
were reviewed, and herein describes the isotype corrected T/B-CLL ratio method where ZAP70 
MFI in CLL CD19+/CD5+ B-cells is compared to the ZAP70 MFI from CD3+ T-cells.299 
Cryopreserved mononuclear CLL cells from 50 patients with matched plasma for ELISA, were 
incubated with 0.5mg/ml DNase (Appendix I, 4.6) for 5 minutes at room temperature to digest 
extracellular DNA. DNase was removed by washing cells in RPMI 1640 complete medium, 
centrifugation at 1500rpm for 5 minutes and resuspending cells at 1x10⁶ cells/ml fresh RPMI 
1640 complete growth medium. Cells were left to rest at 37°C for 2 hours prior to staining. Cell 
viability was measured using the Luna-II™ automated cell counter and cells with viability <80% 
after resting was not taken forward for ZAP70 flow cytometry analysis. Non-specific binding was 
blocked by incubating with 50µl 2% HAG blocking buffer for 20 minutes, followed by cell surface 
co-staining with anti-CD3-APC, anti-CD5-APC/Cy7 and anti-CD19 PE/Cy7 for 30 minutes in the 
dark (Appendix I, 4.3; Table C) for all patient test samples and fluorescence-minus-one (FMO) 
control tubes. Isotype controls were included and stained with mouse anti-IgG1κ conjugated to 
either APC, APC/Cy7 or PE/Cy7 (Appendix I, 4.3; Table C). Cells were washed with 2% FBS wash 
buffer and then permeabilised and fixed with 50µl CytoFix/CytoPerm for 20 minutes. Non-
specific binding in permeabilised cells was blocked with 50µl 2% HAG blocking buffer, followed 
by intracellular staining with anti-ZAP70-AF-488 clone IE7.2 for patient test samples, or mouse 
anti-IgG1κ AF488 for FMO and isotype controls (Appendix I, 4.3; Table C). Cells were washed 
with 2% FBS wash buffer and resuspended in 300µl flow wash buffer for flow cytometry data 
acquisition. AF-488 signal measured using the blue laser (488nm) at bandpass B530/30; APC and 
APC/Cy7 signals were measured under the red laser (641nm) at bandpass R670/14 and R780/60, 
respectively; PE/Cy7 signal was measured using the yellow-green laser (560nm) at bandpass 
YG780/60. Data was recorded for 10,000 events and lymphocytes and single cells were gated 
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for analysis. ZAP70 positive gates were set subject to isotype controls and FMO sample gates. 
Values for ZAP70 MFI from CD5+/CD19+ CLL cells, CD3+ T-cells and isotype control MFI values 
were exported from FlowJo Version 10 software for statistical analysis.  
2.4.3 Evaluation of CLL cell death by Annexin V/PI assay 
Cell death can be assessed by a flow cytometric procedure called Annexin V assay. Annexin V 
conjugated to FITC binds to the phospholipid phosphatidylserine (PS) that is exposed from the 
cytoplasmic side of the plasma membrane to the extracellular side during early apoptosis.300 
Propidium iodide (PI) was included in this assay as a marker for dead cells, by intercalating 
between DNA bases in a sequence independent manner. DNA is exposed to PI in necrotic and 
secondary necrotic dead cells that have lost membrane integrity, but not in viable cells with 
normal plasma membranes. Therefore, this assay allows determination of viable cells (Annexin 
V-/PI-), early apoptotic events (Annexin V-FITC+/PI-) and late apoptotic (secondary 
necrotic)/dead/necrotic cells (Annexin V-FITC+/PI+).301 Fresh primary CLL cells were 
resuspended at a cell density of 2x10⁶/ml in RPMI 1640 complete growth medium. Cells were 
treated with 10µl sterile PBS, 200ng/ml HMGB1, 500ng/ml HMGB1 or 10µg/ml neutralising anti-
RAGE antibody (Appendix I, 13.1-13.2) for 48 and 120 hours at 37°C in a humidified 5% CO₂ 
incubator to assess the effect of these treatments on CLL cell death in vitro. After treatment, 
cells were washed in 4ml ice-cold PBS to quench cell signalling and resuspended at 1x10⁶ cells 
per flow tube in 100µl 1x Annexin V Binding Buffer (Appendix I, 4.7; BD Pharmingen FITC Annexin 
V Apoptosis Detection Kit I). Cells were co-stained with 5µl FITC Annexin V and 5µl PI for 15 
minutes in the dark (Appendix I, 4.7; BD Pharmigen FITC Annexin V Apoptosis Detection Kit I). 
Stain was removed by washing with 4ml ice-cold PBS and resuspension in 300µl 1x Annexin V 
Binding Buffer. Data for CLL cell death was acquired immediately after staining using a LSR 
Fortessa Cell Analyser. Annexin V-FITC and PI signals were measured using the blue laser 
(488nm) at bandpass B530/30 and B695/40, respectively. Compensation was included to limit 
spectral overlap. Values for the percentage of viable cells (Annexin V-/PI-), early apoptotic cells 
(Annexin V+/PI-) and necrotic/dead cells (Annexin V-/PI-) per treatment compared to unstained 
controls were exported for statistical analysis. 
2.4.4 Evaluation of CLL cell purity in PBMCs 
CLL cell purity is highly heterogenous among CLL patient PB. It was important to assess CLL purity 
to factor in the presence of supportive cell types for cell death assays; and for mass spectrometry 
sample inclusion criteria to ensure phosphoproteomic signals originate from CLL cells. Standard 
CLL cell identification by flow cytometry is performed by assessing CD5 and CD19 antigen double 
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positive expression in whole PBMCs, with gating set in comparison to isotype controls.302 Freshly 
isolated CLL PBMCs were incubated at 5x10⁶ cells/ml at 37°C in RPMI complete growth medium 
overnight prior to staining. Non-specific binding was blocked for 1x10⁶ cells/flow tube by 
incubating with 50µl 2% HAG blocking buffer for 20 minutes, followed by cell surface co-staining 
with anti-CD5-PE/Cy7 and anti-CD19-APC for 30 minutes in the dark (Appendix I, 4.3; Table C). 
Isotype controls were included and patient cells were stained with mouse anti-IgG1κ PE/Cy7 and 
APC (Appendix I, 4.3; Table C). Cells were washed with 4ml 2% FBS containing wash buffer, and 
resuspended in 300µl 2% FBS containing wash buffer with 50ng/ml DAPI prior to flow cytometry 
to distinguish live/dead cells during data acquisition. CD19-APC and CD5-PE/Cy7 signals were 
measured using the red laser (641nm) at bandpass R670/14, and the yellow-green laser (560nm) 
at bandpass YG780/60, respectively. Values for the percentage of CLL cells (CD5+/CD19+) 
compared to isotype control gates were exported for statistical analysis. 
2.4.5 Evaluation of membrane RAGE shedding 
HMGB1 receptor, RAGE, can undergo membrane shedding from the surface of cells into cell 
culture medium under stimulatory conditions. Membrane RAGE cleavage is catalysed by 
ADAM10 as an inflammatory dampening response; ADAM10 activity can be induced by 
ionophore, ionomycin, or selectively inhibited by GI25423X without targeting other ADAM 
proteases. In this work, cell surface RAGE and ADAM10 expression was assessed by flow 
cytometry following stimulation or inhibition of ADAM10 activity. 2x10⁶/ml Mec1 cells and 
1x10⁶/ml HEK293 FL-RAGE transfected cells were cultured in 6-well plates in 2ml serum-free 
RPMI medium 1 hour before stimulations. ADAM10 sheddase activity was blocked, prior to other 
stimulations with ADAM10 inhibitor GI254023X 5μM, 10μM or 20μM for 1 hour (Appendix I, 
13.4). ADAM10 inhibited cells were washed in sterile PBS and resuspended in 2ml RPMI serum-
free medium. Cells were then treated with PBS, HMGB1 50ng/ml, HMGB1 200ng/ml, HMGB1 
500ng/ml, DMSO, ionomycin 500nM or GI254023X 5μM, 10μM and 20μM again combined with 
ADAM10 stimulator, ionomycin 500nM (Appendix I, 13.1; 13.4; 13.5). All treatments were 
performed for 1 hour at 37°C in a humidified 5% CO₂ incubator. Following treatments, 
conditioned medium from cell lines was collected by centrifugation at 1500rpm for 5 minutes to 
pellet cells and removal of conditioned medium supernatant; supernatant aliquots were stored 
in -20°C for ELISA. Live cells were harvested for flow cytometry by spinning 1x10⁶ cells/flow 
cytometry tube at 1500rpm for 5 minutes. Non-specific binding was blocked by incubating cell 
lines with 50µl 2% HAG blocking buffer for 20 minutes, followed by separate cell surface staining 
with primary antibodies for rabbit anti-RAGE and rabbit anti-ADAM10-N-terminal for 30 minutes 
(Appendix I, 4.3; Table C). Cells were washed in 2% FBS containing wash buffer and primary 
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antibody binding was detected using AF-488 or AF-647 conjugated goat anti-rabbit IgG 
secondary antibodies for 30 minutes at room temperature in 50µl 2% HAG blocking buffer. Cells 
were washed in 2% FBS containing wash buffer and resuspended in 300µl 2% FBS wash buffer 
with 50ng/ml DAPI prior to flow cytometry to distinguish live/dead cells during data acquisition. 
RAGE and ADAM10 signals were measured using the blue laser (488nm) at bandpass B530/30, 
and the red laser (641nm) at bandpass R670/14, respectively. Values for RAGE and ADAM10 MFI 
in viable FL-transfected HEK293 and Mec1 cells were exported from FlowJo Version 10 software 
for statistical analysis. 
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2.5 Enzyme-Linked Immunosorbant Assay (ELISA) 
The plasma concentrations of HMGB1, S100B and soluble RAGE were determined in 54 CLL 
patients and 15 healthy controls using HMGB1, S100B and sRAGE sandwich ELISA kits (Appendix 
I, 5.0; Merck Millipore, Abcam and Cambridge Bioscience, respectively). This quantitative 
method is a powerful tool to measure protein concentration in solution, particularly for human 
plasma and cell culture supernatants. The antigen of interest is ‘sandwiched’ between a capture 
antibody immobilised on the plate base and a detection antibody. The detection antibody is 
either directly conjugated to an enzyme reporter system, or indirectly using a secondary 
antibody. ELISAs used in this study utilised a biotin-streptavidin HRP direct detection system. 
Anti-HMGB1, S100B and RAGE biotinylated detection antibodies bind to HRP-conjugated 
streptavidin; this reporter enzyme catalyses production of coloured product in proportion to the 
amount of HMGB1/S100B/RAGE bound to the capture antibodies (Figure 2-3). The use of 96-
well polystyrene plates makes this method high-throughput and easy to perform.  
Fresh plasma was obtained by centrifugation of whole CLL and healthy blood at 1500rpm 5 
minutes. The top plasma layer was removed and contaminating cells and insoluble material were 
removed from plasma by centrifugation again at 4000×g at 4°C for 10 minutes. Plasma aliquots 
were stored at -80°C prior to ELISA. Appropriate protein standards and reagents were included 
in all ELISA kits and standard curves were generated while CLL and healthy plasma concentration 
was assayed. The ELISA assay procedure was similar for all ELISA kits. All ELISA plates were 
manufactured with pre-bound capture antibodies specific for the human antigen of choice – 
HMGB1, S100B and sRAGE. ELISA kit reagents and protein standards were prepared prior to 
running the assay with the materials provided (Appendix I, 5.1-5.3). ELISA plates were washed 
with provided 1X Tris-Buffered Saline with 0.1% Tween-20 (TBST) wash buffer to ensure wells 
were clear of contaminants and to pre-wet the capture-antibodies at the base of each well 
before incubating with plasma/cell culture supernatant. Fixed volumes of CLL plasma, healthy 
control plasma, cell culture supernatant and protein standards were incubated in ELISA wells 
with immobilised antibodies for fixed time points, dependent on the ELISA kit (2-24 hours). Wells 
were washed 3-5 times with provided 1X TBST wash buffer to remove unbound plasma analytes. 
Antigen-immobilised antibody reactions were detected by incubating with anti-S100B, anti-
RAGE or anti-HMGB1 biotinylated detection antibodies for fixed incubation time points (2-24 
hours dependent on ELISA kit). Unbound biotinylated antibodies were rinsed from wells with 1X 
TBST wash buffer 3-5 times. Immobilised-biotinylated antibodies were then conjugated to HRP 
detection enzyme via streptavidin for 2 hours. ELISA wells were washed 3-5 times with 1X TBST 
to remove unbound HRP-conjugate. HRP substrate, 3, 3’,5,5’-tetramethylbenzidine (TMB), was 
added to each well with H₂O₂ for 5-30 minutes (dependent on ELISA kit) to catalyse oxidation of 
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TMB, production of water and a solution colour change to blue. Stop solution (0.3M HCl or 
0.35M H₂SO₄) was added to the ELISA plates to quench further activity of HRP and formation of 
blue-product. The colour change induced by HRP activity was measured by absorbance at 450nm 
using POLARstar Optima plate reader; the absorbency is directly proportional to the amount of 
HMGB1/S100B/sRAGE captured in wells. The concentration of each analyte per patient were 
derived by interpolation from the standard curve generated in the same assay from ELISA kit-
specific protein standard readouts.  
 
 
Figure 2-3. Principles of sandwich ELISA. Adapted from http://www.abcam.com/protocols/sandwich-
elisa-protocol-1.  ELISAs were purchased with pre-coated capture antibodies at the base of ELISA wells. 
ELISA plates were incubated with primary CLL or healthy plasma, cell culture supernatant and ELISA kit 
protein standards. Antigen-antibody reactions were visualised by addition of a biotinylated secondary 
antibody to the antigen of interest. HRP was conjugated to the sandwich antibody complex via biotin-
streptavidin reaction. HRP catalysed the oxidation of TMB to produce a blue colour solution change. Stop 
solution was added (0.3M HCl or 0.35M H₂SO₄) to quench HRP enzyme activity. Absorbance measured at 
450nm is directly proportional to the amount of antigen captured in ELISA wells.   
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2.6 Immuno-fluorescent Microscopy 
Immuno-fluorescent microscopy (IFM) is a qualitative technique used to investigate protein 
expression with additional spatial localisation information and can reveal protein-protein 
interactions.303 Proteins are fluorescently labelled with primary antibodies and fluorochrome-
conjugated secondary antibodies. For this study, AF-488 (excitation/emission wavelengths: 
495nm/519nm) and AF-546 conjugated secondary antibodies (excitation/emission wavelengths: 
556nm/573nm) were used that have limited spectral overlap on the Nikon eclipse fluorescence 
microscope (Figure 2-2). By targeting specific proteins with fluorescent tagged antibodies and 
imaging cells are 100x magnification, immunofluorescent microscopy provides a window to 
assess physiological processes at a molecular level which is lacking from expression-based 
assays.  
Fresh primary CLL cells were isolated from whole blood outlined in section 2.2.3. CLL cells were 
resuspended at a density of 5x10⁶/ml in fresh RPMI 1640 complete growth medium in a 12-well 
plate and left to rest for 2 hours prior to treatments. CLL cells were stimulated with 200ng/ml 
HMGB1 (Appendix I, 13.1) with or without anti-RAGE neutralising antibody (Appendix I, 13.2) for 
2 and 4 hours. Where anti-RAGE antibody was used, cells were pre-treated with anti-RAGE 
antibody for 30 minutes to allow inhibition of surface RAGE, before addition of HMGB1 for 2 and 
4 hours. Control samples were treated with PBS vehicle control at the same volume used for 
HMGB1 treatments. Following treatments, cells were pelleted by centrifugation for 5 minutes 
at 1500rpm and then washed with PBS. Cells were pelleted and mixed with 10µl RPMI 1640 
complete growth medium to give a concentrated cell suspension. Superfrost™ slides were 
divided into 4 sections using a hydrophobic barrier pen (Appendix I, 3.0); 3µl of concentrated 
cell suspension was spread onto the surface of the Superfrost™ slide in each section and left to 
air-dry for 5 minutes. Once bone-dry, cells in each section were fixed and permeabilised with 
50µl CytoFix/CytoPerm solution (Appendix I, 6.0) for 30 minutes at room temperature for 
intracellular protein staining. Slides were rinsed in a beaker of TBST (Appendix I, 6.1) and non-
specific binding was blocked by incubating each slide section with 50µl TBS blocking buffer (pH 
7.4) containing 2.5% goat serum and 2.5% donkey serum and 0.1% saponin for 30 minutes 
(Appendix I, 6.2). Cells were co-stained for TLR9 and RAGE, MyD88 and TLR9, or separately for 
NF-κB and STAT3-PY705 with primary antibodies (Appendix I, 6.3; Table D) in 50µl 2.5% goat and 
2.5% donkey blocking buffer in a humidified opaque box. Slides were rinsed in TBST for 3 rounds 
of 5 minutes before primary antibodies were detected with donkey anti-mouse IgG or goat anti-
rabbit IgG secondary antibodies conjugated to AF-488 or AF-546 (Appendix I, 6.3; Table D) in 
50µl blocking buffer for 1 hour in a humidified opaque box. Unbound antibody was removed by 
3 washes with TBST. The nuclei of cells stained for NF-κB and STAT3 were counterstained with 
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DAPI (Appendix I, 6.4) in TBST for 5 minutes in a humidified opaque box. Background DAPI was 
removed by rinsing slides in TBST before leaving slides to air-dry completely. Slides were 
mounted with ProLong Gold anti-fade reagent to prevent fluorochome quenching and stain-
bleed and slides were imaged on the same day. 
Immunofluorescence was observed at 100x magnification using the Nikon eclipse Ci-E 
fluorescence microscope using the green, blue and red channels.76 Protein colocalisation and 
protein nuclear translocation using DAPI nuclear stain were analysed by WCIF ImageJ software. 
The intensive correlation analysis method was used for protein colocalisation analysis.  
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2.7 ImageStream X Mark II Flow Cytometry 
The introduction of Imagestream X Mark II (ISS) instrument and IDEAS analysis software has 
advanced flow cytometry and imaging technology. This system integrates features of high 
throughput flow cytometry with fluorescence microscopy allowing multiparameter analysis. 
This effective combination allows for acquisition of statistically powerful data and detailed 
morphological fluorescence information that is used for various applications.304 For this study, 
ImageStream X Mark II flow cytometry was used to measure protein colocalisation and nuclear 
localisation as a quantitative comparison to qualitative-based fluorescence microscopy.  
Like flow cytometry, immuno-labelled cells in suspension are focused into a core stream and 
illuminated by brightfield light, 488nm blue, 405nm violet and 633nm red lasers (Figure 2-4). 
The instrument objective lens detects scattered light, transmitted light and up to 4 independent 
fluorescence signals for up to 10⁴ events. Signals are decomposed into 6 defined wavelength 
ranges (4 fluorescence images, 1 brightfield and 1 darkfield image) and collected using a charge-
coupled device camera.305 Compared to standard photomultiplier tubes in flow cytometry, the 
charge-coupled device camera converts photons into photocharges in an array of pixels, 
correlating fluorescence and brightfield signals to distinct morphometric locations in an image. 
Spectral compensation is performed using separate stained samples for every fluorochrome 
used to limit fluorescence emission spill over.  
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Figure 2-4. The ImageStream X Mark II flow cytometer. Adapted from Zuba-Surma et al.306 
2.7.1 Immunostaining procedure  
Fresh primary CLL cells were isolated from whole blood outlined in section 2.2.3. CLL cells were 
resuspended at a density of 5x10⁶/ml in 2ml fresh RPMI 1640 complete growth medium in 6-
well plates and left to rest for 2 hours prior to treatments. CLL cells were stimulated with 
200ng/ml HMGB1 (Appendix I, 13.1) with or without anti-RAGE neutralising antibody (Appendix 
I, 13.2) for 2 and 4 hours. Where anti-RAGE antibody was used, cells were pre-treated with anti-
RAGE antibody for 30 minutes to allow inhibition of surface RAGE, before addition of HMGB1 
for 2 and 4 hours. Control samples were treated with PBS vehicle control at the same volume 
used for HMGB1 treatments. Following treatments, cell suspension was collected in Eppendorf 
tubes and centrifuged for 5 minutes at 1500rpm. Cell culture medium supernatant was removed 
and cell pellets washed in PBS, before centrifugation again. All samples were fixed and 
permeabilised with CytoFix/CytoPerm for 30 minutes on ice to allow for intracellular staining. 
Cells were washed with TBST (Appendix I, 6.1). Non-specific binding was blocked by incubating 
with 50µl TBS (pH 7.4) containing 5% goat serum, 5% donkey serum and 0.1% saponin for 30 
minutes (Appendix I, 6.2). Cells were co-stained for TLR9 and RAGE, MyD88 and TLR9, or 
separately for NF-κB and STAT3-PY705 with primary antibodies (Appendix I, 7.1; Table F) in 50µl 
5% goat and 5% donkey blocking buffer. Cells in Eppendorf tubes were washed in TBST and 
primary antibodies were detected with donkey anti-mouse IgG or goat anti-rabbit IgG secondary 
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antibodies conjugated to AF-488 or AF-647 for 1 hour in the dark (Appendix I, 7.1; Table F). 
Unbound antibody was removed by 2 washes with TBST and centrifugation at 1500rpm for 5 
minutes. The nuclei of cells stained for NF-κB and STAT3 were stained with DAPI 1:1000 in TBST 
for 10 minutes in the dark. Background DAPI was removed by washing in TBST and all stained 
cell pellets were resuspended in 50µl TBST in Eppendorf tubes for ImageStream Mark II flow 
cytometry. Single stained cells for fluorochromes AF-488, AF-647 and DAPI were included to 
perform compensation. Unstained samples are not needed for ImageStream flow cytometry 
data acquisition due to the use of brightfield light to set gating parameters. Data was collected 
for 5000 single cells in focus at 40x or 60x magnification where stated.  
2.7.2 ImageStream data analysis – IDEAS software 
The IDEAS analysis software package calculates over 200 photometric and morphometric 
parameters for each individual cell collected, in addition to gating percentages and fluorescence 
images, allowing a huge range of applications from one experiment.304 In this study, the 
ImageStream was used to measure protein colocalisation and transcription factor nuclear 
translocation. 
The colocalisation coefficient, Similarity Bright Detail Score (SBDS), was used to test if 2 probes 
were localised in the same region of a cell. The SBDS was calculated on a pixel by pixel basis 
between 2 fluorescent channels; i.e. RAGE detected by AF-488 secondary antibody and TLR9 
detected by AF-647 secondary antibody. The IDEAS software calculates optimal background 
fluorescence erosion from original images to concentrate bright spots. Next, the Pearson’s 
correlation coefficient measured the spatial location similarity of bright spots in the AF-488 and 
AF-647 image pair. This coefficient is log transformed to give the SBDS; cells with a higher SBDS 
have higher levels of bright spots in the same spatial location between an image pair. Nuclear 
translocation of NF-κB and STAT3 transcription factors were measured using the Similarity 
Eroded Score (SEC). Measured by a similar algorithm to SBDS, the spatial correlation between 
nuclear fluorescence from DAPI staining, and NF-κB and STAT3 was an indication of nuclear 
translocation. The Pearson’s correlation coefficient was log-transformed to give SEC; a higher 
SEC reflects increased nuclear translocation and transcription factor activation. 5000 events 
were recorded and single cells in focus were gated for analysis; the mean SBDS or SEC was 
measured for every cell per treatment group and raw data was exported for statistical analysis.  
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2.8 Western Blotting 
Western blotting is a routine gold standard procedure for protein expression analysis introduced 
nearly 40 years ago.307 Proteins extracted from cells are denatured, made linear and negatively 
charged with sodium dodecyl sulphate (SDS) before separation by polyacrylamide gel 
electrophoresis (PAGE) based solely on protein mass. Proteins of smaller molecular weight 
migrate through the gel faster than larger proteins to the anode. Separated proteins bands are 
transferred from the gel to a nitrocellulose or PVDF membrane for subsequent detection. Target 
antigens are identified from the complex mixture of separated proteins by specific antigen-
antibody reactions and visualised using a chemiluminescent detection system.  
2.8.1 Preparation of cell lysates 
Cells were stimulated at a density of 2x106 cells/ml for 15x106 Mec1 total cells and 5x106 cells/ml 
for 30x106 total primary CLL cells. After treatment, cells were pelleted by centrifugation at 
1300rpm for 5 minutes at 4°C, followed by washing with PBS. PBS wash supernatant was 
removed and primary CLL cell pellets incubated with 0.5mg/ml DNase (Appendix I, 4.6) for 5 
minutes at room temperature to decrease sample viscosity. DNase was removed by washing 
with PBST and centrifuged at 8000rpm for 2 minutes at 4°C. PBST supernatant was removed and 
cell pellets lysed with 50µl cell lysis buffer containing protease and phosphate inhibitors 
(Appendix I, 8.1). Cell lysates were incubated on ice for 20 minutes with intermittent vortexing 
followed by centrifugation at 13000rpm for 15 minutes at 4°C to remove cellular debris; protein 
containing cell lysate supernatant was removed and stored at -80°C. Patient plasma samples 
were centrifuged at 13000rpm for 15 mins for cell debris clearing and stored at -80°C before 
measuring protein concentration.   
2.8.2 Determination of protein concentration – Bradford Assay 
The protein concentration of cell lysates and patient plasma was measured using the Bradford 
assay. This assay utilises the binding of acidic Coomassie Blue G-250 to positive amine groups of 
amino acids. Protein binding induces an absorbance shift from 465nm to 595nm and a solution 
colour change from red/brown to blue.308 The absorbance at 595nm can be measured with a 
spectrometer and the protein concentration of cell lysates extrapolated from a standard curve 
generated by a set of BSA protein standards with increasing known protein concentration.  
A 96-well flat-bottom plate was prepared by adding 100µl of 1X Bio-Rad protein assay dye 
reagent to the appropriate number of wells (Appendix I, 8.2); protein standards and test samples 
were assayed in triplicate. Increasing concentrations of BSA protein standard were prepared by 
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diluting different volumes 0.5mg/ml BSA stock solution (Appendix I, 8.3) in 100µl Bio-Rad protein 
assay dye reagent to generate a standard curve (Table 4). Test protein lysates were diluted 1:10 
and patient plasma 1:100 in deionised water to ensure spectrometer readings were within a 
measurable range. 1µl of diluted cell lysate was mixed with 100µl 1X Bio-Rad reagent. The 
absorbance was measured at 595nm on a spectrophotometer and protein concentrations 
calculated by linear regression using the equation y=mx+c, where y is the average sample 
absorbance at 595nm and x is protein concentration (µg/µl).  
Table 4. BSA standard curve for Bradford assay. 
0.5mg/ml BSA (µl) BSA Concentration (µg) 
0 0 
0.5 2.5 
1 5 
2 10 
4 20 
 
2.8.3 Western blotting procedure 
After determination of cell lysate protein concentration, 50µg protein containing cell lysate was 
made up to a final volume of 24µl in cell lysis buffer with 6µl 4X LDS loading buffer (to give a 
final 1X LDS buffer concentration). Plasma samples were incubated with 0.5mg/ml DNase for 5 
minutes at room temperature, before diluting in 30µl cell lysis buffer and 10µl 4X LDS loading 
buffer. Samples were boiled for 10 minutes at 90°C to ensure full protein denaturation. The wells 
of a 12-well NuPAGE 4-12% Bis-Tris gel were rinsed with 1X MOPS running buffer (Appendix I, 
8.4) before loading 20µl of denatured sample lysate per well. 4µl of MagicMark Western blotting 
molecular weight ladder was diluted in 20µl LDS sample loading buffer and loaded onto the first 
well. Where reducing SDS-PAGE was used, 2.4µl of 10X NuPAGE® reducing agent was added to 
LDS sample buffer and NuPAGE antioxidant included in MOPS running buffer (Appendix I, 8.5). 
Proteins were separated by gel electrophoresis at 200V for 50 minutes in 1X MOPS running 
buffer and transferred by semi-dry method onto pre-methanol soaked and transfer buffer pre-
balanced PVDF membranes for 1 hour at 20V (Appendix I, 8.6). Non-specific binding was blocked 
by incubating in polyvinylpyrolidine (PVP) blocking buffer (Appendix I, 8.7) with rocking for 1 
hour at room temperature. Membranes were incubated with primary antibody in 10ml PVP 
blocking buffer for 1 hour at room temperature with rocking (Appendix I, 8.8; Table H), or 
overnight at 4°C in PVP blocking buffer with 10% azide to limit bacterial growth (Appendix I, 8.9). 
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Membranes were washed in 3 rounds of 10 minutes in TBST to remove unbound primary 
antibody and incubated with HRP-conjugated anti-rabbit or anti-mouse secondary antibodies in 
PVP blocking buffer (Appendix I, 8.7; Table H); azide inhibits HRP so was not included in this 
incubation. Membranes were washed for 3x10 minutes again with TBST and visualised by 
chemiluminescence. Enhanced chemiluminescent (ECL) HRP substrate was prepared 
immediately before use and 1ml applied to membranes for 5 minutes with rocking (Appendix I, 
8.10). Luminol is oxidised in the presence of HRP and peroxide, producing chemiluminescene at 
specific antigen spatial locations. Protein bands were visualised using a FujiFulm LAS 4000 
developer following 2-5 minute exposures. ECL was removed by washing membranes for 5 
minutes with TBST and antibodies stripped using Western blot stripping buffer for 5 minutes, 
before re-blocking and re-probing as described earlier; GAPDH was used as a loading control for 
all Western blots.  
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2.9 Co-Immunoprecipitation (Co-IP) 
Co-IP is a pull-down assay used to assess stable protein complexes in cell lysate or serum. In this 
study, co-IP was used to pull-down TLR9 from primary CLL cells and assess protein-protein 
interactions with MyD88 and RAGE in response to a variety of CLL-cell stimulations.76 Primary 
antibody against a primary protein target is incubated with Dynabeads™ Protein A that bind with 
high affinity to IgG. The Dynabead-antibody complex is mixed with cell lysate to pull-down 
protein target complexes and removed from cell lysate by magnetic separation. The antibody-
protein complexes are eluted form the Dynabeads™ Protein A solid support by denaturation and 
separated by SDS gel electrophoresis. Anti-IgG primary antibody is used as a negative pull-down 
control and non-precipitated whole cell lysate analysed on the same blot to assess target protein 
whole cell expression. The primary protein target is probed first (i.e. TLR9) to verify co-IP success, 
followed by re-probing for interacting proteins of interest (i.e. MyD88 and RAGE).  
Procedure 
5µg of mouse anti-TLR9 or anti-mouse IgG primary antibodies diluted in 200µl PBS with 0.02% 
Tween-20 (PBST; Appendix I, 9.1) were incubated with 1.5mg (50µl) of Dynabeads™ Protein A 
per treatment for 20 minutes at room temperature, with rotation. Dynabead-antibody 
complexes were washed with 1ml PBST followed by magnetic separation. 500µg protein-
containing CLL cell lysate (procedure outlined in section 2.8.1) in 500µl cell lysis buffer (Appendix 
I, 8.2) was mixed with the Dynabeads™-antibody complex and incubated for 30 minutes at room 
temperature, with rotation. Following antigen incubation, Dynabeads™-protein complexes were 
removed from unbound cell lysate by magnetic separation and washed 3 times with 500µl PBST. 
During the final wash, Dynabeads™-protein complex mix was transferred to fresh Eppendorf 
tubes to prevent co-elution of non-specific proteins bound to the tube wall. Target protein and 
associated protein complex was eluted from Dynabeads™ by mixing with 20µl elution buffer 
(Appendix I, 9.2) and boiling samples at 100°C for 10 minutes to denature proteins. Dynabeads™ 
were separated from the denatured antibody and target protein complex mix by placing samples 
in the magnetic rack and 20µl of eluted protein supernatant loaded onto a 4-12% NuPAGE® Bis-
Tris gel. Blots were probed with anti-TLR9, anti-MyD88 and anti-RAGE antibodies (Appendix I, 
9.3; Table J, Table K) by Western blotting (outlined in section 2.8). 
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2.10 LC MS/Mass Spectrometry   
LC MS/mass spectrometry is an analytical technique that combines the physical separation 
capabilities of liquid chromatography with the mass analysis capabilities of mass spectrometry. 
Measuring protein expression, using antibody-based methods gives a good indication of protein 
levels, but protein concentration does not always correlate with enzyme activity. LC-MS/MS 
phosphoproteomics can measure tens of thousands of phosphorylation sites per sample, 
whereas antibody technologies can only measure 10s-100s of phosphorylation sites per sample 
analysis. Therefore, we are able measure the markers of kinase activity directly (i.e. substrate 
phosphorylation). In this study, we will treat fresh CLL B-cells with HMGB1 and/or CpG-ODN (B 
class) and/or anti-RAGE neutralising antibody to identify the major signalling pathway(s) up- or 
down-regulated.  
Cell pellets are prepared for LC MS/MS by a specific lysing buffer, containing non-detergent 
components with protease and phosphatase inhibitors to minimise degradation or artefactual 
modification of enzymes. Proteins will be reduced and alkylated with dithiothreitol and 
iodoacetamide, respectively, to irreversibly prevent free sulfhydryl’s from reforming disulphide 
bonds. Proteins are then fragmented to peptides with trypsin, and samples de-salted to remove 
non-peptide ions that would be detected by mass spectrometry. Finally, peptide samples are 
enriched for phospho-peptides by titanium dioxide (Ti02) pull-down method, prior to LC-
MS/MS, and bioinformatics analyses as in previous publications.309,310 
2.10.1 Preparation of cell lysates 
Freshly isolated CLL cells with a CD19+/CD5+ purity >90%, were left to rest in vitro for 2 hours in 
complete medium prior to cell stimulation. Following 2 hours rest, cells were seeded at a density 
of 10x106 cells/ml for 30x106 total primary CLL cells in FBS-free medium to limit cell signalling 
activation. Cells were then treated for 15 minutes and 2 hours with 10μl PBS, 200ng/ml HMGB1, 
1μM CpG-ODN, 200ng/ml HMGB1 and 1μM CpG-ODN combined, and 2 hours only for 10μg/ml 
anti-RAGE neutralising antibody with 200ng/ml HMGB1. Where anti-RAGE antibody was used, 
cells were pre-blocked for 30 minutes with 10μg/ml anti-RAGE, before addition of HMGB1 for 2 
hours.  
To obtain protein from whole cells, cells were immediately placed on ice for 5 minutes to limit 
continuation and activation of further cell signalling. 500μl 1mg DNase (Sigma) was added to 
prevent cell clumping for 5 minutes before centrifugation at 1300rpm at 4°C for 5 minutes. Next, 
cells were carefully resuspended in 10ml PBS with phosphatase inhibitors (Appendix I; 10.1) 
(1mM Na3VO4 and 1mM NaF) and centrifuged at 1300rpm at 4°C for 5 minutes; this was 
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repeated twice. Samples were then lysed in 500µL ice-cold denaturing lysis buffer (8M urea with 
phosphatase inhibitors) (Appendix I; 10.2) for 15 minutes before being sonicated (40 cycles; 30 
seconds on; 30 seconds off; high intensity at 4°C). Following sonication, samples were left on ice 
for 5 minutes before being centrifuged at 16,400rpm for 15 minutes at 4°C. Protein 
concentration was measured using the Pierce Bicinchonic (BCA) Protein Assay Kit (Thermo 
Scientific). A standard curve was created using the provided Albumin Standard Ampules. The 
protein sample aliquots were dispensed in triplicates onto a 96-well plate. BCA working reagent 
was prepared by mixing Reagent A and Reagent B 50:1 and was added to each well as per the 
manufacturer’s protocol. Following incubation at 37°C for 30 minutes, absorbance was 
measured using a spectrophotometer set at 562m. The protein concentrations of each sample 
were calculated from the mean values of the technical triplicates. Lysates were then normalised 
to 350µg/300µl urea (Appendix I, 10.2).  
2.10.2 Trypsin digest  
First, 3µl 1M Dithiothreitol (DTT) was added to each sample and left on a shaker at 24°C at 
1200rpm for 30 minutes in the dark. Next, 12 µl 415mM iodoacetimide (IAM) was added to each 
sample and left on a shaker at 24°C at 1200rpm for 30 minutes in the dark. Samples were then 
diluted with 1250 µl HEPES (pH 8.0).  
During the IAM incubation, trypsin beads were conditioned as follows. The appropriate volume 
of mobilised trypsin beads was aliquoted into a 1.5ml LoBind Eppendorf tube and centrifuged at 
2000Xg at 4°C for 5 minutes. After the supernatant was removed, the volume of remaining beads 
was calculated and washed by adding an equal volume of HEPES (Appendix I; 10.3) and 
centrifuging the beads at 2000Xg at 4°C for 5 minutes. The wash step was repeated 3 times 
before the final addition of an equal volume of HEPES. 100 µl trypsin beads were added to each 
lysate sample and left overnight with agitation at 37°C in the dark. 
2.10.3 De-salting for phosphoenrichment 
A vacuum manifold block was first set to ~5 inHg and the necessary number of OASIS 1cc HLB 
(10mg) cartridges were inserted into the manifold. Waste containers were positioned 
underneath each cartridge. The cartridges were first conditioned with 1ml 100% Acetonitrile 
(ACN). Next, cartridges were incubated with 1mL 99% H2O; 1% ACN; 0.1% Trifluoroacetic acid 
(TFA), followed by 0.5ml of the same solution. The samples were then loaded into the cartridges 
and the flow rate was kept as low as possible. The cartridges were then washed with 0.75ml 99% 
H2O; 1% ACN; 0.1% TFA. The taps and cartridges were then completely purged, and the waste 
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containers were replaced with fresh 2ml LoBind Eppendorf tubes. Finally, the samples were 
eluted with 0.25 mL 1M glycolic acid (80% ACN; 5% TFA). 
2.10.4 Phosphopeptide-enrichment  
For each sample, 50µg of TiO2 beads were used per 1µg protein. First, the OASIS eluted fraction 
volumes were all normalised to 500µl with 1M Glycolic acid (80% ACN; 5% TFA). 17.5mg of re-
suspended TiO2 beads were added to each eluted fraction and samples were incubated for 5 
minutes with rotation.  
During this time, the Glygen EMPTY (TF2EMT) tips were equilibrated. The Glygen EMPTY 
SpinTips were placed in 2ml Eppendorf tubes 200µl 100% ACN was applied. The SpinTips were 
centrifuged for 3 minutes at 1500Xg and the flow-through was discarded.  
After the samples had been incubated with TiO2 for 5 minutes, samples were centrifuged for 30 
seconds at 2000rpm. 400µl of the remaining supernatant was removed and transferred to a 
fresh 1.5ml LoBind Eppendorf tube and placed on ice. The TiO2 beads were then resuspended in 
the remaining solution and 100µL of the re-suspended sample was transferred to the empty 
SpinTips and centrifuged for 2 minutes at 1500Xg. 100µl of 1M Glycolic acid (80% ACN; 5% TFA) 
was added to the sample tube to re-suspend the remaining TiO2 beads before being transferred 
once again to the SpinTips and centrifuged for 2 minutes at 1500Xg. The flow-through was 
discarded and the remaining 400µl previously aliquoted samples were transferred to the TiO2-
filled SpinTips (2x200µl batches) and centrifuged for 3 minutes at 1500Xg. Next the SpinTips 
were washed with 100µl 1M Glycolic acid (80% ACN; 5% TFA), 100µl 100 mM Ammonium 
Acetate (25% ACN) and 100µl 90/10 H2O/ACN each time being centrifuged for 2 minutes at 
1500rpm. The final wash step with100µl 90/10 H2O/ACN was repeated a total of three times to 
ensure complete removal of non-phosphorylated peptides.  
SpinTips were then transferred to fresh 2ml LoBind Eppendorf tubes and 50 µL 5% NH4OH (10% 
ACN) was applied to each SpinTip. Spintips were centrifuged for 2 minutes at 1500g and the 
flow-through was retained. This step was repeated three times to elute phosphopeptides from 
the TiO2 layer. The pooled elute from each sample was then snap-frozen in dry ice and placed in 
speed-vac to dry overnight. Finally, samples were stored at -80°C and were reconstituted before 
being analysed by liquid chromatography tandem mass spectrometry. 
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2.10.5 Bioinformatic analysis 
Mass spectrometry data is interpreted by matching the mass to charge ratios of fragment ions 
in mass spectrometry spectra, to peptide fragments of all proteins. The MASCOT search engine 
is used to compare peptide sequences against those in the UNITPROT database.311 Once the 
peptides have been derived, the localisation of phosphorylation sites is determined using the 
MASCOT delta score, which compares scores for both the probability of correct peptide 
sequence identification and phosphosite localisation.311 As LC-MS/MS phosphoproteomics 
measures the markers of kinase activity directly (i.e. substrate phosphorylation), enzyme activity 
can be inferred using algorithms such as Kinase Substrate Enrichment Analysis (KSEA).310 A single 
mass spectrometry experiment can measure thousands of phosphosites, which can be analysed 
using the PhosphoSitePlus database. All phosphorylation sites are targeted by a given kinase, 
meaning they can be grouped together in a substrate set. For KSEA, the log2- fold change of the 
abundance of a phosphosite between the initial and treated samples is compared.310 Therefore, 
KSEA activity scores describe the activity of a kinase in one condition relative to another.  
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2.11 Molecular Biology Techniques 
Soluble RAGE is not commercially available, so to assess the in vitro effects of sRAGE, 
endogenous-secreted RAGE (esRAGE) containing conditioned media was produced by 
transfecting HEK293 cells with esRAGE plasmid. HEK293 cells express low levels of full-length 
RAGE (FL-RAGE), so FL-RAGE transfected HEK293 cells were used as a positive control for 
membrane RAGE shedding assays. 
2.11.1 Plasmid Selection 
20µg of plasmid DNA for FL-RAGE and es-RAGE on a pcDNA3 backbone were purchased from 
HMGBiotech via IBL International (Appendix I, 11.1); inserted FL-RAGE and es-RAGE sequences 
were not given. Dried plasmid DNA was reconstituted to 1.4µg/µl and 0.768µg/µl in RNase-free 
water for FL-RAGE and es-RAGE, respectively, and stored at -20°C. The pcDNA3 vector includes 
a CMV promoter for mammalian expression and genes for ampicillin bacterial resistance and 
neomycin selectable marker.  
2.11.2 Bacterial Inoculation 
Prior to transfection, plasmid DNA is expanded by transformed competent bacteria and 
subsequently purified for downstream transfections. For this study, Subcloning Efficiency™ 
DH5α™ Competent Cells were used, a chemically altered strain of E. coli that provides higher 
transformation efficiencies. Competent cells were thawed on ice and 50µl of DH5α cells mixed 
with 10ng of FL-RAGE and es-RAGE pcDNA3 plasmids, and 250pg of provided pUC19 empty 
vector control; competent cells were incubated on ice for 30 minutes. Cells were then heat 
shocked at 42°C for 20 seconds in a heat block to promote plasmid uptake and placed back on 
ice for 2 minutes to recover. After transformation, 950µl of pre-warmed luria broth (LB; 
Appendix I, 11.2) was added to tubes and incubated at 37°C for 1 hour with shaking to allow 
plasmid expression and ampicillin resistance. LB-agar 10cm plates with 100µg/ml ampicillin 
were prepared in a sterile environment with a working flame (Appendix I, 11.3) and stored at 
4°C before use. 50µl and 200µl of FL-RAGE, es-RAGE and pUC19 transformed cells were streaked 
onto ampicillin-agar plates and left to incubate overnight at 37°C; different volumes of 
transformed cells were plated to ensure well-spaced colonies were produced. Following 
overnight incubation, single colonies were picked using a sterile filtered tip and inoculated into 
4ml pre-warmed LB media with 100µg/ml ampicillin. Bacterial inoculation was incubated at 37°C 
for 8 hours with shaking (300rpm); then 2.5ml diluted in 25ml pre-warmed LB media and 
incubated at 37°C for 8 hours with shaking (300rpm) to promote logarithmic growth of bacteria 
before harvesting. Glycerol stocks of bacterial inoculation were stored by mixing 500µl of 
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overnight culture with 500µl 50% glycerol in a cryovial at -80°C (Appendix I, 11.4); this method 
stabilises alive transformed frozen bacteria for many years. When used, a sterile filtered tip was 
used to scrape some frozen bacteria which were then spread onto pre-warmed ampicillin-agar 
plates.  
2.11.3 Plasmid Purification 
Following overnight bacteria culture, plasmid DNA was isolated by alkaline lysis and isopropanol 
precipitation using the QIAGEN midiprep purification kit; all buffers used were included in the 
kit. Bacteria were harvested by centrifugation at 6000xg for 15 minutes at 4°C and the bacteria 
pellet was resuspended in 4ml resuspension buffer (50mM Tris-Cl, 10mM EDTA; pH 8.0) with 
100µg/ml RNase. Bacteria were lysed with 4ml lysis buffer (200mM NaOH and 1% SDS) at room 
temperature for 5 minutes. Cell lysis was stopped by addition of 4ml ice-cold neutralisation 
buffer (3M potassium acetate; pH 5.5), mixed and incubated on ice for 15 minutes to enhance 
formation of genomic DNA, protein and cell debris precipitate. Bacterial lysate was centrifuged 
at 20,000xg for 30 minutes at 4°C and the supernatant containing plasmid DNA was removed 
immediately; the lysate was cleared again by centrifugation at 20,000xg for 15 minutes at 4°C 
and supernatant removed. A QIAGEN-tip 100 was equilibrated with 4ml equilibration buffer 
(750mM NaCl, 50mM MOPS, 15% isopropanol and 0.15% Triton X-100) and drained by gravity-
flow, before loading all the cleared plasmid DNA supernatant from the previous step. Unbound 
plasmid DNA was washed from the QIAGEN-tip 100 column with 2x 10ml wash buffer (1M NaCl, 
50mM MOPS, 15% isopropanol; pH 7.0) and drained by gravity-flow. Plasmid DNA was eluted 
and collected in 5ml elution buffer (1.25M NaCl, 50mM Tris-Cl, 15% isopropanol; pH 8.5). DNA 
precipitation was performed addition of 3.5ml isopropanol to eluted DNA at room temperature 
to avoid salt precipitation, mixed and centrifuged at 15,000xg for 30 minutes at 4°C. Supernatant 
was removed and the DNA-isopropanol pellet washed with 2ml 70% ethanol to remove 
precipitated salt. DNA was centrifuged again at 15,000xg for 10 minutes at 4°C. Isopropanol and 
ethanol supernatant was removed and plasmid DNA pellets air-dried for 10 minutes. Plasmid 
DNA was dissolved in 500µl TE buffer (10mM Tris-Cl; pH 8.0; Appendix I, 11.5) and DNA yield 
and purity assessed with a NanoDrop 2000 spectrophotometer.  
2.11.4 DNA Quantification – NanoDrop Spectrophotometer  
Purified plasmid DNA concentration and purity was assessed by measuring absorbance at 260nm 
using a NanoDrop 2000 spectrophotometer. The NanoDrop was blanked with 1µl TE buffer, then 
1µl of each sample measured in duplicate at 260nm. DNA purity was assessed by measuring the 
260nm/280nm nucleic acid to protein ratio. Es-RAGE plasmid concentration was 702ng/µl; FL-
Chapter II Materials and Methods 
93 
 
RAGE plasmid concentration was 475ng/µl; pUC19 plasmid concentration was 78ng/µl. 50µl 
aliquots were stored at -20°C.  
2.11.5 Restriction Digest 
A diagnostic restriction digest was performed to verify purification of the correct plasmid by 
analysing plasmid DNA fragments separated by gel electrophoresis. FL-RAGE and es-RAGE 
plasmids were cut into fragments using BamHI and Sma1 restriction enzymes; these enzymes 
were chosen based on known restriction sites in the pcDNA3 backbone and different cut sites in 
FL-RAGE and es-RAGE sequences, and restriction enzyme availability (Appendix I, 11.6). 1µg of 
FL-RAGE and es-RAGE plasmid DNA was mixed with 2µl fast digest green buffer and 12µl 
nuclease free water. Plasmid DNA was either left uncut, subject to single digest or subject to 
double digest by addition of 1µl nuclease free water, 1µl of BamHI or Sma1, or with 1µl of both 
BamHI and Sma1, respectively. Samples were heated to 37°C for 5 minutes in a heat block to 
activate enzyme activity, then heated to 80°C for 5 minutes to inactivate restriction enzymes. 
Digest products were separated by gel electrophoresis using a 1% agarose gel in Tris-base, boric 
acid and EDTA (TBE) buffer containing GelRed nucleic acid stain, at 50V for 1 hour (Appendix I, 
11.7). Digested nucleic acid products were imaged using the Gene Flash Syngene Bio Imager.  
2.11.6 HEK293 Cell Line Transfection 
HEK293 adherent cell line was used as a vehicle for the expression of FL-RAGE and es-RAGE 
pcDNA3 plasmids due to the ease of transfection and production of conditioned media. Polymer 
based jetPRIME® reagent was used for transient DNA transfection based on high transfection 
efficiency and very low cytotoxicity. 1x106 HEK293 cells were cultured in 10ml RPMI complete 
growth medium in 75cm2 flasks and cultured at 37°C in a humidified 5% CO₂ incubator until cells 
were 60-80% confluent. At the time of transfection, 5µg of FL-RAGE, es-RAGE and empty pUC19 
plasmid DNA were mixed with 500µl jetPRIME® buffer and 10µl jetPRIME® reagent (Appendix I, 
11.8) and incubated for 10 minutes at room temperature to promote formation of plasmid-
polymer complexes. 500µl of transfection mix was added to the medium of cells in a dropwise 
manner and left for 4 hours at 37°C in a humidified 5% CO2 incubator with gentle rocking. After 
4 hours, HEK293 cells transfected for conditioned medium were washed with sterile PBS and 
resuspended in serum-free RPMI medium for 24 hours. Then, conditioned medium was 
collected by centrifugation at 2000rpm for 5 minutes and passed through a 0.22µM filter; 
conditioned medium was stored at 4°C and used for in vitro assays within 24 hours. HEK293 cells 
transfected for FL-RAGE or es-RAGE HEK293 cell expression were resuspended in fresh RPMI 
complete growth medium after 4 hours of transfection and left for 24 hours before harvesting. 
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After 24 hours, cells were pelleted by centrifugation at 1500rpm for 5 minutes, washed with ice 
cold PBS and used for western blot cell lysates or flow cytometry analysis. A pLenti6-GFP 
expressing plasmid was included in the transfection step as a control to evaluate transfection 
efficiency after 24 hours using a Nikon inverted wide-field microscope. 
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2.12 Statistical Analysis 
2.12.1 General statistical Analysis  
IBM SPSS 22 and GraphPad Prism 5.03 statistical software were used for data analysis. Data are 
shown as either mean ± standard deviation (SD) or median with interquartile range when 
variation was high. All pairwise comparisons were analysed using the Mann-Whitney U test 
between groups with unequal size and the student’s t test for equal sized groups. For 
comparisons of more than 2 groups, One-Way ANOVA was used. Correlations were analysed by 
Pearson product-moment correlation to assess the linear correlation between 2 groups. 
Statistical significance for all tests was set at 0.05. *, ** and *** indicate P value < 0.05, 0.01, or 
0.001., respectively.  
2.12.2 Obtain cut off point using X-tile 
Continuous data, generated from LN TMA RAGE, TLR9 and Ki67 expression, was categorised into 
subgroups based on the levels of biomarker expression and patient overall survival outcome 
using X-tile software.312,313 Categorising variable expression into subsets is a clinically relevant 
method, but there is currently no standardised statistical method to determine optimal data cut 
points for expression variables that don’t have prior defined subsets. X-tile software avoids the 
statistically invalid method of hunting for the best P-value (outcome-oriented) or dividing the 
cohort 1:1 (data-oriented) by dividing continuous data into 1:2 test/validation sets.313 Different 
data divisions are assessed in the ‘test’ cohort and then applied to the ‘validation’ cohort. The 
software then produces the optimal number of cut points with associated P-values based on 
applying the test-defined cut points to the validation dataset. Using X-tile helps to identify sub-
populations of expression biomarkers rooted with unknown biology which would otherwise be 
left unnoticed.  
2.12.3 Survival Analysis 
The association between protein expression and overall survival (OS) was analysed by uni-and 
multivariate Cox regression analysis on both continuous and categorical variables to increase 
statistical robustness. OS, meaning death from any cause was used to measure outcome from 
the date of diagnosis, to event occurring, or date of last follow up. Variables assessed as 
continuous data was used to determine the prognostic impact of each variable by the Cox 
proportional hazards model. Hazard ratios (HR) with 95% confidence intervals for OS outcome 
were generated using this method for continuous RAGE, TLR9, Ki67 biomarkers and age. 
Continuous data were divided into categories based on levels of biomarker expression using X-
Chapter II Materials and Methods 
96 
 
tile described earlier. Chi-square test was used to analyse the frequency of distribution between 
2 categorical variables. P-values and HR with 95% confidence intervals for categorical data 
defined by these cut points were measured by Cox regression analysis, and Kaplan-Meier 
survival curve analysis using a log-rank test. 
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Chapter 3 Determine the prognostic values of RAGE and TLR9 
expression in CLL lymph nodes 
 
 
 
 
 
Chapter III 
 
Assess the prognostic impact of HMGB1 receptors 
RAGE and TLR9 and their effects on CLL overall 
survival 
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3.1 Introduction 
CLL is a highly diverse and heterogeneous disease, reflected in variations in prognostic 
biomarkers and genetic aberrations in patients. The disease heavily relies on 
microenvironmental interactions for external survival signals, densely located in the CLL LN.47 
Although increased CLL cell proliferation is highly observed CLL LNs compared to quiescent cells 
in CLL PB, CLL LN biopsies are not routinely removed and examined to aid in CLL diagnosis or 
disease staging. Correlation of PB markers with CLL LN biology would give deeper insight into 
CLL pathogenesis and more accurate disease staging. 
The Rai and Binet staging criteria are routine classical systems to classify CLL disease based on 
clinical features such as thrombocytopenia, lymphadenopathy and lymphocytosis (low to high 
risk is A-C and 0-III, respectively).84,85 However, these staging systems do not provide an 
understanding of the underlying molecular biology that could be used to classify disease. CLL 
patients can be stratified into aggressive and indolent subsets based on IGHV gene region 
mutation status.50 Approximately 35% of patients carry unmutated IGHV gene regions in CLL (U-
CLL) and have a worse prognosis (predicted mean survival of 8 years), compared to patients with 
mutated IGHV genes (M-CLL; predicted mean survival of 24 years).51 Both CLL subsets share a 
similar gene expression profile except for a marked increase in ZAP70 and CD38 expression in 
U-CLL.93 Other risk factors associated with poor disease outcome include cytogenetic 
aberrations del(17p), del(11q), trisomy 12, and genetic lesions in NOTCH1, SF3B1, TP53, ATM, 
PAX5, MYD88 contributing to disease pathogenesis.49,314,315 
The CLL LN harbours the proliferative CLL fraction, indicated by enhanced activation of BCR 
signalling pathways, NF-κB activation, c-MYC, E2F and Ki67 expression.47 The CLL LN is a niche 
site, rich in tumour-associated cells and inflammatory cytokines, chemokines and mediators that 
sustain CLL cell survival. This molecular and cellular understanding is translating into emerging 
therapies to target CLL such as Ibrutinib and PDL1 blockade. One established CLL 
microenvironment interaction includes HMGB1; our group identified increased levels of HMGB1 
in the plasma of CLL patients, inducing the differentiation of NLCs and associated with poorer 
clinical outcome.76 The main HMGB1 receptors include TLR2, TLR4, TLR9 and RAGE, but 
expression levels of these receptors and usage in CLL cells in sites of active proliferation is 
unknown. HMGB1 has dual roles in cancer, capable of both pro- and anti-tumour responses by 
activating various immune cell subsets. Although increased plasma HMGB1 levels are associated 
with poorer clinical outcomes in CLL, it is yet to be established if the HMGB1-receptor signalling 
axis results in pro- or anti-tumour responses in CLL. Assessing receptor expression and 
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determining the prognostic significance of these receptors in the CLL LN will give an indication 
of the outcome response. 
With increasing development of signalling inhibitors and therapies that target and shape the CLL 
microenvironment, easily attainable biomarkers that correlate with LN biology would give 
deeper insight into disease pathogenesis and therapy choice, i.e. plasma HMGB1 and LN HMGB1 
receptor expression. Moreover, better biomarkers of inflammation could be used as feasible 
monitors in a clinical setting to assess microenvironment polarisation and predict disease 
outcome.  
The work in this chapter will determine i) the main HMGB1 receptors in CLL; ii) if HMGB1-
receptor signalling is pro- or anti-tumour; and iii) if HMGB1 receptor expression could be used 
as a clinical prognostic marker for CLL.  
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3.2 Results 
3.2.1 RAGE and TLR9 expression is heterogeneous among CLL patients and lower 
compared to RA-LN tissue 
Using available gene expression datasets,316 we first determined gene expression of HMGB1 
receptors RAGE, TLR2, TLR4 and TLR9, and of all other TLRs in CLL patient peripheral blood 
samples compared to age-matched healthy controls.316 RAGE and TLR9 gene expression is 
significantly increased in CLL patients compared to age-matched controls (P<0.01 and P<0.001, 
respectively; Figure 3-1). Whereas, TLR2 and TLR4 have significantly lower gene expression. 
Although mRNA levels are not accurate indicators of protein levels, this data combined with 
reports of low TLR4 protein expression in CLL suggests RAGE and TLR9 are the most likely 
candidate receptors for HMGB1 in CLL cells.76,317  
For other non-HMGB1 receptor TLRs, TLR7 gene expression was significantly increased 
compared to controls (P<0.001), owing to a mature B-cell phenotype and a similar TLR 
expression profile as memory B-cells.317-319 TLR8 expression was significantly decreased 
(P<0.001). 
 
Figure 3-1 RAGE and TLR gene expression in CLL patient PB B-cells and age-matched healthy control PB 
B-cells 
Comparison of RAGE and TLR1-10 mRNA expression in CLL PB B-cell to normal PB B-cells; n=41 and n=11, 
respectively. Levels of mRNA expression were obtained from an available GEO dataset assessing gene 
expression profiles of untreated CLL patient samples.316 Transformed count represents log2 transformed 
and RMA normalised mRNA expression data. Data are presented as mean ± SD and differences compared 
with an unpaired Mann Whitney U test; P<0.05*, P<0.01*; P<0.001*. 
 
To establish HMGB1 receptor expression in the LN of CLL patients, a key site of 
microenvironment CLL pathogenesis, we performed IHC on LN tissue biopsies arrayed onto 
TMAs from a cohort of 91 CLL patients and compared to RA-LN TMAs from 42 healthy controls.47 
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CLL LN biopsies were sourced from CLL patients who were either untreated or post-treatment, 
where tissue biopsies were removed to aid in diagnosis or assess disease progression; RA-LN 
biopsies were sourced from non-malignant patients.  
TMA slides were stained for RAGE and TLR9 in antibody-specific batches, for accurate 
comparison, and protein expression image analysis performed using the Ariol automated digital 
analysis software. CD5 positive areas in CLL LN cores were selected for analysis to maximise 
malignant CLL cell-only expression measurements (Appendix Figure 5), and germinal centres of 
RA-LNs were selected to represent an activated B-cell control comparison (Figure 3-2A and C). 
RAGE protein expression, i.e. the intensity of brown DAB staining in LN cores, was measured 
using the Ariol shape and colour image classifiers. First, LN core cell number was determined 
using blue haematoxylin-stained nuclei to train the cell shape classifier. Second, the intensity of 
brown staining for each cell was measured using colour classifier, trained based on saturation, 
hue and intensity of brown pixels. Minimum thresholds were set that excluded brown 
background staining to ensure only strong positive brown pixel/protein expression was 
measured (Figure 3-2). Once the training algorithm was optimised by combining these 2 image 
classifiers per antibody stain, it was applied to all TMAs; the use of automated image analysis 
limits error, bias and variability between TMAs.  
RAGE and TLR9 protein levels are expressed as the percentage of positive cells for brown staining 
in the LN core. Mean percent-positive staining was calculated for each stain per patient. 
Incomplete or damaged LN cores were excluded from analysis and patients with less than 2 full 
intact LNs were discarded to limit LN bias; 17 patients were discarded from analysis leaving 91 
CLL patients in total.  
Comparing LN protein expression, RAGE expression is localised to cell cytoplasm and cell 
membranes in CLL LNs, and highly expressed in the LN proliferation centre (Figure 3-3B; 
indicated by white arrow and assessed by our in-house histopathologist, Andrew Clear). In RA-
LNs, RAGE is highly expressed in the germinal centre where B-cells proliferate and mature, but 
not in the mantle zone where small naïve B-cells are packed (Figure 3-3A). TLR9 is localised to 
the cytoplasm of nearly all cells in CLL-LNs and expressed strongly in mantle zone B-cells, and to 
a weaker extent in the germinal centre of RA-LNs (Figure 3-3C and D).  
Overall RAGE and TLR9 expression in CLL-LNs were significantly lower when compared with the 
germinal centre in RA-LNs (P<0.0001; Figure 3-4). The vast range in RAGE and TLR9 CLL-LN 
expression levels (0.8-100% and 3.4-90.7%, respectively) indicate HMGB1 receptor expression is 
highly heterogeneous among CLL patients, and the levels of these receptors are lower compared 
with areas of inflamed tissue.  
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This data may reflect the clinical heterogeneity in CLL disease and the variability in 
microenvironment dependence among CLL patients. The RA-LN data highlights the routine role 
of RAGE in a healthy setting as an endogenous stress-response receptor and the involvement of 
TLR9 signalling. Our findings suggest that CLL patients do express RAGE and TLR9 proteins in 
niche microenvironment sites of CLL-cell proliferation, in line with the gene expression data, and 
provides us with rationale to further investigate the clinical significance of receptor LN 
expression.  
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Figure 3-2 Representative images of immunohistochemical staining of RAGE and TLR9 in primary CLL 
and RA-LN tissue 
Representative 5x magnified images of RAGE and TLR9 staining in primary CLL and RA LN tissue biopsies 
(A-D).  CLL and RA TMAs were constructed by Andrew Clear and stained with monoclonal mouse anti-
RAGE (A and B) and mouse anti-TLR9 antibodies (C and D) under optimal conditions; nuclei were visualised 
in blue by staining with haematoxylin. Antibody-antigen interactions were visualised using a peroxidase-
labelled system with 3,3’-diaminobenzidine (DAB) chromogen to give brown staining (Super-Sensitive 
Polymer-HRP IHC Detection System). Weak background brown staining was excluded by selecting strong, 
high intensity brown pixels during image analysis training. Germinal centres of RA-LN were selected for 
image analysis, highlighted by white arrows (A and C), and CD5+ areas (Appendix Figure 5) for CLL LN 
whole cores (B and D). 
 
 
Chapter III Results 
104 
 
 
Figure 3-3 RAGE and TLR9 expression in CLL-LN and RA-LN 
20x representative immunohistochemical staining images for RAGE and TLR9 in RA-LN (A and C) and CLL-
LN (B and D). Proteins were stained with either mouse anti-RAGE antibody or mouse anti-TLR9 antibody 
and visualised in brown with DAB chromogen; nuclei of cells are stained blue with haematoxylin. ‘GC’, 
‘MZ’ and ‘PC’ indicates germinal centres, mantle zone and proliferation centre (determined by KI67 IHC 
staining), respectively assessed by Andrew Clear and Professor Maria Calaminici. Magnification x20. 
 
Figure 3-4 Comparison of RAGE and TLR9 expression in whole CLL-LN core with RA-LN germinal centres 
Expression levels of RAGE and TLR9 previously stained by IHC and were quantified using the ARIOL digital 
imaging analysis software. Protein expression were calculated as the % of cells positive for brown staining 
in the LN core based on colour and shape image classifiers. Positive high intensity brown staining was 
selected based on hue, saturation and pixel intensity to remove background staining, and cell number 
determined by blue nuclear staining. Non-viable tissue was removed from image analysis. Statistical 
differences in % of protein expression between germinal centres of RA LN (n=42) and CD5+ areas of CLL 
LN (n=91) for RAGE (A) and TLR9 (B) was analysed by an unpaired Mann Whitney U test. Data are 
presented as medians with interquartile range; P<0.0001***. 
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3.2.2 RAGE expression is associated with cell proliferation and worse prognosis 
Next, we determined the correlation between RAGE and TLR9 LN protein expression to infer a 
possible relationship between these 2 proteins in CLL disease pathogenesis. Then, we 
determined the strength of linkage between RAGE and TLR9 LN expression with established cell 
cycle proliferation marker, Ki67, and poor prognostic and aggressive disease marker, ZAP70, 
assessed by IHC for the same CLL LN TMA patient cohort.  
Using Pearson’s multiple correlation analysis, the levels of RAGE and TLR9 had a significant 
positive correlation (P<0.0001; R=0.416; Figure 3-5). This observation suggests the proteins 
could function in a co-linked manner, facilitating delivery of CpG-ODN to TLR9 via interaction 
with HMGB1, and internalisation by RAGE. However, TLR9 has other reported roles in CLL; TLR9 
stimulation results in dichotic cell proliferation or cell death responses, dependent on IGHV 
mutational status.96,318 The correlation coefficient between RAGE and TLR9 was R=0.416. RAGE 
expression is further positively correlated with ZAP70 (P<0.05; R=0.263; Figure 3-5) and strongly 
with Ki67 (P<0.0001; R=0.573; Figure 3-5). TLR9 LN expression also exhibited a significant 
positive correlation with Ki67 (P<0.0001; R=0.488; Figure 3-5), but not with ZAP70 expression. 
Although ZAP70 expression data used in this study originated from LN, expression scoring 
correlates with ZAP70 PB expression score (Appendix Figure 7). 
Ki67 expression is strictly associated with cell proliferation and is present in the nuclei of cells 
during active phases of the cell cycle (G1, S, G2,  and M phases) and absent during resting phase 
(G0).320 For these reasons, Ki67 is used as an established cell proliferation marker. Correlation of 
both RAGE and TLR9 with Ki67 in CLL LNs, highlights an active role in mediating CLL 
microenvironmental interactions to induce and sustain CLL cell survival. The association 
between RAGE and ZAP70 does imply RAGE expression is more prevalent in aggressive CLL 
subsets, as ZAP70+ expression is highly restricted to unmutated CLL,92 but this will require 
further investigation to fully define CLL subset specificity. The lack of correlation between TLR9 
and ZAP70 could be explained by the opposing cell death/proliferation responses following TLR9 
stimulation in either unmutated or mutated CLL.96 However, further separation of this cohort of 
patients into ZAP70+ and ZAP70- did not reveal a significant difference in TLR9 LN expression for 
this cohort or patients (Appendix Figure 6). 
Following a significant positive correlation with Ki67, we assessed the association between RAGE 
and TLR9 LN expression with proliferation centre size (assessed by expert histopathologist Maria 
Calaminici) and CLL disease Binet staging available on our clinical database. RAGE expression 
was significantly higher in LN cores with large proliferation centres (P<0.05; Figure 3-6A) 
compared to no association for TLR9. This result strengthens a proliferation role for RAGE, in 
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combination with previous data. Again, the lack of association for TLR9 is due to the opposing 
cell death/cell proliferation functions of receptor stimulation in CLL. No association between 
Binet staging and RAGE or TLR9 expression was observed for this cohort of patients (Figure 3-6B 
and D), and only a positive correlation between trisomy 12 and % RAGE LN expression (P<0.05; 
Appendix Figure 8B). 
These results suggest RAGE could have a pro-tumour role in CLL as RAGE is predominately 
expressed in proliferating CLL cells and associated with more aggressive disease. The positive 
correlation between RAGE and TLR9 suggests these proteins could function in a co-linked 
manner but also maintain separate roles in CLL, as have been demonstrated before for TLR9. 
Further investigating the effect of RAGE expression on CLL patient outcome will indicate a 
predominate pro- or anti-tumour role.  
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Figure 3-5 Evaluation of correlation between RAGE and TLR9 CLL-LN expression with Ki67 and ZAP70 LN 
expression 
LN expression levels of RAGE and TLR9 were determined by IHC and analysed with ARIOL image analysis 
software (Figure 3-4); LN expression levels of Ki67 and ZAP70 were previously stained on the same CLL 
TMAs by Andrew Clear and Dr Meg Ashton, respectively, and visualised with DAB chromogen.  Ki67 
protein expression levels were calculated as the % of cells positive for brown staining using the ARIOL 
colour and shape image classifiers. ZAP70 LN protein expression was classified as positive (2) if the % of 
cells positive for ZAP70 was >20 in the LN core, and negative (1) if less than <20%. Linear correlations 
between RAGE, TLR9, Ki67 and ZAP70 CLL expression were assessed by Pearson product-moment multiple 
correlation method (A). Detailed statistical data (B) are presented as R=Pearson correlation coefficient, P-
value and sample size (N); P<0.05*, P<0.01**. 
Ki67 ZAP70 TLR9 RAGE 
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Figure 3-6 Evaluation of RAGE and TLR9 expression association with LN proliferation centre size and 
CLL disease Binet stage 
LN protein expression levels were compared to LN proliferation centre size and CLL disease Binet staging 
for RAGE (A and B) and TLR9 (C and D). Proliferation centre size was previously assessed in whole LN 
biopsies by histopathologist, Professor Maria Calaminici, and Binet staging performed at diagnosis; clinical 
data was extracted from our tissue bank clinical database. Expression levels of RAGE and TLR9 were 
determined by IHC (Figure 3-4). Data are presented as median ± interquartile range. Statistical differences 
assessed by an unpaired Mann Whitney U test for proliferation centre size (A and C) and Kruskal-Wallis 
one-way ANOVA for Binet staging (B and D); P<0.05*. 
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3.2.3 CLL patients with high RAGE expression have a poor overall survival 
We have shown RAGE expression is positively correlated with levels of ZAP70 and Ki67. ZAP70 
is an established independent prognostic marker for CLL.321 Investigating the association of 
HMGB1 receptor expression on CLL patient outcome will indicate a predominate pro- or anti-
tumour role, and if expression of these proteins could be used to predict CLL patient outcome. 
We determined the association of RAGE and TLR9 with clinical outcome by Kaplan Meier 
analysis. Expression levels of all continuous variables were categorised into subgroups using X-
tile software, to statistically define optimal data cut points for variables that lack accepted 
established data ranges. This method limits the loss of biologically relevant subgroups 
commonly performed by dividing datasets using the median value, and prevents P-value driven 
cut point generation. The software separates expression data into test-validation cohorts in a 
1:2 ratio. All possible cut points are rigorously investigated in the test cohort, before being 
applied to the validation cohort. X-tile software generated 2 cut points for RAGE, TLR9 and Ki67, 
separating these continuous variables into low, medium and high expression for CLL patients 
(Table 5); ZAP70 LN expression was previously scored as either positive or negative.  
Kaplan-Meier curves were generated by the log rank test based on X-tile expression data cut 
points to compare differences in outcome between expression subgroups. OS, meaning death 
from any cause was used to measure outcome from the date of diagnosis, to event occurring, 
or date of last follow up for this cohort of patients. Differences in patient OS based on subgroup 
expression were tested using the log-rank test (Mantel-Cox), generating P-values, hazard ratios 
(HR) and 95% confidence intervals (CIs). For this analysis, HR represents the risk of death 
occurring by a certain time point. A HR of 2 indicates death by any cause, is 2x more likely to 
occur in the high expression subgroup compared to the low expression subgroup. 
Separation of variables and association with OS was visualised by Kaplan-Meier curves (Figure 
3-7; Figure 3-8). CLL patients with RAGEHIGH expression confer inferior OS (median OS =3 years; 
HR=2.4; n=13) compared to patients with medium/low RAGE expression (n=29 and 48, 
respectively; median OS =7.5 years; log rank test P<0.05; Figure 3-7A). This indicates that RAGE 
exhibits a pro-tumour function in CLL, and patients with high levels of LN RAGE have a 2.4x 
increased likelihood of death compared to patients with low RAGE expression. Although patients 
TLR9HIGH expression have a 1.6x higher risk of death compared to patients with TLR9LOW, this 
separation was not significant by log rank test (Figure 3-7B). 
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  Table 5. X-tile generated cut points for RAGE, TLR9 and Ki67 
 RAGE TLR9 Ki67 
Low <48.34 <39.08 <5.00 
Medium 48.34–78.07 39.08–61.60 5.00–11.69 
High >78.07 >61.60 >11.69 
 
 
Figure 3-7 Higher expression of RAGE is associated with a poor clinical outcome for patients with CLL 
Evaluation of low, medium and high RAGE (A) and TLR9 (B) LN expression on CLL patient OS. Cut-off points 
for each variable were obtained by X-tile statistical software (Table 5). Kaplan-Meier survival curves were 
generated using these data cut points and P-values, HR and 95% CIs were generated using a log-rank test 
in GraphPad Prism software. HR were produced by comparing the high expression group to the low 
expression group. OS= overall survival, HR= hazard ratio. The P-vale compares the low expression 
subgroup to the high expression subgroup. 
 
Next, we assessed the impact of Ki67 and ZAP70 on patient OS, to test our cohort of CLL patients 
have phenotypic characteristics indicative of the wider CLL population. Although patients with 
Ki67HIGH and ZAP70+ expression have a shorter OS (Ki67 median OS =4.7 years; ZAP70+ median 
OS =5.6 years; Figure 3-8), this association was not significant for this cohort of patients. The HR 
for these variables were >1, suggesting higher expression of these proteins is associated with 
shorter OS.  
All variables were compared by Chi-Square analysis using RAGE-defined cut points (Table 6). This 
test was used to analyse the frequency of distribution between 2 categorical variables. As RAGE 
expression increases, Ki67, TLR9, ZAP70 and age biomarkers increase, alongside a negative 
correlation with median OS rates (Chi-Square analysis; P<0.0001), highlighting the inferior effect 
of overexpression of RAGE on disease outcome. This data indicates that higher expression of 
RAGE, but not TLR9, is associated with a poorer clinical outcome in patients with CLL. This data 
suggests a functional role for RAGE in CLL disease pathogenesis, and further investigation of 
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RAGE prognostic significance could establish RAGE as a newly reported predictive marker of CLL 
disease outcome. 
 
Figure 3-8 Ki67 and ZAP70 LN expression does not predict a shorter OS for this cohort of CLL patients 
Evaluation of low, medium and high Ki67 (A) and positive or negative ZAP70 (B) LN expression on CLL 
patient OS. Cut-off points for Ki67 were obtained by X-tile statistical software (Table 5) and ZAP70 scored 
positive if staining >20% of cells were positive for ZAP70. Kaplan-Meier survival curves were generated 
using these data cut points and P-values, HR and 95% CIs were generated using a log-rank test in GraphPad 
Prism software. HR were produced by comparing the high expression group to the low expression group. 
OS= overall survival, HR= hazard ratio, CI= confidence intervals.  
 
 
              Table 6. Chi-Square analysis for all variables 
Note: the cut points of RAGE were generated by X-tile. All other variables were separated 
according to the categories of RAGE. P<0.0001 
  
 
RAGELOW RAGEMEDIUM RAGEHIGH 
RAGE (median ± SD) 25.99 ± 10.83 58.59 ± 7.12 99.07 ± 5.92 
Overall Survival - Years 
(median ± SD) 
7.49 ± 3.53 7.87 ± 3.18 3.13 ± 2.18 
Ki67 (median ± SD) 2.53 ± 3.24 6.99 ± 4.41 14.24 ± 8.57 
TLR9 (median ± SD) 40.60 ± 12.92 57.78 ± 12.86  55.68 ± 13.84 
CD3 (median ± SD) 16.90 ± 4.54 19.17 ± 8.19 24.47 ± 9.24 
Age (median ± SD) 57.00 ± 9.47 58.50 ± 6.79 64.50 ± 13.82 
ZAP-70 expression 37% 52% 75% 
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3.2.4 Higher RAGE expression combined with ZAP70 and Ki67 predict a worse clinical 
outcome in CLL 
To further evaluate the association between RAGE and TLR9 LN expression and OS for CLL 
patients, we conducted a Cox regression analysis on both continuous and categorical variables 
and compared this with other available risk factors.  
The Cox regression proportional hazards analysis generates HRs with 95% CIs, by measuring the 
association between continuous or categorical variables, and an end-point event occurring – 
death by any cause in this study. In a continuous univariate analysis, the HR is a measure of the 
increase in risk of death occurring, per unit increase in variable expression. A HR>1 indicates 
higher variable expression confers worse clinical outcome and the opposite, higher variable 
expression confers better outcome, if the HR<1. For categorical Cox regression analysis, RAGE, 
TLR9 and Ki67 variable expression was separated into 3 subgroups based on X-tile-generated 
data cut points. ZAP70 and age variables were separated into 2 subgroups based on previously 
established data ranges (positive or negative ZAP70 expression, and >60 or <60 years of age, 
respectively). HRs were calculated by comparing the high expression subgroup to the low 
expression subgroup for RAGE, TLR9, and Ki67, and direct comparison between the 2 subgroups 
for ZAP70 and age. Both continuous and categorical Cox regression analysis was performed to 
increase statistical robustness in a cohort of 91 CLL patients with available survival data. A 
prognostic significant threshold was set to P<0.05 with a HR either >1 or <1 for biomarkers in 
this study. 
Continuous variable data (RAGE, TLR9, Ki67 and age) was used to determine the prognostic 
impact of each variable by the Cox proportional hazards model. We confirmed age was a 
prognosticator for this cohort of CLL patients (P<0.05; HR = 1.03; n=91; Table 7) when comparing 
to patient OS outcome. As CLL is a disease of the elderly, higher age is already established as an 
indicator of disease outcome and for all disease in general, not just CLL-specific. RAGE, TLR9 and 
Ki67 did not show significant prognostic significance for this cohort of patients. HRs for all 
variables were >1 suggesting higher biomarker expression confers inferior OS, except for RAGE 
where the HR=1. However, use of continuous data can result in the loss of statistical robustness 
and underlying biology.  
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Table 7. Univariate Cox regression analysis for continuous variables 
 
Note: Data shown were analysed by Cox proportional hazard model (n=91). Abbreviations: HR, 
hazard ratio; 95% CI, 95% confidence interval; P, P-value.  
 
In a clinically applicable method, biomarker expression levels were categorised by cut points 
defined using X-tile software (Table 5) and assessed by uni- and multivariate Cox regression 
analysis. Univariate categorical analysis revealed patients with either high RAGE expression 
and/or higher age (>60 years old) had an increased risk of death (RAGEHIGH HR=2.41, P=0.042; 
AgeHIGH HR=1.74, P=0.05; Table 8). Other categorical variables (TLR9, Ki67, and ZAP70) did not 
show prognostic significance. Separating patient biomarker expression into groups is i) easier to 
score and assess in clinic; ii) reveals a statistical association that is overlooked when using 
continuous data.  
To assess the prognostic interaction or confounding effects between different biomarkers we 
performed backward selection multivariate analysis on categorical variables (Table 8). To tease 
apart any prognostic relationship between RAGE and TLR9 with other covariates, these variables 
were first included in pairwise multivariate Cox regression analysis, before inclusion of 
additional covariates, to infer any changes on the HRs. Prognostic interaction between 
covariates was measured by calculating the magnitude of difference between univariate HR to 
multivariate HR value: (HRadjusted-HRunivariate)/HRadjusted X 100%). Finally, all categorical variables 
were included in a full backward wald multivariate analysis to identify biomarkers that retained 
prognostic significance. This method removes variables at each step that lack prognostic 
significance, recalculates HRs and prognostic significance, and repeats the backward selection 
process until the final model results in biomarkers that retain strong prognostic significance 
throughout the selection process even when combined with different interacting covariates. 
This final model identifies robust predictors of disease outcome. 
Combining ZAP70 and RAGE categorical variables greatly increased the prognostic significance 
of high RAGE (RAGEHIGH HR = 8.45, P =0.001; Table 8). ZAP70 and RAGE have a prognostic 
interaction effect of 71.5%, indicating the biological correlation between these 2 variables is 
 
Variable Overall survival 
HR (95% CI) P 
RAGE 1.00 (0.99-1.02) 0.492 
TLR9 1.05 (0.98-1.07) 0.270 
Ki67 1.02 (0.99-1.02) 0.524 
Age 1.03 (1.01-1.06) 0.018 
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causal. Inclusion of Ki67 to RAGE and ZAP70 interacting variables further increases the 
prognostic significance of high RAGE and high Ki67 (RAGEHIGH HR = 14.2, P<0.0001; Table 8) with 
an interaction effect of 83.1%. This result, combined with a significant positive correlation 
between RAGE/ZAP70 and RAGE/Ki67 (Figure 3-5), indicates a causal relationship among RAGE 
with ZAP70 and Ki67.  
TLR9 was not an independent prognostic marker and failed to gain prognostic significance when 
combined with other covariates (Table 8). The dual roles of TLR9 in CLL make it a difficult 
predictor of CLL outcome, as the opposing TLR9 responses heavily rely on the status of other 
variables in CLL disease pathogenesis (i.e. IGHV mutation status and BCR signalling capacity) and 
has only recently undergone functional investigation.96 There was also a significant prognostic 
interaction between age and ZAP70 (AgeHIGH HR =2.50, P=0.006; ZAP70 HR =2.27, P=0.015). 
When the prognostic effect of Ki67 was stratified by ZAP70, the prognostic significance of high 
Ki67 increased, but had a confounding effect on ZAP70 (Table 8).  
Finally, all variables were included in a full backward selection multivariate Cox regression 
analysis (Appendix II; Table M). In the final model, high RAGE, high Ki67 and higher age retained 
significance as prognostic factors for OS. These results indicate that higher expression of RAGE 
has important and robust prognostic value, especially when combined with ZAP70 and Ki67 
variables. This study gives us rationale to further investigate the functional impact of the 
HMGB1-RAGE signalling axis in CLL and potential RAGE blockade.  
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Table 8 Uni- and multivariate Cox regression analysis on categorical variables 
 
Note: The cut-off points for RAGE, TLR9 and Ki67 were generated by the X-tile software and 
listed in Table 5; RAGEMED = medium subgroup; RAGEHIGH = high expression subgroup. ZAP70 was 
classified by positive and negative populations. Age >60 years old is defined as AgeHIGH. The 
estimated measures of association before (HRcrude) and after adjusting (HRadjusted) for interaction 
were calculated as: magnitude of interaction = (HRadjusted-HRcrude)/HRadjusted X 100%. The 
interaction effect of ZAP-70 on RAGE is 71.48% without Ki67 and is 83.10% with Ki67; the effect 
of ZAP-70 on Ki67 is 47.80% without RAGE and 54.98% with RAGE.  
 
  
 
Univariate Multivariate 
Covariates OS Covariates OS 
HR (95% CI) P HR (95% CI) P 
 
RAGEMEDIA 
RAGEHIGH 
 
0.97 (0.53-1.78) 
2.41 (1.03-5.61) 
 
0.930 
0.042 
ZAP70 
RAGEMEDIA 
RAGEHIGH 
0.53 (0.30-0.92) 
0.88 (0.46-1.68) 
8.45 (2.31-30.90) 
0.062 
0.702 
0.001 
 
TLR9MEDIA 
TLR9HIGH 
 
 
0.97 (0.52-1.80) 
1.60 (0.77-3.33) 
 
0.913 
0.207 
ZAP70 
TLR9MEDIA 
TLR9HIGH 
1.60 (0.85-3.01) 
1.05 (0.54-2.04) 
1.35 (0.56-3.27) 
0.144 
0.894 
0.508 
 
Ki67MEDIA 
Ki67HIGH 
 
0.89 (0.47-1.72) 
1.90 (0.89-4.04) 
 
0.735 
0.094 
ZAP70 
Ki67MEDIA 
Ki67HIGH 
1.41 (0.75-2.68) 
0.79 (0.34-1.59) 
3.64 (1.36-9.76) 
0.290 
0.504 
0.010 
ZAP70 1.69 (0.93-3.08) 0.084 ZAP70 
RAGEMEDIA 
RAGEHIGH 
Ki67MEDIA 
Ki67HIGH 
1.47 (0.77-2.80) 
0.85 (0.44-1.66) 
14.2 (3.35-60.07) 
0.63 (2.29-1.39) 
4.22 (1.52-11.72) 
0.242 
0.626 
<0.0001 
0.257 
0.006 
 
Age 
 
1.74 (0.99-3.04) 
 
0.050 
ZAP70 
Age 
2.27 (1.17-4.39) 
2.50 (1.29-4.84)  
0.015 
0.006 
RAGEMED 
RAGEHIGH 
 
TLR9MED 
TLR9HIGH 
 
Ki67MED 
Ki67HIGH 
 
ZAP70 
RAGEMED 
RAGEHIGH 
 ZAP70 
TLR9MED 
TLR9HIGH 
 
ZAP70 
Ki67MED 
Ki67HIGH 
 ZAP70 
RAGEMED 
RAGEHIGH 
 Ki67
MED 
Ki67HIGH 
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3.3 Discussion 
In this chapter, we have shown that HMGB1 receptors, RAGE and TLR9 are heterogeneously 
expressed in CLL patients. Increased RAGE expression in CLL LNs positively correlated with 
established proliferation marker, Ki67, and aggressive disease marker, ZAP70. Moreover, high 
RAGE expression is associated with shorter OS and prognostic significance increased when 
stratified with ZAP70 and Ki67 categorical variables for patients with CLL. This data 
demonstrates for the first time that high RAGE expression in CLL LNs in patients with CLL, confer 
inferior clinical outcome. 
The main HMGB1 receptors involved in initiating DAMP-associated inflammatory responses 
include TLR2, TLR4, TLR9 and RAGE.123,131,143 RAGE and TLR9 were the only HMGB1 receptors 
with increased mRNA expression in CLL peripheral blood compared to healthy age matched 
controls.316 The TLR gene expression profile in CLL PB was similar to that of memory B-cells, 
owing to a mature CLL B-cell phenotype.322 Increased expression of TLR7 and TLR9 in CLL are 
likely due to prior activation in vivo with endogenous TLR7 ligands (single strand RNA) and 
dichotic responses following TLR9 stimulation with Class B-CpG-ODN previously documented in 
CLL.96,318 Growing evidence highlights CLL LNs as a key site of CLL pathogenesis and host-tumour 
interactions.47 From our results, RAGE and TLR9 LN expression is highly heterogeneous among 
patients, reflecting the biological and clinical diversity of CLL disease. RAGE is predominately 
expressed in large proliferation centres in CLL LNs; a niche site associated with the proliferation 
and survival of CLL cells, infiltration of T-cells and macrophages, activation of inflammatory 
pathways, aggressive disease and inferior survival.323-325 RAGE and TLR9 expression in CLL LNs is 
overall lower compared to germinal centres in RA-LN. As sites of acute B-cell proliferation, high 
RAGE and TLR9 expression in reactive germinal centres highlight their routine roles in the 
activation and proliferation of healthy B-cells, as well as in CLL.326,327  
An increased understanding of CLL biology is enhancing our capacity to identify patients with 
high risk disease, by using a wealth of risk factors.328,329 The most powerful molecular prognostic 
marker utilised clinically is the IGHV mutational status. The two main subsets differ markedly, 
patients with no somatic hypermutations in the IGHV gene region (unmutated-CLL) generally 
have a more aggressive disease.50 However, IGHV sequencing is not routinely available for all 
patients at diagnosis, owing to the difficulty and cost in performing this procedure as a clinical 
test.330 Gene expression profiling studies identified high expression of ZAP70 and CD38 in U-CLL 
subsets, and ZAP70 expression can distinguish the U-CLL/M-CLL subsets with high 
significance.51,92,331 Del(17p) and del(11q) are associated with U-CLL and used in disease 
management algorithms.332 Although Ki67 expression is not a CLL prognostic marker, tumour 
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proliferation can be quantified by measuring levels of Ki67, an antigen that is strictly associated 
and expressed during active phases of the cell cycle (G1, S, G2 and M).47,320 The current 
prognostic markers used clinically have greatly improved patient stratification and disease 
management, but no molecular markers to date truly reflect the microenvironmental-biology 
occurring in CLL LNs and contributing to disease pathogenesis. Our results show RAGE 
expression in CLL LNs highly correlates with levels of Ki67 and ZAP70, and poor disease outcome, 
indicating a predominate association with proliferative and aggressive disease.  
Our group have previously shown that increased levels of extracellular HMGB1 in CLL plasma 
are associated with poorer clinical outcomes in these patients, but the prognostic impact of 
HMGB1 receptors and pathway remains elusive.76 Previous reports demonstrate RAGE blockade 
supresses tumour growth in models of solid cancer,168 but whether HMGB1 signals in a pro- or 
anti-tumour manner in CLL is unknown. Although RAGE expression is highly heterogeneous 
among CLL patients, we have shown that patients with high RAGE expression confer inferior OS. 
The use of X-tile software to statistically define optimal data cut points for RAGE and TLR9 that 
lack accepted established data ranges, limits p-value driven cut point generation.313 Confirmed 
by Chi-Square analysis, RAGE-defined cut points positively correlated with levels of Ki67, TLR9, 
ZAP70 and age and negatively with OS rates. This suggests the HMGB1-RAGE signalling axis has 
a predominate pro-tumour role in CLL, and highlights this signalling axis as an important survival 
pathway to investigate in CLL. Using Cox regression univariate analysis, Ki67, RAGE and TLR9 
continuous variables and ZAP70 categorical variable are not significant. The age of the patient 
has prognostic significance, but worse disease outcome is due to older age, not underlying 
biology. However, when we categorically divide variable expression, as would be applied 
clinically, RAGEᴴᴵᴳᴴ gains independent prognostic significance for this cohort of patients. ZAP70 
and Ki67 do not have independent prognostic significance, highlighting the need to combine 
with other data cohorts, or assess larger sample sizes, to ensure our results are indicative of the 
wider CLL population. The hazard ratio and prognostic significance of RAGEᴴᴵᴳᴴ increases when 
stratified with ZAP70 and Ki67, indicating an interacting relationship between RAGE and these 
variables. Moreover, TLR9 signalling results in opposing anti- or pro- apoptotic signalling 
associated with unmutated or mutated IGHV gene status respectively and ZAP70 positivity.96 
In summary, these results possible demonstrate RAGE plays an important microenvironmental 
role in CLL LNs. Increased CLL LN RAGE expression predicts shorter OS and is associated with 
expression other poor CLL disease markers. Validation of our findings with independent data 
cohorts will strengthen our hypothesis, and further functional validation will give insight into the 
precise role of RAGE and contribution to CLL disease pathogenesis.  
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Chapter 4 Determine the clinical relevance of 
extracellular HMGB1 and soluble RAGE in CLL 
 
 
 
 
 
Chapter IV 
 
Determine the clinical relevance of the HMGB1-
RAGE signalling axis 
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4.1 Introduction 
RAGE is a multifunctional receptor, heavily involved in initiating and sustaining inflammatory 
signalling in response to a multitude of stress-related ligands such as HMGB1, S100 proteins and 
AGEs.186 Our results in the previous chapter support a pro-tumour role for RAGE in CLL-LNs, but 
other RAGE ligands and receptor expression on other LN infiltrating cell subsets, may also drive 
this response in CLL. Further investigation of extracellular HMGB1 ligand levels with other RAGE 
ligands associated with cancer, their correlation with clinical data, and quantifying expression of 
HMGB1 receptors in different cell populations, will strengthen the clinical relevance of the 
HMGB1-RAGE signalling axis in CLL.  
Increased expression of HMGB1 receptor, RAGE, is detected in various solid cancers, although 
molecular details linking RAGE expression to neoplastic transformation is limited. Few studies 
focus on the mechanistic link between RAGE ligands and pro- or anti-tumour cell signalling, 
owing to varied downstream RAGE signalling in a manner that is cell-type specific. Extracellular 
HMGB1 and S100B are the only RAGE ligands with reported extracellular roles in cancer, linked 
to a poor clinical outcome for CLL and melanoma patients, respectively.76,333 Moreover, the 
interplay between membrane-bound RAGE and its isoforms, particularly the pool of extracellular 
soluble RAGE, are pivotal in regulating chronic inflammation through ‘decoy’ receptor ability.334 
In a healthy setting, extracellular HMGB1 and sRAGE levels are inversely correlated, highlighting 
circulating sRAGE captures and eliminates HMGB1 to limit inflammatory responses.209 The 
relationship between extracellular HMGB1 or other RAGE ligand S100B, and antagonistic sRAGE 
in CLL is currently unknown.  
Association between molecular markers and CLL clinical data provides a link to disease severity. 
CLL disease staging based on clinical/symptomatic features under the Rai and Binet classification 
systems, and assessment of chromosome aberrations, aids in disease management. However, 
determination of the IGHV mutational status is the gold standard molecular prognostic factor 
for CLL patients, guiding individualised therapy.50,51 IGHV gene sequencing is not routinely 
available for patients at diagnosis in UK clinical practice, owing to the difficulty and cost in 
performing this procedure as a clinical test.330 ZAP70 is one of the few genes with differential 
expression between the CLL subsets, with high expression associated with unmutated IGHV 
mutational status; therefore, ZAP70 expression serves as an alternative method for prognostic 
grading.92,335 Currently, ZAP70 expression is assessed by flow cytometry using patient PB CLL B-
cells, but there is no standardised method to allow reliable and reproducible testing between 
diagnostic laboratories.336 A few main methods have been developed, rigorously tested and 
used in clinic as a surrogate for IGHV gene sequencing.298  Our previous results showed RAGE LN 
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expression is associated with ZAP70 LN expression; further comparison of plasma HMGB1 with 
PB ZAP70 expression will give an indication of CLL subset specificity.  
In the CLL disease setting, plasma HMGB1 levels are significantly increased in untreated and 
relapsed patients compared to healthy controls and HMGB1 induces the differentiation of NLCs 
that harbour CLL cell survival.76 We have shown LN RAGE expression confers inferior OS, but 
whether HMGB1 drives pro-survival signalling responses directly in CLL B-cells is unknown. 
Assessing HMGB1-induced CLL cell proliferation in vitro is near impossible without co-culture 
with stromal cells and supporting growth factors, making it difficult to tease apart direct 
functional signalling outcomes.337 Circulating CLL cells undergo cell cycle arrest in the G0 or G1 
phase of the cell cycle until they re-enter the CLL LN/BM niche sites for regulatory signals. CLL 
cells spontaneously undergo apoptosis when cultured in vitro, compared to uncontrolled 
necrotic cell death.338 Therefore, assessing if HMGB1 could rescue or prolong CLL cells from 
spontaneous cell death in vitro, may be a better measure of HMGB1-RAGE signalling outcome 
directly in CLL B-cells than measuring cell proliferation. 
The work in this chapter will determine if i) RAGE and TLR9 are mainly expressed in CLL B-cells; 
ii) HMGB1 is the main RAGE ligand and association with CLL disease markers; iii) the outcome of 
HMGB1 signalling in primary CLL cells.  
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4.2 Results 
4.2.1 RAGE and TLR9 are predominantly expressed in CLL B-cells  
Our group previously demonstrated increased plasma HMGB1 levels in CLL compared to healthy 
controls,76 and high RAGE LN expression confers inferior OS, highlighting a pro-tumour role for 
this signalling axis in CLL. However, HMGB1 receptors are expressed by numerous immune cell 
subsets, notably macrophages, dendritic cells, B-cells and stromal cells that comprise the CLL LN 
microenvironment.72,131 In this study, we determined the cell types that mainly express RAGE 
and TLR9 in CLL PB, to further decipher a role for HMGB1 and its receptors, RAGE and TLR9 on 
CLL B-cell activation and strengthen the clinical relevance of the HMGB1-RAGE signalling axis in 
CLL.  
RAGE and TLR9 expression was determined in T-cells, B-cells and monocytes from CLL PBMCs by 
flow cytometry for 6 patients. CD3, CD14 and CD19 surface staining was performed prior to 
permeabilisation/fixation and intracellular staining for RAGE and TLR9; surface RAGE was 
stained in non-permeabilised cells at the same time as CD3, CD14 and CD19 surface staining. 
Dead cells were excluded from flow cytometry analysis by staining with viable dye, and RAGE 
and TLR9 positive staining in CD3+ T cells, CD14+ monocytes and CD19+ B-cells were compared 
to isotype-matched controls (Figure 4-1 and Figure 4-2). 
7.7% of the whole PBMC population express surface RAGE on CD19+ B-cells, compared to <1% 
of the PBMC population expressing surface RAGE on CD14+ monocytes, and significantly higher 
compared to CD3+ T-cells (P<0.0001; Figure 4-3A). When cells are permeabilised, 56.6% of the 
PBMC population is positive for intracellular RAGE and CD19, significantly higher than 
intracellular RAGE expressed in CD3+ T-cells (P<0.0001; Figure 4-3B). This expression pattern 
was similar for intracellular TLR9; 65.8% of the PBMC population was positive for TLR9 and CD19, 
compared to 5.4% TLR9+ and CD3+ (P<0.0001; Figure 4-3C).  
When we consider the expression levels of RAGE and TLR9 within individual cell populations, 
17.7% of CD14+ cells express RAGE on the cell surface, whereas only 8.4% of all CD19+ B-cells 
express surface RAGE, and 3% of CD3+ T-cells (Figure 4-3D). Although a higher proportion of 
CD14+ monocytes expressed RAGE on the cell surface, 60.4% of all CD19+ B-cells expressed 
intracellular RAGE, indicating RAGE internalisation. This was significantly higher than CD3+ T-
cells (P<0.01; Figure 4-3E). Nearly all CD3+ T-cells, CD14+ monocytes and CD19+ B-cells 
expressed intracellular TLR9 (81.7%, 72.1% and 81.2%, respectively; Figure 4-3F). 
The MFI was higher for surface RAGE expression in CD14+ monocytes compared to CD3+ T-cells 
and CD19+ B-cells (Figure 4-3G), but we observed significantly increased intracellular RAGE MFI 
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for CD19+ B-cells compared to CD3+ T-cells (P<0.01; Figure 4-3H). TLR9 MFI was similar for all 
cell subsets (Figure 4-3I).  
Taking these data together, as CD19+ B-cells predominate CLL PB, RAGE and TLR9 expression is 
largely expressed in B-cells compared to T-cells and monocytes. Interestingly, RAGE MFI is lower 
on the surface of B-cells but much higher intracellularly. This could reflect ligand-induced 
internalisation and recycling to the plasma membrane. Therefore, RAGE and TLR9 are 
predominately expressed in circulating CD19+ B-cells and these results support our hypothesis 
that HMGB1 ligand could drive pro-tumour signalling via RAGE on CD19+ B-cells. 
 
 
Figure 4-1 Flow cytometry gating procedure using FACS Diva software 
RAGE and TLR9 staining was assessed using the Fortessa Flow Cytometer and FACS Diva software. 
Lymphocytes and single cells were gates, and dead cells excluded from data acquisition and analysis using 
viability dye. Positive fluorescence gates were set by using appropriate isotype controls for CD3, CD14, 
CD19, TLR9 and RAGE conjugated fluorochromes and secondary antibodies.  
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Figure 4-2 Representative flow plots for RAGE and TLR9 staining in CLL PBMCs 
Cryopreserved CLL mononuclear cells from 6 patients with cell viability >90% were used for immune-
staining. Cells were stained for surface markers CD3, CD14 and CD19 before permeabilization/fixation and 
intracellular staining for RAGE and TLR9. Surface RAGE expression was stained in non-permeabilised cells. 
Positive fluorescence was gated by comparing to isotype-matched controls and the expression of surface 
RAGE, intracellular RAGE and intracellular TLR9 compared in CD3+ T-cells, CD14+ monocytes and CD19+ 
B-cells.  
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Figure 4-3 Statistical analysis of RAGE and TLR9 expression in T-cells, monocytes and B-cells 
Surface RAGE (A, D, G), intracellular RAGE (B, E, H) and intracellular TLR9 (C, F, I) expression was assessed 
in CD3+ T-cells, CD14+ monocytes and CD19+ B-cells. Expression levels were compared by assessing the 
% of the whole PBMC population positive for RAGE and specific cell surface marker (A-C), the % of specific 
cell population RAGE or TLR9 positive, (D-F) and the MFI of surface RAGE, intracellular RAGE or TLR9 (G-
I). Data are presented as the mean ± SD for 6 patients and statistical differences was analysed by a non-
parametric One-way ANOVA; P<0.05*, P<0.01**, P<0.001***. 
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4.2.2 Extracellular HMGB1 is significantly higher in CLL compared to healthy controls, 
but not S100B 
We have demonstrated RAGE is expressed in circulating PB CD19+ CLL cells and CLL LNs, but 
whether a different RAGE ligand outcompetes HMGB1 in CLL is unknown. Plasma levels of 
HMGB1 and S100B were assessed by ELISA in the same cohort of 54 CLL patients and compared 
to 15 healthy volunteers (Figure 4-4). Plasma was isolated from fresh whole blood by 
centrifugation at 1500rpm for 5 minutes at room temperature, and removal of the top plasma 
layer; plasma aliquots were stored at -80°C. S100B was chosen as a RAGE ligand comparison, as 
this plasma-derived RAGE ligand is the only S100 protein used clinically as a diagnostic marker 
for melanoma, with high levels of S100B associated with poor prognosis.333 Although other S100 
proteins have reported roles in cancer, particularly stress responses, these studies are focused 
on cellular expression of S100 proteins rather than extracellular ligand clinical relevance.339 
HMGB1 plasma levels were significantly increased compared to healthy controls (median 
72.2ng/ml and 3.4ng/ml, respectively; P<0.0001; Figure 4-4A), consistent with our previous 
published work in a smaller cohort of CLL patients.76 Whereas, levels of plasma S100B were 
unaltered between CLL and healthy controls (median 0.0pg/ml for both CLL and healthy 
controls; Figure 4-4B).  
Following a significant increase in HMGB1 plasma levels in CLL patients, we assessed the 
association between HMGB1 plasma levels and available clinical data (Figure 4-5). There was no 
association between HMGB1 plasma levels and poor cytogenetic risk factors, del(17p), del(11q) 
and trisomy 12, or good cytogenetic risk factor, del(13q) (Figure 4-5A), compared to CLL patients 
with a normal karyotype. Nor were HMGB1 levels associated with disease Binet staging (Figure 
4-5B). CLL patients with untreated or relapsed disease had significantly higher extracellular 
HMGB1 levels compared to healthy controls (Figure 4-5C), and the statistical difference was 
higher between healthy controls and patients with relapsed disease. However, HMGB1 plasma 
levels do not correlate with time to first treatment (Figure 4-5D). 
These results indicate HMGB1 is the main RAGE ligand in CLL, and S100B, the only other RAGE 
ligand with a documented clinical extracellular role in cancer, does not have altered levels in CLL 
patients compared to healthy controls. Therefore HMGB1-RAGE signalling will dominate RAGE-
associated biology in CLL. 
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Figure 4-4 Detection of extracellular HMGB1 and S100B in healthy controls and CLL plasma 
Comparison of HMGB1 (A) and S100B (B) plasma levels in primary CLL patient samples and healthy 
controls; n=54 and n=15, respectively. Plasma concentrations of HMGB1 and S100B were determined by 
sandwich ELISA. All samples were tested on the same plate with known protein concentration standards, 
and the concentration of test samples were extrapolated from the generated standard curve. Data are 
presented as median with interquartile range and analysed by a Mann Whitney U-test; P<0.0001***. 
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Figure 4-5 Evaluation of extracellular HMGB1 levels association with CLL cytogenetic aberrations, CLL 
disease Binet stage, disease clinical outcome and time to first treatment 
HMGB1 plasma levels were compared with CLL patient (A) cytogenetic aberrations, (B) CLL patient Binet 
staging, (C) treatment and treatment outcome, and (D) time to first treatment. Fresh plasma was collected 
from 54 CLL patients and stored at -80°C before measuring HMGB1 concentration by ELISA. Clinical data 
was extracted from our tissue bank clinical database. Data presented (A-C) are median ± interquartile 
range and statistical differences assessed by One-way ANOVA. HMGB1 plasma levels and time to first 
treatment was assessed by Linear Regression. Samples sizes (n) are stated in graphs, P= P-value, P<0.05*, 
P<0.01**, Rsq= coefficient of determination.  
 
 
 
 
  
Chapter IV Results 
128 
 
4.2.3 Soluble RAGE levels are significantly higher in CLL compared to healthy controls 
and correlate with time to first treatment 
Next, we assessed the plasma concentration of sRAGE in the same cohort of CLL patients and 
healthy controls, and compared this to extracellular HMGB1 levels. High plasma levels of HMGB1 
in CLL may be signalling-incompetent if the RAGE ligand is sequestered by similar levels of ‘decoy 
receptor’ sRAGE. Diminished levels of sRAGE are associated with progression in different types 
of solid cancer, but many HMGB1-RAGE cancer studies fail to consider the extracellular role of 
sRAGE.128 Moreover, as sRAGE displays decoy receptor ability, we also investigated whether 
extracellular sRAGE levels confer a protective effect in CLL. 
In this study, sRAGE was significantly higher in the plasma of CLL patients compared to healthy 
controls (median 60.0pg/ml and 31.0pg/ml, respectively; P<0.01; Figure 4-6A). This result was 
surprising, but sRAGE plasma concentration was 3 orders of magnitude lower than plasma 
HMGB1 in CLL, so unlikely to fully inhibit HMGB1 and down-modulate HMGB1-RAGE signalling. 
Moreover, healthy controls were not age-matched due to availability – repeating this with a 
cohort of age-matched controls will confirm our findings and constitute a better comparison for 
CLL patients. We further investigated the strength of linkage between HMGB1, S100B and sRAGE 
in CLL patients and healthy controls using Pearson product-moment multiple correlation 
method (Figure 4-7B). In a healthy setting, HMGB1 and sRAGE plasma levels are inversely 
correlated, with increased levels of sRAGE limiting inflammatory responses. The classical 
negative inverse trend was observed for the healthy controls in this study, although this result 
was not significant (R=-0.112; P=0.692; Figure 4-7). In CLL, HMGB1 and S100B significantly 
positively correlated, owing to their stress-DAMP related roles (R=0.427; P<0.001; Figure 4-6B). 
S100B demonstrated a negative correlation with sRAGE (R=-0.041; P=0.766; Figure 4-6B), and 
HMGB1 had a positive correlation with sRAGE (R=0.084; P=0.547; Figure 4-6B), but these 
correlations were not significant for this cohort of CLL patients.  
Next, we compared extracellular sRAGE levels with available clinical data to decipher any impact 
on patient outcome. Patients with poor prognostic karyotypes, del(17p), del(11q) and trisomy 
12 had lower sRAGE levels than CLL patients with a normal karyotype or good prognostic marker 
del(13q); although specific comparisons were not significant (Figure 4-8A). Most of the patients 
included in this study were assigned a CLL disease Binet stage of A at diagnosis (n=32) i.e. less 
aggressive clinical characteristics, compared to Binet stage B (n=2) or Binet stage C (n=5). Again, 
specific comparisons between Binet staging were not significant, but the overall One-way 
ANOVA was significant owing to higher levels of sRAGE for patients with Binet stage A compared 
to B and C (P<0.05; Figure 4-8B). Although we observed significantly higher levels of sRAGE in 
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CLL patients compared to healthy controls, when we split the CLL patients into untreated, 
relapsed and partial remission subgroups, all subgroups share similar levels of extracellular 
sRAGE (Figure 4-8C); and these are not significantly increased compared to the healthy controls. 
Finally, to assess if levels of sRAGE associate with patient outcome we compared extracellular 
sRAGE levels to patients’ time to first treatment. Patients with higher levels of extracellular 
sRAGE had a longer time to first treatment (P<0.05; Figure 4-8D).  
These results demonstrate sRAGE is increased in CLL compared to healthy controls, but fell 
below levels capable of full HMGB1 inhibition for the same patient cohort. Absence of a negative 
correlation between HMGB1 and sRAGE suggested a breakdown in the negative feedback loop 
in CLL. Moreover, sRAGE does confer a protective effect by prolonging time to first treatment 
and highlights HMGB1-RAGE signalling as a clinically relevant pathway to investigate in CLL.  
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Figure 4-6 Detection of extracellular sRAGE in CLL and healthy plasma, and correlation with plasma 
HMGB1 and S100B levels in CLL 
Comparison of sRAGE plasma levels in primary CLL patient samples and healthy controls (A); n=54 and 
n=15, respectively. Plasma concentrations of sRAGE were determined by sandwich ELISA. All samples 
were tested on the same plate with known protein concentration standards, and the concentration of 
test samples were extrapolated from the generated standard curve. Data are presented as median with 
interquartile range and analysed by a Mann Whitney U-test. Linear correlations between plasma S100B, 
sRAGE and HMGB1 levels were assessed by Pearson product-moment multiple correlation method (B). 
Detailed statistical data (C) are presented as R=Pearson correlation coefficient, P-value and n=sample size; 
P<0.001**.  
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Figure 4-7 Pearson multiple correlation analysis of extracellular HMGB1, S100B and sRAGE levels in 
healthy controls 
Linear correlations between plasma S100B, sRAGE and HMGB1 levels were assessed by Pearson product-
moment multiple correlation method (A). Plasma concentrations of HMGB1, S100B and sRAGE were 
determined by sandwich ELISA on the same plate as known protein standards and healthy controls. 
Detailed statistical data (B) are presented as R=Pearson correlation coefficient, P-value and n=sample size; 
P<0.05*.  
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Figure 4-8 Evalulation of extracellular sRAGE association with clinical data 
sRAGE plasma levels were compared with CLL patients’ cytogenetic aberrations (A), CLL disease Binet 
staging (B), treatment and treatment outcome (C) and time to first treatment (D). Fresh plasma was 
collected from 54 CLL patients and stored at -80°C before measuring sRAGE concentration by ELISA. 
Clinical data was extracted from our tissue bank clinical database. Data presented are median ± 
interquartile range (A-C) and statistical differences assessed by One-way ANOVA. sRAGE plasma levels 
and time to first treatment was assessed by Linear regression. Samples sizes (n) are stated in graphs, P=P-
value, P<0.05*, Rsq=coefficient of determination.  
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4.2.4 HMGB1 and sRAGE extracellular levels do not vary with CLL ZAP70 expression 
For the patients included in this study, IGHV mutational status or ZAP70 expression was not 
measured at diagnosis. To further explore an association between HMGB1 and sRAGE plasma 
levels and CLL disease subsets, patient ZAP70 expression was determined in-house to define 
aggressive and indolent CLL disease subsets.  
ZAP70 expression is determined by flow cytometry in comparison to a setting control. However, 
the type of control used, impacts the threshold set between positive and negative ZAP70 
expression. The advantage of flow-based methodology compared to other expression assays 
(i.e. Western blotting, IHC, gene expression) is the ability to co-stain and analyse CLL cell-only 
populations (CD5+/CD19+ cells) compared to other cells in PB that also express ZAP70 (i.e. 
CD56+ NK and CD3+ T-cells).336 The 4 main methods utilised in clinic include (Figure 4-9): 1) 
assessing ZAP70 positivity by comparing to a negative control isotype-matched antibody;340 2) 
assessing ZAP70 positivity by comparing to patient internal positive controls, NK and T-cells;341 
3) assessing ZAP70 positivity by comparing to a ZAP70 antibody block negative control;342 4) 
assessing ZAP70 positivity by comparing CLL-cell ZAP70 MFI values to internal positive control T-
cell MFI values.343,344  
Using the first 3 methods described above, ZAP70 expression is determined as positive if the 
percentage of CLL-cell ZAP70 signal is above a threshold of 20% compared to the specific control 
used. For example, using the first method a patient is defined as ZAP70+ if at least 20% of 
CD19+/CD5+ CLL cells stain positive for ZAP70 and exceed the signal from the isotype-matched 
antibody control.340 However, these 3 methods are highly subjective on user-gating, rendering 
the results difficult to reproduce. Other caveats of these methods include the use of NK cells as 
an internal positive control, in which ZAP70 protein is less stable compared to B-cells/T-cells, 
and the reliability of the unconjugated ZAP70-antibody block method.336  
In a bid to standardise the method, the European Research Initiative on CLL (ERIC) conducted a 
harmonisation study across 20 centres in 2006, comparing ZAP70 flow-based methods and 
different conjugated-ZAP70 antibodies. The most reproducible method, with lower 
interlaboratory variation, was the T-cell/CLL-cell ZAP70 expression ratio.298,343 This method relies 
on ZAP70 expression from T-cells as an internal positive control, so accounts for similar ZAP70 
degradation rates as observed in B-cells, limits variation observed from different ZAP70 
commercial antibodies, and avoids user variability in gating cursor placement. Previous studies 
recommend establishing a laboratory determined range of  ZAP70 T-cell/CLL-cell ratios, and then 
dividing this patient cohort in half, giving ZAP70+ and ZAP70- expression.343 A consequent larger 
study established a ZAP70 MFI T-cell/CLL-cell cut-off ratio of 3.0 in a test set of 173 patients, and 
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validated this in an independent cohort of 341 patients.344 Observed ZAP70 ratios were 
unaffected by choice of ZAP70 commercial antibody (1E7.2-PE, 1E7.2-AF488, 2F3.2-FITC) 
compared to high interlaboratory variability when analysing ZAP70 positivity using traditional 
20% threshold based methods.298,345  
For these reasons, the ZAP70 MFI T-cell/CLL-cell ratio method was used in this study with ZAP70 
1E7.2-AF488 antibody, and a cut-off ratio value of 3.0.   
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Figure 4-9 The four main methods of ZAP70 expression assessment by flow cytometry for CLL 
prognostic stratification 
CLL ZAP70 expression is determined by flow cytometry using patient PB CLL B-cells. Currently, there is no 
standardised procedure, but four main methods are utilised in clinic. 1) ZAP70 expression is positive when 
20% of the signal from CD19+/CD5+ CLL B-cells exceeds the signal from an isotype-matched negative 
control. 2) ZAP70 expression is positive when 20% of the ZAP70 signal from CD19+/CD5+ CLL B-cells are 
comparable to ZAP70 signals from T-cells and NK-cells patient intrinsic positive controls. 3) ZAP70 
expression is positive when 20% of the ZAP70 signal exceeds that from a ZAP70 antibody block matched 
patient sample negative control. 4) ZAP70 expression is positive when the ratio of ZAP70 MFI from T-cells 
to CD19+/CD5+ CLL B-cells is <3.0.  
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ZAP70 expression was assessed for the same cohort of CLL patients included in the HMGB1, 
S100B and sRAGE ELISAs, using matched PBMCs that were previously cryo-stored at the time of 
plasma isolation; all PBMCs were stored within 24 hours of isolation to limit ZAP70 degradation. 
9/54 patients with a cell viability <80% after thawing, were excluded from this study, leaving 45 
patients for ZAP70 analysis. Surface CD19, CD5 and CD3 were co-stained prior to 
permeabilisation and fixation, and intracellular ZAP70 stained with anti-ZAP70 1E7.2-AF488 
conjugated antibody. ZAP70 expression was measured as the ratio of ZAP70 MFI from CD3+ T-
cells to CD19+/CD5+ CLL cells; patients with a ratio >3.0 were ZAP70- and patients with a ratio 
<3.0 were ZAP70+.344  
Using this method, 16 patients were ZAP70- and 29 patients were ZAP70+ for this cohort of 
patients. The normality of our calculated ZAP70 ratios was significant using the Shapiro-Wilk test 
(P=0.023; Figure 4-10A), revealing a non-normal data distribution with skewing towards MFI 
ratios <3.0, i.e. ZAP70+ expression (Figure 4-10B). We did not observe an association between 
extracellular HMGB1 levels and cytogenetic risk factors or Binet staging (Figure 4-5), and HMGB1 
was not significantly altered between ZAP70+/- subsets (ZAP70- mean HMGB1=105.1ng/ml and 
ZAP70+ mean HMGB1=93.9ng/ml; P=0.43; Figure 4-11A). Moreover, there was no association 
between ZAP70+/- expression and extracellular sRAGE levels (ZAP70- mean sRAGE=61.6pg/ml 
and ZAP70+ mean sRAGE=59.9pg/ml; P=0.43; Figure 4-11B). These results demonstrate HMGB1 
and sRAGE release are not CLL-subset specific.  
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Figure 4-10 ZAP70 T-cell/CLL-cell MFI ratio data test of normaility and data distribution plot 
The Shapiro-Wilk test was used to measure data normality (A); a significant result indicates a non-normal 
data distribution. Data are presented in a histogram plot (B) to show data spread; data are skewed 
towards ratios <3.0, i.e. ZAP70 positive expression.  
 
 
Figure 4-11 Evaluation of CLL patient HMGB1 and sRAGE plasma levels in ZAP70 positive or negative 
subsets  
Plasma levels of CLL HMGB1 (A) and sRAGE (B) were determined by ELISA and compared to PB CLL cell 
ZAP70 positive or negative expression subsets determined by flow cytometry. Data are presented as 
medians with interquartile ranges, ZAP70+ n=29 and ZAP70- n=16; statistical difference between samples 
was analysed by Mann-Whitney U test. 
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4.2.5 Blocking HMGB1 receptor, RAGE, does not induce cell death in vitro 
Extracellular HMGB1 has reported dual roles in cancer, driving pro-tumour or anti-tumour 
responses that are partly dependent on the microenvironment ‘make-up’ in the same spatial 
location.131 To investigate the functional significance of increased HMGB1 plasma levels in CLL 
patients (aside from NLC differentiation), we assessed if exogenous HMGB1 stimulation prolongs 
CLL cell survival in vitro and if blockade of HMGB1 receptor, RAGE, can block survival signals. 
A cell survival assay was used compared to a cell proliferation assay, due to the quiescent in vitro 
CLL-cell phenotype that is observed when primary cells are grown in culture. This phenomenon 
renders cell proliferation assays difficult to successfully perform in vitro. Cell death was assessed 
by the Annexin V assay in 11 freshly isolated PBMCs from CLL patients. Freshly isolated PBMCs 
were cultured at high density (10x106 cells/ml) in complete medium and treated with PBS, 
200ng/ml HMGB1, 500ng/ml HMGB1 or 10µg/ml neutralising anti-RAGE antibody. Increasing 
doses of HMGB1 were used to recapitulate the CLL plasma concentrations previously 
determined by our ELISA results (Figure 4-4A). Cells were cultured for 48 hours or 120 hours 
prior to staining with Annexin V-FITC and PI. CLL cells rapidly die in culture upon removal from 
niche sites rich in supporting microenvironment signals; therefore, a 48-hour time point was 
used to assess cells before committing to spontaneous cell death, and a longer time point of 120 
hours to capture spontaneous cell death. Using the Annexin V assay, alive (PI-/Annexin V-), 
apoptotic (PI-/Annexin V+) and dead cells (PI+/Annexin V+) were distinguished (Figure 4-12A). 
There was no difference in cell survival in vitro at the 48 or 120-hour time points in response to 
HMGB1 stimulation or RAGE blockade for CLL patient PBMCs (Figure 4-12B and C).  
CLL patients exhibit varying CLL-cell purity in PB, with infiltrating cell subsets supporting and 
maintaining CLL cell survival, particularly M2- polarised macrophage cell subsets. Next, we 
assessed the effect of HMGB1 and RAGE blockade directly on isolated pure CLL B-cell 
populations by using CD19+ positive selection and negative selection kits. CD19 positive 
selection isolates CD19+ B-cells by using CD19-conjugated magnetic beads. B-CLL negative 
selection works in reverse, and depletes the PBMC of other cell populations by using conjugated 
magnetic microbeads to a panel of cell surface markers. Both isolation methods were used to 
account for possible CD19-mediated cell stimulation via microbead conjugation. Our data shows 
CD19-positive and CLL-negative isolated cells are more susceptible to spontaneous cell death in 
vitro (Figure 4-13). This result was expected, as CLL cells heavily rely on the surrounding 
microenvironment for survival signals and anti-apoptotic signals that are not intrinsic to CLL 
cells.337 Exogenous HMGB1 and RAGE blockade had no significant effect on cell survival in vitro 
on our isolated CLL-cell population (Figure 4-13).  
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An in vitro experimental setting is not an ideal model system to perform a CLL cell survival 
assay.338 CLL dependence on growth signals and microenvironment support, as established in 
CLL LNs, outweighs experimental modifications as performed here, and rapidly leads to in vitro 
spontaneous cell death. Therefore, we could not successfully model the effect of HMGB1 on CLL 
cell proliferation or survival in this study. 
 
Figure 4-12 Evaluation of cell survival in fresh primary CLL PBMCs in response to exogenous HMGB1 
stimulation and RAGE blockade in vitro 
Fresh CLL patients PBMCs were stimulated with 200ng/ml and 500ng/ml HMGB1 or blocked with 10µg/ml 
neutralising anti-RAGE antibody before measuring cell death using the Annexin V assay. Dead cells 
(PI+/Annexin V+), apoptotic cells (PI-/Annexin V+) and live cells (PI-/Annexin V-) were measured by flow 
cytometry; representative flow plot (A). PBMCs were cultured for 48 (B) or 120 hours (C) before cell 
survival was assessed. Data are presented as mean ± SD and statistical differences between samples was 
analysed by Two-way ANOVA; n= 11 patients. The percentages on graph bars are the % of live cells 
measured as PI-/Annexin V-.   
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Figure 4-13 Evaluation of cell survival in fresh CD19-positive selection or CLL-negative isolated CLL cells 
in response to exogeneous HMGB1 stimulation and RAGE blockade in vitro 
CD19+ B-cells were isolated from fresh CLL PBMCs by CD19+ MACS selection (A-B) and CLL cells were 
isolated from fresh PBMCs by B-CLL negative selection kit (C-D). Freshly separated cells were treated with 
200ng/ml and 500ng/ml HMGB1 and RAGE blocked with 10µg/ml neutralising anti-RAGE antibody and 
cultured for 48 (A and C) and 120 (B and D) hours. Cells death was assessed by Annexin V assay and data 
for dead cells (PI-/Annexin V-), apoptotic cells (PI-/Annexin V+) and live cells (PI+/Annexin V+) was 
recorded. Data are presented as the mean ± SD and statistical difference between samples was analysed 
by Two-way ANOVA; n=4 for CD19+ selection and n=2 for B-CLL negative selection. The percentages on 
graph bars = % of live cells measured as PI-/Annexin V-.  
 
  
Chapter IV Results 
141 
 
4.3 Discussion 
In this chapter, we have confirmed plasma HMGB1 levels are significantly increased in untreated 
and relapsed patients, compared to S100B and antagonistic sRAGE. Extracellular HMGB1 and 
sRAGE levels are CLL subset independent, and HMGB1 receptor expression is more prevalent in 
CD19+ B-cells in CLL PB. Although we could not model the outcome of HMGB1 stimulation in CLL 
B-cells in vitro, the work in this study strengthens the clinical relevance of HMGB1 and RAGE in 
CLL disease pathogenesis.  
RAGE and TLR9 mRNA expression is increased in CLL B-cells compared to healthy controls, but 
other leukocyte subsets also express these receptors.316 Surface RAGE MFI was higher in 
circulating CD14+ monocytes in PB, but intracellular RAGE was significantly higher in circulating 
CD19+ B-cells. When we consider CD19+ B-cells make up >90% of the PBMC population, HMGB1 
ligand will clearly be sequestered by receptors on CD19+ B-cells and activate signalling pathways 
predominately in this cell subset. Higher intracellular levels of RAGE in B-cells hint at receptor 
internalisation – a key mechanism involved in mediating RAGE signalling.194 These results, 
combined with RAGE and TLR9 LN expression, provide rationale to further investigate HMGB1 
signalling directly in CLL B-cells.  
RAGE is a key mediator between acute and chronic inflammation implicated in several 
pathological diseases.176 To perform this function, RAGE binds various DAMPs via 3 extracellular 
Ig-domains. The main ligands include HMGB1, S100 proteins (family of 21 members) and AGEs. 
Although extracellular ligand-RAGE signalling contributes to tumour progression, as occurs 
continuously within the tumour microenvironment,339 S100B is the only other RAGE ligand (aside 
from HMGB1) with a defined prognostic association with patient outcome in cancer – 
specifically, melanoma.333 Our results show HMGB1 levels are significantly higher than S100B in 
CLL, and compared to healthy controls, demonstrating HMGB1-RAGE is more prevalent in CLL. 
However, the extracellular role of HMGB1 is dependent on its redox state.346 Fully oxidised 
HMGB1 at Cys23, Cys45 and Cys106 is inactive but promotes immune tolerance 347. Disulphide 
HMGB1 between Cys23-Cys45 has cytokine activity and drives leukocyte activation, and all-thiol 
HMGB1 with fully reduced Cys23, Cys45 and Cys106 displays chemokine activity.348 Oxidative 
stress was detected in CLL patients and associated with poor prognosis 349. It is likely all 3 states 
occur in the tumour microenvironment as the extracellular redox status within the tumour 
vicinity is continually changing. Few studies have successfully reported HMGB1 post-
translational modifications, due to the unavailability of antibodies specific to the different 
functional isoforms of HMGB1.346 In CLL, increased levels of HMGB1 may not possess biological 
functional activity if fully oxidised which we have not measured here, but we propose a cycle of 
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reduction upon entering and leaving CLL LNs and BM, key sites of disease pathogenesis, and re-
oxidation when released into PB.  
Soluble RAGE circulating in human plasma, is modulated in chronic diseases impacted by RAGE 
and its ligands. The extracellular pool of sRAGE derives from 2 origins – membrane shedding 
catalysed by ADAM10 as an anti-inflammatory mechanism, or alternative splicing to produce an 
endogenous-secreted RAGE isoform.192,215 Membrane shedding is a tightly controlled process 
under normal physiological conditions, but is deregulated in pathological conditions that display 
altered metalloproteinase activity, as observed in this study.219 Tracking levels of sRAGE is 
increasingly gaining recognition as a biomarker for inflammatory chronic disease.350-352 
Surprisingly we observed higher levels of sRAGE in CLL compared to healthy controls, the 
opposite result to down-modulated sRAGE levels frequently reported in solid cancer.353 
Extracellular HMGB1 levels are significantly higher than sRAGE in CLL so will fail to fully inhibit 
HMGB1, but this highlights that increased sRAGE may be due to ligand-induced membrane 
receptor shedding catalysed by ADAM10 activity. Moreover, the involvement ADAM10 may be 
a side-product of NOTCH1 signalling in CLL.218 We identified higher extracellular sRAGE levels 
confer a protective effect in CLL so further investigation of sRAGE origin and involvement of 
ADAM10, as described in Chapter VI, will pinpoint the precise role of sRAGE in CLL.  
U-CLL status and PB ZAP70 expression are powerful, associated prognosticators for CLL disease. 
The association with either U-CLL or ZAP70+ expression helps to determine the severity of other 
molecular markers, i.e. RAGE and HMGB1. Although the standard prevalence of ZAP70-/M-CLL 
to ZAP70+/U-CLL disease is usually 60%:40%;50 ZAP70+ expression to ZAP70- was 29:16 for our 
cohort of CLL patients by in-house flow cytometry. The ZAP70 MFI T-cell/CLL-cell ratio method 
is the most robust method to date, following extensive testing across diagnostic laboratories 
with different commercial antibodies. The skewing of our cohort of CLL patients towards ZAP70+ 
may be due to our patient inclusion criteria rather than experimental false positives. Recent 
improvements in the ZAP70 MFI flow cytometry method to increase robustness, include 
correcting T-cell and CLL-cell ZAP70 MFI by removing background fluorescence with an isotype-
matched control.299 However, this method currently has no validated data range or cut off-value, 
so the traditional ZAP70 MFI ratio was used in this study instead. These results demonstrate that 
RAGE expression in CLL LN may be linked to disease severity, but HMGB1 release is independent 
of CLL subtype.  
To functionally investigate the biological effect of high HMGB1 plasma levels we assessed the 
longer-term outcome of HMGB1 signalling in vitro. CLL-cells circulating in PB undergo cell cycle 
arrest and are resistant to programmed cell death, contributing to chemotherapy resistance in 
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CLL.354 However, as soon as cells are removed ex vivo, CLL-cells rapidly lose their anti-apoptotic 
mechanisms and undergo spontaneous cell death in vitro.338 To dissect a direct role for HMGB1 
in CLL B-cell proliferation, we tried to model and investigate if HMGB1 contributes to the 
acquired anti-apoptotic mechanisms for CLL-cell survival in vitro. HMGB1 is a known inducer of 
NLC differentiation, and this cell population is observed in vitro following 1 week of culture, after 
an initial drop in CLL-cell viability.76,337 However, without the support of other key growth factors 
and co-culture with stromal cells, particularly using time-points prior to NLC differentiation, we 
did not measure a direct difference in HMGB1-induced cell survival with this in vitro model.  
In summary, these results demonstrate that the HMGB1-RAGE signalling axis is more prevalent 
in CLL than other RAGE ligands, or in other cell populations. HMGB1 release is CLL-subset 
independent, but the signalling capacity of HMGB1 will likely coincide with BCR-signalling 
responsiveness. sRAGE levels are deregulated in CLL, compared to the classical inverse trend 
between HMGB1 and sRAGE observed in the healthy controls, but confers a protective effect. 
These results demonstrate extracellular HMGB1 and cellular RAGE are clinically relevant, and 
deciphering the signalling pathways activated by these proteins will reveal key targets for 
therapeutic intervention.  
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5.1 Introduction 
We have identified an association between extracellular HMGB1 levels and receptor expression, 
RAGE, with poor CLL disease outcome but the functional significance of these results in CLL is 
currently not known. Although we could not model the direct impact of HMGB1 on CLL cell 
survival in vitro, these results give us rationale to further investigate the HMGB1-RAGE signalling 
axis and demonstrates a pro-tumour role for the DAMP. Insight into the HMGB1 
phosphoproteome will reveal receptor usage, co-activation of other unidentified HMGB1 
signalling pathways, and potential therapeutic targets for the treatment of CLL.  
Identified receptors for inflammatory DAMP, HMGB1, include RAGE and TLRs 2, 4 and 9.146 
Receptor selection heavily relies on the cell-type specific expression profile; i.e. activation of 
TLRs are responsible for myeloid cells and RAGE in endothelial cells.146 The full HMGB1 signalling 
pathway is not fully elucidated, but has been demonstrated to activate NF-κB and stimulate IFN-
α, TNF, IL-6 and IL-12 production and can contribute to both pro- and anti-tumour 
responses.145,149 To fulfil its role as a DAMP, HMGB1 can function as a free molecule or complex 
with other ligands/signalling mediators to increase their immunogenicity.131 This renders 
HMGB1 particularly difficult to target, as the preference in signalling pathway activation is 
dependent on the presence of other ligands and cell type;144 moreover, HMGB1 blockade could 
result in a bias towards pro- or anti-tumour activity.  
A B-cell specific synergism has been observed between RAGE and TLR9 following HMGB1 
stimulation. HMGB1 can bind to DNA in a sequence independent manner, and has demonstrated 
ability to bind to both A and B classes of CpG-ODNs.145,149 For SLE B-cells, DNA-containing 
autoimmune complexes are internalised by BCR endocytosis,260 but an autoantibody-
independent mechanism exists. Double stranded extracellular DNA bound to HMGB1 is 
internalised via RAGE, and stimulates TLR9 activity.145 Our group previously demonstrated that 
extracellular HMGB1 levels positively correlate with extracellular DNA levels in CLL, indicative of 
passive HMGB1 release.76 Therefore, it is plausible that HMGB1 exists in DNA-bound complexes 
circulating in CLL disease. Following TLR9 engagement, CpG-ODN drives dichotic responses in 
CLL dependent on ZAP70 expression.96 Our group have already shown RAGE/TLR9 dependent 
differentiation of NLCs in response to HMGB1,76 but whether RAGE and TLR9 function in a co-
linked manner directly in CLL cells, as is observed in CLL NLCs, and lead to the activation of NF-
κB is unknown. Using 2 imaging approaches and an unbiased phosphoproteomic approach, we 
will be able to assess whole cell signalling network activation following treatment with RAGE 
agonist, HMGB1, a TLR9 agonist, CpG-ODN (B-class).  
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The work in this chapter will determine i) the main HMGB1 receptor in CLL; ii) HMGB1-mediated 
colocalization of RAGE and TLR9; iii) HMGB1-mediated activation of cell signalling pathways. 
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5.2 Results 
5.2.1 RAGE and TLR9 are the most likely binding partners of HMGB1 in CLL B-cells 
We have demonstrated increased gene expression of HMGB1 receptors, RAGE and TLR9, in CLL 
patients compared to age-matched healthy controls using available gene expression datasets,316 
and overexpression of RAGE in CLL LNs confers a worse overall survival for CLL patients. 
However, the signalling capacity of these receptors in response to HMGB1 stimulation in CLL 
cells is unknown. HMGB1 can potentially interact with multiple cellular receptors leading to the 
activation of several signalling pathways that are cell-type specific.76,149,281 In combination with 
the gene expression data from Chapter III, we first assessed the binding affinities of multiple 
receptors for HMGB1 using available online database, STRING (https://string-db.org/), to 
determine the main functional HMGB1 receptors in CLL.355 
The main receptors for HMGB1 include TLR1, 2, 4, 9 and RAGE (Figure 5-1). STRING computes a 
protein-protein association functional score from 0-1 based on high-throughput experimental 
data, online database mining, literature searches and predictions from genomic context 
analysis.356 TLR1, TLR2, TLR4 and RAGE displayed the highest scores for HMGB1 functional 
associations of >0.9 (0.900, 0.997, 0.998 and 0.972, respectively; Table 9). TLR9 displayed a 
functional score of 0.8 and all other TLRs displayed little or no functional association with 
HMGB1, displaying scores <0.1 (Table 9). We demonstrated decreased gene expression of TLR1, 
TLR2 and TLR4 in CLL compared to age-matched healthy controls (Figure 3-1), but this does not 
give an indication of receptor protein levels. Performing a literature search, TLR4 lacks 
expression at the protein level in CLL B-cells, so will not mediate HMGB1 cell activation directly 
in CLL cells (Table 9). The other 4 HMGB1 receptors with high functional association scores, TLR1, 
TLR2, TLR9 and RAGE, are expressed to protein level in CLL. The TLR expression profile in CLL 
cells is similar to a mature B-cell phenotype, and we previously demonstrated RAGE and TLR9 
mRNA expression was significantly increased in CLL PB cells compared to healthy controls, and 
(Figure 3-1).317 Taking this data together, we hypothesise that extracellular HMGB1 in the CLL 
microenvironment interacts with high affinity to RAGE and could lead to the co-activation of 
intracellular receptor TLR9 as previously reported in B-cells.  
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Figure 5-1 Interaction network map of HMGB1 and its receptors predicted by STRING database 
The functional association scores and interaction map were calculated and produced by STRING 
database.355 Each node represents a different protein and the thickness of each connecting line 
represents the degree of functional association between two proteins; the thicker the line, the 
higher the association score. AGER = RAGE.  
 
 
Table 9. STRING HMGB1 receptor functional association scores, mRNA expression and evidence of 
protein expression in CLL 
Receptor Functional 
association score 
Gene expression 
transformed count 
Protein expression in 
CLL (Refs) 
RAGE 0.972 2.98 + 76 
TLR1 0.900 3.92 + 317,357 
TLR2 0.997 2.55 + 317,357 
TLR3 0.073 2.93 - 
TLR4 0.998 3.74 - 76,317 
TLR5 0.073 2.52 - 
TLR6 0.073 3.43 + 317,357 
TLR7 0.073 4.86 + 317,318 
TLR8 0.073 2.82 - 
TLR9 0.800 6.09 + 76,96,317 
TLR10 0 5.99 + 357 
Note: Functional association score extracted from STRING database;356 gene expression 
transformed count represents log2 transformed and RMA normalised mRNA expression data 
from online GEO dataset (GSE22529).316  
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5.2.2 Treatment with recombinant HMGB1 mediates RAGE/TLR9 colocalization 
HMGB1 links RAGE and TLR9 in an inflammatory triad, as an established DNA and CpG-ODN 
binding partner.145,149 This signalling triad is responsible for the activation of NF-B in malignant 
and non-malignant inflammatory conditions.76,145,281 Our group previously reported HMGB1-
mediated activation of RAGE and TLR9, driving CLL NLC differentiation.76 Moreover, the HMGB1-
RAGE signalling axis poses as a BCR-independent route for nuclear complex internalisation, and 
activation of TLR9 by presentation of CpG-ODN ligand in autoreactive B-cells.145 It is currently 
unknown whether HMGB1 induces RAGE and TLR9 colocalization and signalling activation in CLL 
B-cells.  
We used 2 imaging systems to qualitatively and quantitatively measure protein colocalization 
and nuclear translocation. Immunofluorescent microscopy was used as a qualitative technique 
to investigate protein expression with additional spatial localisation information, and can reveal 
protein-protein interactions.303 Imagestream X Mark II flow cytometry was employed as a 
quantitative comparison – the combination of flow cytometry with fluorescence microscopy 
allows for acquisition of statistically powerful data and detailed morphological fluorescence 
information of every cell.304  
Using fluorescent microscopy, we determined the activation of RAGE and TLR9 in response to 
exogenous HMGB1 treatment in primary CLL cells. Protein colocalization was measured with 
ImageJ analysis software using dual colour images to perform the pixel intensity spatial 
correlation analysis. The Pearson’s correlation coefficient measures the degree of colocalization 
of fluorescent pixels in two colour channels, i.e. RAGE in the red channel and TLR9 in the green 
channel; a coefficient of +1 indicates perfect correlation, 0 for no correlation and -1 for perfect 
anti-correlation. We observed strong colocalization of RAGE and TLR9 in primary CLL cells 
following exogenous treatment with 200ng/ml HMGB1 for 2 and 4 hours (yellow aggregates 
indicate pixel overlap and colocalization; Figure 5-2A), and following in vitro culture for 1 week, 
conditions which induce HMGB1 release into cell culture medium to levels of 150ng/ml (Figure 
5-2A).76 RAGE and TLR9 protein colocalization was significantly higher than untreated 0 hour 
control sample after 2 hours HMGB1 stimulation (0hr control mean Rr= 0.36, 2hr HMGB1 mean 
Rr= 0.59; P<0.01; Figure 5-2B) and 4 hours HMGB1 stimulation (0hr control mean Rr= 0.36, 4hr 
HMGB1 mean Rr= 0.57; P<0.05; Figure 5-2B). Treatment with 10µg/ml neutralising anti-RAGE 
antibody, followed by addition of 200ng/ml HMGB1 for 2 and 4 hours prevented (not significant) 
HMGB1-mediated RAGE and TLR9 colocalization (Figure 5-2B). 
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Figure 5-2 Fluorescent microscopy analysis of HMGB1-mediated RAGE and TLR9 colocalisation in 
primary CLL cells 
(A) Representative images of RAGE and TLR9 colocalization. Fresh CLL cells (control), cells cultured for 1 
week (1 week), or cells treated with 200ng/ml HMGB1 for 2 hours (+ HMGB1) were fixed and 
permeabilized on slides. Cells were then co-stained with anti-RAGE/AF-488 and anti-TLR9/AF-546 
antibodies. Areas where green pixels (RAGE) and red pixels (TLR9) overlap give yellow aggregates, 
representing protein colocalization. Magnification x60 and x100. (B) Pixel intensity spatial correlation 
analysis of HMGB1-mediated colocalization of RAGE and TLR9. Fresh CLL cells were left untreated for 0-
hours or incubated with 200ng/ml HMGB1 for 2 and 4 hours with or without 10µg/ml neutralising anti-
RAGE antibody (α-RAGE). RAGE and TLR9 protein colocalization was analysed using ImageJ software and 
‘Rr’ indicates Pearson’s correlation coefficient. Data are mean ± SD from 5 individual CLL patients and 
differences compared with unpaired t test; P<0.05*, P<0.01**. 5 images were analysed per patient 
sample. Immunofluorescence was observed at 100x magnification using the Nikon eclipse Ci-E 
fluorescence microscope using the green, blue and red channels.  
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To confirm this quantitatively, on a larger population of cells, we performed ImageStream X 
Mark II flow cytometry. Using this method, we can collect fluorescence intensity and microscopy 
images of 5000 cells simultaneously. Protein colocalization was measured in the same manner 
as the pixel intensity spatial correlation analysis with ImageJ. The ImageStream IDEAS software 
removes background fluorescence to concentrate bright spots, and calculates the Pearson’s 
correlation coefficient for each pixel in the dual-colour image. The Pearson’s correlation 
coefficient is then log transformed to give the similarity bright detail score (SBDS) – the higher 
the SBDS, the higher the level of pixel overlap and protein colocalization. The colocalization of 
RAGE and TLR9 was significantly higher following treatment with 200ng/ml HMGB1 for 2 and 4 
hours compared to the untreated control cells (2 hours untreated mean SBDS=1.263, 
HMGB1=1.282, P<0.01; 4 hours untreated mean SBDS=1.250, HMGB1 1.278; P<0.001, 
respectively; Figure 5-3). Treatment with 10µg/ml neutralising anti-RAGE antibody and 
200ng/ml HMGB1 addition abrogated HMGB1-mediated RAGE and TLR9 colocalization at 4 
hours (4 hours HMGB1 mean SBDS=1.278, anti-RAGE=1.250, P<0.001; Figure 5-3), but not at 2 
hours (2 hours HMGB1 SBDS=1.282, anti-RAGE=1.274; Figure 5-3). In both fluorescence 
microscopy and ImageStream images, internalization of RAGE is visible following addition of 
HMGB1, compared to the localization of RAGE at the cell membrane in non-stimulated or RAGE-
neutralised cells.  
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Figure 5-3 ImageStream analysis of HMGB1-mediated RAGE and TLR9 colocalisation in primary CLL 
cells 
(A) Representative images of RAGE and TLR9 colocalization captured by the ImageStream X Mark II flow 
cytometer; magnification x40. Fresh CLL cells were treated with 200ng/ml HMGB1 (+ HMGB1) with or 
without 10µg/ml goat anti-RAGE neutralising antibody (α-RAGE) for 2 and 4 hours. Cells were 
fixed/permeabilised, co-stained with anti-RAGE/AF-488 and anti-TLR9/AF-647 antibodies and 
data/images assessed by ImageStream flow cytometry and colocalizaiotn analysed by IDEAS software. (B) 
Statistical analysis of RAGE and TLR9 protein colocalization using the IDEAS software. Protein 
colocalization was measured as the log transformed Pearson’s correlation coefficient termed the 
Similarity Bright Detail Score, and was measured for every cell recorded in 5 patients. Data are presented 
as median with interquartile range. 2 hours untreated n= 17428, HMGB1 n=16604, anti-RAGE n=10007; 4 
hours untreated n=13348, HMGB1 n=13752, anti-RAGE n=7192. Differences were compared with an 
unpaired Mann Whitney U test; P<0.01**, P<0.001***.  
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Next, we assessed the colocalization of TLR9 and MyD88 in the same cohort of patients, as an 
indicator of TLR9 signalling pathway activation. Using fluorescent microscopy, TLR9 and MyD88 
colocalization was not increased following 2 and 4 hours stimulation with 200ng/ml HMGB1 
compared to fresh untreated CLL cells (0-hour control Rr=0.38, 2 hours HMGB1 Rr=0.44, 4 hours 
HMGB1 Rr=0.37; Figure 5-4). However, surface RAGE neutralisation with 10µg/ml goat anti-
RAGE antibody significantly decreased HMGB1-mediated TLR9 and MyD88 colocalization after 
2 hours, but not at 4 hours compared to stimulation alone with HMGB (2 hours HMGB1 Rr=0.44, 
anti-RAGE Rr=0.23, P<0.05; 4 hours HMGB1 Rr=0.37, anti-RAGE Rr=0.23; Figure 5-4). Using 
quantitative ImageStream flow cytometry for the same patient samples, 200ng/ml HMGB1 
stimulation induced significantly higher TLR9 and MyD88 protein colocalization following 4 
hours stimulation compared to untreated controls (4 hours untreated mean SBDS=1.117, 
HMGB1=1.135, P<0.05; Figure 5-5), but not at 2 hours (2 hours untreated mean SBDS=1.059, 
HMGB1=1.086; Figure 5-5). Blockade of RAGE with 10µg/ml neutralising anti-RAGE antibody 
significantly abrogated HMGB1-mediated TLR9 and MyD88 colocalization at both 2 and 4 hours 
(2 hours HMGB1 mean SBDS=1.086, anti-RAGE=1.067, P<0.001; 4 hours HMGB1 mean 
SBDS=1.135, anti-RAGE=1.061, P<0.001; Figure 5-5).  
Taken together, these results demonstrate that HMGB1 does mediate RAGE and TLR9 
colocalization, which is blocked when surface RAGE is neutralised. We did observe TLR9 and 
MyD88 colocalization at longer time points, but the nature of RAGE and TLR9, and TLR9 and 
MyD88 interactions need further investigation.  
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Figure 5-4 Fluorescent microscopy analysis of HMGB1-mediated TLR9 and MyD88 colocalisation in 
primary CLL cells 
(A) Representative images of TLR9 and MyD88 colocalization. Fresh CLL cells were left untreated for 0 
hour (control), or cells were treated with 200ng/ml HMGB1 for 2 hours (HMGB1 2hr) and 4 hours (HMGB1 
4hr) and then fixed and permeabilized on slides. Cells were co-stained with anti-MyD88/AF-488 and anti-
TLR9/AF-546 antibodies. Areas where green pixels (MyD88) and red pixels (TLR9) overlap give yellow 
aggregates, representing protein colocalization. Magnification x100. (B) Pixel intensity spatial correlation 
analysis of HMGB1-mediated colocalization of TLR9 and MyD88. Fresh CLL cells were left untreated for 0-
hours or incubated with 200ng/ml HMGB1 for 2 and 4 hours with or without 10µg/ml neutralising anti-
RAGE antibody (α-RAGE). TLR9 and MyD88 protein colocalization was analysed using ImageJ software and 
‘Rr’ indicates Pearson’s correlation coefficient. Data are mean ± SD from 4 individual CLL patients and 
differences compared with an unpaired student t test; P<0.05*. 5 images were analysed per patient 
sample.  
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Figure 5-5 ImageStream analysis of HMGB1-mediated TLR9 and MyD88 colocalisation in primary CLL 
cells 
(A) Representative images of TLR9 and MyD88 colocalization captured by the ImageStream X Mark II flow 
cytometer; magnification x40. Fresh CLL cells were treated with 200ng/ml HMGB1 (+ HMGB1) with or 
without 10µg/ml goat anti-RAGE neutralising antibody (α-RAGE) for 2 and 4 hours. Cells were 
fixed/permeabilised, co-stained with anti-MyD88/AF-488 and anti-TLR9/AF-647 antibodies and 
data/images assessed by ImageStream flow cytometry and colocalization analysed by IDEAS software. (B) 
Statistical analysis of TLR9 and MyD88 protein colocalization using the IDEAS software. The Similarity 
Bright Detail Score was measured for every cell recorded in 5 patients. Data are presented as median with 
interquartile range. 2 hours untreated n= 10489, HMGB1 n=10610, anti-RAGE n=10536; 4 hours untreated 
n=13185, HMGB1 n=14778, anti-RAGE n=10668. Differences were compared with an unpaired Mann 
Whitney U test; P<0.05*, P<0.01**, P<0.001***.  
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5.2.3 Treatment with recombinant HMGB1 results in the nuclear translocation of transcription 
factor NF-B 
TLR9 signalling results in the activation of transcription factor, NF-B, resulting in inflammatory 
cytokine induction. We further investigated whether activation of RAGE and TLR9 receptors with 
HMGB1 stimulates signal transduction pathways by assessing the activation of transcription 
factor NF-B. Nuclear translocation of the p65 NF-B subunit elicits activation of this 
transcription factor, therefore, fluorescence microscopy and ImageStream flow cytometry were 
used to assess p65 nuclear translocation by measuring pixel colocalization with nuclear 
fluorescent dye, DAPI.  
Stimulation of fresh primary CLL cells with recombinant HMGB1 for 2 and 4 hours significantly 
induced p65 NF-B nuclear translocation compared to the untreated 0-hour control (0-hour 
control Rr=0.11; 2 hours HMGB1 Rr=0.33, P<0.05; 4 hours HMGB1 Rr=0.35, P<0.01; Figure 5-6). 
Consistent with RAGE and TLR9 colocalization, RAGE blockade with 10µg/ml neutralising anti-
RAGE antibody significantly decreased HMGB1-mediated p65 NF-B nuclear translocation at 4 
hours (4 hours HMGB1 Rr=0.35, anti-RAGE=0.07; P<0.01; Figure 5-6). Overall, the fluorescence 
microscopy images reveal p65 localised to the cytoplasm of unstimulated cells, and bright 
expression of NF-B in the nuclei of cells following HMGB1 stimulation (Figure 5-6A). We further 
investigated HMGB1-mediated activation of NF-B using the nuclear translocation ImageStream 
flow cytometry technique. The similarity eroded score (SEC) is the background-eroded, log 
transformed Pearson’s correlation coefficient that measured the degree of colocalization 
between nuclear stain, DAPI, and NF-κB fluorescence. Using this method, no difference was 
measured in NF-B nuclear translocation between untreated, 200ng/ml HMGB1 treated and 
anti-RAGE neutralised cells at 2 hours (2 hours untreated mean SEC=1.506, HMGB1 mean 
SEC=1.510, anti-RAGE mean SEC=1.489; Figure 5-7). After 4 hours treatment, cells treated with 
200ng/ml HMGB1 displayed significantly higher NF-B nuclear translocation compared to 
untreated cells, and neutralising anti-RAGE antibody blocked HMGB1-mediated NF-κB activation 
(4 hours untreated mean SEC=1.435, HMGB1 mean SEC=1.520, anti-RAGE mean SEC=1.496; 
Figure 5-7). These results demonstrate that HMGB1-mediated activation of RAGE/TLR9 
pathways in CLL cells leads to the activation of NF-B.  
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Figure 5-6 Fluorescent microscopy analysis of HMGB1-mediated NF-B activation 
(A) Representative images of p65 NF-κB nuclear translocation. Fresh CLL cells were left untreated for 0 
hour (control), or cells were treated with 200ng/ml HMGB1 for 2 hours (HMGB1) or with 10µg/ml 
neutralising anti-RAGE antibody (α-RAGE) and then fixed and permeabilized on slides. Cells were co-
stained with anti—p65 NF-B/AF-488 antibodies and nuclear stain DAPI. Areas where green pixels (NF-
B) and blue nuclei (DAPI) overlap give light blue aggregates, representing nuclear translocation. 
Magnification x100. (B) Pixel intensity spatial correlation analysis of HMGB1-mediated nuclear 
translocation of p65 NF-B. Fresh CLL cells were left untreated for 0-hours or incubated with 200ng/ml 
HMGB1 for 2 and 4 hours with or without 10µg/ml neutralising anti-RAGE antibody (α-RAGE). P65 NF-B 
nuclear translocation was analysed using ImageJ software and ‘Rr’ indicates Pearson’s correlation 
coefficient. Data are mean ± SD from 4 individual CLL patients and differences compared with an unpaired 
student t test; P<0.05*, P<0.01**. 5 images were analysed per patient sample.  
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Figure 5-7 ImageStream analysis of HMGB1-mediated p65 NF-B nuclear translocation in primary CLL 
cells 
(A) Representative images of p65 NF-κB nuclear translocation captured by the ImageStream X Mark II flow 
cytometer; magnification x40. Fresh CLL cells were treated with 200ng/ml HMGB1 (+ HMGB1) with or 
without 10µg/ml goat anti-RAGE neutralising antibody (α-RAGE) for 2 and 4 hours. Cells were 
fixed/permeabilised, co-stained with anti-p65 NF-B/AF-488 647 antibodies and nuclei stained with DAPI. 
Data and images were assessed by ImageStream flow cytometry and nuclear translocation analysed by 
IDEAS software. (B) Statistical analysis of p65 NF-B nuclear translocation using the IDEAS software. The 
Similarity Eorded Score was measured for every cell recorded in 4 patients. Data are presented as median 
with interquartile range. 2 hours untreated n= 14468, HMGB1 n=13980, anti-RAGE n=14341; 4 hours 
untreated n=13432, HMGB1 n=13537, anti-RAGE n=13300. Differences were compared by an unpaired 
Mann Whitney U test; P<0.001***.  
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5.2.4 HMGB1 does not mediate a stable interaction between RAGE and TLR9 in CLL 
cells 
Colocalization of RAGE and TLR9 assessed by immunofluorescence does not indicate a direct 
protein-protein interaction. RAGE and TLR9 play pivotal roles in mediating HMGB1 inflammatory 
signalling activation, with evidence of direct binding and recruitment/activation of MyD88 in CLL 
NLCs, transfected HEK293 cells and lung epithelial cells.76,145,358 Therefore, we evaluated whether 
HMGB1 induces an interaction between TLR9 with RAGE, and TLR9 with MyD88 using co-IP.  
Fresh CLL cells were cultured for 2 hours with PBS control, 200ng/ml HMGB1, 10µg/ml anti-RAGE 
with addition of HMGB1 or 1µM CpG-ODN positive control. After 2 hours, cells were lysed and 
300µg of cell lysate incubated with 5µg of mouse anti-TLR9 antibody conjugated to Dynabead™ 
Protein A. TLR9-containing protein complexes were removed from the cell lysate by magnetic 
precipitation and denatured protein complexes were separated by gel electrophoresis. Blots 
were probed for RAGE, MyD88 and TLR9; co-IP with mouse anti-IgG antibody was used as a 
negative control. Using this method, no binding was observed between endogenous RAGE and 
TLR9, or TLR9 and MyD88 following treatment with HMGB1 for 2 hours (Figure 5-8) in 3 
independent co-IPs performed with 3 fresh primary CLL samples. Moreover, CpG-ODN failed to 
induce an interaction between TLR9 and MyD88, an established agonist of TLR9 signalling and 
MyD88 receptor recruitment.253 We failed to observe a band for TLR9 post-co-IP for all 3 patient 
samples, demonstrating unsuccessful attempts at precipitating TLR9 (Figure 5-8). Input cell 
lysates, pre-co-IP, express MyD88, RAGE and TLR9 (Figure 5-8). Therefore, co-IP was repeated 
for 1 patient sample using rabbit anti-RAGE antibody for precipitation. However, we failed to 
observe RAGE IP or TLR9 and MyD88 co-IP (data not shown). These results demonstrate we 
could not detect a stable interaction between RAGE and TLR9 or TLR9 and MyD88 in CLL cells, 
but these proteins do colocalise following stimulation with HMGB1. This suggests that the 
interaction between these proteins may be indirect via other protein(s) in CLL cells. 
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Figure 5-8 Co-IP of TLR9 and RAGE and MyD88 in CLL cells. 
Fresh CLL cells were treated with 200ng/ml HMGB1 with or without 10µg/ml goat anti-RAGE blocking 
antibody for 2 hours. TLR9 agonist 1µM CpG-ODN was included as a positive control for TLR9 and MyD88 
interaction. 5µg mouse anti-TLR9 antibody was incubated with Dynabeads protein A and then incubated 
with 300µg protein lysate. IP with 5µg mouse anti-IgG was used as a negative control. Pre-co-IP cell lysates 
and co-IP proteins were separated by gel electrophoresis and proteins probed with rabbit anti-RAGE and 
rabbit anti-MyD88. Immunoprecipitation of TLR9 was checked by probing with mouse anti-TLR9 antibody. 
Data are representative of 3 patients (10904). 
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5.2.5 Deciphering HMGB1-mediated intracellular signalling networks using 
comparative phosphoproteomics 
To fully investigate the signalling capacity of HMGB1 and synergism with TLR9 signalling 
pathway, we assessed intracellular signalling network activation using a phosphoproteomic 
approach. TLR and TLR9 signalling pathways are fully deciphered,246 while the precise signalling 
capacity of RAGE is unclear and highly cell-type specific. Although the 40-amino acid cytoplasmic 
tail of RAGE does not contain any known signalling motifs, it is vital for RAGE-mediated 
signalling,359 while other reports demonstrate the importance of receptor internalisation for 
HMGB1-mediated responses.194 On the other hand, HMGB1 has been identified as a component 
of autoantigens in SLE disease pathogenesis, and may play a role in CLL BCR activation.260 The 
full signaling pathways of HMGB1 and RAGE, or synergy with TLR9 signalling are currently not 
known. 
Using an unbiased phosphoproteomic approach with the help of Dr David Britton and Dr Pedro 
Cutillas’s mass spectrometry laboratory, we will be able to identify the signalling pathways 
activated following HMGB1 stimulation and synergy with CpG-ODN TLR9 agonist. We chose 2 
patient samples with high CLL purity (patient ID 8231: 97.2%; patient ID 6799: 94.3%; Figure 5-9) 
and from our earlier ZAP70 expression analysis, patient 8231 was ZAP70+ and patient 6799 was 
ZAP70- (Section 4.2.4; Appendix II, Table P). Both patients had not required therapy at the time 
of phosphoproteomic analysis (Appendix II, Table P). High CLL purity is important to ensure 
phosphorylated peptide signals originate from CLL cells, not contaminated by other cell types, 
particularly macrophages and dendritic cells for HMGB1 biology. Samples were stimulated for 
15 minutes, to capture rapid short-term signalling pathways, and 2 hours to assess downstream 
kinase cascade signalling. 200ng/ml HMGB1 alone, 1μM CpG-ODN alone, and 200ng/ml HMGB1 
+ 1μM CpG-ODN combined stimulation was assessed at 15 minutes and 2 hour time-points, and 
10μg/ml anti-RAGE antibody blockade and 200ng/ml HMGB1 stimulation combined was 
assessed at 2 hours. PBS stimulation was performed as baseline comparison controls at both 15 
minutes and 2 hours.  
5.2.5.1 Comparing the abundance of phosphorylated and de-phosphorylated peptides 
between patients  
We analysed 2 independent patient samples and each experiment was performed for three 
times. Following phosphopeptide enrichment, a total of 4185 unique phosphorylated peptide 
ions across 7 different experimental conditions and the 2 patient samples were detected. The 
abundance of phosphorylated peptide ions in each experimental condition was compared to the 
PBS baseline control. The significance of the difference in the means of log2-transformed data 
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across samples was assessed by Student’s t test, and an increased abundance phosphopeptide 
threshold was set log2 fold change ≥1 and P<0.05 compared to PBS treated sample; a decreased 
abundance threshold was set at log2 fold change ≤-1 and P<0.05 compared to PBS treated 
sample (Table 10).  
For both patient 8231 and 6799, 15 minutes stimulation with HMGB1 alone did not induce the 
phosphorylation of many peptides compared to PBS alone (32 and 20, respectively; Table 10). 
15 minutes CpG-ODN stimulation alone induced the significant phosphorylation of 119 
phosphopeptides in patient 8231 (ZAP70+ patient) compared to the PBS control, whereas this 
remained low in patient 6799 (36 phosphopeptides; ZAP70- patient). The combination of 
HMGB1 and CpG-ODN at 15 minutes induced the phosphorylation of a similar number of 
phosphopeptides compared to CpG-ODN alone in patient 8231 (125 phosphopeptides), and a 
similar number of phosphopeptides that were significantly de-phosphorylated compared to the 
PBS control (11 for CpG-ODN 15 minutes alone; 18 for HMGB1 and CpG-ODN 15 minutes; Table 
10). Although patient 6799 demonstrated a much higher abundance of phosphopeptides 
following HMGB1 and CpG-ODN stimulation at 15 minutes, when comparing to the abundance 
of phosphopeptides following to CpG-ODN alone (189 and 36, respectively), the abundance of 
dephosphorylated peptides for HMGB1 and CpG-ODN combined, was more than 
phosphorylated peptides (219; Table 10).  
The 2-hour time-point for all experimental conditions demonstrated an increase in cell signalling 
activity, based on the abundance of phosphorylated and dephosphorylated peptides, compared 
to PBS baseline. For patient 8231, HMGB1 alone at 2 hours resulted in 125 significantly abundant 
phosphopeptides compared to baseline, and 12 phosphopeptides down-regulated. Again, 
patient 6799 had a low amount of abundant phosphopeptides at 2 hours following stimulation 
with HMGB1 alone (55; Table 10), but a high level of down-regulated phosphopeptides 
compared to baseline (232; Table 10). CpG-ODN alone had an impact on the phosphoproteome 
for both patients. Patient 8231 demonstrated the abundance of 401 significantly 
phosphorylated peptides, and the down-regulation of 212 phosphopeptides compared to PBS 
baseline. Patient 6799 had a similar level of phosphorylated peptides, but a high number of de-
phosphorylated peptides compared to baseline (477 and 407, respectively). The combination of 
HMGB1 and CpG-ODN together induced the phosphorylation of 655 peptides for patient 8231 
at 2 hours, and the down-regulation of 212 phosphopeptides compared to baseline control. A 
similar number of peptides were phosphorylated following HMGB1 and CpG-ODN stimulation 
combined compared to CpG-ODN alone for patient 6799 (493 and 477, respectively). Again, the 
combination of HMGB1 and CpG-ODN resulted in the abundance of more phosphopeptides that 
were significantly dephosphorylated compared to PBS control at 15 minutes and 2 hours for 
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patient 6799 (530 down-regulated at 2 hours; Table 10). Pre-blockade of RAGE for 30 minutes 
before addition of HMGB1 for 2 hours, resulted in the up-regulation of 107 phosphopeptides 
and the down-regulation of 15 phosphopeptides compared to PBS baseline for patient 8231, 
and the up-regulation 152 phosphopeptides and down-regulation of 445 for patient 6799. These 
results give an indication of cell activity but investigating the specific peptides and kinases with 
increased or decreased activity under each experimental condition, and their respective 
signalling pathways, will give further insight into the mechanism of HMGB1 biology.  
 
Figure 5-9. Representative flow plots for CD19+/CD5+ CLL purity 
The CLL-cell purity of freshly isolated CLL PBMCs from patient 8231 and 6799 was assessed by flow 
cytometry. Non-permeabilised fresh PBMCs were stained for surface markers CD5 and CD19, using anti-
CD5-PE/Cy7 and anti-CD19-APC, respectively. Positive fluorescence was gated by comparing to isotype-
matched controls, and the purity of CLL cells was the % of cells that were CD5+/CD19+ (gate Q2).  
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Table 10. Abundance of significantly phosphorylated and dephosphorylated peptides across 
each experimental condition compared to PBS baseline control 
   8231 6799 
   Up Down Up Down 
HMGB1 15 mins   32 12 20 11 
CpG 15 mins   124 11 36 47 
HMGB1 + CpG 15 mins   119 18 189 219 
HMGB1 2 hours   125 12 55 232 
CpG 2 hours   401 212 477 407 
HMGB1 + CpG 2 hours  655 212 493 530 
Anti-RAGE and HMGB1 
2 hours  
107 15 152 445 
Note: Up-regulated threshold set at log2 fold change ≥1 and P<0.05 compared to PBS treated 
sample; down-regulated threshold set at log2 fold change ≤-1 and P<0.05 compared to PBS 
treated sample.   
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5.2.5.2 HMGB1 treatment alone modulates the activity of the MAPK pathway following 15 
minutes stimulation for the ZAP70 positive patient 
First, we aimed to assess the impact of HMGB1 treatment at 15 minutes and 2 hours on whole-
cell signalling pathways compared to PBS baseline control. To decipher the signalling pathways 
that correspond to the significantly abundant phosphopeptides in Table 10 (log2 fold change ≥1 
and P<0.05), the Database for Annotation, Visualization and Integrated Discovery (DAVID) online 
bioinformatics resource (https://david.ncifcrf.gov/home.jsp) was used. The uniprot IDs (i.e. 
gene list) for the list of phosphopeptides significantly abundant following 15 minutes HMGB1 
treatment (patient 8231, 32 phosphopeptides; patient 6799, 20 phosphopeptides; Table 10) and 
2 hours HMGB1 treatment (patient 8231, 125 phosphopeptides; patient 6799, 55 
phosphopeptides; Table 10) were submitted to DAVID bioinformatics (Appendix II; Table N) and 
pathway functional annotation was assessed using KEGG pathway mapping. Using this available 
online database, the list of uniprot IDs/gene list can be mapped to known signalling pathways 
based on experimental knowledge. The KEGG pathway output gives:  
i) a list of signalling pathways associated with the gene list input 
ii) the number of genes involved in the signalling pathway from the input list 
iii) the percentage of involved genes compared to total genes from the input list 
iv) the modified fisher exact P-value, i.e. the smaller the P-value the more enriched the 
pathway is with genes from the input list    
Following 15 minutes HMGB1 stimulation, 3/32 input genes from patient 8231 are associated 
with herpes simplex infection, only. For patient 6799, 2/20 input genes following 15 minutes 
HMGB1 stimulation are associated with spliceosome signalling, only. No other signalling 
pathways were identified from each gene list at this time-point.  
At 2 hours HMGB1 treatment for patient 8231, 14 signalling pathway groups were identified 
(Table 11) that are associated with the 125 uniprot IDs for the up-regulated phosphopeptides in 
Table 10; 10/125 are associated with spliceosome signalling, 6/125 are associated with oxidative 
phosphorylation and the others are linked to inflammatory conditions. The gene list for the 55 
abundant phosphopeptides following 2 hours HMGB1 treatment for patient 6799 yielded no 
results. When we input the list of 232 down-regulated phosphopeptides from patient 6799 
following 2 hours HMGB1 stimulation, 17 signalling pathway groups were identified. Of interest, 
3/6 of the top associated pathways from the KEGG pathway results were associated with 
metabolism (glycolysis/gluconeogenesis, carbon metabolism, pyruvate metabolism) indicating 
a down-regulation of anaerobic metabolism, and a switch to oxidative phosphorylation 
following HMGB1 treatment for 2 hours for patient 6799.  
Chapter V Results 
166 
 
Table 11. Patient 8231 2 hours HMGB1 treatment KEGG pathway results for upregulated 
phoshopeptides 
Signalling pathways Gene count % P-Value 
Spliceosome 10 8.9 9.70E-07 
Parkinson's disease 8 7.1 1.30E-04 
Alzheimer's disease 7 6.2 2.20E-03 
Alcoholism 7 6.2 2.90E-03 
Oxidative phosphorylation 6 5.4 4.30E-03 
Huntington's disease 7 6.2 4.40E-03 
Systemic lupus erythematosus 6 5.4 4.40E-03 
Cardiac muscle contraction 4 3.6 2.30E-02 
Gap junction 4 3.6 3.40E-02 
Serotonergic synapse 4 3.6 6.10E-02 
Carbon metabolism 4 3.6 6.30E-02 
Pathogenic Escherichia coli infection 3 2.7 6.40E-02 
Long-term depression 3 2.7 8.50E-02 
Pathways in cancer 7 6.2 9.70E-02 
 
Table 12. Patient 6799 2 hours HMGB1 treatment KEGG pathways results for downregulated 
phosphopeptides 
Signalling pathways Gene count % P-Value 
Spliceosome 15 7.4 1.30E-08 
Glycolysis / Gluconeogenesis 9 4.5 7.80E-06 
Carbon metabolism 10 5 5.70E-05 
Pathogenic Escherichia coli infection 7 3.5 1.20E-04 
Biosynthesis of antibiotics 12 5.9 4.10E-04 
Pyruvate metabolism 5 2.5 3.20E-03 
Shigellosis 5 2.5 1.70E-02 
Herpes simplex infection 8 4 2.30E-02 
Biosynthesis of amino acids 5 2.5 2.70E-02 
Phagosome 7 3.5 3.10E-02 
Viral carcinogenesis 8 4 3.90E-02 
Salmonella infection 5 2.5 3.90E-02 
Fc gamma R-mediated phagocytosis 5 2.5 4.10E-02 
Alzheimer's disease 7 3.5 4.60E-02 
Ribosome 6 3 5.90E-02 
Parkinson's disease 6 3 6.90E-02 
SNARE interactions in vesicular transport 3 1.5 9.70E-02 
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Next, to infer pathway activity, we used a computational approach developed by Dr Pedro 
Cutillas, termed kinase-substrate enrichment analysis (KSEA), to determine the activation of 
given kinase pathways from mass spectrometry–based phosphoproteomic analysis.310 As 
phosphorylation sites are the result of kinase activity (i.e. kinase substrates), using several 
known phosphorylation sites downstream of each kinase, it is possible to use this data as a way 
to quantify kinase activity - the master regulators of signalling pathways. This is a better measure 
of overall global signalling activity, as an individual phosphorylation site may be targeted by 
multiple kinases, the nature of this post-translational modification is dynamic and can quickly 
change, along with experimental stress that all impact protein kinase activity, and impact signal-
to-noise ratio. Therefore, using this approach, we can gain deeper and more reliable biological 
insight on the activity of kinase pathways from MS-based phosphoproteomics.  
Substrate groups enriched for different kinases was calculated using the KSEA algorithm (with 
the PhosphoSite database: https://www.phosphosite.org), and fold-enrichment was based on 
the abundance of phosphopeptides under each experimental condition, divided by the 
abundance in the PBS treated cells. The unique 4185 phosphopeptide ions detected in this 
dataset correspond to 330 kinase substrate groups in total. 
Focusing on substrate groups with significant activity compared to PBS baseline control 
following 15 minutes HMGB1 stimulation, 18 substrate groups were identified with significant 
activity in patient 8231 with ZAP70+ expression status (column of interest indicated by arrow; 
(Figure 5-10) and 0 substrate groups with significant activity in patient 6799 with ZAP70- 
expression status. 12/18 substrate groups for patient 8231 demonstrated an increase in 
abundancy, shown in red in the heat map for Figure 5-10 (corresponding to kinases MEK2, AurA, 
Ret, JAK2, PLK3, JNK2, ERK7, MEK1, VRK1, PKR, CDK19 and HcK) and 6/18 substrate groups 
demonstrated a decrease in abundancy in blue shades in the heat map (corresponding to kinases 
MEKK3, LRRK2, LOK, GRK2, Cot, PKCT; Figure 5-10). Of interest, MEK2, Ret, JAK2, MEK1 
significantly contribute to the activation of the MAPK pathway, via the phosphorylation of 
MAPK1 (at tyrosine 187 and threonine 185) and MAPK1 (tyrosine 204 and threonine 202) 
substrates. PLK3, JNK2, ERK7 and VRK1 contribute to the activation of transcription factor AP-1, 
by the phosphorylation of Jun (at serine 73).  
Interestingly, the substrate groups leading to MAPK pathway activation (corresponding to 
kinases MEK2, Ret, JAK2, MEK1) at 15 minutes, are not significantly enriched at 2 hours, whereas 
the substrate groups for AP-1 activation (due to kinases PLK3, JNK2, ERK7 and VRK1) are 
enriched (patient 8231 comparing 15 minutes HMGB1 column and 2 hours HMGB1 column; 
Figure 5-10). The substrate groups with significant abundancy (increased or decreased) in 
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patient 8231 following 15 minutes HMGB1 treatment, do not overlap with patient 6799, as the 
15 minutes HMGB1 column for patient 6799 in Figure 5-10 does not contain notable enrichment 
or any significant results. 
 
 
 
Figure 5-10. Heat map showing the enrichment of substrate groups for the different kinases calculated 
by KSEA algorithm with significant abundance following 15 minutes HMGB1 treatment for patient 
8231 
Fresh CLL cells were treated with 200ng/ml HMGB1 alone, 1μM CpG-ODN alone, 200ng/ml HMGB1 and 
1μM CpG-ODN combined for 15 minutes and 2 hours. Blockade of surface RAGE was performed with 
10µg/ml goat anti-RAGE neutralising antibody for 30 minutes before addition of 200ng/ml HMGB1 for 2 
hours. Cell lysates were processed for mass spectrometry and phosphorylated peptides were enriched 
with TiO2 and identified and quantified by LC-MS/MS. Enrichment of substrate groups was calculated by 
the KSEA algorithm and divided by the abundance of phosphopeptides in the PBS treated sample. The 
coloured enrichment key indicates -5 to +5-fold enrichment compared to PBS treated sample. Statistical 
significance of these changes was calculated by Student’s t test compared to PBS treated samples; 
P<0.05*, P<0.01**, P<0.001***, P<0.0001****. ‘m’, number of substrates in the indicated kinase 
substrate group. KSEA results were filtered based on significantly abundant substrate groups for patient 
8231 following 15 minutes HMGB1 treated (column indicated by arrow). 
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After 2 hours HMGB1 treatment, patient 8231 demonstrated the significant abundancy of 8 
substrate groups (column of interest indicated by arrow; Figure 5-11) and patient 6799 
demonstrated the abundancy of 9 substrate groups (column of interest indicated by arrow; 
Figure 5-12). For patient 8231, substrate groups for AurA, PLK3, JNK2, ERK7, Cot and PKCT 
overlap with 15 minutes HMGB1 treatment. Of these, substrates for PLK3, JNK2 and ERK7 with 
significant increased abundancy contribute to the activation of transcription factor AP-1 via Jun 
phosphorylation at serine 73. Cot and PKCT substrate groups with significant decreased 
phosphorylated abundancy, act as cross-linkers between plasma membranes and actin-based 
cytoskeletons. Again, these significantly abundant substrate groups for patient 8231 following 2 
hours’ HMGB1 treatment, do not overlap with significant results for patient 6799 under the 
same experimental condition (Figure 5-11).  
For patient 6799 with ZAP70- expression status, substrate groups for kinases Wee1, Myt1, HER2 
and MEKK3 showed increased significant enrichment following 2 hours HMGB1 treatment 
(column of interest indicated by arrow; Figure 5-12). Of these, Wee1, Myt1 and Her2 substrate 
groups are associated with the phosphorylation of CDK1 and CDK2, vital components of cell cycle 
transitions. Whereas substrate groups Ret, JAK2, GSK3A, JNK3 and Syk demonstrated decreased 
significant abundancy in patient 6799 following 2 hours HMGB1 treatment, components of 
MAPK and MYC signalling. This result demonstrates a decrease in activity of MAPK and MYC 
signalling for patient 6799 following longer-term HMGB1 signalling compared to the PBS 
baseline control. 
Taken together, this data demonstrates 2 hours HMGB1 stimulation results in opposing MAPK 
signalling pathway activity in 2 patients with different clinical background and ZAP70 expression 
status.  
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Figure 5-11. Heat map showing the enrichment of substrate groups for the different kinases calculated 
by KSEA algorithm, with significant abundance following 2 hours HMGB1 treatment for patient 8231  
Cell samples were treated, processed and phosphopeptides quantified by LC/MS-MS as previously 
described in Figure 5-10. Enrichment of substrate groups was calculated by the KSEA algorithm and 
divided by the abundance of phosphopeptides in the PBS treated sample. The coloured enrichment key 
indicates -5 to +5-fold enrichment compared to PBS treated sample. Statistical significance of these 
changes was calculated by Student’s t test compared to PBS treated samples; P<0.05*, P<0.01**, 
P<0.001***, P<0.0001****. ‘m’, number of substrates in the indicated kinase substrate group. KSEA 
results were filtered based on significantly abundant substrate groups for patient 8231 following 2 hours 
HMGB1 treated (column indicated by arrow). 
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Figure 5-12. Heat map showing the enrichment of substrate groups for the different kinases calculated 
by KSEA algorithm, with significant abundance following 2 hours HMGB1 treatment for patient 6799 
Cell samples were treated, processed and phosphopeptides quantified by LC/MS-MS as previously 
described in Figure 5-10. Enrichment of substrate groups was calculated by the KSEA algorithm and 
divided by the abundance of phosphopeptides in the PBS treated sample. The coloured enrichment key 
indicates -5 to +5-fold enrichment compared to PBS treated sample. Statistical significance of these 
changes was calculated by Student’s t test compared to PBS treated samples; P<0.05*, P<0.01**, 
P<0.001***, P<0.0001****. ‘m’, number of substrates in the indicated kinase substrate group. KSEA 
results were filtered based on significantly abundant substrate groups for patient 6799 following 2 hours 
HMGB1 treated (column indicated by arrow). 
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5.2.5.3 HMGB1 combined with CpG-ODN results in the phosphorylation of more peptides in 
ZAP70 positive cells compared to CpG-ODN alone 
A synergistic mode of action has been demonstrated for CpG-ODN and HMGB1 in autoimmune 
disease and lung cancer.145,148,149 Next, we aimed to investigate any synergistic signalling 
between HMGB1 and CpG-ODN (class B) in a CLL setting, by phosphoproteomic analysis of 
primary CLL cells following individual and combined HMGB1 and CpG-ODN treatment for 15 
minutes and 2 hours. Referring to the relevant data from Table 10, Table 13 outlines the number 
of significantly increased and decreased abundant phosphopeptides in HMGB1 alone, CpG-ODN 
alone and combined HMGB1 and CpG-ODN treated samples. For patient 8231, the combination 
of HMGB1 and CpG-ODN at 15 minutes resulted in a similar number of increased and decreased 
phosphopeptides as CpG-ODN alone when compared to PBS baseline; at 2 hours, the 
combination of HMGB1 and CpG-ODN induces the phosphorylation of 154 more peptides than 
CpG-ODN alone. For patient 6799, both 15 minutes and 2 hours combined HMGB1 and CpG-
ODN treatment results in more abundant phosphopeptides (either increased or decreased), 
compared to CpG-ODN alone. However, whether the same phosphopeptide ions and signalling 
pathways are modulated in response to combined stimulation, requires further investigation of 
specific kinase cascades. 
Table 13. Comparing the abundance of significantly increased and decreased  phosphopeptides 
in HMGB1 alone, CpG-ODN alone and HMGB1 + CpG-ODN treated samples  
   8231 6799 
   Up-regulated Down-regulated Up-regulated Down-regulated 
HMGB1 15 mins   32 12 20 11 
CpG 15 mins   124 11 36 47 
HMGB1 + CpG 15 mins   119 18 189 219 
HMGB1 2 hours   125 12 55 232 
CpG 2 hours   401 212 477 407 
HMGB1 + CpG 2 hours  655 212 493 530 
 
Note: Data from Table 10. Up-regulated threshold set at log2 fold change ≥1 and P<0.05 
compared to PBS treated sample; down-regulated threshold set at log2 fold change ≤-1 and 
P<0.05 compared to PBS treated sample.  
DAVID bioinformatics and KEGG pathway functional annotation resource was used to initially 
assess overlap of signalling pathways, across experimental conditions, for the phosphopeptides 
with increased significant abundancy. For patient 8231, the list of uniprot IDs for abundant 
phosphopeptides at 15 minutes HMGB1 alone, CpG-ODN alone, or combined HMGB1 and CpG-
ODN, did not yield many pathway results (Table 14). Following 2 hours treatment, combined 
HMGB1 and CpG-ODN resulted in more than double the signalling pathway hits than HMGB1 or 
CpG-ODN alone (30 for combined HMGB1 and CpG-ODN, 12 for CpG-ODN alone, 14 for HMGB1 
Chapter V Results 
173 
 
alone; Table 14). Main signalling pathways such as MAPK, BCR and mTOR overlapped in both 
CpG-ODN alone and combined HMGB1 and CpG-ODN; whereas other signaling pathway hits in 
both experimental conditions were linked to clinical conditions and had a low gene count (≤2 
genes) out of all input gene from the uniprot ID list. For patient 6799 the input gene list 
corresponding to HMGB1 alone and CpG-ODN alone at both 15 minutes and 2 hours, resulted in 
less than 4 results (Table 14). Upon combining HMGB1 and CpG-ODN, the number of KEGG 
pathway outputs containing genes from the input list is notably increased (41 pathways for 15 
minutes, 34 pathways for 2 hours; Table 14). Again, the core pathways of this list include BCR, 
MAPK, mTOR and ErbB signalling.  
Table 14. KEGG pathway results for upregulated phoshopeptides in patient 8231 and 6799 
following HMGB1 alone, CpG alone and HMGB1 and CpG combined treated samples 
   8231 6799 
   15 mins 2 hours 15 mins 2 hours 
HMGB1 alone  1 14 1 0 
CpG alone   5 12 1 4 
HMGB1 + CpG  2 30 41 34 
 
Although KEGG pathway functional annotation can offer insight into the main signalling 
pathway(s) utilised based on gene name for significantly up-regulated phosphopeptides, this 
method loses detailed information that is gained from phosphoproteomic analysis. This includes 
information regarding the specific phosphorylation site(s) per protein, the magnitude of up-
regulation/down-regulation of these phosphorylation sites, upstream information regarding the 
kinase responsible, and corresponding increased or decreased kinase activity across different 
experimental conditions. Therefore, to fully investigate and compare signalling pathway 
activation across HMGB1 and CpG-ODN experimental conditions, KSEA was performed to gain a 
better insight into kinase activity. 
KSEA of the phosphoproteome was performed for each patient following 15 minutes and 2 hours 
CpG-ODN and HMGB1 combined treatment, to identify substrate groups of kinases with 
significant activity compared to PBS baseline controls. For patient 8231, 15 minutes HMGB1 and 
CpG-ODN combined treatment demonstrated the significant abundancy (increased or 
decreased) of 9 substrate groups (column of interest indicated by arrow; Figure 5-13). Of these, 
8/9 kinases had increased activity compared to PBS baseline and 1 had decreased activity. All 9 
of these kinases overlap with kinases with significant activity following 15 minutes CpG-ODN 
treatment alone (Figure 5-13; Appendix II Figure 11). The signalling pathways and cellular activity 
associated with these kinases and substrate groups include cell cycle signalling, c-Jun oncogene 
activation, transcriptional regulation and RNA splicing. MAPK signalling was the only signalling 
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pathway demonstrating activation following 15 minutes CpG-ODN treatment, but not when 
HMGB1 and CpG were combined at this time points (Figure 5-13; Appendix II Figure 11). 
 
 
Figure 5-13. Heat map showing the enrichment of substrate groups for the different kinases calculated 
by KSEA algorithm, with significant abundance following HMGB1 and CpG treatment for 15 minutes 
for patient 8231 
Cell samples were treated, processed and phosphopeptides quantified by LC/MS-MS as previously 
described in Figure 5-10. Enrichment of substrate groups was calculated by the KSEA algorithm and 
divided by the abundance of phosphopeptides in the PBS treated sample. Heat map colours correspond 
to the coloured enrichment key in Figure 5-10 and indicates -5 to +5-fold enrichment compared to PBS 
treated sample. Statistical significance of these changes was calculated by Student’s t test compared to 
PBS treated samples; P<0.05*, P<0.01**, P<0.001***, P<0.0001****. ‘m’, number of substrates in the 
indicated kinase substrate group. KSEA results were filtered based on significantly abundant substrate 
groups for patient 8231 following HMGB1 and CpG-B class for 15 minutes (column indicated by arrow). 
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For patient 6799, 15 minutes HMGB1 and CpG-ODN combined treatment demonstrated the 
significant abundancy (increased or decreased) of 14 substrate groups (column of interest 
indicated by arrow; Figure 5-14). For this patient (ZAP70-), most substrate groups were negatively 
enriched following combined treatment, with 11/14 kinases demonstrating decreased activity 
compared to PBS baseline. This translates into a decrease in clathrin-mediated endocytosis, 
cytoskeletal rearrangement and chemotaxis (CXCR4 mediated) activity. These substrate groups 
overlap with significant kinase activity following CpG-ODN alone stimulation, except for GRK6 
involved in CXCR4 chemotaxis, and PIKCI and ROCK1 involved in cytoskeletal reorganisation 
(Figure 5-14; Appendix II Figure 12). P38B, CK2A1 and SRPK1 demonstrate increased kinase 
activity following combined HMGB1 and CpG-ODN treatment, but not after CpG-ODN treatment 
alone (Figure 5-14). These kinases and substrate groups correspond to MAPK signalling, a central 
kinase for multiple cellular processes, and RNA splicing, respectively. For this patient, 15 minutes 
CpG-ODN stimulation alone resulted in 12 kinases with significant activity; 11 with decreased 
activity compared to baseline and 1 with increased activity (Appendix II Figure 12). The down-
regulated substrate groups correspond to clathrin-mediated endocytosis, cytoskeletal 
regulation (consistent with combined HMGB1 and CpG-ODN treatment), cell cycle signalling and 
the unfolded protein response. 
Interestingly, MAPK signalling was uniquely induced in the ZAP70- patient (6799) following 
HMGB1 and CpG-ODN combined, but not by CpG-ODN alone, whereas the opposite was 
observed in the ZAP70+ patient (8231); CpG-ODN alone induced MAPK signalling in patient 8231, 
which showed little activity following HMGB1 and CpG-ODN combined.  
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Figure 5-14. Heat map showing the enrichment of substrate groups for the different kinases calculated 
by KSEA algorithm, with significant abundance following HMGB1 and CpG-ODN treatment for 15 
minutes for patient 6799 
Cell samples were treated, processed and phosphopeptides quantified by LC/MS-MS as previously 
described in Figure 5-10. Enrichment of substrate groups was calculated by the KSEA algorithm and 
divided by the abundance of phosphopeptides in the PBS treated sample. Heat map colours correspond 
to the coloured enrichment key in Figure 5-10 and indicates -5 to +5-fold enrichment compared to PBS 
treated sample. Statistical significance of these changes was calculated by Student’s t test compared to 
PBS treated samples; P<0.05*, P<0.01**, P<0.001***, P<0.0001****. ‘m’, number of substrates in the 
indicated kinase substrate group. KSEA results were filtered based on significantly abundant substrate 
groups for patient 6799 following HMGB1 and CpG-B class for 15 minutes (column indicated by arrow). 
 
At the longer 2-hour time-point, KSEA of the phosphoproteome for patient 8231 revealed the 
significant activity of 28 substrate groups and respective kinases (Figure 5-15); 21 with increased 
activity compared to PBS baseline and 7 kinases with decreased activity. The up-regulated 
substrate groups correspond to mTORC1 regulation, MAPK signalling, c-Jun oncogene activation, 
MYC signalling, RNA splicing activity and microtubule regulation. Of these abundant substrate 
groups and respective associated signalling pathways, only kinases corresponding to mTORC1 
regulation (mTOR) and MAPK signalling (ERK1, MEK2, Ret, JAK2, MEK1) have unique increased 
activity following 2 hours combined HMGB1 and CpG-ODN, when comparing to the KSEA results 
following 2 hours CpG-ODN alone for patient 8231 (Figure 5-15; Appendix II Figure 13). 
Therefore, at 15 minutes for this ZAP70+ patient, CpG-ODN alone stimulates MAPK activity, 
whereas by 2 hours treatment, MAPK signalling has ceased following CpG-ODN alone but is 
induced following HMGB1 and CpG-ODN combined. The increased mTOR activity following 
HMGB1 and CpG-ODN combined treatment suggests the involvement of the PI3K/Akt pathway 
H
M
G
B
1
C
p
G
H
M
G
B
1
 +
 C
p
G
H
M
G
B
1
C
p
G
H
M
G
B
1
 +
 C
p
G
A
n
ti
-R
A
G
E 
+
 H
M
G
B
1
H
M
G
B
1
C
p
G
H
M
G
B
1
 +
 C
p
G
H
M
G
B
1
C
p
G
H
M
G
B
1
 +
 C
p
G
A
n
ti
-R
A
G
E 
+
 H
M
G
B
1
m Associated signalling 
P38B **** **** **** *** *** *** 2 MAPK signalling
CK2A1 ** ** ** *** 55 Multiple cell processes
SRPK1 **** ** **** **** *** *** ** * ** 8 Splicing/ mitosis
AAK1 * **** **** 1 Clathrin-mediated endocytosis
GRK6 * * 2 CXCR4 chemotaxis
MST4 ** **** ** ** 1
PKCI **** ** 2
LRRK2 ** * *** **** **** **** 3
LOK ** * *** **** **** **** 3
GRK2 ** * *** **** **** **** 3
ROCK1 * 10
PKCT *** * ** **** **** **** **** 5
Cot *** * ** **** **** **** **** 4
MEKK3 **** **** **** **** ** **** **** **** **** **** 2
Cytoskeletal regulation
15 minutes 2 hours 15 minutes 2 hours
8331 6799
Chapter V Results 
177 
 
at this longer time-point. Interestingly, the response to RNA processing and splicing is reversed 
when HMGB1 and CpG-ODN is combined (Figure 5-15); CpG-ODN alone for 2 hours results in 
decreased CK2A2 and SRPK1, whereas combined HMGB1 and CpG-ODN results in increased 
kinase activity.  
The 7 down-regulated substrate groups following 2 hours combined treatment, are unique to 
HMGB1 and CpG-ODN combined, and not significant following CpG-ODN alone (Figure 5-15; 
Appendix II Figure 13). These substrate groups are associated with clathrin-mediated 
endocytosis, transcriptional regulation and cytoskeletal regulation/reorganisation. Following 2 
hours CpG-ODN stimulation alone (Appendix II Figure 13), all significant enriched substrate 
groups overlap with significant results for 2 hours HMGB1 and CpG-ODN combined. 
Therefore, these results demonstrate that for this ZAP70+ patient, HMGB1 and CpG do act 
synergistically by inducing long-term MAPK activation, which is observed at 15 minutes HMGB1 
alone (Figure 5-12) or CpG-ODN alone (Appendix II Figure 13), but ceased by 2 hours. 
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Figure 5-15. Heat map showing the enrichment of substrate groups for the different kinases calculated 
by KSEA algorithm, with significant abundance following HMGB1 and CpG treatment for 2 hours for 
patient 8231 
Cell samples were treated, processed and phosphopeptides quantified by LC/MS-MS as previously 
described in Figure 5-10. Enrichment of substrate groups was calculated by the KSEA algorithm and 
divided by the abundance of phosphopeptides in the PBS treated sample. Heat map colours correspond 
to the coloured enrichment key in Figure 5-10 and indicates -5 to +5-fold enrichment compared to PBS 
treated sample. Statistical significance of these changes was calculated by Student’s t test compared to 
PBS treated samples; P<0.05*, P<0.01**, P<0.001***, P<0.0001****. ‘m’, number of substrates in the 
indicated kinase substrate group. KSEA results were filtered based on significantly abundant substrate 
groups for patient 8231 following HMGB1 and CpG-B class for 2 hours (column indicated by arrow). 
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For patient 6799, KSEA of the phosphoproteome following 2 hours combined HMGB1 and CpG-
ODN treatment revealed the significant enrichment of 29 substrate groups and respective 
kinases (Figure 5-16); 15/29 of these demonstrated increased activity compared to PBS baseline 
and 14/29 kinases with decreased activity. Comparing to the KSEA results following CpG-ODN 
alone 2 hours treatment for this patient (Appendix II Figure 14), nearly all 23 significant kinases 
under this experimental condition overlap with combined HMGB1 and CpG-ODN 2 hours, except 
for PKR and MEK2 in the CpG-ODN alone cohort (Appendix II Figure 14).  
The substrate groups with significant enrichment following combined 2 hours HMGB1 and CpG-
ODN treatment, correspond to PKC signalling, TLR9 signalling, PI3K/mTOR signalling, cell cycle 
and microtubule regulation (Figure 5-16). For this patient, kinases involved in MAPK signalling 
have demonstrated differing activity; HMGB1 and CpG-ODN combined 15 minutes treatment 
and 2 hours CpG-ODN alone treatment resulted in increased MAPK kinase activity, whereas 2 
hours HMGB1 treatment alone resulted in decreased MAPK activity. For the 4 substrate groups 
under MAPK signalling with significant enrichment following HMGB1 and CpG-ODN combined 
treatment in patient 6799, 2 respective kinases had increased activity, and 2 with decreased 
activity (Figure 5-16).  
For the 14/29 substrate groups with decreased enrichment compared to PBS baseline following 
combined HMGB1 and CpG-ODN treatment, some overlap with the direction of kinase activity 
following 2 hours CpG-ODN alone. These include kinases associated with BCR signalling, CK2 
family of kinases and splicing/mitosis (Figure 5-16). The decreased activity of kinases associated 
with c-Jun activation, transcriptional regulation and cytoskeletal regulation, are unique to 
combined HMGB1 and CpG-ODN 2 hours alone.  
These results do not reveal the increased activity of any alternative signalling pathways on the 
combination of HMGB1 and CpG-ODN compared to either alone. However, we have identified 
differing MAPK pathway activity, dependent on the length of time of stimulation and whether 
CpG-ODN was combined with HMGB1.  
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Figure 5-16. Heat map showing the enrichment of substrate groups for the different kinases calculated 
by KSEA algorithm, with significant abundance following HMGB1 and CpG treatment for 2 hours for 
patient 6799 
Cell samples were treated, processed and phosphopeptides quantified by LC/MS-MS as previously 
described in Figure 5-10. Enrichment of substrate groups was calculated by the KSEA algorithm and 
divided by the abundance of phosphopeptides in the PBS treated sample. Heat map colours correspond 
to the coloured enrichment key in Figure 5-10 and indicates -5 to +5-fold enrichment compared to PBS 
treated sample. Statistical significance of these changes was calculated by Student’s t test compared to 
PBS treated samples; P<0.05*, P<0.01**, P<0.001***, P<0.0001****. ‘m’, number of substrates in the 
indicated kinase substrate group. KSEA results were filtered based on significantly abundant substrate 
groups for patient 6799 following HMGB1 and CpG-B class for 2 hours (column indicated by arrow). 
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5.2.5.4 Anti-RAGE blockade does not neutralise HMGB1 activity 
Finally, using phosphoproteomics we aimed to determine the impact of surface-RAGE blockade 
on 2 hours HMGB1 signalling, by assessing whole-cell signalling pathways. Referring to the 
relevant data from Table 10, Table 15 outlines the number of significantly increased and 
decreased abundant phosphopeptides in HMGB1-treated and anti-RAGE pre-blockade treated 
samples.  
Table 15. Comparing the abundance of significantly increased and decreased  
phosphopeptides in HMGB1-stimulated samples with or without RAGE blockade 
   8231 6799 
2 hours:   Up Down Up Down 
HMGB1   125 12 55 232 
Anti-RAGE and HMGB1   107 15 152 445 
 
Note: Data from Table 10. Up-regulated threshold set at log2 fold change ≥1 and P<0.05 
compared to PBS treated sample; down-regulated threshold set at log2 fold change ≤-1 and 
P<0.05 compared to PBS treated sample.  
HMGB1 treatment for 2 hours resulted in the up-regulation of 125 phosphopeptides and 
downregulation of 12 phosphopeptides for patient 8231, while pre-blockade of RAGE for 30 
minutes before addition of HMGB1 for 2 hours, resulted in the up-regulation of 107 
phosphopeptides and the down-regulation of 15 phosphopeptides compared to PBS baseline.   
HMGB1 treatment for 2 hours resulted in the up-regulation of 55 phosphopeptides and down-
regulation of 232 phosphopeptides for patient 6799; while pre-blockade of RAGE for 30 minutes 
before addition of HMGB1 for 2 hours, resulted in the up-regulation of 152 phosphopeptides 
and the down-regulation of 445 phosphopeptides compared to PBS baseline.   
Anti-RAGE blockade does not have much impact on the abundance of increased or decreased 
phosphopeptides for patient 8231, but these may be of different phosphorylation sites; whereas 
there is a big increase in the abundance of both increased and decreased phosphopeptides for 
patient 6799. Assessing the signalling pathways affected using DAVID bioinformatics resource 
and KSEA of the phosphoproteomes will reveal the true impact of RAGE blockade on kinase 
activity.  
The list of uniprot IDs for the significantly increased abundant phosphopeptides following 2 
hours anti-RAGE blockade with HMGB1 were submitted to DAVID bioinformatics (Appendix II; 
Table O) and pathway functional annotation was assessed using KEGG pathway mapping. 14 
signalling pathways were identified with genes associated with the input uniprot ID list following 
2 hours HMGB1 stimulation alone for patient 8231 (5.2.5.2; Table 11). Addition of pre-RAGE 
blockade for 30 minutes, followed by 2 hours HMGB1 stimulation gave 10 KEGG pathway results 
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(Table 16). 9/10 of these pathways overlap with results from 2 hours HMGB1 stimulation alone 
for patient 8231, except for glycolysis/gluconeogenesis. For patient 6799, the list of uniprot IDs 
for the significantly increased abundant phosphopeptides following 2 hours treatment with 
HMGB1 yielded 0 results for association with signalling pathways - this result was maintained 
upon addition of pre-RAGE blockade for 30 minutes.  
The KEGG pathway results for patient 8231 imply similar pathways are activated by HMGB1, 
regardless of RAGE-blockade. However, prior in vivo cell activation may contribute to the 
activation of some observed pathways through KEGG analysis (i.e. the pathways associated with 
pathological conditions), and the gene count for the observed pathways is not consistent 
between HMGB1 alone stimulation, and RAGE blockade with HMGB1. Further investigation of 
kinase activity may reveal inhibition of certain pathways and switching to others due to RAGE 
blockade.  
Table 16. Patient 8231 2 hours anti-RAGE and HMGB1 treatment KEGG pathway results for 
upregulated phoshopeptides 
Signalling pathways Gene count % P-Value 
Spliceosome 7 7 2.30E-04 
Alcoholism 7 7 1.00E-03 
Parkinson's disease 6 6 2.40E-03 
Pathogenic Escherichia coli infection 4 4 4.60E-03 
Huntington's disease 6 6 8.60E-03 
Systemic lupus erythematosus 5 5 1.20E-02 
Alzheimer's disease 5 5 2.50E-02 
Carbon metabolism 4 4 3.90E-02 
Oxidative phosphorylation 4 4 5.80E-02 
Glycolysis / Gluconeogenesis 3 3 7.30E-02 
 
KSEA of the phosphoproteome was performed for each patient following 2 hours anti-RAGE and 
HMGB1 combined treatment, to identify substrate groups of kinases with significant activity 
compared to PBS baseline controls. For patient 8231, 2 hours HMGB1 treatment alone, 
demonstrated the significant abundancy (increased or decreased) of 8 substrate groups (column 
of interest indicated by arrow; Figure 5-11). When RAGE was neutralised for 30 minutes prior to 
addition of HMGB1, 9 substrate groups were identified with significant abundancy (increased or 
decreased; column of interest indicated by arrow; Figure 5-17). Comparing these results to KSEA 
for patient 8231 following 2 hours HMGB1 treatment alone (Figure 5-11), substrates of AurA, 
PLK3, JNK2 and ERK7 are still significantly enriched despite RAGE blockade, contributing to the 
activation of transcription factor AP-1, via Jun phosphorylation at serine 73. Other substrate 
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groups that remained significantly enriched include those of CK2A2 and SRPK1 - both with roles 
in the regulation of alternative splicing. DYRK1A, CDK19 and MEKK3 are the only substrate 
groups with significant negative enrichment compared to the PBS baseline, and the only results 
that were not significant for 2 hours HMGB1 treatment alone. RCAN1 regulates transcriptional 
responses and is a mutual substrate for both DYRK1A and MEKK3. Decreased phosphorylation 
of RCAN1, as observed following anti-RAGE blockade, relieves the inhibitor function of RCAN1, 
allowing transcriptional activity to occur. An interesting result was a decrease in the enrichment 
of substrates for CDK19, which showed significantly increased enrichment following 15 minutes 
HMGB1 treatment alone for patient 8231. CDK19 is a component of the Mediator coactivator 
complex, responsible for the regulation of several transcription factors. In this setting, decreased 
CDK19 activity was due to a decrease in PAK1 phosphorylation. The significant KSEA results for 
RAGE blockade for patient 8231 do not overlap with patient 6799. 
 
 
Figure 5-17 Heat map showing the enrichment of substrate groups for the different kinases calculated 
by KSEA algorithm, with significant abundance following pre-RAGE blockade for 30 minutes and 
addition of HMGB1 for 2 hours for patient 8231 
Cell samples were treated, processed and phosphopeptides quantified by LC/MS-MS as previously 
described in Figure 5-10. Enrichment of substrate groups was calculated by the KSEA algorithm and 
divided by the abundance of phosphopeptides in the PBS treated sample. Heat map colours correspond 
to the coloured enrichment key in Figure 5-10 and indicates -5 to +5-fold enrichment compared to PBS 
treated sample. Statistical significance of these changes was calculated by Student’s t test compared to 
PBS treated samples; P<0.05*, P<0.01**, P<0.001***, P<0.0001****. ‘m’, number of substrates in the 
indicated kinase substrate group. KSEA results were filtered based on significantly abundant substrate 
groups for patient 8231 following RAGE blockade for 30 minutes and addition of HMGB1 for 2 hours 
(column indicated by arrow). 
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For patient 6799, KSEA of the phosphoproteome following 2 hours HMGB1 treatment alone, 
resulted in 9 enriched substrate groups (column of interest indicated by arrow; Figure 5-12). Pre-
blockade of RAGE followed by 2 hours HMGB1 treatment, resulted in the enrichment of 25 
substrate groups (column of interest indicated by arrow; Figure 5-18). Comparing the KSEA 
results, all 9 enriched substrate groups following 2 hours HMGB1 treatment (HER2, Myt1, Wee1, 
Syk, Ret, JAK2, JNK3, GSK2A, MEKK3) were also significantly enriched in the same direction 
(increased or decreased) despite RAGE blockade (Figure 5-18). BCR and MYC signalling activity 
(via Syk, and JNK3 and GSK3A, respectively) was still decreased compared to the PBS baseline. 
Moreover, RAGE blockade failed to supress cell cycle signalling (via HER2, Myt1, Wee1) and 
MAPK signalling (via Ret, JAK2). RAGE blockade further induced the activity of MEK2, 
contributing to MAPK signalling, and the activity of GRK6 enhancing CXCR4 chemotactic activity.  
The enrichment of substrate groups for CDK19, P38B, PKR, MST4, PKCI, Akt2, LRRK2, LOK, GRK2, 
PKCT and Cot, were significantly decreased compared to PBS baseline, and enrichment levels 
were different when comparing to 2 hours’ HMGB1 alone (Figure 5-18). Decreased CDK19 
activity was due to decreased PAK1 phosphorylation at serine 174; PAK1 regulates cytoskeleton 
reorganisation. The decrease in P38B activity is indicative of decreased RPTOR phosphorylation 
at serine 863 – a key activating phosphorylation site important for the positive regulation of 
mTORC1 activity, cell growth and cell survival. The decrease in activity of MST4 through to Cot 
is due to the decreased phosphorylation of EZR (threonine 567), RDX (threonine 564) and MSN 
(threonine 558). These 3 substrates function as cross-linkers between the plasma membrane 
and actin-based cytoskeleton.  
Therefore, anti-RAGE blockade and HMGB1 treatment combined, does not impact HMGB-
mediated outcome on increased MAPK and cell cycle signalling, or decreased BCR and MYC 
signalling. However, RAGE blockade does appear to have an inhibitory action on cytoskeletal 
reorganisation and cell motility signalling pathways for patient 6799 (ZAP70- patient).  
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Figure 5-18. Heat map showing the enrichment of substrate groups for the different kinases calculated 
by KSEA algorithm, with significant abundance following pre-RAGE blockade for 30 minutes and 
addition of HMGB1 for 2 hours for patient 6799 
Cell samples were treated, processed and phosphopeptides quantified by LC/MS-MS as previously 
described in Figure 5-10. Enrichment of substrate groups was calculated by the KSEA algorithm and 
divided by the abundance of phosphopeptides in the PBS treated sample. Heat map colours correspond 
to the coloured enrichment key in Figure 5-10 and indicates -5 to +5-fold enrichment compared to PBS 
treated sample. Statistical significance of these changes was calculated by Student’s t test compared to 
PBS treated samples; P<0.05*, P<0.01**, P<0.001***, P<0.0001****. ‘m’, number of substrates in the 
indicated kinase substrate group. KSEA results were filtered based on significantly abundant substrate 
groups for patient 6799 following RAGE blockade for 30 minutes and addition of HMGB1 for 2 hours 
(column indicated by arrow).  
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5.3 Discussion 
In this chapter, we have demonstrated RAGE and TLR9 as the most likely binding partners of 
HMGB1 using available bioinformatic databases. RAGE and TLR9 colocalise in CLL cells following 
HMGB1 stimulation, although this interaction is not stable by co-IP. Using an unbiased 
phosphoproteomic approach to assess cellular signalling networks, we identified MAPK 
signalling as a key pathway mediator of HMGB1 signalling. Blockade of RAGE did not inhibit 
MAPK signalling induced by HMGB1. 
HMGB1 receptor selection and signalling pathway activation has not been fully elucidated in CLL 
B-cells. To successfully act as a DAMP, HMGB1 needs the ability to activate a variety of cell types, 
under stressed conditions.131 To fulfil this role, HMGB1 targets several receptors (TLR1, 2, 4, 9 
and RAGE), with the ability to bind other ligands and gain wider access to further receptors.123,148 
Using a combination of available online sources and literature search for receptor protein 
expression in CLL B-cells, we hypothesised RAGE and TLR9 as the most likely binding partners 
for HMGB1 in CLL B-cells. RAGE is highly expressed in epithelium of the lung and gastrointestinal 
tract and up-regulated in activated endothelium and immune cells following receptor 
engagement.146 TLR9 is highly expressed in antigen presenting cells of the immune system, 
localised intracellularly in endosomes.360 These expression patterns ensure rapid activation and 
removal of any exogenous or endogenous pathogenic threats. In the CLL B-cell setting, TLR9 
activation results on dichotic cell responses, reliant on the expression of ZAP70 to engage BCR 
signalling pathway;96 RAGE does not have a clear defined function in CLL B-cells so far. Further, 
previous studies in CLL NLCs and autoreactive B-cells, demonstrate cross-linked activity of RAGE 
and TLR9, and support a co-linked function of these receptors in HMGB1 biology.76,145,260  
To infer linked activity of these receptors, we used two different imaging techniques to assess 
RAGE and TLR9 colocalisation following HMGB1 stimulation or blockade. Using fluorescent 
microscopy and ImageStream flow cytometry, we demonstrated the colocalisation of RAGE and 
TLR9 following 2 and 4 hours’ exogenous HMGB1 treatment, consistent with the findings in CLL 
NLCs.76 Both techniques were employed to gain quantitative and qualitative assessment of RAGE 
and TLR9 localisation.304 While fluorescent microscopy at a magnification of 100x provides 
detailed morphological information, the number of cells imaged and analysed by ImageJ pixel 
intensity spatial correlation analysis makes this technique quantitatively unpowerful and could 
result in false conclusions. ImageStream flow cytometry overcomes this, by imaging 5000 cells 
at a magnification at 60x.304 However, a stable interaction was not identified between RAGE and 
TLR9, or MyD88 and TLR9, following HMGB1 stimulation by co-IP.76 Downstream from RAGE and 
TLR9 colocalisation, HMGB1, RAGE and TLR9 form an inflammatory triad contributing to the 
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activation of NF-κB in NLCs and autoreactive B-cells;76,260,281 we demonstrated the nuclear 
translocation of NF-κB p65 subunit to the nuclei of CLL B-cells. 
The entire HMGB1 signalling pathway has not been fully elucidated,195 so assessment of cell 
signalling by biased approaches, such as Western blotting may miss important signalling events. 
We utilised an unbiased phosphoproteomic approach to assess HMGB1 signalling, synergy with 
CpG-ODN, and RAGE blockade in primary CLL B-cell samples.311 Further, we analysed our 
phosphoproteomic dataset using KSEA, to measure the change of abundance of phosphosites 
between initial and treated samples, and therefore, infer differences in kinase activity.310 We 
selected 2 fresh CLL patient samples with CD5+/CD19+ cell purity >90% to ensure 
phosphoproteomic signals were sourced from CLL B-cells, and with opposing ZAP70 expression 
status (assessed in-house using our method optimised in Chapter 4). ZAP70+ status correlates 
with IGHV mutational status, which was not performed at clinical diagnosis for our patient 
cohort.91,92 The subsets differ by their signalling responsiveness to IgM antigen and CpG-ODN 
ligand.95,96 Our phosphoproteomic data demonstrate ZAP70+ patient (Pat ID: 8231) with a higher 
number of significantly up-regulated phosphopeptides than down-regulated phosphopeptides, 
following HMGB1, CpG-ODN and HMGB1 and CpG-ODN combined; while patient 6799 had more 
down-regulated phosphopeptides than up-regulated under the same treatment conditions. 
These results reflect different signalling responsiveness of ZAP70+ and ZAP70- patient samples 
in vitro.95,96 
HMGB1 has extensive roles in leukocyte biology, including apoptosis, chemotaxis and immune 
activation.116,122,123 HMGB1 signalling pathways remain elusive, due to the complexity in receptor 
usage, ligand-synergy with IL-1, CXCL12, DNA, RNA, histones, CpG-ODN or LPS,346 and cell-type 
selection and dependence on HMGB1 redox status.139 In myeloid cells, HMGB1-TLR activation is 
one route leading to the activation and maturation of dendritic cells, monocytes and 
macrophages in innate immunity, and characterised by the up-regulation of the IFN response 
and pro-inflammatory cytokines.146 Phosphorylation and activation of IRAK1,2,4, TRAF6, IKKα or 
IKKβ leads to NF-κB, IRF3 and IRF7 transcription factor activation is involved in the TLR signalling 
cascade.253 The full RAGE signalling pathways is not well defined, but RAGE engagement in cells 
of myeloid and lymphoid lineage, endothelial cells and lung epithelial cells,146 frequently results 
in the activation of MAPK, RAS pathways and NF-κB.147 Our phosphoprotemic results for patient 
8231 demonstrates the activation of MAPK signalling, AP-1 transcription factor activation, cell 
cycle regulation following 15 minutes HMGB1 stimulation, indicative of RAGE signalling. At 2 
hours HMGB1 stimulation, AP-1 transcription factor activation is sustained. However, HMGB1 
had no significant positive impact on the ZAP70- patient 6799, with no significant results 
following 15 minutes stimulation but induced the down-regulation of MAPK, BCR and Myc 
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signalling following 2 hours HMGB1 compared to the PBS baseline. These results reflect different 
signalling responsiveness profile of ZAP70+ and ZAP70- patients in the 2 patients included in this 
study, and demonstrate that HMGB1 has an anti-tumour effect in ZAP70- cells.93,95,96  
HMGB1 can function synergistically with other cytokines, enhancing the immunogenicity of 
many ligands and giving HMGB1 the ability to target the various arms of immunological 
responses.148 CXCL12 and CpG-ODN are widely known co-ligands of HMGB1. Moreover, CpG-
ODN alone, and HMGB1 and CpG-ODN combined have demonstrated roles in CLL.76,96 For patient 
8231 (ZAP70+), our phosphoproteomic dataset demonstrates 15 minutes CpG-ODN alone 
induces up-regulation of cell cycle signalling, Fc receptor activation, AP-1 transcription factor 
activation and MAPK signalling; at 2 hours, AP-1 transcription factor activation and MAPK 
signalling are sustained along with activation of MYC signalling, while Fc receptor activation is 
down-regulated. Addition of HMGB1 with CpG-ODN for this patient for 15 minutes’ stimulation, 
reduced MAPK signalling. This may be the result of different receptor usage, compared to CpG 
alone. At 2 hours’ combined HMGB1 and CpG-ODN treatment, a higher number of 
phosphopeptides involved in MAPK signalling are up-regulated compared to 2 hours CpG-ODN 
alone; activation of mTOR signalling was identified following 2 hours’ combined HMGB1 and 
CpG-ODN stimulation, while Myc signalling, microtubule regulation and AP-1 transcription factor 
activation are sustained upon addition of HMGB1 with CpG-ODN. HMGB1 bound to extracellular 
CpG-ODN and circulating immune complexes is responsible for the activation of TLR9 and BCR 
in B-cells, respectively.149 Although our data reflects the up-regulation of more phosphopeptides 
following 2 hours’ combined HMGB1 and CpG treatment for patient 8231, it is not distinctly clear 
whether this is due to dual use of TLR9 and HMGB1 pathways, or due to effective delivery of 
more CpG-OND ligand by HMGB1-RAGE.  
For patient 6799 (ZAP70-), 15 minutes HMGB1 and CpG-ODN combined treatment results in the 
activation of MAPK compared to CpG-ODN alone. The down-regulation of phosphopeptides 
involved in cytoskeletal rearrangement and clathrin-mediated endocytosis are common to both 
CpG-ODN alone and CpG-ODN with HMGB1. At 2 hours, combination of HMGB1 with CpG-ODN 
did not result in the up-regulation and activation of any unique signalling pathways compared 
to CpG-ODN alone. However, while all MAPK phosphopeptides were upregulated after 2 hours 
CpG-ODN alone, some phosphopeptides had opposing down-regulated status following the 
combination of HMGB1 and CpG-ODN. In CLL cells, CpG-ODN signalling results in dichotic 
responses, dependent on the expression of ZAP70. In ZAP70+ cells, TLR9 signalling can fully 
engage the BCR pathway via ZAP70 and Syk crosslinking leading to proliferation; in ZAP70- cells, 
this crosslink does not occur and TLR9 signalling leads to apoptosis.96 In our dataset, MYC 
signalling is up-regulated following 2 hours CpG-ODN in the ZAP70+ patient, and BCR signalling 
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is down-regulated under the same conditions for the ZAP70- patient; these results reflect 
previously published work on CpG-ODN stimulation in CLL cells.96 Whereas HMGB1 and CpG-
ODN enhances the activity of proliferative signalling kinases in the ZAP70+ patient, there is little 
impact of the addition of HMGB1 with CpG-ODN in the ZAP70- patients, and actually induced 
the opposing kinase activity score of some kinases involved in MAPK signalling. These results 
demonstrate HMGB1 induces dichotic responses dependent on the ZAP70 status, in line with 
the signalling responsiveness to CpG-ODN.  
Elevated expression and perpetuation of RAGE signalling and associated inflammatory loops, 
has been demonstrated in a variety of cancers and chronic inflammatory disorders.123,182-185,224 
Intracellular RAGE signalling is not well defined, but evidence for the activation of MAPK 
pathway (via ERK1/2, p38 activation), PI3K and AKT, and JAK-STAT pathway has been established 
in a variety of cell types.145,196,197 Our phosphoprotemic dataset demonstrates the activation of 
MAPK following HMGB1 treatment, suggesting the use of RAGE signalling cascade. Due to the 
uncertainty of intracellular RAGE mediators across multiple cell types, current RAGE antagonists 
target the membrane-bound receptor.235-237 In this study, we used a monoclonal RAGE antibody 
to block HMGB1 from binding to the ligand-binding site of membrane-RAGE, which was 
previously used to ameliorate sepsis and tumour progression in animal models.168,238 Anti-RAGE 
antibody successfully blocked HMGB1-mediated NLC differentiation in CLL,76 and blocked RAGE 
and TLR9 colocalization in our study. However, assessing kinase activity scores, 2 hours anti-
RAGE antibody and HMGB1 combined treatment did not block signalling pathways activated 
following 2 hours HMGB1 alone in our phosphoproteomic dataset for both patients. 
Interestingly, blockade of RAGE in the ZAP70- patient 6799 induced the activation of Ret, JAK2 
and MEK2, reversing the status of MAPK signalling. These results demonstrate membrane RAGE 
blockade does not affect HMGB1 signalling in CLL cells, suggesting other receptor usage, or that 
anti-RAGE blockade did not fully block membrane RAGE. Further studies are required with MAPK 
signalling inhibitors to fully investigate the association between HMGB1, RAGE and MAPK 
signalling in ZAP70+ patients. Moreover, RAGE blockade has a pro-tumour effect in ZAP70- CLL 
cells; this result combined with the down-regulation of MAPK signalling following HMGB1 alone 
in the ZAP70- patient suggests HMGB1 contributes to anti-tumour signalling. Further studies 
with a larger cohort of ZAP70+ and ZAP70- are required to confirm this observation.  
In summary, our results demonstrate that MAPK is a central pathway involved in HMGB1 
signalling. With the limited sample size we have assessed in our study, our preliminary results 
suggest a dichotic response to HMGB1 in CLL patients, dependent on ZAP70 expression status. 
Further experiments with MAPK and TLR inhibitors in a larger cohort of patients will help 
decipher key mediators in HMGB1 signalling and signalling outcomes.
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Chapter 6 The role of soluble RAGE in CLL 
 
 
 
 
 
 
 
Chapter VI 
 
Determine the origin of soluble RAGE in CLL 
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6.1 Introduction 
Extracellular sRAGE sequesters extracellular RAGE ligands and displays ‘decoy’ receptor ability. 
We determined significantly increased levels of extracellular sRAGE in CLL patients compared to 
healthy controls, the reverse of down-modulated levels measured in the plasma of patients with 
cancer or autoimmune disease.128 Extracellular sRAGE displays a protective effect in CLL and 
correlates with time to first treatment, but the origin of extracellular sRAGE and functional 
impact in CLL has not been studied. Further insight into the functional significance of sRAGE as 
an antagonist of HMGB1, could provide an intrinsic mechanism to regulate HMGB1-mediated 
CLL disease pathogenesis.  
The pool of sRAGE derives from 2 main sources – alternative splicing to produce endogenous 
secreted RAGE (esRAGE), or from surface RAGE ectodomain shedding. The es-RAGE isoform 
lacks the transmembrane region found in FL-RAGE but contains a C-terminal amino acid 
sequence that differentiates this isoform from the FL-RAGE sequence. Membrane RAGE 
shedding is catalysed by ADAM10 (a disintegrin and metalloproteinases), member of a zinc-
dependent family of metalloproteases. In a healthy setting, HMGB1 and sRAGE plasma levels 
are inversely correlated.209 Although extracellular HMGB1 concentration always exceeds sRAGE 
in healthy subjects, elevated levels of sRAGE regulates inflammatory responses by neutralising 
circulating ligands. In chronic disease, the HMGB1-sRAGE inverse relationship breaks down.361 
Lower levels of sRAGE are associated with a higher risk of disease or poor disease outcome for 
patients with type 2 diabetes, rheumatoid arthritis, SLE, malignant melanoma, advanced 
pancreatic cancer and breast cancer.158,228,350,352,353,362 For these reasons, easily attainable 
extracellular sRAGE levels pose as a suitable plasma marker for chronic inflammation monitoring 
in pathological conditions. 
Artificially inducing intrinsic receptor ectodomain shedding could provide beneficial RAGE ligand 
neutralisation - an area of current active research. Surface RAGE undergoes proteolysis 
dependent on ADAM10 γ-secretase activity.215 Deregulation of extracellular sRAGE in CLL may 
be due to altered levels of ADAM10 expression, commonly observed in various pathological 
diseases.363 Moreover, production of sRAGE may be a by-product of Notch cleavage/signalling 
catalysed by ADAM10 in CLL, and levels of sRAGE could be associated with NOTCH1 mutations 
(~10% prevalence in CLL).364 Ligand-RAGE binding affects the accessibility of ADAM10 to the 
RAGE cleavage site, 12 amino acids upstream of the transmembrane region, rather than altering 
the cleavage site motif.219 Therefore, saturating levels of RAGE ligand such as HMGB1, combined 
with increased expression of ADAM10 could be the driving factor behind sRAGE production in 
CLL; It is currently unknown whether saturating levels of HMGB1 observed in CLL could 
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functionally induce RAGE shedding. Es-RAGE and sRAGE produced by cleavage are functionally 
similar, as they both share identical ligand-binding sites, but the full extracellular roles of sRAGE 
in disease pathogenesis are still unclear. 
The work in this chapter will determine if i) the origin of sRAGE in CLL; ii) if RAGE shedding is 
ADAM10-dependent and HMGB1 can induce RAGE cleavage in CLL; iii) if sRAGE antagonises 
HMGB1-mediated differentiation of NLCs.  
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6.2 Results 
6.2.1 Extracellular sRAGE levels are stable for untreated CLL patients 
We observed significantly higher extracellular sRAGE levels in the plasma of CLL patients 
compared to healthy controls assessed by ELISA, contrary to the frequent downregulation 
reported in inflammatory disease settings.128,353 A lack of correlation between HMGB1 and 
sRAGE plasma levels in CLL suggest deregulated control of sRAGE isoform expression or RAGE 
membrane shedding. Although extracellular sRAGE levels confer a protective effect for CLL 
patients, whether extracellular sRAGE levels remain stable over the course of the disease is not 
known. 
In our study, extracellular sRAGE levels were significantly higher in CLL patients compared to 
healthy controls (median 60.0pg/ml and 31.0pg/ml, respectively; Figure 4-6). High extracellular 
sRAGE levels were associated with a longer time to first treatment, but plasma sRAGE levels may 
not be stable over time. We assessed temporal sRAGE levels by using consecutive CLL patient 
plasma samples from 10 CLL patients. Plasma sRAGE levels were relatively stable (Figure 6-1), 
9/10 patients had a coefficient of variation (CV) below 30% when comparing sRAGE levels across 
different time points (Table 17). For the 7 patients who did not undergo therapy at the time of 
plasma isolation, 5 patient plasma samples displayed a negative Pearson’s correlation 
coefficient, highlighting a gradual decline in extracellular sRAGE levels over the course of the 
disease (Table 17; Figure 6-1). 3 CLL patients who progressed to front-line therapy (patient ID 
8550, 7888, 8553), displayed higher sRAGE levels following therapy (of differing treatment 
regimens) and positive Pearson’s correlation coefficients (coloured arrows indicate time of 
treatment; Figure 6-1; Table 17). These 3 patients reached partial remission. In our cohort of 54 
patients, patients with samples assayed while in remission did not have significantly higher levels 
of sRAGE compared to plasma samples assayed from untreated or relapsed patients (Figure 
4-8C); these temporal plasma results do indicate there is an initial increase in extracellular sRAGE 
following treatment. This could be due to treatment-related release of DAMPs and cell debris, 
that stimulate RAGE membrane shedding and metalloproteinase activity.  
  
Chapter VI Results 
194 
 
 
Figure 6-1 Evaluation of plasma sRAGE levels over time 
Consecutive plasma samples from 10 CLL patients were assayed by ELISA to determine extracellular sRAGE 
concentration. Date of diagnosis and date and type of treatment was extracted from our tissue bank 
clinical database. 9 CLL patients remained untreated for the duration of these sample collection 
timepoints, and 3 CLL patients received treatment during these timepoints. Coloured lines represent 
different patients, linked to patient ID. For the 3 patients which received treatment, the same coloured 
arrows indicate time of treatment with details of their treatment in Table 17 below.  
 
 
Table 17 Coefficient of variation and Pearson’s correlation coefficient for consecutive 
extracellular sRAGE levels for 10 CLL patients 
 
Note: CV= coefficient of variation; FC= fludarabine, cyclophosphamide; R=Rituximab.  
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6.2.2 sRAGE originates from ectodomain shedding in CLL patient plasma 
Understanding the origin of deregulated sRAGE levels will aid in understanding the driving 
mechanism behind sRAGE release in CLL. Moreover, this molecular understanding could reveal 
intrinsic antagonistic methods to dampen HMGB1-mediated inflammatory signalling and/or 
provide an easily attainable patient plasma marker that is coupled to chronic inflammatory 
dysregulation.  
First, we assessed patient plasma sRAGE molecular weight to determine the main origin of 
extracellular RAGE. Cleaved RAGE produced by membrane RAGE shedding is of shorter length 
than endogenous secreted RAGE (alternatively spliced RAGE; 37kDa), and both are smaller than 
the main isoform full-length RAGE (42kDa). Using SDS-PAGE to denature and linearise RAGE 
isoforms, we can assess RAGE size based on protein mass alone, rather than shape. Human 
plasma is densely concentrated with extracellular proteins, particularly serum albumin and IgG, 
forming protein aggregates during protein denaturation steps for Western blotting. For these 
reasons, ELISA is the easiest and most quantitative method of choice when assessing plasma 
proteins but does not give an indication of protein size. Plasma protein concentration was 
measured by Bradford assay to ensure 40µg of protein was loaded per patient, and to limit 
albumin and IgG protein aggregation.  We compared sRAGE from 6 CLL patient plasma samples 
with high levels of extracellular sRAGE, to a healthy control plasma sample (C90) and 1 matched 
patient CLL B-cell lysate (Figure 6-2). By Western blotting, the molecular weight of sRAGE in CLL 
patient plasma is of shorter length than FL-RAGE and es-RAGE in the patient whole cell lysate, 
indicating plasma RAGE originates from membrane receptor shedding. Transferrin expression 
(80kDa) was used as a loading control. However, Western blot protein smears caused by IgG 
heavy chain (50kDa) and albumin (66.5kDa) protein aggregates made it difficult to clearly 
evaluate transferrin expression (Appendix Figure 9). The same smearing was observed with 
Ponceau Red staining. Overall, as Western blotting was used here to assess protein size rather 
than for quantitative purposes, these results demonstrate membrane RAGE ectodomain 
shedding contributes to the pool of extracellular sRAGE.  
ADAM10 is the main reported metalloproteinase that catalyses RAGE ectodomain shedding.215 
We compared patient extracellular HMGB1 and sRAGE concentrations to ADAM10 whole cell 
expression by using matched plasma samples and cryopreserved PBMCs. ADAM10 precursor 
(90kDa) is processed in the endoplasmic reticulum to give the cleaved active form (68kDa) 
expressed on the cell surface. Assessing ADAM10 whole cell expression in patients with high or 
low HMGB1 and sRAGE plasma levels revealed expression of ADAM10, and processing to 
produce the active form, is independent of extracellular HMGB1 and sRAGE (Figure 6-3). These 
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results demonstrate that CLL cells do express ADAM10 and extracellular sRAGE in CLL disease 
pathogenesis is primarily from RAGE ectodomain shedding.  
 
Figure 6-2 Western Blotting analysis of sRAGE isoforms in CLL patient plasma.  
Extracellular RAGE protein mass was assessed in 40µg of plasma protein from 6 CLL patients with high 
sRAGE (lanes 1-6) and compared with healthy control patient plasma (C90) and CLL patient (5959) whole 
cell lysate. CLL patient and healthy control extracellular sRAGE concentration outlined in Table 18. FL-
RAGE = Full-length RAGE, and es-RAGE = alternatively spliced endogenous secreted RAGE isoform whole 
cell lysate expression labelled in figure.  
Table 18 sRAGE plasma concentration in CLL patients and healthy control (C90) from Figure 6-2 
Lane 1 2 3 4 5 6 7 
Pat ID 5959 9746 9853 5313 T-2472 8692 C90 
sRAGE (pg/ml) 156.7 103.1 108.7 133.4 114.5 144.2 9.6 
 
 
Figure 6-3 Western Blotting analysis of ADAM10 in CLL whole cell lysates.  
ADAM10 whole cell expression was assessed in 50µg of whole cell lysate protein from 4 CLL patients that 
demonstrated high or low sRAGE plasma levels measured previously by ELISA, outlined in Table 19. Mec1 
whole cell lysate was used as an ADAM10 expression control and GAPDH was probed as a loading control. 
Precursor ADAM10 (Pre-ADAM10, 90kDa) is cleaved to give active ADAM10 (68kDa).  
Table 19 sRAGE and HMGB1 plasma concentrations in CLL patients from Figure 6-3 
Lane 1 2 3 4 
Pat ID 8921 T-1789 10450 8009 
sRAGE (pg/ml) 1.47 136.4 0 101.89 
HMGB1 (ng/ml) 78.9 205.9 72.7 394.1 
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6.2.3 Producing RAGE-transfected HEK293 cell line 
We have demonstrated a protective effect for soluble RAGE in CLL, which is predominately 
produced by RAGE ectodomain shedding. To investigate the functional significance of RAGE 
shedding and sRAGE, we produced FL-RAGE transfected HEK293 cells, and es-RAGE-containing 
conditioned media from es-RAGE transfected HEK293 cells.  
sRAGE cannot be purchased commercially so FL-RAGE and es-RAGE pcDNA3 plasmids were 
purchased from HMGBiotech (Appendix I; Figure 1). Plasmid numbers were expanded by 
transforming DH5α™ competent cells with FL-RAGE pcDNA3, es-RAGE pcDNA3 and pCU19 
empty vector control plasmids. Plasmid DNA was purified from bacterial inoculation by plasmid 
midiprep and DNA concentration measured using Nanodrop spectrometer. To confirm we 
expanded and isolated the correct plasmid products, we quantified purified plasmid DNA by 
restriction digest and agarose gel electrophoresis (Figure 6-4A). We used SmaI and BamHI 
restriction enzymes, as both enzymes have cut sites in the pcDNA3 backbone and RAGE gene 
sequence. To differentiate between FL-RAGE and es-RAGE plasmids, FL-RAGE gene sequence 
has 2x BamHI and 1x SmaI cut sites in the gene sequence, compared to 1x BamHI and 1x SmaI 
cut site in es-RAGE gene sequence (Appendix I; Figure 2). The restriction digest products 
confirmed we isolated the correct plasmids; SmaI produced 2 bands from 2x cut sites in the es-
RAGE-pcDNA3 and FL-RAGE-pcDNA3 plasmids, and BamHI produced 2 bands from 2x cut sites 
in es-RAGE-pcDNA3 plasmid and 3 bands from 3x cut sites in FL-RAGE-pcDNA3 plasmid (Figure 
6-4A).  
HEK293 cell line was transfected with 5µg purified plasmid DNA using JetPRIME transfection 
reagent. Lipid-based transfection reagent interacts with negatively charged plasmid DNA to 
produce transfection complexes. The positive charge from the transfection reagent allows the 
complex to interact with heparan sulphate proteoglycans on the cell surface and promote 
endocytosis. Plasmid DNA enters the nucleus and is transiently expressed following genome 
integration. We used a GFP expressing plasmid under the same conditions as FL-RAGE, es-RAGE 
and pCU19 plasmid transfections to assess transfection efficiency. 24 hours post transfection, 
nearly all HEK293 cells express GFP, indicating very high transfection efficiency (Figure 6-4B). 
Western blot analysis using cell lysates from FL-RAGE and es-RAGE transfected HEK293 cells 
confirmed cellular expression of the correct RAGE isoforms, and little RAGE was detected in the 
pCU19 control HEK293 cells (Figure 6-4C). Cell culture supernatant was collected from all 
transfected cells 24 hours-post transfection (transfection reagent removed before 24-hour 
culture; Figure 6-4C). Western blotting analysis and measurement of sRAGE concentration by 
ELISA confirmed es-RAGE was released into cell culture medium (2.4ng/ml), FL-RAGE resulted in 
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some RAGE release (1.1ng/ml) and pCU19 empty control vector displayed little RAGE shedding 
after 24 hours (23pg/ml). Using this method, FL-RAGE HEK293 cells can be used for downstream 
experiments, but not enough sRAGE was collected from es-RAGE cell culture medium (2.4ng/ml) 
to use for HMGB1 inhibitor functional studies. 
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Figure 6-4 Producing FL-RAGE and es-RAGE transfected HEK293 cell line for sRAGE production. 
FL-RAGE and es-RAGE expressing pcDNA3 plasmids were purified from transformed DH5α competent 
bacteria and quantified by restriction enzyme digest. (A) FL-RAGE and es-RAGE plasmids were digested 
with SmaI and BamHI restriction enzymes individually and subject to double digest. Digest products were 
separated by agarose gel electrophoresis and resulting bands were imaged. (B) HEK293 cells were 
transfected with 5µg of purified plasmid DNA and transfection efficiency was assessed with a GFP 
expressing plasmid control using brightfield and fluorescent microscopy; magnification x40. (C) FL-RAGE, 
es-RAGE and empty pCU19 vector expression was assessed by western blot analysis of conditioned media 
and cell lysates collected 24-hours post-transfection from HEK293 cells. A Mec1 cell lysate was included 
as a positive control. 
Chapter VI Results 
200 
 
6.2.4 RAGE shedding could be induced with ionomycin and HMGB1, and blocked with 
specific ADAM10 inhibitor  
Our results show sRAGE originates from ectodomain shedding and CLL cells express ADAM10, 
but whether saturating levels of HMGB1 can stimulate RAGE shedding, or if ADAM10 is the 
specific RAGE sheddase in CLL, is currently unknown. We investigated RAGE shedding into cell 
culture medium following ADAM10 stimulation and ADAM10 inhibition in FL-RAGE transfected 
HEK293 cell line, Mec1 cell line and primary CLL cells.  
We have demonstrated PB CLL B-cells express lower levels of surface RAGE compared to CD14+ 
monocytes, but higher levels of intracellular RAGE. To reliably assess the specific role of ADAM10 
in surface RAGE shedding we established a transiently transfected HEK293 cell line with the FL-
RAGE gene sequence. HEK293 cells normally express low levels of RAGE (Figure 6-4C), so any 
RAGE shedding measured in cell culture medium by ELISA is produced directly by RAGE shedding 
from FL-RAGE transfection. ADAM10 activity can be experimentally induced using calcium 
ionophore, ionomycin, in a PKCα/β1-dependent manner and by phorbol-12-myristate 13-
acetate (PMA).214,215 In this study, ADAM10 activity was induced by stimulating cells for 1 hour 
with ionomycin,215 and ADAM10 activity blocked with specific inhibitor, GI254023X, for 1 hour 
prior to another hour of ionomycin stimulation in combination with the inhibitor. We assessed 
if saturating levels of RAGE ligand, HMGB1, also induced RAGE shedding; sRAGE released into 
cell culture supernatant was measured by ELISA, and cell surface expression of RAGE and 
ADAM10 by flow cytometry.  
FL-RAGE transfected HEK293 cells expressed high levels of surface RAGE (MFI of 2426), and 
stimulation with 500nM ionomycin for 1 hour induced significant release of RAGE into cell 
culture medium compared to PBS and DMSO controls (PBS 1095pg/ml and ionomycin 
2270pg/ml; P<0.01;  Figure 6-5C). Moreover, when HEK293 cells were pre-treated for 1 hour 
with increasing doses of ADAM10 inhibitor, GI254023X, followed by stimulation with ionomycin, 
RAGE shedding was completely abrogated (GI254023X 5µM 45.6pg/ml, 10µM 30.1pg/ml, 20µM 
49.4pg/ml; P<0.0001; Figure 6-5C). This observed shedding induced by ionomycin was not due 
to cell death (Appendix Figure 10). Levels of surface RAGE and ADAM10 were not altered when 
cells were treated with PBS and DMSO controls, or with ionomycin and ADAM10 inhibition 
(Figure 6-5A-B). We next investigated if increasing HMGB1 concentrations induces RAGE 
shedding using our FL-RAGE transfected HEK293 cell line model. HEK293 cell stimulation with 
50ng, 200ng and 500ng HMGB1 did not result in ligand-induced RAGE shedding (PBS 1095pg/ml, 
HMGB1 50ng 1088pg/ml, 200ng 1316pg/ml, 500ng 1135pg/ml; Figure 6-5F). These results 
demonstrate ADAM10 is responsible for RAGE shedding.  
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We performed the same treatments and measurements in a CLL-specific cell line, Mec1. Surface 
RAGE expression was much lower compared to FL-RAGE transfected HEK293 cells, and 
stimulation with ionomycin did not induce measurable RAGE shedding into cell culture medium 
(PBS 7.9pg/ml, ionomycin 0.0pg/ml; Figure 6-6C). ADAM10 inhibition also failed to block RAGE 
shedding and we did not observe any changes in surface RAGE or ADAM10 expression (Figure 
6-6A-C). Moreover, when we stimulate RAGE with increasing doses of HMGB1, in a B-cell line 
model, there were no measurable changes in RAGE shedding into cell culture medium (PBS 
7.6pg/ml, HMGB1 50ng 16.4pg/ml, 200ng 0.0pg/ml, 500ng 6.8pg/ml; Figure 6-6F). 
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Figure 6-5 Evaluation of RAGE shedding in FL-RAGE transfected HEK293 cell line. 
RAGE shedding in FL-RAGE transfected HEK293 cells was measured following ADAM10 stimulation with 
500nM ionomycin for 1-hour or ADAM10 inhibition with GI254023X 5µM, 10µM and 20µM for 1-hour 
prior to addition of 500nM ionomycin. Cell surface RAGE (A) and ADAM10 (B) expression were assessed 
by flow cytometry with primary antibodies to rabbit anti-RAGE and rabbit anti-ADAM10 before labelling 
with AF-647 conjugated secondary antibodies. RAGE shedding into cell culture medium was measured by 
ELISA (C) following the same treatments. Ligand-induced RAGE shedding was measured in FL-RAGE 
transfected HEK293 cells by 1-hour stimulation with 50ng, 200ng and 500ng exogenous HMGB1. Cell 
surface RAGE (D) and ADAM10 (E) levels were assessed by flow cytometry and RAGE shedding measured 
in cell culture medium by ELISA (F). PBS and DMSO were used as vehicle controls and data are presented 
as the mean ±SD; n=3. P<0.05*, P<0.01**, P<0.0001***. + indicates addition of 500nM ionomycin; iono = 
ionomycin.  
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Figure 6-6 Evaluation of RAGE shedding Mec1 cell line. 
RAGE shedding in CLL cell line, Mec1, was measured following ADAM10 stimulation with 500nM 
ionomycin for 1-hour or ADAM10 inhibition with GI254023X 5µM, 10µM and 20µM for 1-hour prior to 
addition of 500nM ionomycin. Cell surface RAGE (A) and ADAM10 (B) MFI levels were assessed by flow 
cytometry with primary antibodies to rabbit anti-RAGE and rabbit anti-ADAM10 before labelling with AF-
647 conjugated secondary antibodies. RAGE shedding into cell culture medium was measured by ELISA 
(C) following the same treatments. Ligand-induced RAGE shedding was measured in Mec1 cells by 1-hour 
stimulation with 50ng, 200ng and 500ng exogenous HMGB1. Cell surface RAGE (D) and ADAM10 (E) MFI 
were assessed by flow cytometry and RAGE shedding measured in cell culture medium by ELISA (F). PBS 
and DMSO were used as vehicle controls and data are presented as the mean ±SD; n=3. + indicates 
addition of 500nM ionomycin; iono= ionomycin.  
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As we induced artificially high levels of FL-RAGE expression in HEK293 cells, and Mec1 cell line 
express low levels of surface RAGE,  we next investigated RAGE shedding in 6 primary CLL patient 
samples. We previously demonstrated CLL cells express variable levels of RAGE on the cell 
surface, and high intracellular expression which is likely due to ligand-induced receptor 
internalisation and signalling. Whether saturating levels of HMGB1 induce RAGE shedding in CLL 
cells is unknown. Pre-treatment with ADAM10 inhibitor, GI254023X induced apoptosis in 
primary CLL cells so only ligand-induced receptor shedding was compared to ADAM10 positive 
stimulation with ionomycin. After 1-hour treatment, 500nM ionomycin and 500ng HMGB1 
induced RAGE shedding into cell culture medium compared to PBS control (PBS 23.2pg/ml, 
ionomycin 41.3pg/ml, 500ng HMGB1 33.9pg/ml; P<0.05; Figure 6-7C). Surface levels of RAGE 
and ADAM10 remain unaltered (Figure 6-7A-B). Taking these data together, ionomycin 
stimulated ADAM10 activity in transfected HEK293 cells and primary CLL cells resulting in RAGE 
shedding into cell culture medium, dependent on ADAM10, which was also inducible by high 
levels of HMGB1 in primary CLL cells.  
 
Figure 6-7 Evaluation of RAGE shedding in primary CLL cells.  
Ligand-induced RAGE shedding was measured in 6 primary CLL patient samples following 1-hour 
stimulation with 50ng, 200ng and 500ng exogenous HMGB1. Cell surface RAGE (A) and ADAM10 (B) MFI 
levels were assessed by flow cytometry and RAGE shedding measured into cell culture medium by ELISA 
(C). PBS was used as a vehicle control and data are presented as the mean ±SD; n=6. P<0.05*; iono = 
ionomycin. ADAM10 inhibitor treatment, GI254023X, followed by ionomycin treatment induced apoptosis 
in primary CLL cells.   
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6.3 Discussion 
In this chapter, we have demonstrated sRAGE levels are variable over time between patients, 
and display treatment-induced release. Extracellular sRAGE protein mass is shorter than FL-
RAGE and es-RAGE indicating sRAGE derives predominantly from ectodomain shedding. 
ADAM10 is responsible for RAGE shedding in our transfected HEK293 cell line model, and 
HMGB1 could induce RAGE release in primary CLL samples.  
Attention on the clinical applicability of measuring extracellular sRAGE levels in chronic 
pathological conditions is increasing. There is a clear association between low plasma sRAGE 
levels and poor outcome in cancer.228,353,362 Moreover, we have identified a protective effect of 
extracellular sRAGE in CLL, but plasma levels were not altered between patients who were either 
untreated, reached remission or who had relapsed diseased. However, the patient-specific 
variability in extracellular sRAGE levels are unknown. Patient sRAGE extracellular levels were 
constant and stable in diabetic patients with vascular risk across a 3-year period, highlighting 
plasma sRAGE concentration could be measured at any time point to evaluate disease risk.365 In 
our study, extracellular sRAGE levels slightly dropped for CLL patients who did not require 
treatment, but increased in patient plasma samples post-treatment, regardless of the treatment 
regime. We previously demonstrated a lack of inverse correlation between extracellular HMGB1 
and sRAGE in CLL, highlighting DAMP-mediated deregulation of HMGB1 and sRAGE plasma levels 
in CLL. The increase in sRAGE levels following treatment is most likely due to treatment-related 
release of DAMPs during apoptosis and necrosis, driving RAGE ectodomain shedding.121,366 
Repeating the measurement of sRAGE plasma samples in conjunction with extracellular HMGB1 
and S100B would confirm this. Regardless, patients who received treatment and displayed 
increased extracellular sRAGE levels reached partial remission. 
The pool of extracellular sRAGE originates from alternative splicing or membrane RAGE 
shedding. The FL-RAGE and esRAGE spliced isoforms are the only isoforms of RAGE to reach 
protein expression.210 It is not clear if RAGE alternative splicing is regulated upon different 
conditions; the ratio between FL-RAGE and es-RAGE expression is highly cell-type specific.212 
ADAM10 metalloproteinase is responsible for cleaving membrane FL-RAGE approximately 12 
amino acids upstream of the transmembrane region.219 Ligand-RAGE binding facilitates 
increased RAGE shedding, thereby dampening inflammatory responses, by increasing the 
accessibility of ADAM10 to the RAGE cleavage site, rather than revealing a cleavage motif.219 In 
most chronic disease states, either cleaved RAGE or esRAGE contributes to the pool of sRAGE, 
compared to an equal combination of both, but the origin in CLL has not been investigated 
before.215 By Western blotting, extracellular sRAGE in CLL is of shorter length than FL-RAGE and 
es-RAGE indicating sRAGE production is from membrane RAGE ectodomain shedding. Using an 
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antibody raised against the sequence-specific es-RAGE C-terminal end for Western blotting will 
confirm the origin of sRAGE in CLL patient plasma, but this antibody is not currently 
commercially available. Our results suggest sRAGE derives from ectodomain shedding, utilising 
this intrinsic mechanism to drive further RAGE release could dampen HMGB1 responses.  
Surface RAGE ectodomain shedding is solely dependent on ADAM10 activity, and not reliant on 
shared-substrate metalloprotease ADAM17.215 CLL cells express ADAM10, but protein levels and 
activation status are not associated with extracellular sRAGE levels. RAGE ectodomain shedding 
can be induced in vitro using PMA or calcium ionophore, ionomycin, using FL-RAGE transfected 
HEK293 cell line, which was recapitulated in this study.214,215 We confirmed ADAM10 is the main 
RAGE sheddase using ADAM10 inhibitor GI254023X, and could induce RAGE shedding into 
culture medium following ionomycin stimulation in our HEK293 model. HMGB1 induces a 
conformational change in the membrane receptor, facilitating ADAM10 access to the cleavage 
site, but we did not observe RAGE shedding following HMGB1 stimulation in our HEK293 
model.219 FL-RAGE transfected HEK293 cells lack the intracellular signalling pathways 
downstream of RAGE expressed in B-cells; similar to ionomycin PKC-mediated ADAM10 
activation, ligand-induced RAGE shedding may require activation of intracellular signalling, in 
combination with ligand-mediated conformational changes in the RAGE ectodomain structure 
to activate membrane RAGE shedding. Saturating levels of HMGB1 induced RAGE shedding into 
cell culture medium in primary CLL patient samples in vitro, but not in CLL cell line, Mec1. 
ADAM10 is responsible for the cleavage of several inflammatory and chemokine receptors, 
particularly the Notch receptor in CLL.367 Using fresh CLL samples, ADAM10 may be in a higher 
primed state of activation reflecting prior in vivo activation when compared to ADAM10 
expressed in the Mec1 cell line. Taken together, our results demonstrate ADAM10 activity and 
RAGE shedding can be induced in CLL in vitro. However, ionomycin and HMGB1 are not suitable 
stimulatory candidates to drive sRAGE production. A physiological approach could be the use of 
Lovastatin, a cholesterol-lowering agent that induces RAGE shedding in vitro in a ADAM10-
dependent manner.241 Although statins reportedly interfere with Rituximab efficacy, by inducing 
conformational changes in CD20,242 patients with relapsed/refractory CLL displayed improved 
outcome when treated with FCR therapy while using statins and aspirin.368  Moreover, inducing 
ADAM10 activity in CLL in vivo may stimulate Notch signalling that would drive CLL-cell 
survival.369 
Although the regulation of RAGE ectodomain shedding is well documented, the biological 
function of sRAGE as an antagonist of RAGE ligands has only recently undergone functional 
investigation.219 RAGE ectodomain shedding limited the migration of RAGE transfected C6 
glioma cells. Although sRAGE decreased cell migration by sequestering RAGE ligands, 
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downstream signalling of the cleaved RAGE intracellular domain (ICD) revealed a more complex 
signalling network that contributed to a decrease in cell migration. We have shown sRAGE 
confers a protective effect in CLL and originates from ectodomain shedding; RAGE cleavage may 
produce a signalling-competent ICD that contributes to a favourable outcome compared to 
extracellular decoy receptor ability alone. In this study, we did not investigate the decoy 
receptor ability of esRAGE or the functional implication of endogenous RAGE ectodomain 
shedding. Modelling the biological effect of RAGE shedding in primary CLL cells or a B-cell line 
would be difficult. Comparison of FL-RAGE and cleavage-resistant FL-RAGE isoforms would help 
identify the role of RAGE ICD, but B-cells are notoriously difficult to successfully transfect. 
Secondly, inducing RAGE shedding with calcium ionophore, ionomycin, would lead to the 
activation of various off-target signalling pathways following calcium influx. Further functional 
studies into the intrinsic RAGE shedding mechanism in CLL are required for sRAGE or RAGE 
cleavage to fully define its role in CLL disease pathogenesis, and as a HMGB1 antagonist.  
In summary, these results demonstrate that surface RAGE ectodomain shedding contributes to 
the pool of sRAGE in CLL. High levels of HMGB1 activate ADAM10-mediated RAGE shedding, 
contributing to sRAGE deregulation in CLL. This work demonstrates extracellular levels of 
HMGB1 and sRAGE as suitable, easily-attainable, circulating markers of chronic inflammation.  
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This thesis has investigated the roles of HMGB1 and RAGE in CLL disease progression. The 
involvement of HMGB1 in CLL disease pathogenesis is not well known, and the implications of 
the HMGB1-RAGE signalling axis in inflammatory disorders is only just starting to undergo 
investigation in clinical intervention studies.128 To elucidate the roles of HMGB1 and RAGE in 
CLL, four main aims were set out for this study:  
1. Assess the prognostic impact of RAGE and TLR9 receptors and effect on CLL overall 
survival  
2. Determine the clinical relevance of the HMGB1-RAGE signalling axis 
3. Determine HMGB1-mediated cellular signalling pathway 
4. Determine the origin of soluble RAGE in CLL  
 
7.1 Summarised findings addressing aims of PhD 
7.1.1 Assess the prognostic impact of RAGE and TLR9 receptors and effect on CLL overall 
survival 
Finding: RAGE and TLR9 are heterogeneously expressed in CLL patients LNs 
Prior to assessing the prognostic impact of RAGE and TLR9 expression in Chapter 3, we first 
determined expression levels of HMGB1 receptors, RAGE and TLR9 in CLL. The results 
demonstrate RAGE and TLR9 gene expression is significantly higher in CLL cells compared to 
healthy controls using GEO datasets, while other HMGB1 receptors, TLR2 and TLR4 were 
significantly lower in CLL cells. When we assessed receptor expression in CD5+ CLL LN using 
TMAs comprised of 80 patient samples, an important site of CLL disease pathogenesis and 
microenvironment interactions, we found RAGE and TLR9 expression was significantly lower 
compared to reactive LN, and CLL LN expression of both receptors was highly heterogeneous in 
CLL patients, reflecting the clinical heterogeneity and variability in microenvironment 
dependence among CLL patients. 
Finding: Higher RAGE expression in CLL LNs positively correlated with established proliferation 
marker, Ki67, and aggressive disease marker, ZAP70 
ZAP70 is an established poor prognostic marker for CLL disease.93 TLR9 and RAGE LN staining 
was compared to Ki67 and ZAP70 LN staining performed on the same CLL TMAs used in this 
study to gain insight into the association with poor prognosis. RAGE LN expression levels 
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positively and significantly correlated with both Ki67 and ZAP70 LN markers, indicating an 
association with aggressive disease for this cohort of patients. TLR9 expression had no 
association with ZAP70 expression, but TLR9 has established opposing roles in both ZAP70+ and 
ZAP70- CLL subsets, so this result was expected.96,271,273 
Finding: CLL patients with high RAGE expression have a shorter overall survival 
RAGE has not been studied in CLL before, so there is no indication of whether the HMGB1 
receptor has a pro-tumour or anti-tumour function in CLL. We assessed the prognostic impact 
of RAGE expression, in CLL LNs, to assess whether expression is associated with CLL disease 
outcome, and further provide us with rationale to move forward with functional studies.  
The results in Chapter 3 demonstrate for the first time that CLL patients with higher RAGE 
expression have a shorter OS when assessed by Kaplan Meier analysis, with data cut points 
determined by X-tile software. Moreover, using the same data cut points, high RAGE expression 
demonstrates prognostic significance using categorical univariate cox regression analysis. 
Interestingly, the prognostic significance of high RAGE expression increased when stratified with 
ZAP70 and Ki67 categorical variables for patients with CLL, meaning patients with high RAGE 
expression, Ki67 and ZAP70 LN staining had the poorest disease clinical outcome. However, we 
also demonstrated that RAGE expression in CLL-LN is lower than reactive-LN; these results 
highlight the routine role of RAGE in a healthy setting as an endogenous stress-response 
receptor and the involvement in inflammatory LN biology. The results from Chapter 3 
demonstrate RAGE plays an important microenvironmental role in CLL LNs for further 
investigation, but the clinical applicability of RAGE as a prognostic marker requires further 
validation in independent data cohorts using the data cut points generated by X-tile.  
 
7.1.2 Determine the clinical relevance of the HMGB1-RAGE signalling axis 
Finding: Plasma HMGB1 levels are higher than other RAGE ligand, S100B, in CLL patients 
In chapter 3 we established RAGE LN expression was associated with shorter CLL patient overall 
survival, and previous work in our group demonstrated increased levels of plasma HMGB1 in CLL 
patients compared to healthy controls. Prior to performing functional studies on HMGB1 and 
RAGE, it was important to assess the plasma levels of another main RAGE ligand, S100B, to 
ensure S100B-RAGE signalling does not dominate HMGB1-RAGE signalling in CLL. The results 
from chapter 4 demonstrate HMGB1 plasma levels are significantly higher than S100B in CLL 
patients.  
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Finding: Plasma HMGB1 levels are higher than plasma decoy receptor, soluble RAGE, and both 
plasma isoforms are independent of patient ZAP70 expression status 
High plasma levels of HMGB1 in CLL may be signalling-incompetent if the RAGE ligand is 
sequestered by similar levels of ‘decoy receptor’ sRAGE. Further to the previous finding 
regarding S100B plasma levels, it was important to establish plasma levels of sRAGE in CLL. The 
results from chapter 4 demonstrate plasma levels of HMGB1 were significantly higher than 
sRAGE (ng levels vs pg levels, respectively) in our cohort of CLL patients. To assess if plasma 
protein levels were CLL subset specific, we compared the plasma concentrations of these 
proteins in ZAP70+ and ZAP70- cohorts; both plasma isoforms were independent of ZAP70 
expression status. 
Finding: Higher levels of soluble RAGE correlate with a longer time to first treatment 
Lower plasma sRAGE levels compared to healthy controls is frequently reported in cancer, and 
is associated with progression of different types of solid cancer.128 Surprisingly, our results 
demonstrate significantly higher levels of plasma sRAGE in CLL patients compared to healthy 
controls. An explanation for increased levels of sRAGE in CLL patients may be due to increased 
ligand-induced membrane receptor shedding catalysed by ADAM10 protease, indicative of 
ongoing chronic inflammation.215,219 This is supported by a lack of inverse correlation observed 
for plasma sRAGE and HMGB1 levels in our cohort of CLL patients, that is classically observed in 
a healthy setting;128,209 ie in a healthy setting, increasing levels of HMGB1 drives RAGE shedding, 
and plasma sRAGE consequently sequesters free plasma HMGB1. Although increased sRAGE 
levels in CLL was a surprising result compared to healthy controls in our study, we observed that 
CLL patients with high sRAGE levels had a longer time to first treatment, conferring a protective 
effect in CLL.  
 
7.1.3 Determine HMGB1-mediated cellular signalling pathway 
Finding: Recombinant HMGB1 induces the colocalization of RAGE and TLR9 assessed by 
imaging methods 
Consistent with previous fluorescent microscopy results in CLL NLCs,76 the results from chapter 
5 demonstrate RAGE and TLR9 colocalization assessed by 2 imaging methods, following longer-
term HMGB1 stimulation for 2 and 4 hours in primary CLL cell samples. Our fluorescent 
microscopy / ImageStream results indicate HMGB1 induces RAGE and TLR9 colocalization, 
suggesting the possibility of co-linked cell signalling; however, a stable interaction was not 
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detected between RAGE and TLR9 by co-IP. We identified downstream translocation of NF-B 
p65 subunit to the nuclei following HMGB1 treatment, which was blocked following RAGE 
neutralisation with anti-RAGE antibody, but as HMGB1 signalling is unknown, we may be missing 
key signalling events. To support these initial results, and fully decipher HMGB1 signalling and 
synergism with TLR9 signalling, phosphoproteomics was performed to measure kinase activity 
under different experimental conditions.  
Finding: Phosphoproteomic analysis of HMGB1-stimulated CLL samples identified the 
activation of MAPK substrate groups in the ZAP70+ patient, but RAGE blockade did not 
neutralise HMGB1 activity 
The full HMGB1 and RAGE signalling pathways have not been fully elucidated,195 so assessment 
of cell signalling by biased approaches, such as Western blotting may miss important signalling 
events. We analysed our phosphoproteomic dataset using KSEA, to measure the change of 
abundance of phosphosites between initial and treated samples, and therefore, infer 
differences in kinase activity.310 The results from chapter 5 demonstrate the ZAP70+ patient as 
more signalling responsive to HMGB1 than the ZAP70- patient. MAPK pathway activity was 
significantly and rapidly increased following short-term HMGB1 treatment for the ZAP70+ 
patient. This had ceased by 2 hours, but the increased activity of kinases involved in c-Jun 
transcription factor activation was sustained. For this patient, blocking membrane bound RAGE 
with neutralising anti-RAGE antibody had little impact on HMGB1 signalling kinase activity. The 
signalling activity of the ZAP70- patient reflected the signalling profile responsiveness already 
established for ZAP70- CLL patients; short-term HMGB1 stimulation yielded no significant results 
compared to PBS baseline, and 2 hours HMGB1 treatment led to decreased activity of kinases 
involved in BCR, MAPK and MYC signalling pathways. Surprisingly, when RAGE blockade was 
performed for this patient, BCR, mTOR, and MYC signalling remained downregulated while the 
status of MAPK signalling switched to increased kinase activity. These results suggest HMGB1 
elicits pro- and anti-tumour effects dependent on the CLL subset.  
Finding: HMGB1 and CpG-ODN combined treatment activates and sustains MAPK signalling 
TLR9 agonist, CpG-ODN, results in opposing responses in U-CLL and M-CLL subsets, dependent 
on the expression of ZAP70.96,273 In autoreactive SLE B-cells, HMGB1 is an essential component 
of DNA-containing immune complexes that stimulate RAGE internalisation and TLR9 
activation.145,260 After recapitulating RAGE and TLR9 colocalization in response to HMGB1 
stimulation alone in CLL cells, as is observed in NLCs,76 the next step was to investigate a 
synergistic relationship between HMGB1 and CpG-ODN using an unbiased whole cell signalling 
phosphoproteomic approach. The results did not reveal activation of signalling pathways unique 
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to either CpG-ODN, or CpG-ODN combined with HMGB1 in either patient, but we did identify 
sustained MAPK signalling at the longer timepoint in the ZAP70+ patient when HMGB1 and CpG-
ODN was combined, highlighting a pro-tumour role. In the ZAP70- patient, the status of MAPK 
signalling was variable depending on whether CpG-ODN was combined with HMGB1 and if 
assessing the short- or long-term timepoint. Taken together, these results confirm previously 
published data on the outcome of CpG-ODN stimulation in CLL sample with opposing ZAP70 
expression status, and suggests the responsiveness of the MAPK signalling pathway to HMGB1 
stimulation, appears to depend on the CLL subset. MAPK signalling should be assessed in a larger 
cohort of patients to confirm these initial findings.  
 
7.1.4 Determine the origin of soluble RAGE in CLL 
Finding: Extracellular sRAGE protein mass is shorter than FL-RAGE and es-RAGE, indicating 
sRAGE derives predominantly from ectodomain shedding 
To ascertain why patient plasma sRAGE levels were higher in CLL patients compared to healthy 
controls, we first assessed which RAGE isoform constitutes the majority of sRAGE. Our data 
demonstrates that sRAGE is shorter than FL-RAGE and es-RAGE, therefore originating from 
ectodomain shedding, in line with previous studies.215,219 This result indicates that smouldering 
ongoing chronic inflammation driving CLL disease pathogenesis, including high levels of HMGB1, 
activates RAGE shedding and contributes to sRAGE deregulation in CLL.  
Finding: ADAM10 is the protease responsible for RAGE shedding in a transfected HEK293 cell 
line model  
Previous studies have identified ADAM10 as the sole RAGE metalloprotease.215 Using a 
transfected HEK293 cell line model, ADAM10 inhibitor and RAGE ectodomain shedding 
stimulator (ionomycin), the results from chapter 6 confirm ADAM10 as the main RAGE sheddase 
in a HEK293 cell line model. Once these conditions were established in a RAGE-expressing cell 
line model, we could further investigate this in primary CLL cells.  
Finding: RAGE shedding could be induced with ionomycin and HMGB1 in fresh primary CLL 
samples 
In chapter 4 we observed that patients with higher levels of sRAGE had a longer time to first 
treatment, and that extracellular sRAGE in CLL originates from ectodomain shedding in chapter 
6. Investigating methods to induce RAGE shedding could help us understand why sRAGE levels 
are higher in CLL compared to healthy controls, and possibly utilise intrinsic mechanisms to 
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increase levels of sRAGE to confer a protective effect. Although we could not experimentally 
measure ADAM10 inhibition in CLL samples, our results demonstrate calcium ionophore, 
ionomycin, and HMGB1 as stimulators of RAGE ectodomain shedding in primary CLL samples in 
vitro. Although this data in vitro suggests HMGB1 directly drives RAGE ectodomain shedding, we 
did not observe a significant correlation (either positive or negative) for these 2 proteins in CLL 
plasma samples (results from chapter 4). Taken together, while ongoing chronic inflammation 
in CLL (including increased levels of HMGB1) could drive increased RAGE ectodomain shedding, 
there is a breakdown in the negative inflammatory feedback loop; plasma sRAGE levels are not 
fully controlling HMGB1 inflammatory dysregulation established in CLL but does elicit a 
protective effect. Further investigational work is required to decipher the function and 
antagonistic potential of sRAGE.  
 
7.2 Limitations of thesis 
7.2.1 Clinical constraints 
Limited independent TMA patient cohorts: An independent patient TMA cohort to confirm our 
findings from chapter 3 using our in-house TMAs would have been useful. This would allow us 
to validate and strengthen our conclusion that high RAGE LN expression has prognostic 
significance in CLL and support further studies to translate this finding to an easily attainable 
clinical marker, as IHC is not routinely performed in clinic for CLL diagnosis.  
Limited patient clinical data: Detailed patient clinical information, including lymphocyte counts, 
cytogenetics, CLL-cell immunophenotype, IGHV mutational status, disease progression, 
treatment regimen and patient outcome would have strengthened our results that show an 
association with risk factors / disease outcome. Further, this information would have facilitated 
investigation of our functional results with different subsets and risk factors established in CLL. 
For example, although plasma HMGB1 and sRAGE levels are independent of ZAP70 expression, 
our results indicate RAGE LN expression is associated with poor-risk patients and signalling 
responsiveness to HMGB1 appear to be CLL-subset specific. Expanding our cohort of patients, 
with pre-selected cytogenetic / IGHV mutational status / prognostic clinical background will 
enrich this study.  
7.2.2 Biological constraints 
Selection and preparation of LNs for TMAs and IHC staining: When preparing TMAs, LN tissue 
is assessed for representative malignant areas following haematoxylin and eosin staining of a 
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3μm LN cross section. Malignant-rich areas are excised and 1mm2 cores arrayed in triplicate per 
patient into a recipient paraffin block to ensure enough of the malignant area is represented. 
3μm thick sections are cut and transferred onto glass slides to make a TMA. This does introduce 
a degree of selection bias; although LN cores are arrayed in triplicate, and are representative of 
malignant areas, this is performed in a 2D fashion using a LN cross section. Staining of TMAs is 
performed using consecutive 3μm cuts; this means the LN composition slightly changes with 
each TMA slide. Consecutive staining is a method to overcome this - slides are stained as per the 
protocol in chapter 2 with a purple chromogen (Vips) instead of DAB. Once image analysis is 
performed for the first batch of staining, antibody binding is stripped by performing heat 
induced antigen retrieval outlined in section 2.3.2. However, when this method was tested in 
our study, residual antibody remained from the previous batch of staining. Therefore, to reduce 
large changes in LN composition, consecutive TMA cuts were used and stained for our proteins 
of interest in this study.  
Age of healthy control plasma samples: Unfortunately, we were unable to obtain age-matched 
controls for our healthy control plasma cohort. Previous work in CLL assessed HMGB1 CLL 
plasma compared to healthy age matched controls, identifying increased levels in CLL.76 
Therefore expanding our cohort of patients, with age-matched healthy controls for sRAGE 
plasma levels will strengthen our findings.  
Measuring anti-RAGE antibody blockade: To confirm use of neutralising anti-RAGE antibody 
successfully blocked membrane RAGE activity, it would have been useful to have a RAGE 
signalling endpoint to measure; but RAGE signalling is not fully deciphered and is cell-type 
specific. Our phosphoproteomic dataset demonstrates RAGE blockade had little effect on MAPK 
signalling in the ZAP70+ patient, but we need to confirm if RAGE activity was inhibited, or 
HMGB1 was utilising another receptor. In our imaging studies, RAGE blockade prevented the 
colocalization of RAGE and TLR9 assessed by ImageStream but not by fluorescent microscopy. 
The effect of RAGE blockade on TLR9/MyD88 colocalization and NF-κB nuclear translocation was 
more prominent at the longer 4 hours timepoint. In combination with out phosphoproteomic 
data, it appears RAGE and TLR9 colocalization is not a signalling-inducing event, and / or MAPK 
signalling is activated by a different receptor following HMGB1 stimulation. Therefore, the 
studies using anti-RAGE blocking antibody were exploratory, and further confirmation with 
other RAGE and MAPK inhibitors are required to confirm the outcome of RAGE blockade and 
HMGB1 signalling.  
Healthy B-cells as a comparison for signalling studies: CLL B-cell BCR signalling kinetics is subset 
dependent, leading to proliferation or anergy.53,70 In our study, we did not assess HMGB1 
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signalling in B-cells from healthy donors. Anergic responses are observed in a subset of mature 
B-cells from healthy individuals.370 Results from our phosphoproteomic dataset suggest 
opposing signalling responsiveness to HMGB1 for the 2 patients assessed that were ZAP70+ or 
ZAP70-. Expanding these findings with data from healthy B-cells would be helpful to examine 
the impact of HMGB1 under homeostatic conditions, and support further studies assessing the 
impact of HMGB1 blockade/inhibition on healthy B-cells and CLL B-cells. 
7.2.3 Statistical constraints 
Testing X-tile data cut points: Categorical separation of biomarker expression is a clinically 
relevant method to define the threshold of a given prognostic marker for disease severity 
grading. For example, estrogen receptor, progesterone receptor and HER2 expression is scored 
using IHC in clinical breast cancer grading.371 There is currently no standardised statistical 
method to determine optimal data cut points for expression variables that don’t have prior 
defined subsets, but using X-tile helps to identify sub-populations of expression biomarkers 
rooted with unknown biology which would otherwise be left unnoticed. In this study, we used 
X-tile as an unbiased approach to determine the optimal data cut points for RAGE and TLR9 LN 
expression. Although this method splits the data cohort into test and validation sets we did not 
have an independent TMA patient cohort to test these data cut points and strengthen our 
finding that high RAGE LN expression had prognostic significance. 
Limited power: A larger cohort of patients would greatly improve the statistical power and 
accuracy of our results, as with many scientific studies. Confirming the IHC and plasma HMGB1 
and sRAGE findings in a larger cohort of CLL patients would ensure our results are indicative of 
the wider CLL population. For functional RAGE shedding and phosphoproteomic studies, where 
we have used fresh CLL samples, expanding this work with a larger cohort of patients and 
appropriate healthy controls will build on these initial results and allow solid conclusions to be 
made. A larger cohort for my studies would also allow investigation of different CLL risk groups.  
Selection bias: For the fresh CLL patient sample studies, we were limited to patients who were 
willing to donate material for research purposes, were treatment and steroid free for 6 months, 
with a lymphocyte count of greater than 20×10⁹/L, and PBMC samples with high CLL B-cell % to 
perform functional studies with. This does mean we were likely selecting for patients with high 
CLL-cell numbers in PB, and missing patients with aggressive disease requiring therapy, or 
patients with indolent disease (as they were below the lymphocyte count set to obtain enough 
patient material).  
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7.3 Future work 
7.3.1 Clinical / therapeutic future directions 
• Confirmation of our CLL LN TMA results with an independent patient cohort:  
Our finding that high RAGE LN expression is associated with shorter overall survival for 
patients with CLL warrants further investigation in a larger cohort of patients, and in 
independent data sets, to ensure our results are indicative of the CLL population. Such 
data would enhance our knowledge of CLL LN biology and aid in design of further 
inhibitor functional studies for RAGE. 
• Investigation to translate our CLL LN TMA results into PB clinical marker:  
Although investigating CLL LN biology is of mechanistic interest to further understand 
the drivers of CLL-cell survival in proliferation centres, any LN marker that is an 
indication of disease outcome would not routinely be assessed for every patient at 
diagnosis. It would be extremely useful if we could translate our findings to an easily 
attainable PB marker. In this study, we assessed RAGE expression in different cell types 
by flow cytometry with fresh CLL PBMCs, but this will be difficult to perform with fresh 
LN samples to compare. Once full TMA analysis has been performed with independent 
datasets, further investigation of RAGE gene expression will be assessed in matched LN 
and PB samples. PBMCs and LNs can be lysed and cryostored upon arrival, and gene 
expression analysis performed with the whole cohort of patients, instead of flow 
cytometry with fresh samples Moreover, gene expression analysis will allow us to assess 
the expression of different RAGE isoforms. 
• Long-term tracking of HMGB1 and sRAGE plasma levels with patient outcome:  
Our initial results indicate that HMGB1 and sRAGE plasma levels are increased in 
patients with CLL compared to healthy controls. We assessed sRAGE levels in 
consecutive CLL patient plasma samples, which demonstrate sRAGE levels to be 
relatively stable over the course of disease and increased following treatment for the 3 
patients that progressed to therapy. Further investigation of HMGB1 and sRAGE 
samples over the course of disease will allow deeper understanding of the relationship 
between these 2 markers, and if they are reliable and stable plasma markers that reflect 
disease progression.  
7.3.2 Biological future directions 
• Expand our signalling studies with a larger cohort of patients from U-CLL and M-CLL 
subsets:  
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We have assessed RAGE and TLR9 colocalization, and HMGB1 signalling in this study. 
Although we do not know the CLL subsets of the patients assessed in our imaging 
studies, our phosphoproteomic results in this thesis indicate that HMGB1 signalling may 
be CLL-subset specific. We cannot make conclusive outcomes from a cohort of 2 
patients, so further signalling studies in a larger cohort of patients, and confirmation by 
western blotting for key signalling mediators, are vital to assess HMGB1 signalling 
outcomes in CLL B-cells. 
• Assess the effect of MAPK and TLR signalling inhibitors on HMGB1 signalling:  
To further tease apart the main signalling mediators in HMGB1 signalling, the next step 
would be to use specific inhibitors for the pathways of interest. Firstly, we would use 
TLR9 and TLR inhibitors for HMGB1 alone, CpG-ODN alone, and HMGB1 and CpG-ODN 
combined treatment conditions to investigate the impact of TLR inhibition on HMGB1-
mediated cell signalling and pathway selection. Secondly, our initial results indicate 
MAPK pathway of importance in HMGB1 signalling. Further investigation of HMGB1 
signalling in combination with MAPK inhibitors will highlight if this is a central pathway 
in HMGB1 signalling in CLL B-cells, and indicate other signalling pathways with increased 
activity when MAPK is blocked.  
• Investigate the effect of different HMGB1 redox states on HMGB1 CLL-cell signalling: 
Complex post-translational modifications regulate the extracellular function of HMGB1, 
dependent on the mode of cell death, metabolism and HMGB1 biology. The redox status 
of the 3 cysteine residues is specifically linked to HMGB1 cytokine or chemokine 
activity.139 Fully reduced HMGB1 displays chemotactic activity, disulphide HMGB1 has 
cytokine activity, and fully oxidised HMGB1 has no immunostimulatory activity. We did 
not assess the difference in redox status on HMGB1 signalling in this study. To directly 
measure the impact of fully reduced (chemotactic) and disulphide HMGB1 (cytokine) on 
HMGB1 signalling, these 2 forms are commercially available to investigate in vitro. 
Stimulation and signalling studies using these 2 HMGB1 forms will help define any 
differences in HMGB1 signalling based on redox status in CLL samples. 
• Investigate the antagonistic effect of sRAGE:  
Once full signalling studies have identified the key mediators of HMGB1 signalling, the 
next step would be to assess the antagonistic effect of sRAGE on CLL-cells. It would be 
interesting to assess if sRAGE could be a direct competitor for HMGB1 in vitro by 
measuring the activation of key signalling mediators identified in our study; our es-RAGE 
HEK293 transfection cell line model did not produce a high enough concentration of 
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sRAGE in conditioned media to inhibit HMGB1, so further work is needed to investigate 
commercially available sRAGE. On a larger scale, in vivo work would be useful in 
assessing if higher levels of sRAGE contribute to the microenvironmental milieu towards 
immunogenic cell death, conferring a protective effect. 
 
7.4 Concluding remarks 
While the results in this thesis provide strong evidence for the importance of HMGB1 and RAGE 
expression in CLL microenvironmental disease pathogenesis, further complexity that remains to 
be addressed is the precise CLL subset-specific roles of HMGB1 and RAGE, and the antagonistic 
effect of sRAGE in CLL. In a larger context, established prognostic indicators are of great use in 
clinically defining CLL risk, but for a disease that is a model system for inflammatory-driven 
cancer progression, there are no established markers to track chronic inflammation or give 
insight into the proliferative communication occurring in CLL LNs.82 Within an established 
prognostic CLL subset, it’s not clear how powerful chronic inflammatory dysregulation is in 
shaping the outcome of CLL disease. As we move forward with targeted treatment options that 
modulate proliferative signalling pathways, acquired immune deficiency and immune 
checkpoints,102 tracking early responses to these therapies with a combination of markers 
covering many aspects of CLL biology would be helpful, in combination with clinical features and 
lymphocyte counts.  
CLL is a highly diverse and heterogeneous disease, reflected in variations in clinical 
manifestations, prognostic biomarkers and need and type of therapeutic management. This was 
observed in our study with highly variable CLL LN TLR9 and RAGE expression, and variable plasma 
HMGB1 and sRAGE levels among CLL patients. Although CLL cells circulate in peripheral blood, 
the LN harbours the proliferative CLL fraction in specialised structures called proliferation 
centres.46 This niche site is enriched with tumour-associated non-neoplastic cells and 
encompasses key microenvironment-CLL interactions;72 i.e. HMGB1-induced differentiation of 
NLCs and in turn, prolonged CLL survival.76 CLL LN biology offers great insight into the 
proliferative fraction of CLL and disease pathogenesis,47 but owing to the invasiveness of the 
procedure and LN-tissue handling, CLL LN biopsies are not routinely removed and examined to 
aid in CLL diagnosis or disease staging. Risk stratification is performed based on clinical features 
and PB samples, comprised of quiescent CLL cells. The results from this thesis indicate for the 
first time that RAGE LN expression has prognostic significance in CLL. Although we need to 
further confirm our results with independent data cohorts, it would be highly useful to translate 
these findings to a marker that was clinically applicable.  
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The clinical course of CLL disease is highly variable - some patients do not require treatment for 
years, if at all, whereas other patients rapidly develop high-risk disease and require treatment 
immediately.58 Following diagnosis and collection of extensive clinical information (cytogenetics, 
prognostic markers, IGHV somatic mutation status), frequent observation / monitoring and 
disease management algorithms are followed to assess for indicators for therapy.58 Assessment 
includes tracking lymphocyte doubling time, disease-related symptoms, or advanced stage Rai / 
Binet disease.58 These are effective measures to manage disease, but as treatment options 
become more targeted, better insight into treatment effectiveness is needed at an earlier stage, 
along with inflammatory and proliferative markers. Inflammatory PB markers could be useful to 
track inflammatory dysregulation over the course of CLL disease. In this study, we have assessed 
HMGB1 and sRAGE plasma levels, which are promising clinical markers for disease progression 
in autoimmune disease and cancer.361 Serum levels of sRAGE are easily attainable and powerful 
circulating disease biomarkers in patients undergoing chemotherapy in advanced pancreatic 
cancer.228,229 Although HMGB1 and sRAGE plasma markers measured here are not linked to the 
effectiveness of a specific treatment, our initial results comparing plasma levels to available 
clinical information, combined with studies in other disease settings,361 indicate these plasma 
markers as promising circulating inflammatory biomarkers. Further investigation is required in 
CLL with detailed clinical data and downstream functional studies.  
A powerful gene expression analysis of matched CLL cells from peripheral blood, bone marrow 
and lymph nodes identified enhanced activation of BCR-associated signalling pathways and NF-
B activation in CLL lymph nodes; this was significantly higher in U-CLL.47 BCR signalling is a 
central pathway in CLL B-cell proliferation, knowledge of which has translated into therapy 
options for the treatment of CLL.88,115 The outcome of BCR signalling is heterogeneous in CLL; 
antigen engagement results in B-cell activation/proliferation, or anergy.70 Moreover, the 
response to TLR9 agonists in CLL is dependent on the expression of ZAP70.96,273 Although HMGB1 
plasma levels are ZAP70 expression independent, our initial phosphoproteomic results indicate 
the signalling response to HMGB1 could be CLL subset-specific in the 2 patients we investigated. 
This requires further investigation with a larger cohort of ZAP70+ / ZAP70- patients. HMGB1 has 
a demonstrated role in smouldering chronic tumour-associated inflammation, and 
immunogenic malignant-cell death in cancer pathogenesis.151 The overall molecular and cellular 
components of the tumour microenvironment will largely decide the polarisation of the HMGB1 
response in tumour-associated inflammation; but on a molecular lever, further investigation is 
required to assess if HMGB1 signalling is truly dichotic in ZAP70+ and ZAP70- CLL-cell samples.  
In summary, CLL is still an incurable disease and relapse is common for high-risk patients. Current 
targeted therapies lead to high overall response rates but complete responses are not 
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common.115 A deeper understanding of molecular mechanisms contributing to disease 
pathogenesis, particularly microenvironmental interactions occurring in the LN, will aid in the 
development of new therapeutic agents and better risk stratification for patients with CLL. In 
combination with HMGB1-driven differentiation of NLCs, the results in this thesis support a 
direct role for HMGB1 in CLL B-cells. Further insight into this signalling pathway in different CLL 
risk groups, and overall microenvironment interactions, will support further HMGB1 / RAGE 
functional and intervention studies. 
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Appendix I  
1. Cell lines and cell culture  
Materials: 
- Heat Inactivated Fetal Bovine Serum (FBS) – Gibco Life Technologies 10500 
- Penicillin and Streptomycin (P/S) – Sigma Aldrich P4333 
- RPMI 1640 – Sigma Aldrich R8758 
1.1 Cell culture medium preparation 
Heat inactivated FBS (56°C for 30 minutes with mixing) was used to ensure complement 
proteins were inactivated. P/S was supplemented into cell culture medium to control bacterial 
contamination. RPMI 1640 medium contains sodium bicarbonate as a buffering system, L-
gluatmine as an amino acid supplement and phenol red to detect changes in medium pH. 55ml 
FBS and 5ml P/S (100x) was added to RPMI 1640 medium to give a final concentration of 10% 
heat inactivated FBS, 2.0mM L-glutamine, 100U/ml Penicillin and 100µg/ml Streptomycin. Cell 
culture medium was stored at 4°C and pre-warmed to 37°C in a water bath before addition to 
cells.  
1.2 Measurement of cell viability  
Cell viability and cell count was measured using the Luna-II™ Automated Cell Counter (Logos 
Biosystems L10001). 10µl of cell culture suspension was mixed with Trypan Blue in a 1:1 ratio 
(Cell Viability PN 2100102) before loading 10µl onto disposable Luna™ Cell Counting Slides 
(Logos Biosystems L12001). Trypan Blue is not absorbed by viable cells but traverses the 
damaged plasma membrane in dead cells staining cells blue, while live cells remain unstained. 
The Luna-II automated cell counter distinguishes dead cells from live cells and gives a measure 
of cell viability and total cell count.   
2. Patient Samples 
Materials: 
- Lymphoprep – Axis-Shield 1114547 
- CD19 MicroBeads human – MACS Miltenyi Biotech 130-050-301 
- B-CLL Cell Isolation Kit human – MACS Miltenyi Biotech 130-103-466 
- LS Columns - MACS Miltenyi Biotech 130-042-401 
- MACS Multistands - MACS Miltenyi Biotech 130-090-976 
- QuadroMACS separator -  MACS Miltenyi Biotech – 130-042-303 
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- Bovine serum albumin (BSA) – Sigma Aldrich A7906 
- Phosphate Buffered Saline (PBS) – Sigma Aldrich D8537 
2.1 0.5% bovine serum albumin-phosphate buffered saline MACS LS column wash buffer 
250mg of BSA was diluted in 50ml sterile PBS to give 0.5% BSA in PBS.  
3. Immunohistochemistry  
Materials: 
- Superfrost Plus slides – VWR 631-0108 
- Xylene – VWR Chemicals 28975.325 
- Industrial Methylated Spirit (IMS) – Fisher Scientific 11482874 
- Peroxidase – VWR Chemicals 23619.264 
- Unmasking Solution – Vector Laboratories H3300 
- 10x Dako wash buffer – Dako S3006 
- ImmEdge Hydrophobic Barrier PAP Pen – Vector Laboratories H-4000 
- Antibody Diluent – Zytomed ZUC025-500 
- Super Sensitive Polymer-Horseradish Peroxidase IHC Detection System – BioGenex 
QD430-XAKE. Kit includes: 
▪ SS label 
▪ Super Enhancer 
▪ Stable DAB buffer 
▪ Liquid DAB 
- Mayer Haematoxylin – Gill’s II 
- DPX mountant (Distrene 80, Dibutyl phthalate and Xylene) – VWR 360294H  
3.1 Peroxidase blocking buffer 
2% hydrogen peroxide in 100% IMS 
3.2 Unmasking solution 
30ml of citrate-based pH 6 unmasking solution was diluted 1:100 into 3L of distilled water. 1x 
unmasking solution was pre-heated to 400°C in a pressure cooker before slides were added. 
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3.3 Wash buffer 
100ml of 10x Dako wash buffer was diluted in 900ml of distilled water to give 0.05 M Tris /HCl, 
0.15 M NaCl, 0.05% Tween-20, pH 7.6 (±1) working solution.  
3.4 Antibody dilutions 
Table A. Primary antibodies used in this study 
Antibody Clone Species Company (Cat. No) Antigen 
Retrieval 
Dilution 
RAGE Monoclonal Mouse Abcam - ab54741 Heat induced 1:100 
TLR9 26C593 Mouse Abcam - ab12121 Heat induced 1:1000 
Ki67 MIB-1 Mouse Dako – M7240 Heat induced 1:1250 
ZAP70 YE291 Rabbit Abcam – ab32429 Heat induced 1:100 
CD5 4C7 Mouse 
Leica Biosystems - CD5-
4C7-L-CE 
Heat induced 1:500 
 
3.5 Dako autostainer programme 
Table B. The Dako autostainer was set up for immunostaining using the following programme. 
Reagent Incubation time 
Primary antibody 40 minutes 
Dako wash buffer Rinse 
Super-enhancer 20 minutes 
Dako wash buffer Rinse 
SS-label 30 minutes 
Dako wash buffer Rinse 
DAB 10 minutes 
dH₂O Rinse 
 
3.6 3,3'-diaminobenzidine (DAB) 
DAB was prepared immediately before use. 1 drop (38µl) was added to 1ml stable DAB buffer 
included in the detection kit. 
3.7 Acid Alcohol 
1% HCl acid in 70% IMS 
3.8 DPX 
A commercially purchased ready to use, xylene-based permanent mountant used to coverslip 
TMA slides.  
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4. Flow Cytometry  
Materials: 
- Human γ-Globulin (HAG) – Sigma 4386 
- BD Cytofix/Cytoperm Solution – BD Biosciences 554722 
- PBS – Sigma Aldrich D8537 
- FBS - Gibco Life Technologies 10500 
- 4’, 6’-Diamidino-2-Phenylindole, Dihydrochloride (DAPI) – Sigma D9564 
- Deoxyribonuclease I from bovine pancreas (DNase) – Sigma D4513 
- Recombinant Human HMGB1 – R&D Systems 1690-HMB-050 
- Polyclonal neutralising goat anti-RAGE IgG antibody – R&D Systems AF1145 
- FITC Annexin V Apoptosis Detection Kit I – BD Biosciences 556547. Kit includes: 
▪ 10X Annexin V Binding Buffer 
▪ FITC Annexin V 
▪ Propidium Iodide Staining Solution  
- Ionomycin – Sigma I0634 
- GI254023X – Sigma SML0789 
4.1 2% Human γ-Globulin (HAG) 
1g HAG was dissolved in 50ml sterile PBS for 30 minutes at room temperature and store in 
0.5ml aliquots at -20°C. 50µl per 1x10⁶ cells was used as blocking buffer and antibody diluent. 
4.2 2% FBS flow cytometry wash buffer 
Flow cytometry wash buffer was prepared by diluting 1ml FBS in 50ml PBS (2%).  
4.3 Antibodies and dilutions used for flow cytometry 
Table C. Conjugated, primary and secondary antibodies used in this study 
Antibody Clone Isotype Fluorochrome 
Company (cat. 
No) 
Dilution for 
10⁶ cells 
RAGE Polyclonal Rabbit, IgG - Abcam ab37647 
 
1:100 
TLR9 26C593.2 
Mouse, 
IgG 
- Abcam ab12121 1:100 
TLR9 5G5 
Mouse, 
IgG2a κ 
FITC Abcam ab58864 1:50 
CD14 61D3 
Mouse, 
IgG1 κ 
PE-Cy5 Abcam ab25395 1:20 
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CD19 SJ25-C1 
Mouse, 
IgG1 κ 
PE-Cy7 Abcam ab81997 1:20 
CD19 HIB19 
Mouse, IgG1 
κ 
APC 
BD Biosciences 
555415 
1:5 
CD3 UCHT1 
Mouse, IgG1 
κ 
FITC DAKO F0818 1:20 
CD3 UCHT1 
Mouse, IgG1 
κ 
APC 
BD Biosciences 
555335 
1:20 
CD5 UCHT2 
Mouse, IgG1 
κ 
APC-Cy7 
BD Biosciences 
563516 
1:20 
CD5 UCHT2 
Mouse, IgG 
1κ 
PE/Cy7 
eBioscience 25-
0059-42 
1:20 
CD163 GH1/61 
Mouse, IgG1 
κ 
APC Biolegend 333609 1:20 
CD68 Y1/82A 
Mouse, IgG1 
κ 
PE Biolegend 333808 1:20 
ZAP70 IE7.2 
Mouse, IgG1 
κ 
AF-488 
ThermoFisher 
MHZAP7020 
1:20 
ADAM10 N-
terminal 
Polyclonal 
Rabbit, 
IgG 
- Abcam ab39153 1:100 
Rabbit IgG Polyclonal 
Goat, whole 
IgG 
AF-488 Invitrogen A11034 
1:200 
 
Rabbit IgG Polyclonal 
Goat, whole 
IgG 
AF-647 Invitrogen A21244 1:200 
Mouse IgG Polyclonal 
Donkey, 
whole IgG 
AF-647 Invitrogen A31571 
1:200 
 
Mouse IgG1 κ - - FITC 
BD Biosciences 
556028 
1:20 
Mouse IgG1 κ - - APC 
BD Biosciences 
555751 
1:20 
Mouse IgG1 κ - - APC/Cy7 
BD Biosciences 
557873 
1:20 
Mouse IgG1 κ - - PE/Cy7 
BD Biosciences 
557872 
1:20 
 
4.4 DAPI working solution (Sigma D9564) 
10mg DAPI was dissolved in 2ml DMSO to give 50mg/ml the first stock solution which was 1:10 
diluted with DMSO to make the second stock solution (50µg/ml). Aliquots were stored at -20°C 
in the dark. For flow cytometry, DAPI was diluted 1:1000 in 2% FBS wash buffer to give a 
working solution of 50ng/ml.  
4.5 2% FBS flow cytometry wash buffer with DAPI 
Cells were collected in 300µl 2% flow wash buffer with 50ng/ml DAPI for flow cytometry. 
4.6 Deoxyribonuclease I from bovine pancreas (Sigma D4513) 
10µg Deoxyribonuclease I (DNase) was diluted in 10ml sterile PBS to give 1µg/ml and stored at 
-20°C in 1ml aliquots.  
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4.7 Preparation of FITC Annexin V Apoptosis Detection Kit I (BD Biosciences 556547) 
1X Annexin V Binding buffer (0.1M Hepes/NaOH (pH 7.4), 1.4M NaCl, 25mM CaCl₂) was 
prepared by diluting 1ml 10X Annexin V Binding Buffer in 9ml sterile distilled water; 100µl was 
used per 1x10⁶ cells. Annexin V-FITC and PI was ready-to-use on arrival; 5µl of each stain was 
used per 1x10⁶ cells.  
5. Enzyme-Linked Immunosorbant Assay (ELISA) 
Materials: 
- Human HMGB1 ELISA Kit – IBL International ST51011. Kit includes: 
• Microtiter Plate (96 wells coated with polyclonal anti-HMGB1) 
• Peroxidase Enzyme Conjugate 
• HMGB1 Standard (from pig) 
• HMGB1 Positive Control (from pig) 
• Diluent Buffer 
• Enzyme Conjugate Diluent 
• 5X Wash Buffer (phosphate buffer, <0.5% Tween 20) 
• Colour Reagent A (TMB) 
• Colour Reagent B (0.005M hydrogen peroxide) 
• Colour Stop Solution (0.35M H₂SO₄) 
• Adhesive Foil 
- Human S100B ELISA Kit – EMD Millipore EZHS100B-33K. Kit includes: 
• S100B ELISA Plate (96 wells pre-titered with human S100B antibodies) 
• 10X HRP Wash Buffer Concentrate (Tris-Buffered Saline with Tween-20) 
• S100B Standard 
• S100B Quality Control 1 and 2  
• Matrix Solution  
• 1X Assay Buffer 
• S100B Detection Antibody  
• Enzyme Solution (pre-titres streptavidin-horseradish peroxidase 
conjugate) 
• Substrate (3,3’,5,5’-tetramethylbenzidine) 
• Stop Solution (0.3M HCl) 
- Human RAGE ELISA Kit – Abcam ab100632. Kit includes: 
• RAGE ELISA Plate (96 wells pre-titre with anti-RAGE antibody) 
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• 20X Wash Buffer Concentrate  
• Assay Diluent A 
• 5X Assay Diluent B 
• Biotinylated Anti-human RAGE 
• Recombinant Human RAGE Standard 
• 200X HRP-Streptavidin Concentrate 
• TMB One-step  
• Substrate Reagent 
• Stop Solution 
 
6. Immunofluorescent Microscopy 
Materials: 
- Superfrost™ Plus Slides – VWR 631-0108 
- BD Cytofix/Cytoperm Solution – BD Biosciences 554722 
- Tris-Buffered Saline with 0.1% Tween-20 (TBST)  
• Tween-20 – Sigma P7949 
- Blocking buffer with: 
• Donkey serum – Sigma D9663 
• Goat serum – Sigma G9023 
• Saponin – Fluka Biochemika 47036 
- 4’, 6’-Diamidino-2-Phenylindole, Dihydrochloride (DAPI) – Sigma D9564 
- ProLong Gold anti-fade mountant – Life Technologies P36930 
6.1 1X TBST 
10X TBS stock was prepared by mixing 300ml 5M NaCl with 500ml 1M Tris-base adjusted to 
pH7.4 with HCl and 200ml deionised water. 1X TBST was prepared by diluting 100ml of 10X 
TBS stock in 900ml of deionised water. 1ml Tween-20 was added to 1L 1X TBS to give 0.1% 
TBST. 
6.2 5% donkey and 5% goat serum blocking buffer 
50ml blocking buffer was prepared by adding 50mg saponin to 47.5ml 1X TBS and addition of 
2.5ml donkey or goat serum. 10ml aliquots were stored at -20°C. Cells that were co-stained 
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with both donkey anti-mouse IgG and goat anti-rabbit IgG secondary antibodies were blocked 
with 50µl 1:1 ratio of mixed 5% donkey and 5% goat serum blocking buffer.  
6.3 Primary and secondary antibodies used in this study 
Table D. Primary antibodies used in this study 
Antibody Clone Isotype Company (cat. No) Dilution 
RAGE Polyclonal Rabbit, IgG Abcam ab37647 1:100 
TLR9 26C593.2 Mouse, IgG Abcam ab12121 1:100 
MyD88 EPR590(N) Rabbit, IgG Abcam ab133739 1:100 
NF-κB p65 F-6 
Mouse, 
IgG1κ 
Santa Cruz sc-8008 1:20 
STAT3-
PY705 
D3A7 Rabbit, IgG 
Cell Signalling Technology 
9145 
1:100 
 
Table E. Secondary conjugated antibodies used in this study. 
Antibody Clone Isotype Fluorochrome Company (cat. 
No) 
Dilution  
Rabbit IgG Polyclonal Goat, whole IgG AF-488 Invitrogen A11034 1:100 
Mouse 
IgG 
Polyclonal 
Donkey, whole 
IgG 
AF-488 Invitrogen A21202 1:100 
Mouse 
IgG 
Polyclonal 
Donkey, whole 
IgG 
AF-546 Invitrogen A10036 1:100 
 
6.4 DAPI 
10mg DAPI was dissolved in 2ml DMSO to give 50mg/ml the first stock solution which was 1:10 
diluted with DMSO to make the second stock solution (50µg/ml). Aliquots were stored at -20°C 
in the dark. For fluorescence microscopy, DAPI was diluted 1:1000 in TBST to give a working 
solution of 50ng/ml. 
7. ImageStream X Mark II Flow Cytometry 
Materials: 
- BD Cytofix/Cytoperm Solution – BD Biosciences 554722 
- Tris-Buffered Saline with 0.1% Tween-20 (TBST)  
▪ Tween-20 – Sigma P7949 
- Blocking buffer with: 
▪ Donkey serum – Sigma D9663 
▪ Goat serum – Sigma G9023 
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▪ Saponin – Fluka Biochemika 47036 
- 4’, 6’-Diamidino-2-Phenylindole, Dihydrochloride (DAPI) – Sigma D9564 
7.1 Primary and Secondary antibodies used in this study 
Table F. Primary antibodies used in this study 
Antibody Clone Isotype Company (cat. No) Dilution 
RAGE Polyclonal Rabbit, IgG Abcam ab37647 1:100 
TLR9 26C593.2 Mouse, IgG Abcam ab12121 1:50 
MyD88 EPR590(N) Rabbit, IgG Abcam ab133739 1:100 
NF-κB p65 F-6 
Mouse, 
IgG1κ 
Santa Cruz sc-8008 1:20 
STAT3-
PY705 
D3A7 Rabbit, IgG 
Cell Signalling Technology 
9145 
1:100 
 
Table G. Secondary antibodies used in this study 
Antibody Clone Isotype Fluorochrome Company (cat. 
No) 
Dilution 
Rabbit IgG Polyclonal Goat, whole IgG AF-488 Invitrogen A11034 1:200 
Rabbit IgG Polyclonal Goat, whole IgG AF-647 A21244 1:200 
Mouse 
IgG 
Polyclonal 
Donkey, whole 
IgG 
AF-488 Invitrogen A21202 1:200 
Mouse 
IgG 
Polyclonal 
Donkey, whole 
IgG 
AF-647 Invitrogen A31571 1:200 
 
8. Western Blotting 
Materials: 
- PBS – Sigma Aldrich D8537 
- TBS – Trizma® Base - Sigma T1503 
- Tween®-20 – Sigma P7949 
- CelLytic M Cell Lysis reagent - Sigma C2978 
- Protease inhibitor cocktail set II - Sigma P8340-1ML 
- Phosphatase inhibitor cocktail set I – Sigma P2850 
- Phosphatase inhibitor cocktail set II - Sigma P5726 
- Bio-Rad Protein Assay Reagent Concentrate – Bio-Rad 500-0006 
- Pierce™ Bovine Serum Albumin (BSA) Standard Ampules – Thermo Scientific 23209 
- 20X MOPS Running Buffer – Invitrogen NP0001 
- Transfer Buffer 
- MagicMark™ XP Western standard – Thermo Fisher Scientific LC5602 
- NuPage® LDS sample loading buffer 4X – Invitrogen NP0007 
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- NuPAGE® Reducing Agent 10X – Invitrogen NP0009 
- NuPAGE® Antioxidant – Invitrogen NP0005 
- Nu-PAGE® 4-12% Bis-Tris gel – Invitrogen NP0322 
- PVDF membrane – EMD Millipore IPVH304FO 
- Polyvinylpyrrolidone (PVP) – Sigma P5288 
- FCS – Gibco Life Technologies 10500 
- Sodium Azide – Sigma S8032 
- SuperSignal™ West Pico PLUS Chemiluminescent Substrate – Thermo Scientific 
1863098 
- Restore PLUS® Western blot stripping buffer – Thermo Scientific 21059 
 
8.1 Preparation of CelLytic M cell lysis buffer 
Protease and phosphatase inhibitors were diluted 1:100 in CelLytic M cell lysis buffer prior to 
use to limit de-phosphorylation and protein degradation. Cell lysis buffer was kept on ice. 
8.2 Preparation of Bio-Rad Protein Assay Dye Reagent 
A 1X Bio-Rad protein assay dye working solution was prepared by diluting 40ml of reagent in 
200ml of deionised water (1:5) and passed through filter paper to remove insoluble material. 
The working solution was kept in the dark at 4°C.  
8.3 Bovine Serum Albumin (BSA) 0.5mg/ml stock solution 
0.5mg/ml stock concentration of BSA was prepared by diluting 500µl of 2.0mg/ml Pierce™ BSA 
ampule in 1.5ml deionised water; 500µl aliquots were stored at -20°C.  
8.4 1X MOPS Running Buffer 
50ml of 20X MOPS running buffer was diluted in 950ml deionised water prior to use, to give a 
1X working solution; MOPS concentrate was stored at 4°C.  
8.5 Reducing LDS sample buffer and antioxidant 1X MOPS buffer 
For reducing SDS-PAGE, NuPAGE® reducing agent was diluted 1:10 in LDS sample lysis buffer - 
2µl in 18µl, respectively. 500µl NuPAGE® antioxidant was mixed with 200ml 1X MOPS buffer 
before pouring into the upper chamber. 
8.6 Transfer Buffer 
A 10X stock solution of transfer buffer was prepared by making 1L 0.25M Tris-base and 1.92M 
Glycine in deionised water. A working 1X transfer buffer solution was prepared by mixing 
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100ml 10X transfer buffer stock with 200ml of methanol and 700ml deionised water. 1X 
transfer buffer was stored at 4°C.  
8.7 Polyvinylpyrolidine (PVP) blocking buffer and antibody diluent 
5% PVP was prepared by dissolving 50g PVP in 1L 0.2% TBST and stored at 4°C. 0.5ml FBS was 
added to 10ml 5% PVP as the non-specific blocking reagent.  
8.8 Antibodies used for Western blotting 
Table H. Primary antibodies used in this study 
Antibody Clone Isotype Company (cat. No) Dilution for probing 
RAGE Polyclonal Rabbit, IgG Abcam ab37647 1:3000 
TLR9 26C593.2 Mouse, IgG Abcam ab12121 1:3000 
MyD88 EPR590(N) Rabbit, IgG Abcam ab133739 1:3000 
HMGB1   Abcam 1:3000 
NF-κB p65 F-6 
Mouse, 
IgG1κ 
Santa Cruz sc-8008 1:500 
NF-κB-P-
(P65) 
93H1 Rabbit, IgG 
Cell Signalling Technology 
3033S 
1:3000 
STAT3-
PY705 
D3A7 Rabbit, IgG 
Cell Signalling Technology 
9145 
1:3000 
STAT3 Polyclonal Rabbit, IgG 
Cell Signalling Technology 
12640S 
1:3000 
GAPDH Polyclonal Rabbit, IgG 
Cell Signalling Technology 
5174S 
1:3000 
 
Table I. Secondary antibodies used in this study 
Antibody Clone Isotype Company (cat. No) Dilution for probing 
Anti-rabbit 
IgG-HRP 
Polyclonal Goat, IgG 
Cell Signalling 
Technology 7074S 
1:3000 
Anti-mouse 
IgG-HRP 
Polyclonal Horse, IgG 
Cell Signalling 
Technology 7076S 
1:3000 
 
8.9 PVP with 10% sodium azide 
10g of sodium azide was dissolved in 100ml deionised water to give a 10% azide stock solution. 
100µl of 10% azide solution was added to 10ml PVP blocking buffer (1:100) for overnight 
primary antibody incubation.  
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8.10 Enhanced chemiluminescent (ECL) reagent preparation 
500µl of SuperSignal West Pico PLUS Luminol/Enhancer Solution was mixed with 500 µl of 
SuperSignal West Pico PLUS Stable Peroxide Solution and left to equilibrate for 5 minutes at 
room temperature. Probed membranes were incubated with 1ml of 1:1 ECL solution for 5 
minutes before exposure. Fresh ECL was used per blot.  
9. Co-Immunoprecipitation (co-IP) 
Materials: 
- CelLytic M Cell Lysis Buffer with protease and phosphatase inhibitors – Sigma  
- PBS – Sigma D8537 
- Tween-20 – Sigma P7949 
- Dynabeads™ Protein A 
- DynaMag™-2 – Thermo Scientific 12321D 
- NuPAGE® LDS Sample Buffer 
- NuPAGE® Sample Reducing Agent 
- Normal anti-mouse IgG – sc 
- Mouse anti-TLR9 – Abcam ab12121 
 
9.1 Phosphate Buffered Saline with 0.02% Tween-20 (PBST) 
50ml PBS was mixed with 20µl Tween-20 to give 0.02% PBST for washing steps and Dynabed™-
antibody incubation.  
9.2 Co-IP Elution Buffer 
18µl LDS sample buffer was mixed with 2µl 10X Reducing agent to make denaturing co-IP 
elution buffer; 20µl was used per sample. Antioxidant was included in SDS gel electrophoresis 
to ensure proteins were not oxidised as they migrate through the gel.  
9.3 Antibodies used in this study 
Table J. Primary antibodies used in this study 
Antibody Clone Isotype Company (cat. No) Dilution 
TLR9 26C593.2 Mouse, IgG Abcam ab12121 
5µg for 
immunoprecipitation 
1:3000 for probing 
IgG  Mouse, IgG Sc- 
5µg for 
immunoprecipitation 
RAGE Polyclonal Rabbit, IgG Abcam ab37647 1:3000 
MyD88 EPR590(N) Rabbit, IgG Abcam ab133739 1:100 
HMGB1 Polyclonal Rabbit, IgG Abcam ab18256 1:3000 
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Table K. Secondary antibodies used in this study 
Antibody Clone Isotype Company (cat. No) Dilution for probing 
Anti-rabbit 
IgG-HRP 
Polyclonal Goat, IgG 
Cell Signalling Technology 
7074S 
1:3000 
Anti-mouse 
IgG-HRP 
Polyclonal Horse, IgG 
Cell Signalling Technology 
7076S 
1:3000 
 
10. Mass Spectrometry  
Materials: 
- Pierce BCA Protein Assay Kit – Thermoscientific 23225 
- Deoxyribonuclease I (DNAse I), from bovine pancreas – Sigma D4513 
- Phosphatase inhibitors – Na3VO4, NaF 
- Protease inhibitors – Pyrophosphate, β-glycerolphosphate 
- Urea – Sigma 08884 
- DTT – Sigma 000000010708984001 
- IAM – Sigma I1149 
- HEPES – Sigma H3375 
- Glycolytic acid  
- TiO2 beads – Merck 539722 
- Glygen EMPTY spintips – Thermoscientific 84850 
- LC-MS/MS instrumentation – Q Exactive Plus  
10.1 Cell wash 
50ml PBS and phosphatase inhibitors (1mM Na3VO4 (0.5ml of 100mM stock per 50 ml) and 
1mM NaF (100μl of 0.5M stock per 50ml)). 
10.2 Cell lysis buffer 
20mM HEPES pH 8.0, 8M Urea, 1mM Na3VO4 (100μl of 100mM stock), 1mM NaF (20μl of 0.5M 
stock), 2.5mM pyrophosphate Na2H2P2O7 (100μl of 0.25M stock), 1mM β-glycerolphosphate 
(10μl of 1M stock). 
10.3 HEPES buffer 
20mM HEPES pH 8.0 
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11. Molecular Biology Techniques 
Materials: 
- Full-length RAGE plasmid – IBL international HM-310 
- Endogenous-secreted RAGE plasmid – IBL international HM-311 
- Subcloning efficiency DH5α competent cells – Invitrogen 18265-017 
- QIAGEN plasmid purification midi kit – QIAGEN 12143 
- FastDigest BamHI – ThermoScientific FD0054 
- FastDigest SmaI – ThermoScientific FD0054 
 
11.1 FL-RAGE and es-RAGE pcDNA3 plasmids 
FL-RAGE and es-RAGE on a pcDNA3 backbone were sourced from HMGBiotech via IBL 
International. 20µg of dried plasmid DNA was reconstituted to 1.4µg/µl and 0.768µg/µl in 
RNase-free water for FL-RAGE and es-RAGE, respectively, and stored at -20°C. The pcDNA3 
vector includes a CMV promoter for mammalian expression and genes for ampicillin bacterial 
resistance and neomycin selectable marker. FL-RAGE was inserted between EcoRI and XhoI 
restriction sites and es-RAGE was inserted between EcoRI and Xba restriction sites.  
 
Appendix Figure 1.  pcDNA3 plasmid backbone  
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11.2 Luria broth (LB) media 
10g tryptone, 5g yeast extract and 10g NaCl was dissolved in 800ml of distilled water. The pH 
was adjusted to 7.0 with NaOH and the volume brought up to 1L with distilled water. LB media 
was sterilised by autoclaving.  
11.3 Ampicillin agar plates 
Bacteria are unable to digest agar, so growing antibiotic resistant bacteria on antibiotic 
containing agar gel allows isolation of single antibiotic resistant bacteria growing on top of the 
gel, compared to growth in solution such as LB media. 5g peptone, 10g peptone from casein, 
10g NaCl, 12g agar-agar was dissolved in 1L sterile distilled water. Agar was sterilised by 
autoclaving and left to set before use. Upon use, agar was warmed in a 60°C water bath until 
molten and ampicillin added to a final concentration of 100µg/ml. Ampicillin-agar was poured 
into sterile 60mm x 15mm plates next to a working flame to ensure sterility and left to set. 
Plates were sealed and stored at 4°C until use.  
11.4 Glycerol bacteria stock 
1ml 100% glycerol was diluted to 50% with 1ml sterile distilled water. 500µl of 50% glycerol 
was mixed with 500µl of overnight bacterial culture in a 2ml cryovial; bacteria stocks were 
stored in -80°C.  
11.5 Tris-EDTA (TE) buffer 
1M Tris-HCl was prepared by adding 60.6g Tris-base to 500ml deionised water; Tris-base was 
adjusted to pH 8.0 with NaOH. 0.5M EDTA was prepared by adding 18.6g EDTA in deionised 
water; the pH was adjusted to 8.0 with NaOH. 500ml of TE buffer was prepared by adding 5ml 
1M Tris-HCl (pH 8.0) and 1ml 0.5M EDTA (pH 8.0) to 494ml deionised water. TE buffer was 
sterile filtered through a 0.22µM filter and plasmid DNA reconstituted in 500µl sterile TE buffer 
inside a tissue culture hood. 50µl aliquots were stored in -20°C for long term storage.  
11.6 Restriction digest map 
BamHI and SmaI restriction enzymes were chosen based on enzyme availability and restriction 
sites in the pcDNA3 plasmid backbone and FL-RAGE and es-RAGE sequences. There is 1x BamHI 
and 1x SmaI cut site in the pcDNA3 plasmid vector. For the FL-RAGE plasmid, BamHI has 3 cut 
sites in total (2x in FL-RAGE sequence and 1x in pcDNA3 backbone) and SmaI has 2 cut sites in 
total (1x in FL-RAGE sequence and 1x pcDNA3 backbone). For es-RAGE plasmid, BamHI has 2 
cut sites in total (1x in es-RAGE sequence and 1x in pcDNA3 backbone) and SmaI has 2 cut sites 
in total (1x es-RAGE sequence and 1x in pcDNA3 backbone). 
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Appendix Figure 2.  pcDNA3 plasmid backbone 
 
Appendix Figure 3. Full-length RAGE plasmid – IBL international HM-310 
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Appendix Figure 4.  Endogenous-secreted RAGE plasmid – IBL international HM-311 
11.7 Tris-borate-EDTA (TBE) buffer 
10X TBE buffer was prepared by adding 108g Tris-base, 55g boric acid to 600ml deionised 
water. 40ml of 0.5M EDTA pH 8.0 (from Appendix I, 11.6) was added and the total volume 
brought up to 1L with deionised water. A working 1X TBE solution was prepared by mixing 
100ml 10X TBE stock with 900ml deionised water.  
11.8 JetPRIME reagent and DNA mix 
5µg of plasmid DNA was mixed with 500µl of jetPRIME buffer and mixed. 10µl of JetPRIME 
reagent was added and the DNA-reagent mix was incubated for 10 minutes at room 
temperature.  
 
12. Drug Preparation 
Materials: 
- Recombinant Human HMGB1 protein– R&D Systems 1690-HMB-050 
- Polyclonal neutralising goat anti-RAGE IgG antibody – R&D Systems AF1145 
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- Class B CpG Oligonucleotide (ODN) – Invivogen 2006 (ODN 7909) 
- Ionomycin – Sigma I0634 
- GI254023X – Sigma SML0789 
12.1 Preparation of HMGB1 200µg/ml stock solution (R&D Systems 1690-HMB-050) 
50µg HMGB1 was diluted in 250µl sterile PBS to give a stock concentration of 200µg/ml and 
stored at -80°C in 5µl aliquots. 200ng/ml and 500ng/ml final concentrations were used in cell 
stimulations. 
12.2 Preparation of rabbit anti-RAGE neutralising antibody (R&D Systems AF1145) 
100µg of polyclonal goat anti-RAGE IgG was diluted in 100µl sterile PBS to give 1µg/ml stock 
concentration; 10µl aliquots were stored in -20°C. 4-12µg/ml can inhibit 50% RAGE in ELISAs, 
so a final concentration of 10µg/ml anti-RAGE was used in vitro for surface RAGE inhibition.  
12.3 Preparation of Class B CpG ODN 500mM stock solution (Invivogen 2006 ODN 7909) 
200µg ODN 2006 was resuspended in 52µl provided endotoxin-free water to give a stock 
concentration of 500µM. Aliquots were stored at -20°C. A working solution of 1µM was used 
for in vitro assays by adding 2µl/ml.  
12.4 Preparation of ionomycin 1mM stock solution (Sigma I0634) 
1mg of ionomycin (molecular weight = 747.08) was diluted in 700µl sterile DMSO to give 2mM 
stock concentration; aliquots were stored at -20°C. A working ionomycin concentration of 
500nM was used for cell stimulations.  
12.5 Preparation of GI254023X 10mM stock solution 
5mg of GI254023X (molecular weight = 391.50) was diluted in 1277µl sterile DMSO to give 
10mM stock concentration; stored at 4°C in the dark. Final GI254023X concentrations of 5µM, 
10µM and 20µM were used to inhibit ADAM10 in vitro.  
Appendix II 
262 
 
Appendix II 
Chapter III TMAs 
 
Appendix Figure 5. Representative images of immunohistochemical staining of CD5 in primary CLL LN 
TMAs 
Representative images of CD5 staining in primary CLL LN tissue biopsies arrayed onto TMAs; 1mm2 imaged 
LN cores are from 2 CLL patients. CD5 staining visualised in brown with DAB chromogen, and nuclei 
visualised in blue with haematoxylin staining. Areas high in brown CD5+ staining was selected for image 
analysis and ARIOL software image analysis training; i.e. right half of the first LN core and the whole of the 
second LN core.  
 
 
Appendix Figure 6. Comparison of CLL TLR9 whole LN core expression with ZAP70 positivity 
Expression levels of CLL TLR9 stained by IHC were quantified using the ARIOL digital image analysis 
software (Figure 3-4). ZAP70 positive or negative expression levels were obtained from our clinical 
database and stained by IHC on the same CLL LN TMA. Statistical differences between ZAP70+/- % TLR9 
expression levels was analysed by an unpaired Mann Whitney U test; data are presented as medians with 
interquartile range.  
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Table L. Clinical information of CLL patient samples used in IHC/CLL LN TMAs 
Patient ID Ki-67 % RAGE % TLR9 % Survival (years) Censored survival Zap70 (tissue) Age Binet Stage 
 
0.83 0.83 36.92 3.58 0 1 42 
 
5393 1.25 2.63 30.73 2.41 1 1 62 B 
5313 3.70 2.74 60.43 14.01 0 1 52 A 
5496 2.40 3.20 27.15 2.63 1 1 55 B 
9303 3.18 4.31 40.84 5.38 1 2 53 A 
5907 1.14 4.88 13.38 10.18 1 1 51 B 
9480 18.49 10.58 66.22 11.76 0 
 
50 
 
 
0.64 13.70 10.46 9.00 0 1 59 A 
7799 3.99 13.71 40.36 7.32 1 2 66 A 
5474 2.25 13.87 32.18 13.98 1 2 52 A 
 
2.45 16.13 34.08 1.17 1 1 73 
 
4380 1.33 16.55 28.48 7.41 1 1 69 A 
10278 2.62 18.29 15.94 8.89 0 1 71 A 
1970 1.15 18.53 10.85 4.60 1 2 62 
 
7075 1.22 19.02 33.67 3.16 1 1 63 
 
421 2.97 20.53 3.48 8.05 0 2 31 
 
7234 3.02 21.31 44.31 9.83 1 1 48 A 
8236 7.66 21.46 50.67 4.79 1 1 57 
 
 
2.81 21.77 47.20 6.00 0 
 
59 
 
8369 7.87 22.44 47.81 5.96 1 1 63 A 
5428 0.43 23.71 25.98 6.55 1 2 55 B 
7105 6.23 23.83 38.75 11.41 0 1 63 A 
8556 10.71 25.30 53.08 7.96 1 1 58 A 
 
2.67 25.96 43.84 12.00 0 
 
79 A 
5441 0.27 26.03 42.35 3.45 1 2 68 A 
 
0.77 26.08 16.56 5.00 1 2 
  
1934 0.61 26.08 20.45 24.70 0 
 
52 A 
7631 2.42 27.57 29.22 7.89 0 2 56 A 
7161 3.05 28.50 44.33 7.21 1 1 80 A 
 
0.24 28.70 51.82 6.67 0 1 40 B 
7987 8.48 31.62 43.01 3.21 1 2 63 B 
8154 8.28 32.20 42.40 5.80 1 2 48 A 
5959 5.00 32.42 36.01 15.09 0 1 46 A 
5464 0.21 35.47 33.70 21.54 1 
 
27 B 
8137 12.82 35.64 37.64 5.77 1 2 69 A 
7247 0.96 35.77 3.93 9.07 0 1 78 A 
5471 0.48 38.43 43.08 5.08 1 2 64 A 
7754 2.30 38.54 61.79 6.44 1 1 57 B 
6744 5.89 39.63 48.74 12.09 0 1 38 A 
7398 4.22 41.02 28.64 8.71 1 1 64 C 
8591 12.60 42.92 65.62 2.05 1 1 36 A 
10584 2.40 43.52 47.28 12.46 0 2 41 B 
1380 0.67 43.82 46.48 10.60 1 1 58 
 
7770 11.69 45.21 75.27 8.48 1 
 
48 A 
7536 9.55 45.23 61.46 18.65 0 1 69 
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8590 0.76 45.28 40.87 5.39 0 1 50 
 
8774 9.70 47.50 61.25 7.58 0 2 46 A 
5478 2.18 48.34 25.81 9.10 1 
 
57 B 
7446 3.46 49.27 23.52 2.52 1 1 63 
 
5483 0.26 49.88 40.78 9.45 1 1 63 A 
 
1.64 51.21 57.76 9.25 1 1 55 
 
8314 10.92 51.30 60.50 3.46 1 2 50 A 
7675 7.46 51.89 43.01 16.67 0 1 43 A 
8368 7.42 52.70 63.31 11.26 1 2 57 A 
6351 1.68 52.80 53.84 12.33 0 
 
67 
 
 
5.02 53.88 64.19 4.58 1 2 50 
 
7431 4.48 54.07 46.93 5.36 1 2 63 A 
5390 1.46 54.57 35.24 7.87 1 1 68 B 
4798 4.44 56.25 61.60 15.81 0 1 61 
 
8371 11.25 56.56 57.78 7.79 0 1 74 A 
9095 6.99 56.62 69.66 4.21 0 
 
59 
 
7921 4.96 57.85 42.93 9.16 1 1 43 A 
1861 0.40 58.59 31.98 11.44 1 
 
58 
 
8131 9.63 59.72 59.81 6.85 0 2 54 A 
7124 5.61 60.49 31.71 4.91 1 2 55 
 
5426 11.99 60.57 69.19 18.22 0 2 44 
 
10583 9.15 62.75 60.84 11.52 0 
   
8315 3.82 63.50 54.81 8.20 1 2 57 B 
7585 10.02 64.08 65.00 8.30 0 1 49 A 
6760 17.91 65.50 47.75 0.87 1 1 66 C 
7596 17.56 66.77 77.53 4.57 1 2 59 C 
 
1.01 68.82 27.31 7.58 0 1 61 
 
7903 21.97 73.32 63.54 4.45 1 2 76 
 
8155 11.33 74.48 75.98 6.52 1 
 
76 
 
9935 9.33 75.65 57.93 8.34 0 
 
61 
 
7510 12.42 77.31 62.13 6.58 1 2 56 B 
 
2.86 78.07 22.10 12.00 0 2 56 
 
7230 8.36 78.55 59.63 4.64 1 1 80 
 
7147 4.72 80.80 54.50 0.46 0 2 26 
 
8918 6.26 87.22 56.85 2.98 1 2 59 A 
8779 17.85 91.98 90.62 3.14 1 
 
68 C 
9745 14.81 93.14 61.77 1.82 0 
 
68 
 
5385 1.82 94.40 63.62 0.31 1 2 62 B 
8375 13.66 98.13 46.19 6.25 0 
 
45 A 
10108 4.11 100.00 27.51 3.87 1 
 
73 
 
7549 21.95 100.00 29.86 8.91 0 
 
67 A 
9402 4.73 100.00 35.37 3.12 0 
 
72 
 
9601 27.10 100.00 39.08 5.12 0 
 
31 
 
8321 37.49 100.00 46.59 2.93 1 
 
45 B 
6738 21.71 100.00 66.85 9.38 1 
 
47 A 
7262 22.78 100.00 71.82 0.60 0 
 
71 
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Appendix Figure 7. Evaluation of the association between LN tissue ZAP70 score and PB ZAP70 score  
ZAP70 LN expression levels were determined by IHC and classified as positive if LN brown DAB ZAP70 
staining was >20%; PB ZAP70 expression was determined in clinic by flow cytometry (A). Data for both 
ZAP70 LN and PB expression was extracted from our clinical database for the CLL TMAs. The correlation 
between LN ZAP70 and PB ZAP70 was assessed by Pearson’s product-moment correlation method (B) and 
Spearman’s rho correlation analysis (C). Data are presented as correlation coefficient, P-value and sample 
size (N); P<0.01**.  
 
  
Appendix II 
266 
 
 
Appendix Figure 8. Evaluation of the association between RAGE and TLR9 and CLL cytogenetic 
abberations 
CLL cytogenetic aberrations were compared to LN RAGE (A) and TLR9 (B) expression levels. Cytogenetic 
clinical data was extracted from our tissue bank clinical database and expression levels of RAGE and TLR9 
were determined by IHC. Statistical differences were assessed by linear regression; P<0.05*. 
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Table M. RAGE, TLR9, Ki67, ZAP70 and age full backwards multivariate Cox regression analysis 
 
Note: Multivariate Cox regression analysis with backward selection was used to analyze multiple 
categorical variables. CAT: low expression, CAT(1): media expression; and CAT(2) High 
expression. 
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Appendix Figure 9. Western blot analysis of extracellular sRAGE isoforms in CLL patient plasma 
Extracellular RAGE protein mass was assessed in 40µg of plasma protein from 6 CLL patients with high 
sRAGE (lanes 1-6) and compared with healthy control patient plasma (C90) and CLL patient (5959) whole 
cell lysate. Whole western blot is presented. FL-RAGE = Full-length RAGE, and es-RAGE = alternatively 
spliced endogenous secreted RAGE isoform whole cell lysate expression labelled in figure.  
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Appendix Figure 10. Evaluation of live and dead transfected HEK293 cell line post RAGE shedding by 
flow cytometry 
RAGE shedding in FL-RAGE transfected HEK293 cells was measured following ADAM10 stimulation with 
500nM ionomycin for 1-hour or ADAM10 inhibition with GI254023X 5µM, 10µM and 20µM for 1-hour 
prior to addition of 500nM ionomycin. Cell death in response to these treatments was assessed by DAPI 
staining for cells treated for 1 hours with PBS, 500nM ionomycin, 1-hour pre-treatment with GI254023X 
5µM and 20µM with another hour of ionomycin treatment. DAPI is able to bind to DNA in dead cells with 
permeable cell membranes so can distinguish live cells with intact cell membranes from dead cells.  
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Table N. Significantly abundant phosphopeptides (log2 fold change ≥1 and P<0.05) following 
15 minutes and 2 hours HMGB1 treatment in each patient compared to PBS baseline 
8231 6799 
HMGB1 alone HMGB1 alone 
15 minutes 2 hours 15 minutes 2 hours 
K2C1_HUMAN K1C13_HUMAN YTHD2_HUMAN ZN318_HUMAN 
MPP10_HUMAN UBP24_HUMAN SAFB1_HUMAN DNMBP_HUMAN 
VIME_HUMAN HP1B3_HUMAN TRI33_HUMAN ARHGB_HUMAN 
FUBP1_HUMAN H90B4_HUMAN ZBT22_HUMAN RPR1B_HUMAN 
F122A_HUMAN SAFB1_HUMAN KANL1_HUMAN SFR15_HUMAN 
NCF1B_HUMAN COX5A_HUMAN ZN281_HUMAN TBB8_HUMAN 
RSMB_HUMAN ATPG_HUMAN SP4_HUMAN SFR15_HUMAN 
RAB6A_HUMAN RBG1L_HUMAN TFPT_HUMAN UBE2O_HUMAN 
RAB1A_HUMAN FUBP1_HUMAN CDK13_HUMAN PI4KA_HUMAN 
RB33B_HUMAN RSMB_HUMAN BORG4_HUMAN TBB8_HUMAN 
RAB15_HUMAN G6PI_HUMAN MFAP1_HUMAN TBB4B_HUMAN 
S12A6_HUMAN GNAI2_HUMAN AKP13_HUMAN ZNT4_HUMAN 
MARCS_HUMAN SVIL_HUMAN RBM25_HUMAN TCOF_HUMAN 
HNRL1_HUMAN IL16_HUMAN PSME2_HUMAN NACC1_HUMAN 
EF1D_HUMAN RBBP4_HUMAN HNRPU_HUMAN PERQ2_HUMAN 
SAFB2_HUMAN MDHC_HUMAN TCPB_HUMAN ROA0_HUMAN 
SRSF9_HUMAN IFIX_HUMAN CCD43_HUMAN NUP53_HUMAN 
LEUK_HUMAN MBD3_HUMAN KS6A1_HUMAN SUN2_HUMAN 
ZC3HD_HUMAN CHAP1_HUMAN TPR_HUMAN ZEB2_HUMAN 
USF1_HUMAN RS11_HUMAN SP140_HUMAN NUMA1_HUMAN 
TLK2_HUMAN SMC3_HUMAN  PDLI2_HUMAN 
TPD52_HUMAN S10A8_HUMAN  BMPR2_HUMAN 
PSIP1_HUMAN TBB8_HUMAN  PTN14_HUMAN 
TP53B_HUMAN H2A1A_HUMAN  PTN14_HUMAN 
LC7L2_HUMAN ICAM5_HUMAN  PKCB1_HUMAN 
IL2RG_HUMAN PRDX2_HUMAN  RD23A_HUMAN 
KLDC4_HUMAN MIF_HUMAN  VEZF1_HUMAN 
TPD54_HUMAN DDX5_HUMAN  PKCB1_HUMAN 
CAND1_HUMAN GNA12_HUMAN  NCOR2_HUMAN 
TB10C_HUMAN HP1B3_HUMAN  PSA5_HUMAN 
TR150_HUMAN TCPZ_HUMAN  RBP56_HUMAN 
SP100_HUMAN CU129_HUMAN  SHIP1_HUMAN 
 XPO2_HUMAN  KHDR1_HUMAN 
 H2A1B_HUMAN  ACTY_HUMAN 
 RS25_HUMAN  FOCAD_HUMAN 
 UBC9_HUMAN  RBP56_HUMAN 
 HNRL2_HUMAN  TRAK1_HUMAN 
 TCPQ_HUMAN  MED31_HUMAN 
 H2AV_HUMAN  AGK_HUMAN 
 RAB28_HUMAN  MA7D1_HUMAN 
 ILEU_HUMAN  MYPT1_HUMAN 
 H15_HUMAN  AHNK_HUMAN 
 RL11_HUMAN  KCY_HUMAN 
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 API5_HUMAN  TLE1_HUMAN 
 1433S_HUMAN  VRK3_HUMAN 
 BCR_HUMAN  FIS1_HUMAN 
 SRSF1_HUMAN  FA65B_HUMAN 
 PPIA_HUMAN  SAC1_HUMAN 
 ERP29_HUMAN  PEG10_HUMAN 
 TRIP4_HUMAN  SYNE3_HUMAN 
 K1614_HUMAN  ZEP2_HUMAN 
 RPKL1_HUMAN  ZFAN5_HUMAN 
 ARPC4_HUMAN  MCAF1_HUMAN 
 DBLOH_HUMAN  MYO9B_HUMAN 
 HNRPU_HUMAN  CAC1A_HUMAN 
 ATPB_HUMAN   
 ENOB_HUMAN   
 HNRDL_HUMAN   
 G3P_HUMAN   
 DDI2_HUMAN   
 DDI2_HUMAN   
 BCR_HUMAN   
 RLA0L_HUMAN   
 EF1A1_HUMAN   
 TRY1_HUMAN   
 FA98B_HUMAN   
 APT_HUMAN   
 KI26B_HUMAN   
 PKHJ1_HUMAN   
 H12_HUMAN   
 HMGA1_HUMAN   
 FBLL1_HUMAN   
 HNRH1_HUMAN   
 H2B1B_HUMAN   
 CH10_HUMAN   
 MRE11_HUMAN   
 RAN_HUMAN   
 HNRPD_HUMAN   
 HNRPM_HUMAN   
 SRS10_HUMAN   
 HNRPC_HUMAN   
 NUCKS_HUMAN   
 MRE11_HUMAN   
 SRRM2_HUMAN   
 PROF1_HUMAN   
 LOX12_HUMAN   
 DDX17_HUMAN   
 HNRPK_HUMAN   
 RPRD2_HUMAN   
 RPRD2_HUMAN   
 TR150_HUMAN   
 ADT3_HUMAN   
 SAFB1_HUMAN   
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 TM109_HUMAN   
 HNRPC_HUMAN   
 NUCKS_HUMAN   
 TBA4A_HUMAN   
 UTP18_HUMAN   
 BCLF1_HUMAN   
 ENPL_HUMAN   
 HNRPD_HUMAN   
 CXCR4_HUMAN   
 EVPLL_HUMAN   
 KPCB_HUMAN   
 MCM3_HUMAN   
 HNRPC_HUMAN   
 GBG1_HUMAN   
 ATPA_HUMAN   
 CX7A2_HUMAN   
 TCP4_HUMAN   
 VPS4B_HUMAN   
 H31T_HUMAN   
 SSRP1_HUMAN   
 SSRP1_HUMAN   
 MINK1_HUMAN   
 GDIR2_HUMAN   
 RBMX_HUMAN   
 MECP2_HUMAN   
 COX5B_HUMAN   
 HNRL2_HUMAN   
 API5_HUMAN   
 SRSF6_HUMAN   
 CROCC_HUMAN   
 COTL1_HUMAN   
 TPM1_HUMAN   
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Appendix Figure 11. Heat map showing the enrichment of substrate groups for the different kinases 
calculated by KSEA algorithm, with significant abundance following CpG treatment for 15 minutes for 
patient 8231 
Cell samples were treated, processed and phosphopeptides quantified by LC/MS-MS as previously 
described in Figure 5 10. Enrichment of substrate groups was calculated by the KSEA algorithm and divided 
by the abundance of phosphopeptides in the PBS treated sample. Heat map colours correspond to the 
coloured enrichment key in Figure 5 10 and indicates -5 to +5-fold enrichment compared to PBS treated 
sample. Statistical significance of these changes was calculated by Student’s t test compared to PBS 
treated samples; P<0.05*, P<0.01**, P<0.001***, P<0.0001****. m, number of substrates in the indicated 
kinase substrate group. KSEA results were filtered based on significantly abundant substrate groups for 
patient 8231 following CpG-B class for 15 minutes (column indicated by arrow). 
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Appendix Figure 12. Heat map showing the enrichment of substrate groups for the different kinases 
calculated by KSEA algorithm, with significant abundance following CpG treatment for 15 minutes for 
patient 6799 
Cell samples were treated, processed and phosphopeptides quantified by LC/MS-MS as previously 
described in Figure 5 10. Enrichment of substrate groups was calculated by the KSEA algorithm and divided 
by the abundance of phosphopeptides in the PBS treated sample. Heat map colours correspond to the 
coloured enrichment key in Figure 5 10 and indicates -5 to +5-fold enrichment compared to PBS treated 
sample. Statistical significance of these changes was calculated by Student’s t test compared to PBS 
treated samples; P<0.05*, P<0.01**, P<0.001***, P<0.0001****. m, number of substrates in the indicated 
kinase substrate group. KSEA results were filtered based on significantly abundant substrate groups for 
patient 6799 following CpG-B class for 15 minutes (column indicated by arrow). 
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Appendix Figure 13. Heat map showing the enrichment of substrate groups for the different kinases 
calculated by KSEA algorithm, with significant abundance following CpG treatment for 2 hours for 
patient 8231 
Cell samples were treated, processed and phosphopeptides quantified by LC/MS-MS as previously 
described in Figure 5 10. Enrichment of substrate groups was calculated by the KSEA algorithm and divided 
by the abundance of phosphopeptides in the PBS treated sample. Heat map colours correspond to the 
coloured enrichment key in Figure 5 10 and indicates -5 to +5-fold enrichment compared to PBS treated 
sample. Statistical significance of these changes was calculated by Student’s t test compared to PBS 
treated samples; P<0.05*, P<0.01**, P<0.001***, P<0.0001****. m, number of substrates in the indicated 
kinase substrate group. KSEA results were filtered based on significantly abundant substrate groups for 
patient 8231 following CpG-B class for 2 hours (column indicated by arrow). 
 
Kinase H
M
G
B
1
C
p
G
H
M
G
B
1
 +
 C
p
G
H
M
G
B
1
C
p
G
H
M
G
B
1
 +
 C
p
G
A
n
ti
-R
A
G
E 
+
 H
M
G
B
1
H
M
G
B
1
C
p
G
H
M
G
B
1
 +
 C
p
G
H
M
G
B
1
C
p
G
H
M
G
B
1
 +
 C
p
G
A
n
ti
-R
A
G
E 
+
 H
M
G
B
1
m Associated signalling
Hck **** **** **** **** 1 Fc receptor activation
VRK1 * ** *** *** * *** 2
PLK3 ** ** * ** **** **** ** 1
JNK2 ** ** * ** **** **** ** 1
ERK7 ** ** * ** **** **** ** 1
JNK1 **** **** * 5
JNK3 **** **** **** **** 1
GSK3A **** **** **** **** 2
P38B **** **** **** *** *** *** 2 MAPK signalling
AurA **** **** **** **** **** **** 1
CK2A1 ** ** ** *** 55 Muliple cellular processes
CK2A2 **** **** ** ** * * 2
SRPK1 **** ** **** **** *** *** ** * ** 8
CaMK4 **** **** **** **** **** 1
CAMK2B **** **** **** **** **** 1
PKCB **** **** **** **** 4
P38D **** **** **** *** 3
8231 6799
c-Jun/ AP-1 transcription 
factor
MYC signalling
Microtubule regulation
Splicing/ mitosis
15 minutes 2 hours 15 minutes 2 hours
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Appendix Figure 14. Heat map showing the enrichment of substrate groups for the different kinases 
calculated by KSEA algorithm, with significant abundance following CpG treatment for 2 hours for 
patient 6799 
Cell samples were treated, processed and phosphopeptides quantified by LC/MS-MS as previously 
described in Figure 5 10. Enrichment of substrate groups was calculated by the KSEA algorithm and divided 
by the abundance of phosphopeptides in the PBS treated sample. Heat map colours correspond to the 
coloured enrichment key in Figure 5-10 and indicates -5 to +5-fold enrichment compared to PBS treated 
sample. Statistical significance of these changes was calculated by Student’s t test compared to PBS 
treated samples; P<0.05*, P<0.01**, P<0.001***, P<0.0001****. m, number of substrates in the indicated 
kinase substrate group. KSEA results were filtered based on significantly abundant substrate groups for 
patient 6799 following CpG-B class for 2 hours (column indicated by arrow).  
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m Associated signalling
VRK1 * ** *** *** * *** 2 c-Jun/ AP-1
HER2 * *** ** ** ** 1
Myt1 ** * *** ** *** * 2
Wee1 ** * * **** *** *** *** 2
MEK2 **** **** **** **** **** 2
Ret **** **** **** * ** * * 2
JAK2 **** **** **** * ** * * 2
MAPKAPK2 * ** 6
P38B **** **** **** *** *** *** 2
IRAK4 ** ** 3 TLR9 signalling
PKCD ** **** 13 PKC family
RSK2 * *** 6
p90RSK * ** 9
p70S6K * *** 6
CaMK4 **** **** **** **** **** 1
CAMK2B **** **** **** **** **** 1
PKCB **** **** **** **** 4
P38D **** **** **** *** 3
PKR * *** ** 1 Protein synthesis
Syk * * ** ** 5 BCR signalling
CK2A1 ** ** ** *** 55 Multiple cell processes
MEKK3 **** **** **** **** ** **** **** **** **** **** 2
SRPK1 **** ** **** **** *** *** ** * ** 8 Splicing/ mitosis
8231 6799
Cell cycle
Microtubule regulation
MAPK signalling
PI3K/ mTOR signalling
15 minutes 2 hours 15 minutes 2 hours
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Table O. Significantly abundant phosphopeptides (log2 fold change ≥1 and P<0.05) following 2 
hours HMGB1 treatment with or without 30 minutes pre-RAGE blockade in each patient 
compared to PBS baseline 
8231 6799 
HMGB1 alone 
Anti-RAGE and 
HMGB1 
HMGB1 alone 
Anti-RAGE and 
HMGB1 
2 hours 2 hours 
K1C13_HUMAN KIF1A_HUMAN ZN318_HUMAN SFR15_HUMAN 
UBP24_HUMAN ABHGB_HUMAN DNMBP_HUMAN DNMBP_HUMAN 
HP1B3_HUMAN MOV10_HUMAN ARHGB_HUMAN RPR1B_HUMAN 
H90B4_HUMAN ATPG_HUMAN RPR1B_HUMAN ARHGB_HUMAN 
SAFB1_HUMAN G6PI_HUMAN SFR15_HUMAN SMC5_HUMAN 
COX5A_HUMAN FUBP1_HUMAN TBB8_HUMAN CHTOP_HUMAN 
ATPG_HUMAN COBL1_HUMAN SFR15_HUMAN CHTOP_HUMAN 
RBG1L_HUMAN PA2G4_HUMAN UBE2O_HUMAN PERQ2_HUMAN 
FUBP1_HUMAN ZBT21_HUMAN PI4KA_HUMAN TB10C_HUMAN 
RSMB_HUMAN SELH_HUMAN TBB8_HUMAN KS6A4_HUMAN 
G6PI_HUMAN RBBP4_HUMAN TBB4B_HUMAN DNMBP_HUMAN 
GNAI2_HUMAN IL16_HUMAN ZNT4_HUMAN NEK9_HUMAN 
SVIL_HUMAN GNAI2_HUMAN TCOF_HUMAN FBX42_HUMAN 
IL16_HUMAN RHG30_HUMAN NACC1_HUMAN TB182_HUMAN 
RBBP4_HUMAN LSP1_HUMAN PERQ2_HUMAN AGO2_HUMAN 
MDHC_HUMAN TR150_HUMAN ROA0_HUMAN UN93B_HUMAN 
IFIX_HUMAN RBG1L_HUMAN NUP53_HUMAN CCD12_HUMAN 
MBD3_HUMAN RSMB_HUMAN SUN2_HUMAN PIGR_HUMAN 
CHAP1_HUMAN KPB2_HUMAN ZEB2_HUMAN LAIR1_HUMAN 
RS11_HUMAN NUCL_HUMAN NUMA1_HUMAN RL27_HUMAN 
SMC3_HUMAN TCPQ_HUMAN PDLI2_HUMAN HCFC1_HUMAN 
S10A8_HUMAN ILEU_HUMAN BMPR2_HUMAN ZNT4_HUMAN 
TBB8_HUMAN HP1B3_HUMAN PTN14_HUMAN SVIL_HUMAN 
H2A1A_HUMAN DDX5_HUMAN PTN14_HUMAN PTN12_HUMAN 
ICAM5_HUMAN ACADM_HUMAN PKCB1_HUMAN PTN12_HUMAN 
PRDX2_HUMAN IPP2_HUMAN RD23A_HUMAN UBXN6_HUMAN 
MIF_HUMAN UBC9_HUMAN VEZF1_HUMAN SSH2_HUMAN 
DDX5_HUMAN RLA0L_HUMAN PKCB1_HUMAN RBM15_HUMAN 
GNA12_HUMAN ERP29_HUMAN NCOR2_HUMAN CAP1_HUMAN 
HP1B3_HUMAN APT_HUMAN PSA5_HUMAN PAIRB_HUMAN 
TCPZ_HUMAN ARPC4_HUMAN RBP56_HUMAN BIN2_HUMAN 
CU129_HUMAN EVPLL_HUMAN SHIP1_HUMAN CCD86_HUMAN 
XPO2_HUMAN GBG1_HUMAN KHDR1_HUMAN ERN1_HUMAN 
H2A1B_HUMAN TBB8_HUMAN ACTY_HUMAN FR1L5_HUMAN 
RS25_HUMAN PRDX2_HUMAN FOCAD_HUMAN CHD2_HUMAN 
UBC9_HUMAN FBLL1_HUMAN RBP56_HUMAN VRK3_HUMAN 
HNRL2_HUMAN RL11_HUMAN TRAK1_HUMAN KHDR1_HUMAN 
TCPQ_HUMAN RS25_HUMAN MED31_HUMAN SRSF2_HUMAN 
H2AV_HUMAN GNA12_HUMAN AGK_HUMAN GTF2I_HUMAN 
RAB28_HUMAN ATPB_HUMAN MA7D1_HUMAN SRSF2_HUMAN 
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ILEU_HUMAN HNRPC_HUMAN MYPT1_HUMAN H12_HUMAN 
H15_HUMAN COR1A_HUMAN AHNK_HUMAN RRP12_HUMAN 
RL11_HUMAN ADT3_HUMAN KCY_HUMAN SRRM2_HUMAN 
API5_HUMAN HNRDL_HUMAN TLE1_HUMAN SRRM2_HUMAN 
1433S_HUMAN DDX17_HUMAN VRK3_HUMAN MYPT1_HUMAN 
BCR_HUMAN GDIR2_HUMAN FIS1_HUMAN SCML4_HUMAN 
SRSF1_HUMAN CROCC_HUMAN FA65B_HUMAN SSF1_HUMAN 
PPIA_HUMAN H2A1B_HUMAN SAC1_HUMAN DYH2_HUMAN 
ERP29_HUMAN TM109_HUMAN PEG10_HUMAN CENPA_HUMAN 
TRIP4_HUMAN TBB3_HUMAN SYNE3_HUMAN DNLI3_HUMAN 
K1614_HUMAN HNRPC_HUMAN ZEP2_HUMAN RL1D1_HUMAN 
RPKL1_HUMAN HNRPD_HUMAN ZFAN5_HUMAN NOLC1_HUMAN 
ARPC4_HUMAN ENOB_HUMAN MCAF1_HUMAN TPD52_HUMAN 
DBLOH_HUMAN EF1A1_HUMAN MYO9B_HUMAN DNLI3_HUMAN 
HNRPU_HUMAN COTL1_HUMAN CAC1A_HUMAN DDX17_HUMAN 
ATPB_HUMAN HNRH1_HUMAN  ZN318_HUMAN 
ENOB_HUMAN MIF_HUMAN  WIZ_HUMAN 
HNRDL_HUMAN 1433S_HUMAN  NUTM1_HUMAN 
G3P_HUMAN RAN_HUMAN  VRK3_HUMAN 
DDI2_HUMAN ATPA_HUMAN  LIPB2_HUMAN 
DDI2_HUMAN RAB28_HUMAN  LIPB2_HUMAN 
BCR_HUMAN G3P_HUMAN  RHG04_HUMAN 
RLA0L_HUMAN XIRP1_HUMAN  RHG04_HUMAN 
EF1A1_HUMAN CU129_HUMAN  RL28_HUMAN 
TRY1_HUMAN XPO2_HUMAN  FUBP3_HUMAN 
FA98B_HUMAN PROF1_HUMAN  FUBP3_HUMAN 
APT_HUMAN H2B1B_HUMAN  IRS1_HUMAN 
KI26B_HUMAN K1614_HUMAN  IFIX_HUMAN 
PKHJ1_HUMAN RPKL1_HUMAN  PKCB1_HUMAN 
H12_HUMAN H15_HUMAN  SCAFB_HUMAN 
HMGA1_HUMAN ICAM5_HUMAN  SCAFB_HUMAN 
FBLL1_HUMAN PPIA_HUMAN  ZYX_HUMAN 
HNRH1_HUMAN BCR_HUMAN  H31T_HUMAN 
H2B1B_HUMAN SRSF1_HUMAN  K1551_HUMAN 
CH10_HUMAN BCR_HUMAN  SCIMP_HUMAN 
MRE11_HUMAN RPRD2_HUMAN  H2AY_HUMAN 
RAN_HUMAN RPRD2_HUMAN  IF16_HUMAN 
HNRPD_HUMAN KI26B_HUMAN  PAN3_HUMAN 
HNRPM_HUMAN PKHJ1_HUMAN  CENPA_HUMAN 
SRS10_HUMAN HNRPC_HUMAN  ARHGI_HUMAN 
HNRPC_HUMAN TR150_HUMAN  LMO7_HUMAN 
NUCKS_HUMAN SRS10_HUMAN  ELK3_HUMAN 
MRE11_HUMAN NUCKS_HUMAN  ANKL2_HUMAN 
SRRM2_HUMAN PRP4B_HUMAN  SRRM2_HUMAN 
PROF1_HUMAN T3JAM_HUMAN  SUN2_HUMAN 
LOX12_HUMAN BCLF1_HUMAN  C2C2L_HUMAN 
DDX17_HUMAN H12_HUMAN  EHBP1_HUMAN 
HNRPK_HUMAN H2A1A_HUMAN  CENPA_HUMAN 
RPRD2_HUMAN SRRM2_HUMAN  RGPA1_HUMAN 
RPRD2_HUMAN RBM25_HUMAN  P2RX7_HUMAN 
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TR150_HUMAN HDAC1_HUMAN  TALDO_HUMAN 
ADT3_HUMAN NUCL_HUMAN  TBCD1_HUMAN 
SAFB1_HUMAN TRIP4_HUMAN  Z280D_HUMAN 
TM109_HUMAN H2AV_HUMAN  SC61B_HUMAN 
HNRPC_HUMAN SAFB1_HUMAN  MYO9B_HUMAN 
NUCKS_HUMAN LOX12_HUMAN  IF2M_HUMAN 
TBA4A_HUMAN HMGN1_HUMAN  PRAME_HUMAN 
UTP18_HUMAN SRSF7_HUMAN  MARK3_HUMAN 
BCLF1_HUMAN UTP18_HUMAN  MARK3_HUMAN 
ENPL_HUMAN SRSF7_HUMAN  MET16_HUMAN 
HNRPD_HUMAN MATR3_HUMAN  IF16_HUMAN 
CXCR4_HUMAN RBMX2_HUMAN  SRRM2_HUMAN 
EVPLL_HUMAN ZRAB2_HUMAN  BAZ1B_HUMAN 
KPCB_HUMAN SON_HUMAN  XRN2_HUMAN 
MCM3_HUMAN HMGA1_HUMAN  TFIP8_HUMAN 
HNRPC_HUMAN K1C13_HUMAN  PEA15_HUMAN 
GBG1_HUMAN COX5A_HUMAN  SC61B_HUMAN 
ATPA_HUMAN   NCF1B_HUMAN 
CX7A2_HUMAN   NCF1B_HUMAN 
TCP4_HUMAN   BIN2_HUMAN 
VPS4B_HUMAN   YBOX1_HUMAN 
H31T_HUMAN   SRRM2_HUMAN 
SSRP1_HUMAN   HMHA1_HUMAN 
SSRP1_HUMAN   NOP2_HUMAN 
MINK1_HUMAN   SLTM_HUMAN 
GDIR2_HUMAN   EMAL3_HUMAN 
RBMX_HUMAN   PCBP1_HUMAN 
MECP2_HUMAN   SLTM_HUMAN 
COX5B_HUMAN   SLTM_HUMAN 
HNRL2_HUMAN   AHDC1_HUMAN 
API5_HUMAN   AHDC1_HUMAN 
SRSF6_HUMAN   AHDC1_HUMAN 
CROCC_HUMAN   WIZ_HUMAN 
COTL1_HUMAN   XRN2_HUMAN 
TPM1_HUMAN   P4K2A_HUMAN 
   ZN329_HUMAN 
   MYH16_HUMAN 
   RL7L_HUMAN 
   RIF1_HUMAN 
   RAI1_HUMAN 
   NUTM1_HUMAN 
   P4K2A_HUMAN 
   ING3_HUMAN 
   PKHA6_HUMAN 
   MAGI3_HUMAN 
   SEM3G_HUMAN 
   MYO5C_HUMAN 
   AN32E_HUMAN 
   NUP53_HUMAN 
   NUCKS_HUMAN 
Appendix II 
280 
 
   XRN2_HUMAN 
   XRN2_HUMAN 
   STIM2_HUMAN 
   H2AY_HUMAN 
   MADD_HUMAN 
   YBOX1_HUMAN 
   TFEB_HUMAN 
   SLTM_HUMAN 
   ZGRF1_HUMAN 
   OSB11_HUMAN 
   RBP56_HUMAN 
   ARI5B_HUMAN 
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Table P. Clinical information of CLL patient samples used in vitro 
Patient 
ID 
S100 
(pg/ml) 
HMGB1 
(ng/ml) 
sRAGE 
(pg/ml) 
Cytogenetic 
description 
Binet stage ZAP70 
(inhouse) 
Time to first 
treatment 
(months) 
Date of first 
treatment 
First treatment First response Date of relapse 
10450 88.4 72.7 0.0 TRISOMY 12 B Y 
     
8553 0.0 381.8 27.6 11Q AND 13Q A Y 41 29/01/2013 LENALIDOMIDE STABLE DISEASE 
 
8921 0.0 78.9 1.5 17P DEL A Y 23 23/01/2012 CAMPATH PARTIAL REMISSION 
 
9095 0.0 16.5 25.5 TRISOMY 12 
  
43 26/08/2014 FLUD+CYCLO+RITUX 
  
9887 0.0 16.0 52.2 
 
A N 
     
7921 0.0 8.1 35.1 
 
A Y 36 15/06/2005 CB PARTIAL REMISSION 15/03/2006 
9956 0.0 79.3 90.3 NORMAL A 
      
5959 0.0 30.1 91.5 DEL (13Q) A 
      
6158 0.0 63.6 89.3 NOT DONE A N 116 15/06/2000 CB PARTIAL REMISSION 18/12/2003 
8320 0.0 145.0 141.2 
  
N 0 15/06/2003 FLUDARABINE COMPLETE 
REMISSION 
15/09/2007 
9361 0.0 185.6 103.1 
  
Y 24 15/06/2008 FLUD. CYCLO + RITUX 
 
15/12/2011 
8232 0.0 37.2 34.1 
 
A 
      
9024 79.0 92.4 7.8 17P DEL, 11Q DEL C N 2 07/02/2011 CB TREATMENT DEATH 
 
8560 0.0 71.8 0.0 13Q-, 17P- A N 
     
7549 126.0 328.2 36.6 TRISOMY 12 A Y 80 15/10/2012 LENALIDOMIDE PROGRESSION 
 
7362 0.0 191.5 0.0 DEL13Q, TRISOMY 
12 
B N 1 15/01/2006 FLUDARABINE & CYCLO PARTIAL REMISSION 07/01/2014 
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8009 237.0 394.1 101.9 DEL (13Q) A N 
     
9746 68.2 133.9 133.4 
 
C Y 416 05/02/2013 CB - RANDOMISED 
(CELGENE-008) 
PARTIAL REMISSION 22/04/2015 
9401 0.0 16.3 24.1 13Q DEL A Y 
     
9491 3.6 33.6 25.0 17P DEL C Y 
     
9885 0.0 139.8 0.0 
  
Y 0 15/06/2010 FLUD. CYCLO + RITUX GOOD PARTIAL 
RESPONSE 
15/03/2012 
T-2488 0.0 193.3 108.7 TRISOMY 12 A Y 39 01/09/2011 FLUD. CYCLO + RITUX 
  
9853 0.0 79.6 38.8 13Q DEL A N 25 18/02/2015 FLUD. CYCLO + RITUX 
  
5313 0.0 80.7 56.7 
 
A Y 3 10/04/2000 FMD PARTIAL REMISSION 10/01/2006 
9528 0.0 28.3 29.2 13Q DEL A Y 
     
7893 0.0 42.1 81.1 DEL (13Q) A Y 39 15/09/2003 CB PARTIAL REMISSION 29/01/2013 
9480 0.0 123.2 0.0 
  
Y 24 15/06/2005 CB PARTIAL REMISSION 15/02/2007 
10686 0.0 18.1 114.5 
 
A Y 
     
9685 0.0 15.4 72.2 TRISOMY 12 A Y 
     
8692 0.0 47.9 144.2 
  
Y 
     
10687 0.0 205.9 136.4 11Q22 A Y 
     
7358 79.9 58.1 66.8 DEL (13Q) A N 57 15/02/2005 CB PARTIAL REMISSION 17/10/2006 
8357 0.0 17.7 0.0 
 
A N 
     
7581 0.0 126.6 137.8 DEL (13Q) A N 128 15/06/2015 TREATED ELSEWHERE 
  
9070 0.0 119.9 92.2 13Q DEL A Y 32 15/02/2010 FLUD. CYCLO + RITUX 
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T-2490 0.0 48.6 2.6 11Q AND 13Q C Y 1 23/09/2011 CB + RITUX PARTIAL REMISSION 
 
8231 0.0 244.9 25.7 DEL (13Q) A Y 
     
8550 0.0 53.9 124.2 NORMAL A Y 53 15/03/2013 FLUD. CYCLO + RITUX COMPLETE 
REMISSION 
 
6794 0.0 26.1 65.9 13Q DEL A Y 
     
T-2555 0.0 13.0 49.1 
 
STAGE IV Y 
     
9601 0.0 96.9 37.8 13Q DEL 
 
Y 44 16/10/2012 ARCTIC:FCR-PO COMPLETE 
REMISSION 
 
7888 0.0 12.4 117.1 DEL (13Q) A N 97 01/10/2014 FLUDARABINE & CYCLO COMPLETE 
REMISSION 
 
6799 12.3 48.8 61.3 DEL (13Q) A N 
     
10688 0.0 41.1 30.6 
 
A N 
     
5928 0.0 91.5 70.3 13Q DEL A Y 153 25/02/2015 BENDAMUSTINE+RITUX 
  
T-1985 0.0 78.9 0.0 
 
A (C IN 2013 
STILL AT PRE-
TREATMENT 
N 
     
10278 0.0 50.7 101.2 
 
A Y 115 12/01/2016 GALACTIC STUDY 
  
 
